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Abstract.
Defining HLA-A locus Alleles from DNA using ARMS-PCR.
Submitted for the degree of Doctor of Philosophy by Peter Krausa. B.Sc.
The HLA system is a highly polymorphic group of genes which play a 
central role in the immune response. The definition of the HLA system  
makes an important contribution to a number of fields. In the clinical 
setting it is a requirement for transplantation. For anthropology, the HLA 
system is a useful marker for assessing population groups. Functionally, it is 
an important component of the T cell mediated immune response. The 
definition offered by the established method of serology to HLA class I 
tissue-typing is restrictive since serology fails to discriminate between alleles 
which are functionally distinct. This research represents one of the first 
DNA based approaches and the first by PCR-SSP, to define HLA class I 
specificities, with particularly reference to the HLA-A locus. This thesis 
charts both the development and application of a robust, simple to perform, 
easy to interpret yet highly powerful PCR based system in which allelic 
definition is demonstrated. In addition to resolution, a DNA approach offers 
many practical advantages over the restrictive demands of a serological 
typing. Further more, this thesis examines the functional aspect of 
polymorphism, in defining the peptide binding preferences of a group of 
closely related HLA specificities. By so doing, this thesis shows the relevance 
of a highly definitive approach to HLA typing.
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Introduction;
Définition of HLA polymorphism.
1.1 The HLA system.
1.1.1 Introduction
The Major Histocompatibility Complex (MHC) is a central and important 
component of the immune system. In humans, the MHC or H um an  
Leukocyte Antigen (HLA) region represents a cluster genes on the short arm 
of chromosome 6 (figure 1.1). Many of these genes have been shown to be 
involved in the regulation, processing and presentation of antigen in the 
immune response. The characterisation of the HLA system has revealed, a 
high level of polymorphism amongst the component genes. The 
determination of this polymorphism has proven important with regard to 
understanding histocompatibility and the cellular immune response. This 
chapter discusses the HLA system and the different approaches for its 
definition, the development and application of one approach, forming the 
basis of this thesis.
The need for HLA matching donor and recipient for organ transplantation 
has driven the requirement for identification of specificities in the HLA 
system. As the capability for testing evolved, firstly through detection of 
HLA molecules at the ceU surface and more recently through typing HLA by 
DNA analysis, so the degree and extent of polymorphism found in the HLA
system has grown. Ultimately, the complexity of polymorphism within the 
HLA system has been unravelled by DNA sequencing the genes that 
translate into the many expressed HLA specificities.
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Figure 1.1. A map of the 4Mbp human MHC region on chromosome 6. The MHC is divided into 
class I (pink), class II (blue) and class HI (green) regions. Class II is at the centromeric end, 
whilst class I is at the telomeric end of the MHC complex. The class I region contains genes 
encoding amongst other things, the classical HLA-A, -B, -C antigens. The class II region 
contains genes encoding HLA-DP, DQ, DR antigens. The class III region contains genes 
encoding some of the components of the complement system, including C2 C4 and Bf.
HLA genes are encoded on the short arm of chromosome 6 and represent 
the most polymorphic loci known in man (figure 1.1). In 1987, 12 Class I 
alleles and 9 Class H alleles had been sequenced (Bodmer, J.G. et al 1990). 
This has quickly grown in number so that in the 1995 Nomenclature report 
(Bodmer, J.G. et al 1995), some 213 Class I (A,B,C) and 256 Class II 
(DR,DP,DQ) alleles had been identified. The initial surge of DNA sequencing 
was biased towards HLA Class H aUeles, probably since serological definition 
of Class II antigens was acknowledged as inadequate for clinical purposes. 
This allowed DNA based systems to be developed for Class H, which was 
particularly desirable because of the difficulties in performing Class H typing 
through serology. The revolution of DNA based technology and its 
application to identify polymorphism at the nucleotide level provided m ore 
information as to the relevance of polymorphism in terms of HLA structure 
and function. Detection of HLA through DNA analysis achieved an
increased level of resolution, not possible through serological or 
biochemical means. Characterisation of HLA genes by DNA sequencing and 
the collection of these into an accessible database (Arnett and Parham, 1995; 
Marsh, et al 1995) provided the information for the further design of DNA  
based methods. In turn these methods identified new variants, which w hen  
sequenced consolidate and add to the sequence information already held on  
HLA polymorphism.
Elucidation of the crystal structure of the Class I and Class II m olecules 
(Bjorkman, et al 1987; Gorga, et al 1991; Saper, et al 1991; Brpwn, et al 1993) 
provided a physical model within which the function of HLA 
polymorphism could be better understood. The high level of polymorphism  
found around the peptide binding groove, determines the nature and 
conformation of the peptide bound by the HLA molecule (Saper, et al 1991; 
Kubo, et al 1994; Tanigaki, et al 1994). Therefore, HLA polymorphism has 
implications for antigen presentation in the T cell mediated im m une  
response (Gotch, et al 1985; Latron, et al 1991; Rotzschke, et al 1992; Utz, et al 
1992; Tussey, et al 1994). The significance of these polymorphic differences 
has become increasingly apparent as more HLA specificities have been 
identified.
The HLA system is of major importance in the functioning of the im m une  
response. The polymorphic nature of the HLA system and its function has 
prompted the application of tissue typing techniques in a number of areas, 
including transplantation, epidemiology and disease association, 
anthropology and cellular immunology. To understand better the relevance 
of HLA polymorphism with regard to the immune response, it is first 
necessary to develop accurate methods for determination of HLA 
specificities. This thesis charts the development of one such approach in  
application to the HLA-A locus. It describes the initial development of a 
basic PCR based approach and the subsequent pursuit of methods for 
determining an allelic level of resolution at the HLA-A locus. Through this 
work, the feasibility of high resolution HLA typing is realised.
Detection of HLA polymorphism has utilised a wide array of techniques 
over the years. The observations made in identifying polymorphic 
differences by different methods, have in turn lead to a greater
understanding of the nature of the HLA system. This introduction w ill 
briefly describe the HLA system and how different approaches have been 
applied to detection of polymorphism both for Class I and Class II loci.
1.1.2. HLA stucture and polymorphism.
HLA Class I and Class II antigens are highly polymorphic m olecules 
expressed at the cell surface. HLA Class I molecules comprise a polymorphic 
heavy chain associated with a p2-microglobulin invariant light chain and 
endogenously processed peptide (Bjorkman, et al 1987; Saper, et al 1991). 
HLA Class II molecules comprise two covalently linked heavy chains 
associated with peptide (Brown, et al 1993). The heavy chains for Class I and 
Class n  molecules have transmembrane and cytoplasmic regions. The genes 
coding for the HLA heavy chains are found on the short arm of 
chromosome 6 (figure 1.1). The gene coding for the human P2- 
microglobulin light chain is located on chromosome 15.
HLA Class I antigens are generated from three classical loci, HLA-A, -B, -C. 
These classical Class I molecules are expressed at the surface of most 
nucleated ceUs and act as antigen presenting moleclues for CD8^ T cells. 
Some non-classical HLA Class I antigens also exist, namely HLA-E, -F, -G 
which also associate with p2-microglobulin. These non classical HLA 
molecules have restricted tissue expression. HLA-G is predominantly 
expressed on the trophoblast (Kovats, et al 1990; Rinke, et al 1990).
Classical HLA Class II antigens comprise HLA-DR, -DQ, -DP. The HLA-DR 
antigens comprise a polymorphic beta chain in association with a invariant 
alpha chain. In addition to the DRBl locus which codes for most of the 
HLA-DR polymorphism, the DR alpha invariant chain can combine with  
beta chains coded for at three other DR loci, namely DRB3, DRB4 and DRB5 
to give antigens DR52, DR53 and DR51 respectively. HLA-DQ and DP 
comprise alpha and beta chains, both containing polymorphism. Class II 
antigens are reslricled in tlieir distribution, and are expressed on B cells, 
macrophages, monocytes, activated T cells and a few additional ceU types. 
HLA Class II molecules present antigen to CD4^ T cells.
The function of HLA molecules became better understood through the 
elucidation of their structure. This was first achieved through the 
determ ination of the crystal structure of the HLA-A2 molecule (Bjorkman, 
et al 1987). This revealed the HLA-A2 molecule consisted of a peptide 
binding groove (formed by the alpha-1 and alpha-2 domains) supported by 
the combination of the alpha-3 dom ain and the P2-microglobulin light 
chain (figure 1.2). A similar structure was noted for Class II (Brown, et al 
1993), with the peptide binding groove comprising the alpha-1 and beta-1 
domains. The main regions of sequence hypervariability are found around 
the peptide binding groove reflecting their function for HLA restricted 
antigen presentation. Polym orphism  within the peptide binding groove 
affects the sequence and conform ation of peptide bound within the groove 
(Tussey, et al 1994).
Figure 1.2. A depiction of the HLA class I molecule as viewed from the side looking down the 
peptide binding groove. The peptide is shown in red. The peptide binding groove is formed by 
the a-1 and a-2 domains of the class I heavy chain (green). The binding groove is supported 
by a platform formed by the a-3 domain in association with the P-2microglobulin light chain 
shown in blue. This model, based cn the HLA-B8 molecule was generated in MOLSCRIPT 
(Kraulis, 1991, modification by R.Esnouf), and rendered with RasterSD (Merritt, et al 1994).
The majority of HLA Class I and Class II sequence polymorphism identified 
at the nucleotide level are coding differences, translating into amino add 
substitutions. Very few sequence polymorphisms are silent and most 
polymorphic differences are located in or around the peptide binding 
groove. These observations imply the evolution and maintenace of HLA 
polymorphism through selection mediated by pathogenic pressure (Lawlor, 
et al 1990). Additionally, polymorphism has also been observed in the 
promoter regions (Cereb, et al 1994) and intronic regions of the HLA 
sequences (Cereb, et al 1995). Both may be useful for DNA based tissue 
typing.
A large number of sequences defining HLA specificities have now been 
published (Amett and Parham, 1995). In comparing the HLA sequences, the 
polymorphic differences are in the most part not represented as unique 
sequence motifs. Instead, most alleles gain their uniqueness through a 
mosaic of shared polymorphic differences, each defined at a particular 
hypervariable region (see figure 1.10). The nature of this type of 
polymorphism seems to be the result of gene conversion, recombination or 
exon shuffling events (Parham, et al 1988; Erlich, et al 1991b; Geraghty, et al 
1992; Hildebrand, et al 1992; Kuhner, et al 1992; Zemmour, et al 1992a; 
Hildebrand, et al 1994). The combination of these polymorphic differences 
along the length of the gene (in particular exons 2 and 3 for class I and exon 
2 for Class H) distinguish each antigen.
The importance of polymorphism within the HLA system bears significance 
as to the function of the expressed molecule and how it mediates the 
immune response in terms of antigen presentation. The fact that the 
majority of polymorphism m HLA is found around the peptide binding 
groove underlines the requirements for identification of these sequence 
differences. This can be achieved by two main approaches; detection of the 
expressed molecule or detection of the genes.
1.1.3. MHC restriction, antigen processing and antigen presentation by HLA 
class I molecules.
The HLA class I molecule is a central player in the cellular im m une  
response, acting as an alloantigen in the mixed lymphocyte reaction 
(discussed below 1.2.3) and as a restriction element for recognition of antigen 
by the cytotoxic T cells (CTL). Evidence for the use of MHC class I as a 
restrictive element was noted in murine models (Zinkemagel 1974; 
Zinkemagel and Doherty, 1974a; Zinkemagel and Doherty, 1974b). This 
work demonstrated that virally infected target ceUs were lysed by specific 
CTL which shared at least one mouse class I MHC (H-2) antigenic specificity. 
CTL which did not share a H-2 specificity with the targets, failed to lyse the 
cells, even though they were infected with the same virus to which the CTL 
were raised.
It was thought that these restriction phenomena could be explained by one 
of two theories. Firstly, that there was a physiological interaction, in which T 
cells could recognise cuitigen bound to the cell surface, but for lysis to occur, 
an additional self to self signal was required (Miller, et al 1976). The second 
theory conjectured that lysis required a specific T cell receptor which could 
identify altered self structures coded for within the MHC genes.
The evidence, although not conclusive, seemed to favour the latter altered 
self hypothesis. Experiments using bone marrow chimeras in mice showed 
the presence of two populations of CTL, one specific for syngeneic virally 
infected cells, the other exhibiting cytotoxicity against the tolerated 
allogeneic virally infected cells. The specificity of the CTL was shown to be 
restricted through the H-2 type to which they were raised, and failed to 
crossreact with the other MHC components in the chimeric model. Both 
groups of CTL failed to lyse infected cells of an unrelated H-2 type 
(Zinkemagel, 1976). These experiments showed that the recognition of MHC 
is in one direction, with the T cell receptor specifically recognising virally 
altered MHC. This was supported by observations made in blocking 
experiments where, antisera bound to H-2 specificities on the targets and not 
the CTL abrogated specific lysis (Germain, et al 1975; Schrader and Edelman, 
1976). This further affirmed the notion that the T cell receptor detected MHC 
which had become altered by the viral infection of the target cell.
Elucidation of the process MHC restriction of cell lysis proceeded further to 
determine the nature of altered self.
Further investigation of CTL recognition of influenza nucleoproteins 
transfected into mouse fibroblast cells, provided additional insight into the 
nature of the MHC restricted immune interaction (Townsend, et al 1984). 
The recognition of nucleoprotein, a non membrane component of the virus 
which accumulates in the nucleus of the infected cell, differed with the 
assumed belief that CTL recognised antigens in their native form on the cell 
surface, with T helper cells recognising denatured fragments on professional 
antigen presenting cells (Unanue, et al 1984). This begged the question of 
how the nucleoprotein reached the cell surface. An explanation of the 
results (Townsend, et al 1984), suggested that other cells including the 
transfected fibroblasts, could also process and present viral antigens, 
provided they were generated within the cell. This observation explained 
previous results where antibodies specific for native viral proteins failed to 
diminish CTL recognition (Zinkemagel and Rosenthal, 1981), suggesting 
some type of processing of antigen prior to its expression at the cell surface.
To further investigate the CTL recognition of influenza nucleoprotein, 
deletion mutants of the nucleoprotein were transfected into m ouse 
fibroblast cells (Townsend, et al 1985). The results showed that fragments of 
the nucleoprotein were transported to the cell surface and recognised by 
CTL. The data also revealed that different CTL clones were able to show  
specificity for different regions of the nucleoprotein. The experiments also 
demonstrated that both ends of the nucleoprotein could be independently 
transported to the cell surface. Antibodies raised against the native 
influenza nucleoprotein again failed to abolish CTL recognition. 
Additionally, antibody against the trunctated nucleoprotein could only 
detect very small quantities at the cell surface, which was contradictory to 
the CTL data. These results suggested that viral antigen had been denatured 
prior to surface expression, perhaps as part of the normal cytosolic processes 
of protein degradation.
Experiments then followed to determine whether CTL did indeed recognise 
short fragments of the antigenic protein in a fashion similar to recognition 
of processed antigen by class E restricted T helper cells. This involved the
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generation of short synthetic peptides defining epitopes within the 
influenza nucleoprotein (Townsend, et al 1986). The results showed clearly 
that short peptides representing epitopes of the influenza nucleoprotein 
could be recognised by MHC class I restricted CTL. This further enhanced the 
view that viral proteins required degradation within the cytosol prior to 
presentation at the cell surface in association with the class I molecule.
Hence it was shown that the HLA class I molecules present endogenously 
derived peptide at the ceU surface for surveillance by the immune system. 
CTL wiU normally mount immune responses against cells MHC presenting 
foreign peptide derived from viral infections or malignant transformations, 
while cells expressing peptides derived from the normal self proteins will be 
ignored. To allow presentation of self or foreign peptide requires the 
degradation and processing of the respective proteins within the cell. The 
mechanisms allowing presentation of peptide in combination with HLA 
molecules at the cell surface, have been increasingly studied over recent 
years. The intracellular mechanisms of antigen processing and assembly of 
class I molecules have recently been reviewed (Brodsky, et al 1996; Williams, 
et al 1996) and are outlined below.
The stability of the class I molecule requires the formation of a trimeric 
structure comprising class I heavy chain, p2-microglobulin and peptide 
(Townsend, et al 1989). The HLA molecule binds peptide in the region of 8- 
10 amino acids in length (Rotzschke, et al 1990). The HLA molecule also 
prefers to bind peptides with certain amino acid residues at particular points 
within their sequence (Falk, et al 1991). The binding of a preferred peptide 
motif is more extensively described in chapters 7 and 8.
To achieve the presentation of antigen at the ceU surface therefore requires 
the degradation of endogenous protein, the combination of the class I heavy 
chain with p2-microglobulin, and subsequent loading of peptide. The 
assembly of class I molecules occurs in the endoplasmic reticulum (ER), yet 
the degradation of protein occurs essentially in the cytosol (Engelhard, 1994). 
This is supported by the discovery of an ATP dependent transporter (TAP), 
which actively takes peptide from the cytosol into the ER (Townsend and 
Trowsdale, 1993).
The degradation of peptide in the cytosol has been associated with two 
proteasomes (20S and 26S) (Peters, 1994). These two complexes are associated 
with the major proteolytic activity within the cytosol. The 20S proteosome 
forms the core of the 26S proteosome in a barrel type structure. These 
proteosomes degrade either ubiquitin-conjugated proteins or denatured 
proteins. The link with antigen processing and the proteosome was made 
when two genes coding for two proteosome subunits were identified w ithin  
the MHC complex (Glynne, et al 1991; Kelly, et al 1991). The incorporation 
of these two sub-units into the proteosome complex, alters its cleavage 
characteristics. Expression of these genes known as LMP2 and LMP7, 
together with others implicated in antigen processing, is inducible by y- 
inteferon. Good evidence for the contribution of LMP2 and LMP7 to antigen 
processing is that cells which lack the genes express reduced levels of surface 
class I molecules. This can be reversed by the addition of exogenous peptide 
(Fehling, et al 1994). It is also possible that proteosomes can to some extent 
determine the range of peptide motifs available for presentation. If the 
proteosome has a preferred cleavage site at the centre of a possible motif, 
then this potential peptide would not be available for presentation 
(Niedermann, et al 1995).
The proteosomes degrade protein to produce peptides in the range of 3-15 
amino adds in length, consistent with that required for loading onto and 
presentation by the class I molecule. They are also of the correct size for 
transport into the ER by the TAP molecule, which exhibits a preference for 
peptides in the region of 8-15 amino acids in length (Howard, 1995). The 
transport of peptide into the ER was clarified through the discovery of two 
genes within the MHC complex, near to the LMP2 and LMP7. These two 
genes, (TAPI and TAP2) encode the two subunits of an ATP dependent 
transporter molecule (Trowsdale, et al 1990; Kleijmeer, et al 1992). Cells 
lacking TAP genes have low expression of HLA dass I molecules at the cell 
surface and an accumulation of unstable heavy chain/(32-microglobulin 
complexes within the cell (Howard, 1995). This evidence seems to underline 
the importance of the TAP molecule in transportation of peptide from the 
cytosol into the ER facüitaing stabalisation of the class I molecule.
So far there has only been a limited amount of polymorphism observed in  
the human TAP genes. There is however significant polymorphism
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observed amongst the rat TAP genes, which affect the specificity of the TAP 
molecule in its transportation of peptide. In the mouse, the TAP m olecule 
shows a preference for peptides with a hydrophobic C-termini, which is 
reflected in the peptide motifs bound by the murine class I molecules. The 
human TAP does not seem to have this level of preference, although som e 
peptides are poorly transported (Powis, et al 1992).
Once peptide enters the ER, it may bind to the class I heavy chain /^2- 
microglobulin complex. If the peptide is longer than that preferred, 
additional trimming can occur within the ER. It is unclear whether this 
trimming occurs before or after loading of peptide onto the class I molecule. 
There is also evidence of binding of peptide to a chaperone molecule (gp96) 
within the ER (Srivastava, et al 1994). It appears that this chaperone can 
protect against rapid degradation of the pepide before it is loaded into the 
empty class I molecule. Peptide can also be recycled from the ER into the 
cytosol by an as yet undefined ATP dependent pathway (Brodsky, et al 1996).
The loading of peptide onto the class I molecule requires the association of 
the heavy chain with p2-microglobulin. It has also been shown that the 
heavy chain/p2-microglobulin complex associates with the TAP m olecule 
(Ortmann, et al 1994; Suh, et al 1994), with the interaction occuring through 
the TAPI subunit. This association may have evolved to accommodate 
more efficient loading of peptide onto the empty class I molecule.
Before peptide can be loaded onto the empty class I molecule, the heavy 
chain needs to be correctly folded and assembled with p2-microglobulin. The 
assembly within the ER has been associated with a number of chaperone 
molecules, the most characterised being calnexin (Helenius, 1994; W illiams, 
1995). This chaperone has been shown to assist the folding of the class I 
heavy chain and incorporation of the p2-microglobulin light chain. The 
calnexin-HLA complex then associates with TAP. Disassociation from TAP 
occurs once peptide is bound (Williams, et al 1996). The point at which  
calnexin disassociates from the HLA molecule is unclear. It has also been 
shown that calnexin deficient cells can stül express HLA on their surface, 
which indicates the presence of other chaperones which facilitate the 
assembly of class I molecules (Scott and Dawson, 1995).
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Following disassociation from TAP and calnexin, the class I molecule is 
released from the ER and is transported to the cell surface via the golgi 
apparatus (Brodsky et al. 1996; Williams et al. 1996). Further work is required 
to elucidate the complete picture of antigen processing and presentation. 
However enough is now known to consider the interactions and 
mechanisms as complex. A simplified depiction of the events m entioned 
above is given in figure 1.3.
golgi plasma membrane
Endoplasmic 
reticulum
i^lnexin
m transporter
peptide
proteosome
m
polyp«ptido
Figure 1.3. A simplified representation of antigen processing and class I assembly. Antigen 
processing. Protein (a) containing the relevant peptide is cut by the proteosome (b) in the 
cytosol. The resulting peptides (c) are transported into the endoplasmic reticulum (ER) by the 
TAP transporters (d). In the ER, the peptide (e) can be trimmed further (f) prior to loading 
onto the class I molecule (g) or it can be recycled back to the cytosol (h). It is unclear w hether 
trimming of the peptide occurs before or after it is bound to the class I molecule. Class I 
assembly. Nascent heavy chain is bound by calnexin (1). This allows binding of P2- 
microglobulin (2). When this complex is bound to the TAP transporter, peptide can be loaded 
onto the class I molecule (3). Binding of peptide triggers disassociation from TAP and at some 
point calnexin (4). The class I molecule is then transported through the golgi (5) and expressed 
at the cell surface (6).
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1.1.4 Nomenclature.
There have been a number of different techniques used to define HLA 
polyphorphism, including serological, biochemical, T cell and molecular 
biological methods. These methods gauge the differences present in HLA 
genes or their products from different perspectives. Different methods each 
had their own nomenclature in identifying the specificities they were 
determining.
Initially, HLA specificities were defined by serology and named through a 
combination of a number in conjunction with the gene locus, (e.g. AlO; 
DR2). As an increasing array of sera were used and cells tested, so it became 
possible to split many of the initial specificities into a number of 
serologically defined antigens. Hence AlO could be split into A25, A26, A43, 
A34 and A66, and DR2 could be split into DR15 and DR16. Additionally, the 
use of Isoelectric focusing (lEF) could further split these serologically defined 
specificities into subtypes, and they were named by their serological 
specificity followed by a number (e.g. A2 could be subtyped by IFF into 
subtypes A2.1, A2.2, A2.3, A2.4, A2.5). A list of HLA-A alleles, their broad 
serological specificities and splits, and related IFF specificities, are shown in  
Table 1.1. To confuse matters further, another nomenclature was required to 
define specificities determined through T cell recognition of allogeneic HLA, 
with particular reference to Class II specificities (e.g., serologically defined 
DR4 could be subdivided into Dw4, DwlO, Dwl3, Dw l4 and Dwl5 by specific 
T cell clones).
This complex situation was resolved through the introduction of a 
nomenclature system based on the allelic definition of HLA specificities 
through the DNA sequence of their genes. This system required that alleles 
were defined by their gene locus in combination with a four digit number; 
the first two digits relating to the specificity (mainly on the basis of serology), 
and the last two digits relate to the subtype number. Hence, A*0205 denotes 
tlie fif til HLA-A2 allele. A fiflli digit has been introduced to allow  
distinction between alleles containing silent polymorphisms. This system of 
nomenclature, sanctioned by the World Health Organisation, provides an
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Allele Serological Specificity ,IEF position Local Name
A*0101 A1 A1 -
A*0102 A1 - -
A*0201 A2 A2.2 A2.1
A*0202 A2 A2.1 A2.2F
A*0203 A203 A2.3 A2.3
A*0204 A2 A2.4 A2.4
A*0205 A2 A2.1 A2.2Y
A*0206 A2 A2.2 A2.4a
A*0207 A2 A2.2 A2.4b
A*0208 A2 A2.2 A2.4c
A*0209 A2 A2.3 A2-OZB
A*0210 A210 A2.2 A2-Lee
A*0211 A2 A2.5 A2.5
A*0212
A*0213
A2
A2
A2.2
A2-SLU
A*0214 . A2 - A2-1S
A*0215N - - A2-Null
A*0216 A2 - A2-TUB
A*0217 A2 - A*New
A*0301 A3 A3.2 A3.1
A*0302 A3 - A3.2
A*1101 A ll A11.2 A llE
A*1102 A ll - A llK
A*2301 A23(A9) A23 -
A*2402 A24(A9) A24.1 -
A*2403 A24(A9 A24.1 A9.3
A*2404 A24(A9) - A24AK
A*2405 A24(A9) - A24New
A*2406 A24(A9) - A*24YM
A*2501 A25(A10) A25
A*2601 A26(A10) A26.1 A26.1 A26.3
A*2602 A26(A10) - A26.2 A26.1
A*2603 A26(A10) - A26.4
A*2604 A26(A10) - AlOSA
A*2901 A29(A19) A29.1 -
A*2902 A29(A19) A29.2 A29.2
A*3001 A30(A19) A30.3 A30.3
A*3002 A30(A19) A30.1 A30.2
A*3003 A30(A19) - A30JS
A*3004 A30(A19) A30.2 A30W7
A*31011 A3KA19) A31 A31
A*31012 A3KA19) A31 -
A*3201 A32(A19) - -
A*3301 A33(A19) A33.2 Aw33.1
A*3302 A33(A19) - Aw33.2
A*3303 A33(A19) - A33NC
A*3401 A34(A10) A34.1 -
A*3402 A34(A10) A34.2 -
A*3601 A36 - -
A*4301 A43(A10) • •
A*6601 A66(A10) A26.2 A66.1
A*6602 A66(A10) — A66.2
A*68011 A68(A28) A28.2 Aw68.1
A*68012 A68(A28) A28.2 Aw68.1
A*6802 A68(A28) A28.1 Aw68.1
A*6901 A69(A28) A28.1 -
A*7401 A74(A19) - -
A*8001 - - AXBG’
Table 1.1. List of HLA-A locus alleles adapted from 
(Bodmer, 1995). This table also Hsts the serological, lEF 
locus specificities. Serological types in brackets denote 
given specificity was spHt.
the 1995 WHO Nomenclature report 
and local names given to the HLA-A 
the broad specificities from which the
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unambiguous assignment of HLA specificities within the parameters of 
known HLA alleles.
1.2 Detection of polymorphism in HLA molecules.
1.2.1 Serological determination.
The HLA system was discovered through observations of agglutination of 
leukocytes with antisera taken from unrelated transfused individuals 
(Dausset, 1954). The original specificity found (Dausset, 1954) (Mac) was later 
to be known as HLA-A2. Similarly, specificities relating to Bw4, Bw6 (van 
Rood and van Leeuwen, 1963) were identified, followed by A1 and A3 
(Payne, et al. 1964) and this marked the unfolding of the polymorphic nature 
of the HLA system.
The ability to detect these antigens advanced through the use of the HLA 
specific antisera for complement mediated cytolysis of HLA expressing 
leukocytes (Terasaki, et al 1964; Bodmer, W.F. et al 1967; Kissmeyer, et al 
1969). This microlymphocytotoxicity assay became the standard approach to 
histocompatibility testing from the 1960s through four decades. The use of 
polyclonal antisera from transfused individuals, or more commonly from  
maternal blood (antisera present against paternal HLA determinants), 
provided the means for identification for the increasing polymorphism  
found within the HLA system.
As shown in figure 1.4, serological HLA typing (also known as the 
microlymphocytotoxicity assay), detects expressed HLA antigens through the 
specificity of antisera and their ability to initiate complement mediated 
cellular lysis. Cellular lysis, as detected through the uptake of an appropriate 
dye, confers the specificity of the typing antisera on the sample tested. A 
panel of well characterised antisera, is used to detect all known HLA 
specificities. The panel of antisera is incubated with seperated peripheral 
blood mononuclear cells in Terasaki plates. Complement is added to the 
cells and antisera, and the mixture incubated for a further period. Dye is 
added and a positive reaction with an antisera is detected through the 
diffusion of this dye into the lysed cell. If the antisera does not have
N
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specificity for the HLA expressed on the cell, then lysis does not occur and 
dye is not seen within the cell. Because of their polyclonal and crossreactive 
nature, many antisera are necessary in a typing panel and tissue type 
determined through reaction patterns.
Micro lymphocytotoxicity test
®  . ©  complement _ #
Figure 1.4. The components of the micro-lymphocytotoxicity assay are shown in this figure. 
Viable peripheral blood mononuclear cells (Class I) or separated B cells (Class II) are mixed 
with antisera of known HLA specificity. If antisera is bound to a cell (a), this mediates the 
activation of complement, which is added to the assay. Complement in the presence of the 
appropriate immunoglobulin class of antisera will puncture the cell (b). Dye can then enter 
the dead cell denoting a positive result (c), and this can be visually detected through an 
appropriate microscope. The absence of dye within the cell denotes a negative result and 
indicates the specificity of the antisera is different to that expressed by the cells tested.
Identification of HLA Class I antigens im proved as more antisera were 
tested against larger panels of antigens. Such serological characterisation 
uncovered more and more polym orphism  as initially characterised broad 
specificities were increasingly split. For example, at the HLA-A locus, HLA- 
A9 was spilt into A23 and A24, and HLA-A19 was split into A29, A30, A31, 
A32, A33, A74. Similarly HLA-B and HLA-C specificities were split th rough  
their reactivity w ith panels of antisera.
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Some of this characterisation was made easier through the use of 
homozygous typing cell lines. These cell lines which have hom ozygous 
haplotypes were obtained from individuals resulting from consanguinous 
marriages. The use of panels of such cell lines allows the specificity of 
multispecific antisera to be more readily distinguished.
Serological characterisation of antigens and antisera derived from different 
ethnic groups observed both new specificities and different antigen 
frequencies from populations previously investigated. Many such studies 
were organised through International Histocompatibility W orkshops. They 
provided a large number antisera which were tested against cell line panels 
collected from different populations. This exercise provided an extremely 
useful resource, since antisera and cell lines made available through the 
workshop were subsequently highly characterised. In addition, recent 
workshops have organised 'antigen societies' which intensively 
characterised groups of crossreactive HLA antigens. The antigen societies 
searched for novel specificities and identified any linkage disequilibrium  
prevalent with the antigens of interest. They also identified key antisera for 
identification of new specificities, together with their ethnic distribution.
Serology, particularly for Class I, remains the routine m ainstay m ethod for 
many histocompatibilty testing laboratories. Developments over the years, 
such as the use of two colour fluoresence (Bodmer, W.F. et al 1979), to m ore 
readily detect cell lysis, and varying degrees of autom ation, have allowed 
im provem ents in the basic method. HLA typing by serology does require a 
certain skill. The serologist needs to be aware of the specificity of the antisera 
in his typing panel, and be able to identify rare HLA specificities, which may 
not be immediately apparent from the reactivity obtained with a typing 
panel. Serology is handicapped by its reliance on viable cells. The lower the 
viability, the higher the background which makes detection of com plem ent 
m ediated cellular lysis more difficult.
Serology for Class II specificities (HLA-DR, -DP, -DQ) was developed at a later 
date (van Leeuwen, et al 1973; Ceppellini, et al 1974; Jones, et al 1975; 
Bodmer, J. et al 1976; Bodmer, J. 1978; van Leeuwen, et al 1982). HLA Class II 
antigens were discovered through observations made in the mixed 
lymphocyte test (Amos, et al 1971; Yunis, et al 1971; Mempel, et al 1972). This
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pointed to another component in the HLA system in addition to HLA-A, -B, 
-C. Identification of Class II specificities were then achieved th rough  
serological identification, using sera which had been treated w ith platelets 
(expressing Class I but not Class II) to remove the presence and so 
interference of the Class I component in the polyclonal antisera. The use of 
Class I negative cell lines such as Daudi (de Preval, et al 1983; Rosa, et al 
1983; Browning, et al 1995) provided additional inform ation as to the 
organisation of Class II and the understanding that more than one locus was 
involved (Bodmer, W. et al 1984). Further analysis through amino acid 
sequencing identified Class II molecules as heterodim ers comprised of an a  
and P chain. The genes for these chains are all found in the HLA cluster of 
genes on chromosome 6. In DR specificities, the polymorphic DRBl (and 
DRB3, DRB4 and DRB5) provide the p chain, and this complexes with the 
invariant a  chain (coded by the DRAl gene). Sequence polymorphism in DQ 
and DP can be seen in both a  and p chains.
The molecular analysis of HLA Class II provided the means for 
understanding serological observations. The interpretation of the specificity 
of antisera could be made in the context of antigenic sequence 
polym orphism  found within the HLA molecule. Hence an antisera w hich 
identifies a group of specificities may be detecting a polym orphism  com m on 
to their respective sequences. As the means to generate m onoclonal 
antibodies to HLA specificties became possible, a clearer picture emerged as 
to the epitopes the antibodies were detecting (Marsh, et al 1989).
The use of monoclonal antibodies in the field of histocompatibility testing 
prom ised a renewable source of monospecific reagents which w ould 
circum vent the problem of crossreactivity present in polyclonal antisera 
(Barnstable, et al 1978; Brodsky, et al 1979; Bodmer, J. et al 1989). H ow ever 
the cross-reactivity of antisera could partially be explained in another way, 
particularly with the increasing amount of sequence data available. 
Polyclonal antisera contain m ultiple specificities directed against different 
antigenic determinants on one or more of the im m unising HLA molecules. 
However, as discussed previously, most of these antigenic epitopes or 
'motifs' are not peculiar to a particular HLA specificity, but can be shared by 
several. For instance, a monoclonal antibody has been described which has 
specificity for A2 (but not A*0210) and A69 (Parham, et al 1981). The
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specificity of this monoclonal antibody can be interpreted by looking at the 
sequences of A2 and A69 alleles, with the epitope mapped to a tryptophan at 
amino acid position 107. This is at a position which is accessible for antibody 
detection. Therefore monoclonal antibodies which identify a single 
serologically defined HLA specificity are rare, and typing still relies on  
reaction patterns. But the level of crossreactivity is decreased, reducing the 
size of the typing panel and making interpretation easier. Typing plates 
using monoclonal antibodies have been compiled for Class I and Class II 
typing and are commercially available.
Serological identification of Class II has proved more difficult than Class I. 
Firstly, only the B cells and monocytes, which represent a small proportion 
of peripheral blood m ononuclear cells (PBMC), express HLA Class II. 
Therefore, to perform Class II typing, separation of B cells from the PBMC 
population requires a sufficient volume of blood. Alternatively, B cells can 
be immortalised through EBV transformation, but this does not represent a 
practical approach to routine Class II typing due to the length of time this 
procedure takes. Determining HLA Class II specificities by serology therefore 
has an added layer of complexity compared to typing Class I.
The difficulty in typing for HLA Class II through serological means provided 
the incentive for adopting new approaches to histocompatibility testing, 
namely through DNA analysis. Serological typing for Class I was however a 
more routine affair and there was no great pressure to find alternative 
means for typing. Also the lack of Class 1 alleles sequence data, prohibited 
the development of DNA based typing for these specificities.
Serological typing can only assess those epitopes accessible to antibody. 
Polymorphism not detected by serology was demonstrated by IFF analysis 
(Biddison, et al 1982) and through allo-reactive T cell discrim ination (Gotch, 
et al 1985). The latter showed that the resolution offered by serology was 
potentially inadequate as it failed to identify Class I specificities to the same 
level as T cells, with obvious implications for transplantation matching. To 
this end, additional methods of characterisation had to be considered.
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1.2.2 Biochemical detection of HLA expression.
One dimensional isoelectric focusing (lEF) (Biddison, et al 1982; Yang, 1989b), 
detects amino acid substitutions contributing to changes in charge of the 
HLA molecule. The radio-labelled (usually methionine) class I m olecule 
is im m unoprecipitated with an appropriate antibody. Electrophoresis is 
carried out on the im m unoprecipitate through a pH gradient. The 
immunoprecipitate will focus at a point appropriate to its charge, forming a 
band on an autoradiograph. An example of an IFF gel is given in chapter 6 
(figure 6.3).
The use of IFF for tissue typing has demonstrated a level of polymorphism 
beyond that observed in serological typing. Reports from International 
Histocompatibility workshops (Yang, 1989a) have listed IFF variants, 
identified their relative focal point and described any population and 
frequency data known. For example, five A2 IFF variants, four A24 variants, 
and four A30 variants have been identified. Increasing the resolution in the 
IFF can also show small differences in focal points, as described in  
characterisation of a new A2 IFF variant (Guttridge, et al 1992) later 
confirmed through DNA sequencing (Barber, et al 1994).
Unfortunately, IFF may not be used independently. It requires initial 
information from serology to allow interpretation of the focused bands. This 
is due to m any of the bands focusing in close proximity to each other. So 
although IFF typing fails to provide a clear and easy to interpret m ethod for 
tissue typing, it does provide an extension to serology, offering a further 
level of resolution. Variants not detected through serology can be clearly 
distinguished through IFF analysis. Identification of these variants allows 
their further characterisation through DNA sequencing, so that the 
relevance and nature of polymorphism can be assessed.
1.2.3 Typing through the specificity of T cell recognition.
Concurrent to observations being made using antisera with HLA specificity, 
it was also noted that lymphocytes from two unrelated sources when m ixed 
and cultured, would transform and proliferate (Hirschorn, et al 1963). This
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would not occur when the lymphocytes were obtained from HLA identical 
sib pairs (Bach, et al 1967). The proliferation noted in this mixed lymphocyte 
reaction (MLR) could be quantified through incorporation of radioactive ^H- 
thym idine into the proliferating cells. As illustrated in figure 1.5, the MLR 
was made easier to interpret through inactivation (using irradiation or 
Mytomycin-c treatment) of one of the stim ulator populations (Bach, et al., 
1966). Inactivated stimulator cells that had been well characterised for HLA 
specificities, could be used as typing cells. The use of homozygous typing 
cells as stimulators (Mempel, et al., 1973b), delivered a more concise result 
since only one HLA haplotype need be considered.
The MLR provided an initial technique for determ ination of HLA Class II 
specificities. Specificities identified in the MLR were denoted by the 'D w ' 
nom enclature (Bodmer, W.F. et al 1984) which later showed relation to the 
serologically defined 'DR' specificities (Jaraquemada, et al 1986). The MLR 
also provided a method for matching donor with recipient w hen  
considering transplantation. Studies have shown that serologically m atched 
unrelated individuals can produce a positive MLR (Mempel, et al 1973a). 
This indicates either that serology is insufficiently sensitive to perfectly 
match Class II specificities, or the presence of mismatches amongst other 
'm inor' histocompatibility antigens, not considered in the serological 
typing. The MLR was therefore capable of detecting functional 
polym orphism  not seen by serology. This polym orphism  identified in the 
MLR has been shown to be significant in terms of the survival of the graft in 
the transplant (Morishima, et al 1995). However, negative MLR may not 
indicate perfect matching, and these undetected mismatches may still 
contribute to the rejection of the graft (Tiercy, et al 1991; Fiermann, et al 
1992).
It was noted that the proliferating T cell clones produced in an MLR were 
capable of generating a substantive and rapid secondary response w hen  
repeatedly restimulated with the HLA antigenic determ inant against w hich 
they were raised (Sheehy, et al 1975). This observation was adapted into the 
prim ed lymphocyte test (PLT). Lymphocytes were cultured for 1-2 weeks in  
an MLR using HLA typed inactivated stim ulator cells. The resulting 
proliferative lymphocytes could be cloned through limiting dilution and 
used to type test cells. Proliferation of the PLT clones with the test cells
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would indicate the presence of the same HLA specificity as contained in the 
initial stimulating cell. PLT typing was useful for identifying and 
characterizing HLA-DF specificities (Morling, et al 1980).
One direction mixed lymphocyte reaction
Dw2 Dw3j
Dw2 matched 
no
proliferation
Dw2 L>w2
mismatch
irradiatedHTC 
stimulator cell
proliferation
Figure 1.5. The one directional mixed lymphocyte reaction detects polymorphism on the basis 
that mixing HLA mismatched cells will cause stimulation and proliferation of the cells, the
latter detected through incorporation of ^H-thymidine into the mitotic population. The 
assay can be described as one way, if one of the stimulator cells (of known HLA type), are 
prevented from proliferation through irradiation or mitomycin-C treatment. Use of HLA 
characterised homozygous typing cells (HTC) as the stimulator population further simplifies 
interpretation. In the examples given, the HTC fails to stimulate the Dw2 Dw3 cell through 
being matched at Dw2. However there is no match with the Dw3 Dw4 cell, allowing its 
stimulation and proliferation.
CTL clones can specifically recognise and kill a target cell expressing allo- 
antigen in the context of self-HLA (MHC restriction) (Zinkernagel and 
Doherty, 1974ab). Such CTL can be specific for viral or tum our antigens. In 
addition, allo-reactive CTL can also be generated in the MLR, which exhibit 
specificity for peptide bound to allo-HLA. These cells are produced th rough  
activation and expansion of a precursor CTL population found w ithin the 
unstim ulated lymphocyte population. The activated CTL can recognise allo-
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MHC directly, or indirectly whereby allo-MHC is processed and presented as 
peptide by autologous antigen presenting cells (reviewed in Hilton, et al 
19%).
Both the direct and indirect types of allo-response can be sensitive to HLA 
polymorphism , although this is slightly more marked for the self HLA 
restricted CTL. The generation of such CTL clones provide another 'reagent' 
for demonstrating and characterizing HLA polymorphism. Again, CTL 
assays can demonstrate polymorphism  not detected through standard 
serological approaches (McMichael, et al 1988; Castano, et al 1991; Rotzschke, 
et al 1992; Tussey, et al 1994). More recently, assays to estimate the precursor 
frequencies of cytotoxic T lymphocytes (CTLp) (Zhang, et al 1989) or helper T 
lymphocytes (HTLp), have been used to assess the potential response by the 
recipient to donor alio antigens. Determination of the precursor frequency 
provides another index by which polymorphism  can be detected. D ilutions 
of recipient cells can be cultured with donor cells to assess the precursor 
frequency. The precursor frequencies for the allo-reactive T cells is estim ated 
from the presence or absence of a proliferative, IL-2 or cytotoxic response 
within the context of the recipient cell concentration. A high precursor 
frequency indicates a mismatch in HLA specificity between the donor and 
recipient cells. Precursor frequency studies confirm that T cells can 
discriminate between closely related cross-reactive serological specificities. It 
also provides an indicator of mismatches between donor and recipient 
which predict rejection of a transplant graft and graft versus host disease 
(GVHD) in serologically matched unrelated-donor bone m arrow transplants 
(Kaminski, et al 1991).
CTLp can also be performed using HLA typed target or stim ulator cells. 
These can be cultured with limiting dilutions of responder cells, and the 
precursor frequency estimated. A low precursor frequency in the responder 
cells indicates the presence of the same HLA types as in the typed stim ulator 
cells, a high precursor frequency indicates HLA differences. Knowing the 
HLA type of the stimulator cell can be used to ascertain HLA similarities or 
differences in the responder cells through the specificity of the T cell.
The fine specificity of allo-reactive T cell clones demonstrates the functional 
significance of a level of polymorphism  not readily discriminated by
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serological typing. Failure to identify functionally significant m ism atches 
can cause m isinterpretation of cellular assays and increase the chance of 
rejection in transplantation. T cell clones can however cross-react and they 
may not make ideal typing reagents for this reason (van der Poel, et al 1986). 
However, the generation of proliferative and cytotoxic clones from  
apparently HLA matched stimulator cells, does provide an indicator of the 
inadequacy of a tissue typing method in not identifying a potentially 
significant polymorphic difference. These observations highlighted the 
requirem ent for attainm ent of a typing resolution similar to the 
discrimination of a T cell clone.
1.3 Molecular Biology; determination of polymorphism at the 
nucleotide level.
1.3.1 Introduction.
Analysis of HLA specificities from DNA provided a different approach to 
defining their polymorphic differences. Rather than looking at differences 
in the expressed molecule, polymorphism is characterised at the genetic 
level. DNA based methods hold particular advantages over serological 
means of identification. There is no need to rely on viable cells. Reagents are 
renewable and there is increased potential for standardisation. Recent 
International Histocompatibility W orkshops have been instrum ental in  
encouraging developm ent and im plem entation of new typing techniques 
and providing a forum for their standardisation.
The feasibility for development of DNA typing techniques was facilitated by 
the increasing num bers of HLA alleles which had been sequenced. In 
general terms, the development of DNA typing Class I alleles has 
encountered greater problems than those experienced for Class II. One 
reason for this can be explained in comparing the nature of polym orphism  
between Class I and Class II. Polymorphism within Class II is contained 
mainly w ithin defined hypervariable regions in exon 2, m aking 
differentiation between alleles readily achievable through hybridisation 
with the relevant probe. This situation is more complex in Class I alleles. 
Hypervariable regions are found to different degrees in both exon 2 w hich
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encodes the alpha-1 domain and exon 3 which encodes the alpha-2 dom ain, 
(figures 1.6 and 1.10). These two domains form the peptide binding groove 
of the Class I molecule. Most Class I alleles cannot be differentiated from  
each other by a particular motif at a particular location in the sequence, but 
rather the polymorphic differences along the whole length of sequence has 
to be considered, particularly in exons 2 and 3. This is because, at any 
particular point of polymorphism , the sequence motif may be shared w ith  
not only other alleles w ithin the same locus, but also alleles of other loci 
and pseudogenes. To identify a Class I specificity by PCR-SSOP therefore 
generally requires the use of m ultiple probes, increasing the complexity of 
hybridisation patterns. Further to this, DNA typing Class I lagged behind 
Class II, because of the lack of sequenced alleles and the perceived 
convenience in performing Class I serology.
HLA class I heavy chain gene
JIL
\
__________  VI VII __________  a e n e
4  IV V 3 ’ut
v  f  A # "  ' '
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p ro te in
HLA class II a -  and p-chain genes
J II b s s j  III bs
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Figure 1.6 The genomic organisation of HLA class I and class II genes and the polypeptide 
domains of the HLA molecules they encode, (ss = signal sequence, tm = transmembrane domain, 
ic = intracellular domain, 3'ut = 3' untranslated region).
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1.3.2 R estriction  fragm ent len g th  p o lym orp h ism  (RFLP) an a lysis.
Initially, molecular biological approaches did not have sufficient 
inform ation to design highly definitive DNA typing approaches. Because 
only a few HLA specificities had been sequenced, analysis of DNA was an 
extension of other approaches. One such method was the use of restriction 
fragment length polymorphism  (RFLP) (Moller, et al 1985; Hongming, et al 
1986; Inoko, et al 1986; Sheldon, et al 1986; Tilanus, et al 1986; Bell, et al 1987; 
Bidwell, et al 1987; Bodmer, J. et al 1987; McDaniel, et al 1987; Bidwell, et al 
1988; Hyldig, et al 1988; Lin, et al 1989; Segurado, et al 1990; Dormoy, et al 
1992). This method relies on the use of panels of restriction enzymes to 
digest DNA at specific sequence sites. The resulting digest is then run on a 
gel to separate the different sized DNA fragments. This is then Southern  
blotted onto a membrane and hybridised with a Class I or Class II specific 
labeled probe. Bands are then detected on an autoradiograph. The size and 
pattern of banding with different restriction enzymes and different HLA 
probes is used to determine the HLA specificity.
The size and pattern of bands identified by the HLA probes is a product of 
the specificity of the restriction enzyme. This in turn is determined by the 
polym orphism  in nucleotide sequence present between different HLA 
specificities. The method therefore relies on such differences being at sites 
which can or cannot be cut by the different restriction enzymes. Analysis of 
the band patterns can be difficult, especially if the probe used is not 
particularly specific, or the enzyme does not define any useful 
polym orphism .
RFLP analysis of DNA has been useful in determining polym orphism  at a 
time when very few HLA alleles had been sequenced. RFLP was not 
straightforward to perform. Each typing required a panel of enzymes w hich 
did not necessarily provide unequivocal determ ination of HLA specificity. 
The method was mainly applied to HLA Class II analysis with Class I RFLP 
analysis being considered difficult with no advantage over serology or lEF. 
Methods using the polymerase chain reaction (PCR), were being developed 
which allowed analysis of DNA to identify HLA specificities through known 
sequence polymorphism. The use of RFLP as it stood, was quickly negated by
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these developments, as it provided no real information in terms of DNA 
sequence.
As discussed below, PCR allowed the specific amplification of regions of 
DNA for further analysis. To this end RFLP analysis has been applied to 
HLA PCR product (Maeda, et al 1989; Loiseau, et al 1991; Yunis, et al 1991; 
Hviid, et al 1992; Salazar, et al 1992; Tanaka, et al 1992; Lee, et al 1994; 
Medintz, et al 1994). The specificity of the PCR replaces the need for 
hybridisation with a HLA specific probe. Because many of the sequences of 
HLA alleles were known, enzyme restriction sites could be found within the 
PCR product at sites of polymorphism. This has allowed clearer 
interpretation of PCR-RFLP typing since it is w ithin the context of know n 
sequence. The combination of specific PCR with RFLP has been successfully 
used in several studies.
1.3.3 P olym erase C hain  R eaction.
The polymerase chain reaction (PCR) has been an im portant and pow erful 
development in the field of molecular biology (Saiki, et al 1985; Mullis, et al 
1986; Mullis, et al 1987). It allows specific amplification of stretches of DNA 
sequence through repeated cycles consisting of DNA dénaturation, 
annealing of specific prim er to the DNA single strand followed by 
nucleotide extension from the primers using a thermally stable enzyme. 
PCR allows small am ounts of DNA to generate substantial quantities of 
specifically amplified regions of DNA which can then be used in fu rther 
analysis (Bell, 1989). Hence in tissue typing, the PCR reaction was used to 
specifically amplify the polymorphic regions of HLA genes. This HLA PCR 
product could then be analysed for its polymorphic differences which w ould 
establish the tissue type. Tissue typing by the two step approach of specific 
PCR amplification followed by detection of polym orphism  has been 
described in a num ber of approaches. These include the use of PCR in  
combination with sequence specific oligonucleotide probing (PCR-SSOP) 
(Saiki, et al 1986), probing by reverse dot blot (Saiki, et al 1989), sequencing of 
the PCR product or sequence based typing (SBT) (Santamaria, et al 1992), 
heteroduplex analysis of PCR products (Clay, et al 1994), single stranded 
conformational polym orphism  analysis of the PCR product (PCR-SSCP)
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(Yoshida, et al 1992). Typing is also performed in a one-step PCR using 
sequence specific primers (Olerup, et al 1991). These approaches, used singly 
or in combination, have all been applied as DNA based methods for tissue- 
typing Class I and Class II HLA specificities.
1.3.4 Sequence specific oligonucleotide probing of PCR product (PCR-SSOP).
One initial and still popular m ethod of DNA typing is the use of sequence 
specific oligonucleotide probes (SSOP) for detection of polym orphism  
within PCR amplified regions of HLA genes (figure 1.7). Initial PCR 
amplification of hypervariable regions of the HLA genes (e.g. exons 2 and 3 
of the HLA-A, -B, -C genes and exon 2 of the DRBl genes) provides a 
template which can be probed w ith labeled oligonucleotides which have  
specificity for particular sequence polymorphisms. Panels of these probes 
(SSOP) can then be used to identify which polymorphisms are present in the 
amplified DNA.
PCR-SSOP
detection
labelled SSOP amplified DNA
nylon membrane
Figure 1.7. PCR-SSOP describes the probing of specifically PCR amplified DNA w ith 
labelled sequence specific oligonucleotides. PCR amplified DNA is fixed to a nylon membrane 
through UV cross-linking. Labelled probes are then hybridised with the DNA on the 
membrane. The membranes are then washed to an appropriate stringency, to remove any false
hybridisation. Detection of hybridisation is through the labelled probe. With ^^P labelled 
radioactive SSOP, the hybridised membrane is exposed on an autoradiograph film. This is 
also true for chemiluminesence, in which the label can be reacted to emit light, which is 
detected on film. Chromogenic detection involves mainly biotin labelled probes which bind 
with a streptavidin/horseradish peroxidase ligand, the latter can then react with an 
appropriate substrate, causing a colour change to indicate hybridisation on the membrane.
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Tissue typing by PCR-SSOP relies mainly on a pattern of hybridisation 
reactivity. This is to some extent hampered by the lack of polym orphism  
unique to a particular allele, and the more common presence of 
polym orphism  shared amongst groups of specificities. W hat makes a 
particular HLA allele unique is the combination of these shared sequence 
polym orphism s along the length of the gene. The potentially complex 
patterns of detected reactivity may require detailed analysis to assign 
specificities, and certain heterozygous combinations may prove problematic 
to distinguish, as in most cases, both alleles at a HLA locus are 
simultaneously amplified in the PCR.
Interpretation of hybridisation patterns becomes more complex in relation 
to the lack of specificity within the PCR. A broadly specific PCR product 
requires an extensive panel of probes to differentiate between all the 
potential alleles amplified. This situation can be simplified th rough  
reducing the number of different alleles amplified, by introducing specificity 
into the PCR reaction.
Methods for PCR-SSOP typing therefore rely on a fairly specific PCR 
amplification which contains the hypervariable regions for probing. This 
may be a locus specific or even allele group specific amplification. This PCR 
product is then blotted onto a suitable membrane support and im m obilised 
(UV crosslinked). Using an appropriate means of blotting, many sam ples 
can be loaded onto a single membrane. The membrane can then be probed 
with a labeled oligonucleotide under the required hybridisation conditions. 
Detection initially involved exposure of the membrane hybridised w ith  
radiolabeled probe onto an autoradiograph. To obtain a typing therefore 
requires m ultiple blotted membranes and m ultiple hybridisations, even  
though a membrane can be stripped of one probe and re-hybridised w ith  
another. Because typing required hybridisations with a panel of probes, a 
relatively large am ount of radioactivity was used and so other n o n ­
radioactive methods of labeling have been considered.
A num ber of non-radioactive detection methods have now been developed. 
These include labeling the probe with biotin, which can then be detected by a 
colour change through use of a streptavidin/horseradish peroxidase 
conjugate (Bugawan, et al 1994). Other methods of probe labeling include the
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use of digoxigenin-ll-ddUTP (DIG), (Boehringer-M annheim, Germany). 
Detection is through the use of an anti-DIG antibody conjugated to alkaline 
phosphatase. The DIG - anti-DIG complex can then be detected through the 
ability of the alkaline phosphatase to generate chem ilum inesence w ith the 
appropriate substrate (Yoshida, et al 1992; Cereb, et al 1995).
PCR-SSOP Class II typing. PCR-SSOP was first applied to HLA Class II alleles, 
made possible through the availability of sequenced alleles. Initial studies 
concerned with typing HLA DQ specificities quickly spread to DR specificities 
as more sequence information became available. PCR-SSOP HLA Class II 
typing was applied to forensics studies (Higuchi, et al 1988) and disease 
association (W ordsworth, 1991; Hill, et al 1992) and histocom patibility 
matching for transplantation (Tiercy, et al 1989; Tiercy, et al 1991) 
Consolidation and standardisation of methods for PCR-SSOP typing 
happened through the 1991 International Histocompatibility W orkshop 
(Kimura, et al 1992), which provided the forum for introduction of DNA 
based typing to histocompatibility laboratories worldwide. Participants in the 
workshop typed DRBl, DRB3, DRB4, DRB5, DQAl, DQBl, DPAl, DPBl Class 
II loci using standard reagents and PCR-SSOP protocols. Around 120 probes 
were used in the study by about 132 laboratories. Each laboratory was 
expected to type around 100 individuals. The use of a large num ber of probes 
necessitated a computer program to interpret the complex hybridisation 
patterns possible through this typing. The success of Class II typing by this 
method and experience gained, provided the incentive for fu rther 
im provem ents, particularly to detect through non-radioactive means and 
improve sample handling.
Although a method for non-radioactive detection was offered through the 
workshop (Kimura and Sasazuki, 1992), the majority of typing was done 
using 32p labeled probes. The use of radiation was a problem for rou tine  
typing laboratories. Methods involving biotin labeled probes w ith  
subsequent colour detection (Erlich, et al., 1991a), or chem ilum inesence 
using DIG labeling (Giorda, et al 1993; Chen, et al 1994; Cereb, et al 1995), 
have all been described and successfully incorporated into routine typing 
situations. PCR-SSOP has been described in microtitre plates. Each well 
contains a piece of DNA dotted membrane so allowing m ultip le  
simultaneous hybridisations and non-radioactive detection to be perform ed
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across the plate (Garcia, et al 1995). Many histocompatibility laboratories 
have adopted the PCR-SSOP approaches described, influenced by difficulties 
in performing serological identification of Class II specificities and the 
resolution possible by DNA based methods.
PCR-SSOP Class I typing. HLA Class I PCR-SSOP has been developed in the 
wake of Class II. As already mentioned, this was partly because of the lack of 
sequence data for Class I alleles, but also because many workers were content 
with the continued use of serology. With sequence inform ation becoming 
available over recent years, the application of DNA based typing m ethods to 
Class I typing became possible. The sequencing of increasing num bers of 
Class I alleles made clear that serology lacked the sensitivity to differentiate 
between certain specificities. For this reason, specificities such as the variants 
of HLA-A2, -A68 (Fernandez-Vifia, et al 1992; Tiercy, et al 1994), or 
differentiating HLA-B35, and B53 (Allsopp, et al 1991; Hill, et al 1992) became 
the subject of Class I typing developments. With the realisation that PCR- 
SSOP could work for Class I, more general protocols started to emerge, 
describing broader typing for a particular locus. Hence PCR-SSOP m ethods 
have now been described for typing the HLA-A locus (Oh, et al 1993; Gao, et 
al 1994), the B locus (Yoshida, et al 1992; Fernandez-Vina, et al 1995; 
Middleton, et al 1995) and C locus (Levine, et al 1994).
Methods for typing have had to address the shared nature of sequence 
polym orphism  found amongst HLA Class I alleles and the complex 
hybridisation patterns they potentially generate. The daunting complexity of 
interpreting hybridisation patterns obtained from probing a broadly specific 
Class I PCR product has made a level of specificity w ithin PCR am plification 
a prerequisite for PCR-SSOP typing these alleles. As an example, a m ethod 
for typing HLA-B uses five specific amplifications which divide the B locus 
alleles into manageable and interpretable groups for probing (Fernandez- 
Viha, et al 1995). The PCR product to be probed m ust include all the 
polymorphic sites necessary for determ ination of tissue-type. This usually 
entails amplification of exons 2 and 3 which code for the alpha-1 and -2 
domains of the Class I molecule, using primer sites which specifically 
amplify the alleles of interest. Hence for the A locus, specific PCRs that 
amplifies all or most of exons 2 and 3 have been described (Oh, et al 1993; 
Allen, et al 1994).
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At the B locus, the level of polymorphic complexity required added 
specificity in the PCR amplification. In an early method (Yoshida, et al 1992), 
the B locus was split into two PCR groups as determined by whether they 
contained the sequence coding for the Bw4 or Bw6 public epitopes. 
However, the region of the B locus alleles amplified, consisted of only half 
of exon 2, and many useful polymorphisms in exon 3 were excluded. This 
protocol has been improved by the inclusion of additional prim er 
combinations that amplify across polymorphisms in exon 3 (Middleton, et al 
1995). This allows many more polymorphisms to be tested, so enhancing the 
specificity and resolution of the method. A higher resolution system has 
also been described (Fernandez-Viha, et al 1995), in which an initial PCR 
screen determines which of 5 specific PCR reactions are used for probing. 
The appropriate PCR can then be performed and probed with the required 
set of oligonucleotides as required for the specificities amplified. The use of 
specific PCR which divides alleles into manageable groups for probing 
seems to be the route through which high resolution typing is achieved by 
PCR-SSOP. The combination of the described methods at the different loci, 
has allowed for general PCR-SSOP Class I DNA typing.
1.3.5 T he reverse dot-b lot approach to PCR-SSOP.
In parallel with developm ent of the above conventional PCR-SSOP, a 
variation of the method known as the 'reverse dot blot' has also been 
described (Saiki, 1989). This is the reverse of the conventional PCR-SSOP 
approach since the oligonucleotide probes and not the amplified DNA, are 
immobilised onto the membrane (figure 1.8).
The labeled PCR product can then be sim ultaneously hybridised against all 
the probes bound on a single membrane. This innovation, available as a kit, 
has been widely used. It means that an individual can be typed quickly 
through one hybridisation event, rather than the lengthier conventional 
PCR-SSOP methods.
The raw data obtained by reverse dot blot is the same as conventional PCR- 
SSOP. It therefore may contain complex hybridisation patterns w hich 
require the aid of an appropriate computer program for their interpretation.
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The format of the m embrane, on which positives are identified by a colour 
change, can be quickly entered or even now scanned onto the com puter 
which then determines the tissue type. This method is currently limited to 
Class II typing (Saiki, et al 1989; Erlich, et al 1991a) with Class I typing only 
recently being attem pted (Bugawan, et al 1994). However, the success of 
conventional PCR-SSOP methods should mean in theory that the reverse 
dot blot approach should also be feasible for complete Class I typing, and this 
is currently under development.
Reverse dot blot
detection
/  L  labelled
amplified DNA
SSOP
nylon membrane
Figure 1.8. The reverse dot blot is an alternative technique to PCR-SSOP. Instead of DNA 
being fixed, the SSOP is immobilised onto the membrane. This has the advantage that a 
several different SSOP hybridisations can be performed simultaneously cn the same 
membrane, hence allowing a sample to be typed in one go. Detection is through a labelled 
primer in the initial PCR reaction. The labelled PCR product, bound to the SSOP on the 
membrane, can then be detected usually through a chromogenic approach.
A variation of the reverse dot blot is immobilising probes in m icrotitre 
plates rather than nylon membranes. An advantage of using the m icrotitre 
plates is the array of dedicated equipm ent available for use w ith the format. 
In addition, detection of hybridisation can be performed in an appropriate 
plate reader. Detection in plates therefore makes semi or fully autom ated 
HLA typing possible. The use of microtitre plates to perform the reverse dot 
blot has been reported by a num ber of groups for typing HLA specificities 
(Giorda, et al 1993; Kawai, et al 1994).
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1.3.6 PCR-SSP.
An alternative and subsequent method of typing to PCR-SSOP, is the use of 
sequence specific primers (SSP) in panels of PCR reactions (PCR-SSP), each 
reaction identifying a particular HLA specificity or group of specificities. As 
with the reverse dot blot, PCR-SSP offered an individual sample to be typed 
completely in one step, rather than the multiple hybridisations necessary for 
conventional SSOP procedures. In effect, PCR-SSP removes the need for 
probing a broadly specific PCR product by making the PCR am plification 
highly discriminatory. To achieve this level of specificity, SSPs were 
designed on the basis of the amplification refractory m utation system 
(ARMS) approach (Newton, et al 1989). This entails matching the 3' end of 
the primer w ith the sequence polym orphism  it is required to detect. A 
mismatch at the 3' end of the SSP with the target sequence will under the 
correct conditions, inhibit amplification by disrupting the Taq enzym es 
ability to successfully read through and extend past the primer sequence 
(figure 1.9). The correct conditions rely on stringency, which is determ ined 
by the composition of the reaction mix and the annealing tem perature in  
the PCR amplification program.
Using ARMS for specificity in PCR-SSP.
3' match
CIS strand L/INIA
ssp
no extension
trans strand DNA t ssp 
3' mismatch
HLA types. This is achieved through ARMS, in which a 3' mismatch with the SSP inhibits 
amplification. For amplification to occur under the appropriate PCR stringency, both SSP’s 
need to matched at their 3' residues for amplification to occur. Hence in the figure, although 
the SSP binding to the cis DNA strand is matched, and extension is possible, a 3' mismatch cn 
the SSP binding to the trans strand inhibits extension, so causing the PCR reaction to fail.
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All the PCR reactions in a typing panel are performed simultaneously under 
the same amplification conditions. This is achieved through design of the 
SSPs to have similar melting tem peratures (Thein, et al 1986). This allows 
each PCR reaction in the typing panel to behave comparably under the 
similar levels of stringency. To identify the tissue type requires a panel of 
PCR reactions with each reaction specific for a particular HLA specificity. A n 
internal control amplification is included in each PCR to avoid 
m isinterpretation due to false negative PCR failure. Following the PCR, 
products are visualised on an agarose gel and the tissue type determ ined by 
the presence or absence of the appropriate bands in the appropriate lanes. 
The ease of interpretation of PCR-SSP typing is a major advantage of this 
approach. A more extensive description of the design of PCR-SSP reactions 
is given in chapter 3.2.2.
Multiplex PCR-SSP has also been investigated in which a panel of typing 
reactions is compressed, with more than one specific reaction present per 
reaction mix (Browning, et al 1994). Each individual SSP combination needs 
to produce a product which can be separated from its 'room -m ates' on the 
basis of size. Further to this, all the SSPs used in a reaction mix m ust be 
compatible with each other to avoid inappropriate cross-priming and 
amplification in the presence of certain HLA sequences. This problem does 
have major implications since a newly identified HLA allele may interfere 
with the specificity of a multiplex typing panel and so require its redesign.
Class II PCR-SSP typing. The use of PCR-SSP for HLA typing, was first 
described for Class II specificities (Olerup and Zetterquist, 1991; Olerup and 
Zetterquist, 1992; Zetterquist, et al 1992; Olerup, et al 1993). An im portan t 
study was the description of typing HLA-DR through analysis of sequence 
polym orphism  located in exon 2 of the DRBl alleles. Additionally, DR52 
and DR53 were determined through analysis of DRB3 and DRB4 loci. The 
study demonstrated the ability to DR type using a panel of sim ultaneously  
performed PCR reactions run under the same amplification conditions. SSP 
identifying polymorphism at the 5' region of exon 2 are combined w ith SSP 
identifying polym orphism  in the hypervariable region at the 3' end. The 
SSP combinations in the DRB typing paper produced product varying from  
130-260 base pairs in length (Olerup and Zetterquist, 1992). The advantage of 
knowing the priming site of each SSP is that the resulting PCR product will
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be of an expected size. This ensures that bands of an inappropriate size can 
be ignored. Development of PCR-SSP spread to typing at other Class II loci, 
namely DQ (Bunce, et al 1993; Olerup, et al 1993) and DP (Knipper, et al 1994) 
specificities.
Reports were made of complete DR typing, from blood to result, in 2 hours 
(Olerup, et al 1993). One perceived limitation of PCR-SSP is its n o n ­
suitability for large scale typing as compared to PCR-SSOP. This is m ainly 
due to restriction in sample handling and equipment, especially if PCR 
reactions are performed in individual tubes. However, sample th roughpu t 
has im proved especially through the use of microtitre plates and the 
associated technology.
HLA Class I PCR-SSP typing. Identification of Class I alleles by PCR-SSP 
followed Class II through the restriction of available sequence data. 
Problems were envisaged due to the complexity of polym orphism  defining 
Class I alleles as compared to Class II, especially since these are present 
mainly in two exons rather than one as in Class II typing. In someways the 
nature of polym orphism  between HLA alleles suited PCR-SSP typing. The 
patchwork nature of polymorphism  within hypervariable regions (figure 
1.10), where sequence motifs may be shared between alleles of the sam e 
locus, other loci and pseudogenes, means that in many cases, more than one 
polymorphism has to be identified to ascertain the presence of an allele.
The PCR-SSP assay can to some extent address this problem, through the 
specificity of both SSPs in the PCR reaction. The main polym orphism s 
governing identification of these Class I specificities are found in exons 2 
and 3 of the nucleotide sequence. Hence amplification was performed using 
one SSP in exon 2 in combined with another in exon 3, the product from  
which included the intervening intron when performed from genomic 
DNA. In certain cases, polymorphisms present in exons 1 and 4 have also 
been used for PCR-SSP typing (Bunce, et al 1994; Bunce, et al 1995a; Krausa, 
et al 1995a).
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The contribution of this thesis to the developm ent of PCR-SSP typing at 
HLA-A locus will be discussed more extensively in the following chapters. 
Similar approaches were being applied to typing at HLA-C (Bunce, et al 
1994). Identification of HLA-B alleles (Guttridge, et al 1994; Sadler, et al 1994) 
followed those described at the other loci, mainly due to the highly 
polymorphic and complex nature of this gene. Having dem onstrated the 
feasibility of identifying Class I specificities, further im provem ent in  
resolution were made (Krausa, et al 1993; Bunce, et al 1994; Bunce, et al 
1995a; Krausa, et al 1995a; Krausa, et al 1995b), showing that at each 
particular locus typing could well exceed that achievable through serology.
The advantages of PCR-SSP Class I typing over serology was really 
emphasised by the easy discrimination of HLA-C locus specificities. In 
performing HLA-C locus PCR-SSP typing, it was obvious that serology was 
subject to missing or misassigning HLA-C locus specificities. This has always 
been a weak-point for serology, due to the low expression of HLA-C on the 
cell surface, and crossreactivity of antisera. The ability to type for HLA-C 
locus alleles, including identification of certain C locus 'blanks' underlined  
the worth of DNA based typing.
HLA Phototyping. With improved resolution being shown also at the HLA- 
B locus (Bunce, et al 1995a), PCR-SSP typing had been adequately 
demonstrated at all the major HLA loci (Bunce, et al 1993; Olerup, et al 1993; 
Bunce, et al 1994; Bunce, et al 1995a; Krausa, et al 1996). It seemed a 
reasonable progression to combine all these published typing panels into a 
single integrated system. An obvious consequence of this was the problem  
of sample handling and performing the typing, if a large num ber of PCR 
amplifications have to be run simultaneously and loaded onto a gel for 
interpretation. The use of a 96 well microtitre plate for PCR provided a 
solution to this problem. The use of multitrack pipettes allowed samples to 
be quickly loaded onto a typing plate, and following amplification loaded 
onto a multitrack compatible gel apparatus. Moving away from reaction 
tubes to reaction plates greatly improved PCR-SSP as a technique and 
allowed a format, on which sim ultaneous typing at all the loci could be 
performed. The availability of a 192 well plate with compatible PCR 
machine has further improved the PCR-SSP typing procedure.
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This m ultiple locus PCR-SSP typing procedure, known as 'phototyping ' 
(Bunce, et ak, 1995b) provides a complete DNA based alternative to serology, 
allowing Class I and Class II typing to be performed simultaneously. The 
method describes 144 PCR reactions covering HLA-A, -B, -C, DRBl, DRB3, 
DRB4, DRB5 and DQB loci (figure 1.11). DNA plus reaction mix are 
distributed across the typing plates preloaded with the prim er mixes and, 
following amplification, the whole reaction panel visualised on one gel. 
Tissue type is then interpreted dependent on the pattern of reactivity w ith  
the reaction panel. As with any other DNA based typing approach, the 
publication of new sequences has to be scrutinised and the change in  
specificity of the reaction panel noted, with new or replacement reaction 
combinations added as appropriate.
wm-m
Figure 1.11. An example of an HLA PCR-SSP phototype. 144 PCR-SSP reactions are run 
simultaneously, encompassing HLA-A, -B, -C, -DRBl, -DRB3, -DRB4, -DRB5 and -DQBl 
genes. Interpretation is reached through the presence or absence of the appropriately sized 
bands for each reaction following agarose gel electrophoresis. The common band present in 
each lane represents an internal control, which validates the PCR conditions. The sample 
types as A*03 (3) A*2301 (5,6) Bw4 (26) Bw6 (27) B*38 (47, 48) BH518 (70, 71, 72) Cw*04 (85) 
Cw*0704 (92) DRBl=^0301/4 (109, 110, 126) DRBl'^04 (112) DRB3“^0201 (132, 133) DRB4=^01 
(134) DQBl’^ 02 (137) DQB1*0302 (143). The figures in brackets denote the reaction number 
defining the specificity. (Reproduced by permission of M. Bunce, Oxford)
The publication of a comprehensive PCR based system for defining Class I 
and Class II HLA specificities has prom pted the view that DNA approaches
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will soon replace serology as the main means for assigning tissue types 
(Dupont, 1995).
1.3.7 Heteroduplex analysis and conformational polymorphism.
Another approach to identifying HLA polymorphism , is th rough  
heteroduplex analyses (Clay, et al 1991; Rubocki, et al 1992; Sorrentino, et al 
1992; Sorrentino, et al 1992; Sorrentino, et al 1993; Clay, et al 1994; Oka, et al 
1994; Uhrberg, et al 1994). In the PCR, it is possible that single stranded DNA 
may re-anneal with an inappropriate strand to form a heterodim er or 
rem ain single stranded. Such events produce conformationally distinct 
structures which can be differentiated by their electrophoretic mobilities, 
and be useful in identifying HLA polymorphism.
Generation of PCR heteroduplexes have been used in matching HLA-DR 
specificities (Clay, et al 1991; Sorrentino, et al 1992) together w ith HLA-DQ 
(Rubocki, et al 1992), and HLA-DP (Sorrentino, et al 1992; Sorrentino, et al 
1993; Clay, et al 1994). To enhance the discrimination offered by such 
analyses, an artificial single strand has been used, described as the un iversal 
heteroduplex generator (UHG) (Clay, et al 1994). This is a single strand of 
DNA containing engineered sequence polymorphism s in significant 
hypervariable regions. The PCR product can be denatured, reannealed w ith  
the UHG, with the resulting heteroduplex analysed in a more defined 
m anner.
Heteroduplex analyses have obvious application for crossmatching in  
transplantation, although they do not identify the HLA type of donor and 
recipient. Mismatches can be determined by re-annealing donor and 
recipient amplified PCR product, specific for the particular required HLA 
region. Mismatches can then be detected through the differential m igration 
of heteroduplex as compared to hom oduplex PCR product th rough  
nondenaturing polyacrylamide gels.
The use of single stranded conformational polym orphism  of PCR product 
(PCR-SSCP) is a further method used in typing. The electrophoretic mobility 
of single stranded DNA, under appropriate conditions, can be used to
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discriminate between HLA alleles containing different polymorphisms. This 
approach has been applied to identifying HLA Class II (Shintaku, et al 1993) 
and HLA-B specificities (Yoshida, et al 1992).
1.3.8 Sequence based typing.
The full extent and complexity of HLA polym orphism  can only be 
definitively explored through DNA sequencing. Even though m ethods such 
as PCR-SSOP and PCR-SSP offer high levels of resolution, they are lim ited 
within the context of testing for known sequence polymorphism. The use of 
heteroduplex or conformational polymorphism  can only identify the 
existence of differences, not their exact nature in terms of sequence. 
Therefore the only definitive means of detecting such differences is DNA 
sequencing the region of interest, and identifying all the relevant 
polymorphisms. Although a great deal of polym orphism  seems to be 
conserved and shared amongst several alleles at given hypervariable 
regions, unique polymorphic differences can exist, and these are not always 
within the confines of known hypervariable regions.
DNA sequencing (Sanger, et al 1977) can be a lengthy and labour in tensive 
procedure, and in this form, unsuitable for routine tissue-typing. 
Innovations in DNA sequencing, particularly with the arrival of autom ated 
sequencing, has provided the means for rapid analysis of HLA 
polymorphism, and so making sequence based typing (SBT) a possibility.
Initial reports of SBT were for Class II (Santamaria, et al 1992), typing for 
DRB, DQA and DQB. Four PCR reactions are performed for DRB, one 
reaction for DQAl and one reaction for DQBl. The four DRB PCR reactions 
can then sequenced with a general DRB primer. Three other sequencing 
reactions using more specific primers provide the sequencing inform ation  
necessary for discrim ination of DRB heterozygote combinations by 
preferential amplification of DRBl over DRB3/4/5. For DQA and DQB each 
have a potential of two alleles per sequencing reaction. A lthough this 
approach showed the potential for HLA Class II typing for sequencing, it was 
still difficult to perform routinely. A similar approach was applied to Class I, 
in which two specific sequencing reactions were performed for each of the
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HLA-A, -B and HLA-C loci (Santamaria, et al 1993). Class I and Class II typing 
could potentially be performed using SBT. Im provem ents in the m ethod  
have already been made, particularly in using fluorophor labeled 
sequencing primers in conjunction with an automated sequencer (Versluis, 
et al 1993) and the use of magnetic beads as a sequencing solid support 
(Spurkland, et al 1993). Such approaches allow a larger throughput of 
samples, and potentially increase the generation of sequence inform ation  
per reaction as compared to previous methods. Additionally, SBT has also 
been described for HLA-DP (Rozemuller, et al 1993).
Polymorphism not detected through methods such as PCR-SSOP and PCR- 
SSP, can be seen through SBT. Hence, previously unidentified alleles have 
been described (Santamaria, et al 1992; Santamaria, et al 1993), although the 
possibility of sequencing errors must also be considered (Domena, et al 1994). 
SBT provides the most information as compared to other DNA based typing 
methods. It does have limitations in the complexity of its performance and 
the requirem ent for expensive automated equipment. But as the facilities 
for doing such automated sequencing improve, SBT may soon be a rou tine  
technique for HLA typing and other im portant clinical indicators. The 
clinical relevance of typing at this resolution may well decide w hether SBT 
is adopted as the method of choice.
1.3.9 Hybrid methods.
Many of the approaches described above can be used together in a 
complimentary fashion to elucidate the HLA type. The most com m on 
current combination of methods is to use serology for determ ination of 
Class I and a DNA based method for Class II. However, the recent advances 
and progress made in DNA based approaches, have greatly increased the 
choices available for tissue typing both Class I and Class II specificities. 
Additionally, different methods have been used together for determ ination  
of HLA type. Such developments reflect awareness of the capabilities of the 
different methods and how the specificity of one can provide the means for 
detection by another. Combining methods is usually indicative of the 
requirem ent for a high resolution of typing. Llence, using a highly specific 
PCR-SSP provides the material for analysis by SSOP, RFLP, SSCP,
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heteroduplex or even another round of PCR-SSP as discussed in nested 
PCR-SSP. As an example, HLA-B alleles were divided by specific PCR into  
Bw4 or Bw6 products which were then hybridised by SSOP with additional 
information attained through SSCP analysis (Yoshida, et al 1992).
1.4 The context of this thesis.
This thesis presents some of the groundwork and developm ents made for 
DNA based approaches to Class I typing. This project was initiated at a tim e 
when Class I DNA typing was not seriously considered, and no real attem pts 
had been made into this area. At this time, DNA typing was applied m ainly 
to Class II specificities, and performed by PCR-SSOP.
W ith no available method for HLA Class I, this thesis aimed to develop a 
rapid, simple, easy to interpret, non-radioactive, highly definitive HLA-A 
locus typing system by PCR amplification of specific DNA sequences using 
sequence specific primers designed on the ARMS principle (Newton, et al 
1989). The strategy taken in this project was to;
• First establish whether this approach was feasible in respect to identifying 
HLA-A locus specificities, through developm ent of a very basic panel of 
typing reaction.
• Validate the basic reaction panel using DNA from serologically well 
characterised or sequenced cell lines where available.
• Increase the resolution to one equal or surpassing that of serology at the 
HLA-A locus.
• To develop strategies to achieve allelic definition at the HLA-A locus.
In addition, this thesis has also applied the methods developed in  
application to a num ber of population studies. Several new alleles have 
been identified and DNA sequenced through the course of this work. 
Additionally, a PCR protocol denoted 'gene m apping' was developed 
whereby the polymorphic composition of new alleles could be quickly
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identified, prior to DNA sequencing. As a progression, the functional 
significance of small polymorphic sequence differences in a group of closely 
related HLA-A locus alleles was investigated, to underline the im portance 
of high resolution typing. These areas of research are described over the 
following chapters.
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Materials & Methods.
2.1 The PCR reaction.
2.1.1. Preparation of DNA.
Through the duration of this project, different methods of DNA extraction 
were employed. Initially, DNA was prepared using standard proteinase K 
digestion followed by phenol /  chloroform extraction and ethanol 
precipitation (Strauss, 1990). Latterly, DNA has been prepared with kits 
which negate the use of phenol. Two kits in particular have been used.
Kit 1. Nucleon II DNA extraction kit (Scotlab) uses SDS lysis of cells followed 
by sodium perchlorate protein precipitation. This is followed by chloroform  
separation, and addition of a silica slurry which binds any rem aining  
protein in the aqueous phase. The silica can be spun out, and DNA ethanol 
extracted. The DNA pellet was resuspended in H 2 O.
Kit 2. Puregene DNA Isolation kit (Flowgen) uses a lysis step followed by 
protein precipitation and isopropanol DNA precipitation. This kit does no t 
require the use of chloroform and is simple to perform. This is the m ethod 
currently used to prepare DNA for PCR-SSP typing.
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A locus allele Control cell line DNA in which allele identified.
A*0101 FMB, KLO, KASOl 1, WIN, VOO, MOLT4
A*0102 DAUDI
A*0201 JY, KT2, GRC150, JAP.NF, WDV, C073, RSA.ND, CALOGERO, OMW, DOP.ND, 
W#7079, GRC138
A*0202 M7
A*0203 DKl, GEE018
A*0204 RML
A*0205 WT49, AM
A*0206 AT, CLA, KY, W#7079
A*0207 KNE, AP
A*0208 KLO
A*0209 OZB
A*0210 XLI.ND
A*0211 KIME, GRC138, GRC212
A*0212 KRC033
A*0213 SLUGEO
A*0214 1 S
A*0215N -
A*0216 TUBO
A*0217 AMALA
A*0301 YEN, M7, JS, VOO, PLH, SNA,
A*0302 CGMl
A*1101 LATIF, WEWAK, APA, SLUGEO
A*1102 -
A*2301 WT51
A*2402 WEWAK, AKIBA, KT3, CAM020, ZM
A*2403 THAI742, APA
A*2404 -
A*2405 -
A*2406 -
A*2501 M0LT4, BM92
A*2601 PA, QBE, JAP.NF
A*2602 -
A*2603 -
A*2604 -
A*2901 GEE018
A*2902 C073, PITOUT, CGMl, 32/32, SWEIGH007,
A*3001 LBF, RSH, XLI.ND, 35020
A*3002 32/32, CRB
A*3003 JS
A*3004 W7(CC)
A*3101 GRC150, YEN, DAN723, LATIF, KRC103
A*3201 FMB, AM
A*3301 LWAGS, IBW9
A*3302 -
A*3303 HOR, AP, DOP.ND, DKl, 32367, THAI742
A*3401 RSA.ND
A*3402 7528. 7557
A*3601 2D, #25
A*4301 PSLD
A*6601 TEM, IDF, DYC.ND
A*6602 CRB
A*6801 LBS, GRC212
A*6802 SNA, PA, AMAI, RSH
A*6901 IDF,ZM
A*7401 32367, EEK.ND
A*8001 3 5 0 2 0
Table 2.1. List of control cell line DNA used to test HLA-A locus alleles. Cell lines in 
bold have been sequenced for that particular allele. Cell lines in italics are local samples. 
Alleles not identified denoted by (-).
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In developing the method, DNA was prepared mainly from cultured EBV 
transform ed B cell lines, but also from blood samples. Blood was collected 
into EDTA rather than heparin, which is reported to inhibit amplification in 
the PCR reaction (Satsangi, et al 1994). Samples were obtained from a variety 
of sources, and these are described in the relevant sections of the thesis. 
Many of the HLA characterised and sequenced DNA samples were obtained 
from the Tissue Antigen Laboratory, ICRF, London. A list of some of the 
samples is given in Table 2.1
2.1.2. Components of the PCR reaction.
The basic components of the PCR reactions used in this thesis, are listed 
below. These have generally remained consistent thoughout the course of 
the project. Cycling parameters in terms of incubation times and 
tem peratures have varied and evolved, mainly in response to changes in  
PCR machines used and the necessity to attain correct stringency as the 
resolution of the method increased.
lOX PCR Buffer; 1095mg Ammonium sulphate (166mM) 
33.5ml IM Tris pH8.4 (670mM)
6.7ml 0.5M EDTA pH8.0 (67mM)
85mg BSA (0.17%) 
dH 20 to 50ml
Sterilise through 0.22mm filter - store in 1ml aliquots at -20^C.
PCR mix; lOX buffer 3000pl
dNTPs (lOOmM) 60pl x4
MgCl2 (lOOmM) 600pl
Internal control primers (20mM) 300pl x2
dH20 19600pl
Dispense into 1ml aliquots and store at -20^C. To a 1ml aliquot, add 62.5pl of 
each SSP (4pM) and 5|il Taq (SU/pl). This mix can be dispensed into tubes or 
plates, at the appropriate volumes. The mix should be overlaid w ith  
mineral oil and stored frozen at -20°C. This mix constitutes 90% of the PCR 
reaction leaving 10% in which the test DNA can be added.
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Approximately 100-200ng genomic DNA is added per 50|il PCR reaction. 
This needs to be clean and of good quality.
Making up larger batches of buffer/PCR mix and aliquoting these into usable 
volumes, reduces the am ount of variation between typings and leads to 
more consistent results.
Storing ready to use' panels frozen leads to rapid typing as outlined above. 
Such prepared panels can be stored frozen at -20°C. Successful am plification 
has been noted with reactions stored frozen in excess of 6 months.
Aliquot (& freeze if not 
needed immediately).
add specific 
primers & 
Taq
Aliquot into 
reaction 
tubes or 
plates.
add oil and store frozen.
make batch of PCR mix; 
lOX buffer 
magnesium 
dNTPs
internal control primers
thaw reaction panel, add DNA, 
spin through oil, PCR, visualise on gel.
Figure 2.1. Schematic representation of preparation of PCR reaction mixes and typing panels.
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Coding
SSP SSP sequence (5'-3')
SSP position
(5'-3')
nucleotide
location
CLI5' CCC ACT CCA TGA GGT ATT TC 2 4-23
AL#1 ACC AGG AGA CAC GGA ATA 2 181-198
AL#2 ACA GAC TGA CCG AGC GAA 2 212-229
AL#3 GAC GGG GAG ACA CGG AAA 2 180-197
AL#4 GAG TAT TGG GAC CGG AAC 2 171-188
AL#5 CAC TCC ATG AGG TAT TTC TC 2 6-25
AL#6 CGG AAT GTG AAG GCC CAG 2 192-209
AL#7 GCG ACG CCG CGA GCC A 2 112-127
AL#8 GCC GGA GTA TTG GGA CGA 2 167-184
AL#9 TAT TGG GAC GAG GAG ACA G 2 174-192
AL#10 GAT AGA GCA GGA GAG GCC T 2 152-170
AL#11 CAC AGA CTG ACC GAG AGA G 2 211-229
AL#12 CCG GCC CGG CAG TGG A 2 38-53
AL#13 TGG ATA GAG CAG GAG GGT 2 150-167
AL#14 AGG CCC ACT CAC AGA CTC 2 202-219
AL#15 CCT GCG GAT CGC GCT CC 2 230-246
AL#16 GAC CAG GAG ACA CGG AAT A 2 180-198
AL#17 CGG AGT ATT GGG ACC TGC 2 169-186
AL#18 GAC CGG AAC ACA CGG AAA 2 180-197
AL#19 CAG CGA CGC CGC GAG C 2 110-125
AL#20 TGA AGG CCC ACT CAC AGA T 2 199-217
AL#21 ACT ACA ACC AGA GCG AGG A 2 250-268
AL#22 CAC TCC ATG AGG TAT TTC TT 2 6-25
AL#23 GGC CCG GCC GCG GGA 2 40-54
AL#24 CAC GGA GTT CGT GCG GTT T 2 89-107
AL#25 GAG GTA TTT CTA CAC CTC CA 2 14-33
AL#26 GAC GGG GAG ACA CGG AAT 2 180-197
AL#27 CAC TCC ATG AGG TAT TTC TA 2 6-25
AL#28 GCG ACG CCG CGA GCC G 2 112-127
AL#29 CAG CTC AGA CCA CCA AGC A 3 145-163
AL#30 CGG AAT GTG AAG GCC CAC T 2 192-210
AL#31 CGG AAT GTG AAG GCC CAG T 2 192-210
AL#32 CGA GTG GAC CTG GGG AC 2 222-238
AL#33 GAC CTG GGG ACC CTG CG 2 228-244
AL#34 CTC ACA GAC TGA CCG AGC 2 209-226
AL#35 GGA TGG AGC CGC GGG CA 2 130-146
AL#36 ATA GAG CAG GAG GGG CCG 2 153-170
AL#37 CCT CGT CCC CAG GCT CT 2 (ll)-5
AL#38 AGC CCC GCT TCA TCG CC 2 55-71
AL#39 CCG TGG ATA GAG CAG GAG A 2 147-165
AL#40 GTC CGG AGT ATT GGG ACG 2 166-183
AL#41 CAC TCC ATG AGG TAT TTC AC 2 6-25
AL#42 GAC GCC GCG AGC CAG AA 2 114-130
AL#43 TGT CCC GGC CCG GCA GT 2 34-50
AL#44 CAC AGA CTG ACC GAG TGG 2 211-228
AL#45 TCA CAG ACT GAC CGA GAG A 2 210-228
AL#46 GAG CCC CGC TTC ATC GCA 2 54-71
AL#47 CTA CAA CCA GAG CGA GGC 2 251-268
AL#48 CTG CTA CTC TGG GGG GCT 1 31-48
AL#49 GAC CAG GAG ACA CGG AAT G 2 180-198
AL#50 CGA ACC CTC CTC CTG CTA 1 19-36
AL#51 TCC ATG AGG TAT TTC TTC ACA 2 9-29
AL#53 CGA CTC GCA GTT CGT GCA 2 86-103
AL#54 AAG GCC CAC TCA CAG ACT A 2 201-219
AL#55 AAG GCC CAC TCA CAG ATT G 2 201-219
AL#56 GAC AGC GAC GCC GCG ACC CG 2 108-127
Table 2.2 Coding strand Sequence specific primers and locations.
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Non-coding
SSP SSP sequence (5'-3')
SSP positionr DCA
nucleotide
location
AL#A CTC CAG GTA GAC TCT CCG 3 212-195
AL#B CGT CGT AGG CGT ACT GGT 3 87-70
AL#C TGT AAT CCT TGC CGT CGT AA 3 99-80
AL#D CAC TCC ACG CAC GTG CCA 3 229-212
AL#F GCG CAG GTC CTC GTT CAA 3 122-105
AL#G CCG TCG TAG GCG TGC TGT 3 88-71
AL#H CAA GAG CGC AGG TCC TCT 3 127-110
AL#I TCT CTG CTG CTC CGC CG 3 200-184
AL#J TCA ACT GCT CCG CCA CAC 3 198-181
AL#K TCT CAA CTG CTC CGC CCA 3 200-183
AL#L CAA GAG CGC AGG TCC TCG 3 127-110
AL#M CAG CCA AAC ATC ATC TGG AG 3 31-12
AL#N CCC CAC GTC GCA GCC AA 3 41-25
AL#0 GTC GTA GGC GTG CTG TTC A 3 86-68
AL#P GCC TCC CAC TTG CGC TG 3 175-159
AL#Q CTC CAG GTA GGC TCT CAA 3 212-195
AL#R CTC CAG GTA GGC TCT CTG 3 212-195
AL#S CGC CTC CCA CTT GCG CTT 3 176-159
AL#T CTC AAC TGC TCC GCC CG 3 199-183
AL#U CTC CAG GTA GGC TCT CC 3 212-196
AL#V GAG CCA CTC CAC GCA CGT 3 233-216
AL#W AGG TAT CTG CGG AGC CAC 3 244-227
AL#X GCC CGT CCA CGC ACC G 3 231-216
AL#Y CCG CGG AGG AAG CGC CA 3 64-48
AL#Z GGT ATC TGC GGA GCC CG 3 243-227
AL#AA CTC TCC ACT GCT CCG CCT 3 201-184
AL#AB CAC GTC GCA GCC ATA CAT TA 3 38-19
AL#AC AGC CAC TCC ACG CAC CG 3 232-216
AL#AD GAG CCA CTC CAC GCA CTC 3 233-216
AL#AE TCC GCC TCA TGG GCC GT 3 190-174
AL#AF ACG TCG CAG CCA TAC ATC A 3 37-19
AL#AG CTT CCC GTT CTC CAG GTG 3 257-240
AL#AH CAG GTA GGC TCT CAA CTC G 3 209-191
AL#AI TGT CCG CCG CGG TCC AA 3 141-125
AL#AJ CCC ACT TGT GCT TGG TGG 3 171-154
AL#AK ACT GGT GGT ACC CGC GC 3 77-59
AL#AL TGG AAG GTT CCA TCC CCT T 4 178-160
AL#AM CGT CGT AGG CGT CCT GCC 3 87-70
AL#AN CTC TCA ACT GCT CCG CCT 3 201-184
AL#AO CTC TCT GCT GCT CCG CCA 3 201-184
AL#AP CAT CCA GGT AGG CTC TCA A 3 213-195
AL#AQ CCA TCC AGG TAG GCT CTC T 3 214-196
AL#AR TGG TAC CCG CGG AGG AG 3 70-54
AL#AS CCG TCC GAC CCC ACG TC 3 49-33
AL#AT CTG CTC CGC CGC ATG GA 3 194-178
AL#AU GTG CTT GGT GGT CTG AGC T 3 164-146
AL#AV CTC CAG GTA GGC TCT CCA 3 212-195
AL#AW TGG CCC CTG GTA CCC GT 3 (14)-273
AL#AX TCC ACT GCT CCG CCA CAT 3 198-181
AL#AY CTC CAC TGC TCC GCC AC 3 199-183
AL#AZ GGC CGC CTC CCA CTT GT 3 179-163
AL#BA TAG AAA TAC CTC ATG GAG TGA 3 25-5
AL#BB GAA GCG GGG CTC TCC ACT 2 65-48
AL#BC ATG AAG CGG GGC TCT CCA 2 67-50
AL#BD GGT CCC AAT ACT CAG GCC T 2 183-165
AL#BE AAG CGG GGC TCT CCA CT 2 64-48
AL#BF CCC CAC GTC GCA GCC AT 3 41-25
AL#BG CGT CGC AGC CAT ACA TCC 3 36-19
AL#BJ CCG ACC CCA CGT CGC AGG CAC (mm) 3 45-25
AL#BK AGC CCG TCC ACG CAC TC 3 232-216
Table 2.3 Non-coding strand Sequence specific primers and locations.
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Non-coding SSP position
(5-3')
SSP SSP sequence (5'-3') nucleotide
exon location
AL#BL CTC TCT GCT GCT CCG CCT 3 201-184
AL#BM CCG ACC CCA CGT CGC AGG CAT 3 45-25
AL#BN CCT TGC CGT CGT AAG CGT T 3 93-75
AL#BO GAG CCA CTC CAC GCA CAG 3 233-216
AL#BP CAG CCA AAC ATC ATC TGG AG 3 31-12
AL#BQ ACG TCG CAG CCA AAC ATC A 3 37-19
AL#BR AGC CAT ACA TCC TCT GGA G 3 30-12
AL#BS ATG CTG CAC ATG GCA GGT T 4 242-224
AL#BT AGC CAT ACA TCC TCT GGA C 3 30-12
2901 CCG TCC GAC CCC ACG TG 3 49-33
A0207 CCC CAC GTC GCA GCC AC 3 41-25
CLI3' CCT TCC CGT TCT CCA GGT 3 258-241
Table 2.3 continued. Non-coding strand Sequence specific primers.
Coding primer (B2M#1) 5  ■ -CGA TAT TCC TCA CCT ACT-3 '
Non coding primer (B2M#2) 3  ■ -CAA CTT TCA CCA CCT TAC-3 '
Table 2.4 Internal control primers (B2M#1+B2M#2) amplifying a 330bp region of 
the [3-2microglobulin gene.
Sequence specific primers (SSP) were synthesised by the Imperial Cancer 
Research Fund, Oligonucleotide Synthesis Service, Clare Hall Laboratories, 
UK and by R&D Systems Europe Ltd, Abingdon, UK. SSP were either 
provided as quantified precipitates or solutions. These were then diluted to 
either lOOpM or 20|iM stocks in sterile distilled water and frozen at -20°C. 
SSP working stocks at 4|LiM were also made and stored frozen at -20°C. Each 
PCR reaction comprised a pair SSP's, one to the coding strand and the other 
to the non-coding strand. A list of the SSP sequences, and their anealing 
positions within the HLA-A gene sequence is given in Tables 2.2 and 2.3. 
The location of each primer is given as the 5' to 3' nucleotide postion in the 
given exon. The internal control primers are listed in Table 2.4
The therm al cyclers used include a Hybaid Thermal Reactor in which PCR 
amplification was performed in 0.6ml eppendorf tubes, a MJ-Research PTC- 
100 using non skirted 96 thermowell plates (Costar), and a MJ-Research PTC- 
200 using either non skirted 96 thermowell plates or 192 therm owell plates 
(Costar). The PCR conditions and cycling conditions are described in the 
relevant sections.
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2.1.3. Agarose gel electrophoresis.
10|il of PCR products from the typing reactions were mixed with 2)li1 of 
brom ophenol blue/xylene cyanole loading buffer prior to loading onto 2% 
agarose gel made in 0.5X TBE buffer prestained with ethidium bromide.
Initially, when the number of reactions were small and performed in 0.5ml 
eppendorf tubes, electrophoresis was performed in Biorad Mini Sub™ DNA 
cells. Expansion in the num ber of typing reactions required that PCRs were 
performed in 96 or 192 well microtitre plates. This required the use of 
Flowgen gel apparatus compatible with the use of multitrack pipettes. This 
gel apparatus allows screening of PCR products from 3x96 well plates.
Loading buffer; 0.2% bromophenol blue 
0.2% xylene cyanole 
50% glycerol in H 2 O
Gels; 2% agarose in
1/2X TBE
Ethidium Bromide (3pl lOm g/m l per 50ml gel)
(IL lOX TBE = 108g Tris base + 54g Boric acid + 40ml 0.5M EDTA )
PCR products run out on the gel were then visualised on a UV 
transilluminator and an image recorded using a polaroid camera.
2.1.4. PCR-SSP Phototyping.
The culm ination of developments by a num ber of workers, including the 
contribution of this thesis, has allowed a general PCR-SSP system to be 
described (Bunce, M. et al., 1995), which identifies specificities at HLA-A, -B, - 
C, -DRBl, DRB3, DRB4, DRB5 and DQBl loci. In brief, 26|il of DNA (200- 
300|ig/ml) was added to an aliquot of reaction mix containing all the PCR 
components (PCR buffer, dNTPs, MgCl2 , Taq polymerase) with the exception 
of SSP prim er pairs. The 144 SSP primer pair mixes were pre-aliquoted 
under oil in 96 well microtitre plate, and stored frozen at -20°C, ready for 
use. Each specific reaction also contained an internal control reaction. The
52
DNA and reaction mix were distributed across the typing panel and PCR 
performed through 30 cycles on an MJ-Research PTC-200 Thermal Cycler. 
The Cycling parameters on this thermal cycler comprised;
(96°C-50s, 70°C-50s, 72°C-50s)5 cycles +
(96°C-50s, 63°C-50s, 72°C-50s)21 cycles +
(96°C-50s, 55°C-50s, 72°C-50s)4 cycles
PCR products were then analysed through electrophoresis on an e th id ium  
bromide stained agarose gel. Loading of samples onto the gel was facilitated 
by use of m ultitrack pipettes to which a dedicated gel apparatus (Flowgen, 
UK) was compatible. Using a UV transillum inator, a Polaroid image of the 
gel was taken and the HLA type of the test samples was determ ined by the 
presence or absence of PCR products of expected size in the appropriate wells 
of the reaction panel.
2.1.5. List of materials used for PCR.
Reagent Comoanv & Cat. No.
Nucleon II DNA extraction kit Scotlab
Puregene'^'^ DNA Isolation kit Flowgen D-5000
Ammonium Sulphate Sigma A-4418
Magnesium Chloride Sigma M-9272
Bovine Serum Albumin (BSA) Sigma A-6793
Ultrapure dNTP Set Pharmacia 27-2035-01
Trizma Base Sigma T-1503
EDTA disodium salt BDH 10093
Agarose electrophoresis grade GibcoBRL 15510-027
Boric Acid Sigma B-6768
Ethidium Bromide Sigma E-8751
Bromophenol Blue Sigma B-6131
Xylene Cyanole FF Sigma X-4126
Glycerol BDH 10118
Ethanol Hayman Ltd SIN1170
Isopropanol Fisons P/7500/PB17
Phenol Rathburn RP3024
Chloroform Fisons C/4960/PB17
Proteinase K Sigma P-2308
Mineral oil Sigma M-3516
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2.2 DNA cloning and sequencing.
2.2.1. cDNA preparation.
The general protocol adopted was to extract mRNA (mRNA Isolation kit, 
Stratagene) from the cell line of interest, prepare cDNA by RT-PCR 
(Superscript^^ first strand cDNA synthesis kit, GibcoBRL), and PCR amplify 
out the genes of interest using HLA-A locus specific primers. The lOOpl PCR 
mix consisted of;
lOpl - lOX PCR buffer (as above)
21 pi - cDNA (as prepared with above cDNA kit)
lOpl - primer mix (2pM of each primer given in figure 2.2)
1 pi - Taq enzyme at 5U /pl 
58pl - distilled sterile water 
overlayed with 15pl of mineral oil
(dNTP's, MgClz are present in the cDNA fraction of the PCR mix).
The cycling parameters as performed in 0.6ml eppendorf tubes in a Hybaid 
thermal reactor were;
(95°C-lmin, 65°C-lmin, 72°C-2min)5cycles +
(95°C-lmin, 55°C-lmin, 72°C-2min)25cycles
HLA-A5'EcoRl 5'-gTC . qAA . TTC . gCC . gCC. ATg. gCC . gTC . ATg. gC g . CCC . CgA-3'
EcoRl KOZAK START
HLA-A3'BamHl 9 -C a C.aaA.TCC . TCA . TCA . CAC . TTT . ACA. AgC . TgT-3'
BamHl STOP
Figure 2.2. Primer sequences used for amplification of the full length HLA-A locus gene.
The PCR product was then run out on an ethidium  bromide stained TAB 
Agarose gel, and the llOObp full length HLA-A locus PCR product cut out
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and purified from the gel (Easiclene DNA Isolation kit, Scotlab Bioscience).
The HLA-A specific primers which amplify the full length gene, incorporate 
EcoRl and BamHl restriction sites to facilitate the correct orientation of the 
HLA gene when ligated into the appropriate vector. The primers also 
incorporate kozak, start and stop codons which assist in the expression of 
the HLA-A gene, within the appropriate vector.
2.2.2. cDNA cloning
The PCR product potentially contains two HLA-A locus specificities, and 
therefore a cloning step is necessary to isolate the allele of interest. To this 
end, the isolated PCR product was either digested with E coR l/B am H l 
restriction enzymes (Promega) and ligated into a similarly digested M13- 
m pl8 and 19 bacteriophage vector for single stranded DNA sequencing, or 
ligated directly into pMOSblue T-vector (Amersham Life Sciences), for 
double stranded sequencing.
The ligation reaction used typically consists of;
Ipl - lOX Ligase buffer
0.5pl - lOOmM DTT
0.5pl - lOmM ATP
Ipl - cut vector
2|il - insert (cut as approriate)
5|il - distilled sterile water 
0.5|il - T4 DNA ligase 4U/ pi.
The above ligation reaction was incubated at 16°C overnight.
The main reagents for ligation and transform ation were provided in the 
pMOSblue T vector kit (Amersham). The competent cells provided were 
transformed with the insert ligated bacteriophage vector. This required 
addition of Ipl of the ligation mix to 20|xl of chilled competent cells. This 
was incubated on ice for 30 minutes prior to a heat shock at 42°C for 40 
seconds. The mixture was then rested on ice for 2 m inutes prior to addition 
of 80|il of SOC media and incubation at 37°C for 1 hour. The cells were 
spread onto L agar plates containing 50|Xg/ml ampicillin (and ISpg/m l
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tetracyline for the pMOSblue T-vector transformations). W hite /b lue
selection was used to screen for and exclude 'blue' recombinants by 
including 50pl of 50m g/m l X-gal+lOOmM IPTG in each L agar plate. Plates 
were incubated at 37°C overnight, and clear plaques (M13) or white colonies 
(pMOSblue) were picked and cultured for around 6-8hrs in 3ml of L Broth. 
1ml of this culture was frozen at -20°C in Hogness Media, as a stock for 
further culturing of the plasmid bearing cells.
(i). Single stranded M 13mpl8/19 small-scale DNA preparation.
From 2ml of cells in L Broth, 200pl of PEG/NaCl was added to 1.2ml of 
culture supernatant. This mixture was vortexed and allowed to stand for 15 
m inutes prior to centrifugation at 14,000rpm in an eppendorf benchtop 
centrifuge. All the supernatant was removed and the pellet was
resuspended in lOOpl TE. 50|il of equilibrated Phenol was added to the 
resuspended pellet, mixed and centrifuged. The aqueous phase was then  
removed and added to an equal volume of chloroform and centrifuged. The 
aqueous phase was then added to a fresh tube containing 300pl of a 25:1 
mixture of ethanol to 3M Na Acetate. This was then mixed and left to stand 
for 15 minutes. The precipitated single stranded DNA was recovered by 
centrifugation for 10 minutes at 4°C, and the supernatant removed. The 
pellet was then washed in 70% ethanol, allowed to air dry for 10 m inu tes 
prior to resupension in 50pl TE.
(ii). Double stranded pMOSblue T-vector small-scale DNA preparation.
Plasmid DNA was prepared from 2ml of cells cultured in L Broth. DNA was 
prepared using the QIAprep Spin Plasmid Kit (QIAGEN), using their
standard protocol. Around 20pg of plasmid DNA was recovered in a
volume of lOOpl H 2 O.
Prior to sequencing, this double stranded plasmid preparation required 
dénaturation. This was achieved through the addition of 0.1 volumes of 2M 
NaOH/2m M  EDTA to the plasmid DNA which was then incubated at 37°C 
for 30 minutes. To neutralise the mixture, 0.1 volumes of 3M Na Acetate 
(pH5.5) was added and DNA is precipitated through addition of 3 vo lum es 
of absolute ethanol and left at -75°C for 15 minutes. The DNA pellet was
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washed in ethanol and resuspended in the appropriate volume of distilled 
H 2 O for sequencing.
2.2.3. DNA sequencing reaction protocol.
DNA sequencing of the prepared plasmid DNA was performed using 
standard chain termination reactions (Sanger, F. et al., 1977), as facilitated in  
the use of the Sequenase'^'^ version 2.0 DNA sequencing kit (USB - 
Amersham Life Sciences). In brief, this involved;
• Initial annealing of IpMol of primer with 3-5|ig plasmid DNA in the 
presence of reaction buffer. This was incubated at 65°C for 2 m inutes and 
allowed to cool slowly.
• For the labelling reaction, DTT, labeling mix, (a-^^S)dATP and sequenase 
were added to the annealing mixture.
• The term ination reactions were performed by addition of the labelling 
reaction to each of the four 37°C prewarmed term ination mixes (ddATP, 
ddCTP, ddGTP, ddTTP). After 5 minutes, the reactions were stopped by 
addition of the stop solution. The sequencing reactions were heated for 2 
minutes at 80°C prior to loading onto a gel.
• For each sample, 2.5|il of each sequencing reaction (A,C,G,T) was loaded 
onto a 5% acrylamide/bis (19:1) Sequagel™ sequencing gel (N ational 
Diagnostics) using a Biorad Sequi-gen^^ vertical gel system and 3000xi 
powerpack. The sequencing reactions were run through the pre-w arm ed 
(50°C) gel at @1750V; 50W for approximately 3-4hrs. The gel was then  
placed onto a paper backing and dried prior to exposure with Kodak X- 
omat film overnight or longer as required. The film was developed and 
the sequence read.
2.3. Transfection of HLA genes into CIR cells.
2.3.1. Cloning of expression vector.
As above, full length HLA-A cDNA was prepared and ligated into the
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pMOSblue T-vector, cloned and sequenced to verify the integrity of the HLA 
insert. To transfect into the Class I reduced (CIR) cell line, the HLA insert 
was ligated into the appropriate expression vector pKG4 (obtained from Prof. 
A. Townsend, Institute of Molecular Medicine, Oxford). Due to a lack of 
compatible restriction sites, the HLA insert required subcloning into a 
shuttle vector (pBluescript II KS-, Stratagene). Using EcoRl and Bam H l 
restriction sites incorporated into the HLA-A specific primers, the full 
length gene was cut and subcloned into a similarly digested pBluescript 
vector. Clones were screened by PCR to establish presence of the HLA insert. 
Compatible restriction sites (H indlll/Bam H l) now existed for subcloning 
out of the shuttle vector into the pKG4 expression vector.
2.3.2 Maxiprep preparation.
Following transform ation of MOSblue competent cells (Amersham Life 
Sciences), clones were screened for the presence of the HLA insert. A seeding 
culture of cells containing the positive clone was then used to inoculate IL 
of L broth containing SOpg/ml Ampicillin. The cells were grown overnight 
at 37°C on an orbital shaker. Plasmid DNA was extracted using an alkaline 
lysis m ethod (Birnboim, et al 1979). Cells were pelleted and supernatant 
discarded. The pellet was resuspended in 40ml of Buffer-1 prior to alkali 
lysis by addition of 80ml Buffer-2. This was then neutralised through the 
addition of 40ml of Buffer-3. Buffers 1-3 are given in Table 2.5. The resultant 
precipitate was centrifuged down and the supernatant passed through a 
m uslin gauze. 96ml isopropanol was added and DNA precipitated at -20°C 
for 30 m inutes prior to centrifugation. The pellet was then resuspended in  
10ml TE to which was added lOg CsCl and 1ml Ethidium Bromide solution. 
This was then distributed into 4 polycarbonate tubes compatible for use w ith  
the Beckman TL100.3 rotor. The plasmid DNA was spun through the CsCl 
gradient overnight at 80,000rpm at 20°C. The lower band containing plasm id 
DNA was then carefully removed, and ethidium  bromide extracted w ith  
amyl alcohol. The plasmid DNA was then dialysed in 2L of TE at 4°C 
overnight, and the DNA concentration determined by spectrophotometry.
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Buffer 1 Buffer 2 Buffer 3
50mM Glucose 0.2M NaOH 
1% SDS
3M Na Acetate pH4.8
Table 2.5 Reagents used for maxiprep alkali lysis extraction of plasmid DNA.
2.3.3. Transfection of plasmid DNA into CIR cells.
HLA-A genes were expressed in CIR for the characterisation of peptide m otif 
bound to a particular allelic variant. This was achieved through the 
transfection of the HLA-A gene through the vehicle of the pKG4 expression 
vector into the low expression CIR cells. The transfection protocol followed 
is described below;
20)dg of CsCl purified pKG4/HLA was linearised through cutting with 40 
units of the restriction enzyme Seal at 37°C for 4 hours or overnight. The 
linearised DNA was recovered under sterile conditions by e thanol 
precipitation with 2 volumes absolute ethanol and 0.3 volumes 3M Na 
Acetate. This was washed with 70% ethanol, dried and resuspended in 50|li1 
TE.
As an additional control, the pKG4/HLA was also cut with BamHl and 
H indlll restriction enzymes. This digestion produced a clean doublet 
corresponding to the HLA full length insert and the cut expression vector.
Following screening on an agarose gel, to check that the expression vector 
had indeed been cut cleanly, the 20pg of pKG4/HLA DNA was mixed w ith  
0.8ml of PBS containing 10  ^washed CIR cells. This mixture was added to a 
cooled electroporation cuvette, and the electroporation performed at 250V, 
500|iFd. A control was also electroporated in which no DNA was added to 
the cells. After electroporation, the cuvettes were placed on ice for 10 
m inutes prior to transfer of the cells to 20ml prew arm ed 
RPMI1640/10%HIFCS. This was distributed into two 75ml tissue culture 
flasks and incubated at 37°C/5%C02 overnight. The following day the 
electroporated cells were placed in 2m g/m l G418 selection. Of the two 
control flasks, only one was put in selection to ensure viable cells surv ived  
post electroporation. The transfected cells were then incubated for a further 
2-3 weeks in until it became obvious that they were growing well in
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selection. Still in selection, new flasks were seeded to grow out the live cells. 
Frozen stocks were made from the fresh flasks and the transfectants checked 
for expression by FACs analysis.
The volume of tissue culture was further expanded and transferred to roller 
bottles. At this step, because culture was entering the scale of litres, selection 
was stopped and the percentage of HIFCS was gradually reduced from 10% to 
4%. Following a period of no selection, cells were checked for expression of 
the transfected HLA-gene. Approximately 25L of cells were cultured yielding 
in the region of lOOi cells. These were washed in PBS and the pellet stored 
frozen at -70°C.
2.3.4. FACs analysis of transfectants.
Expression of HLA on transfected cells was determined by FACs analysis. In 
brief;
• l-2ml (1Q6) of viable cells were washed in PBS.
• lOOjil of W 6/32 mAh (@30|ig/ml) was added to the cells and incubated 
on ice for 30 minutes. A negative control containing no mAb was also 
prepared.
• Cells were washed twice in cold PBS.
• 75pl of a 1:40 diluted FITC conjugated goat anti mouse were added to the 
cells and incubated on ice and in the dark for 30 minutes.
• Cells were washed three times in cold PBS.
• Cells were resuspended in 500pl of 1% paraformaldehyde in PBS.
• Cells were stored at 4°C in the dark prior to Facscan analysis.
• Cells were analysed for one colour fluoresence (FLl) with side scatter 
(SSC).
Controls containing untransfected CIR cells, and B cell line expressing the 
allele of interest were also stained and analysed.
2.3.5. Serological analysis of transfectants.
Transfectants were further screened for expression by the 
microlymphocytotoxicity assay (Terasaki, et al 1964; Bodmer, W.F. et al 1979).
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In brief, this involved incubating stained viable cells with a panel of HLA 
specific antisera in Terasaki plates for 30 m inutes at room tem perature. 
Following this period, complement was added to the plates and incubation 
continues for a further hour. The complement requires bound antibody for 
the cell to be lysed. This was detected by the uptake of a counter red 
flouresent dye (ethidium bromide, propidium  iodide) to enable 
discrimination between viable and dead cells. The Terasaki plates were read 
and scored on an inverted UV microscope and the results interpreted 
accordingly.
2.3.6. Peptide elution and sequencing.
Each transfectant was cultured until approximately 10^  ^ cells were available 
(about a 30ml cell pellet) The cell pellets were washed in phosphate buffered 
saline and frozen at -70°C. Endogenously processed peptides were then  
eluted from each of the four transfectants. Peptides were eluted using the 
trifluoroacetic acid (TEA) method, which was performed essentially as 
described previously (Falk, et al 1991).
In brief, the cell pellets were lysed in an NP40 based detergent buffer. The 
cells were then homogenised, ultrasonicated and ultracentrifuged. The 
supernatant was removed without disturbing the upper lipid phase. The 
supernatant was filtered prior to being run overnight, through a glycine 
column and subsequent W6/32 (anti-HLA class 1) antibody column. The 
glycine column acted as a control which determined the proportion of n o n ­
specific material bound. The gel in the columns was then resuspended in  
TFA to elute peptide. The eluate was subsequently ultrafiltrated and peptide 
fractions separated by reverse phase HPLC (Pharmacia SMART system).
The sequence of the peptide was then determined through Edm an 
degradation sequencing performed with an Applied Biosystems protein  
sequencer.
2.5. lEF analysis.
lEF analysis was used to discriminate between serologically identical HLA 
molecules dependent on their comparative charge differences resulting
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from their amino acid composition. The basic method used was as described 
for the 1987 International Histocompatibility W orkshop. (Yang, 1989b). A 
brief description of the protocol is described below;
• Culturing the HLA expressing B cell line in Methionine free medium.
• The cells were labeled with S^^-methionine.
• Cells were washed, treated with a protease inhibitor (PMSF) and lysed
with an NP40 lysis buffer.
• The lysed cells were then precleared with washed pansorbin.
• The class 1 specific mAh W6/32 was used to im m unoprecipitate the lysed 
cells.
• The im m unoprecipitate was then incubated with Protein A prior to 
neuram inidase treatment.
• The sample was then suspended in sample buffer and loaded onto into 
an 30% acrylamide-bis gel containing ampholines (pH3.5-10, pH5-7, pH6- 
8).
• The gel was run at 10mA for 16 hours.
• The gel was then fixed in 10% acetic acid, washed and treated w ith
'A m plify '.
• Following drying, the gel was exposed with X-ray film overnight. The 
film was developed and the IFF banding interpreted.
Aspects of the different methods described above are discussed in the 
following chapters.
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Establishing the basic method for PCR typing the 
HLA-A gene.
3.1 Introduction.
This chapter describes the general principles followed in designing the basic 
PCR-SSP typing system for identifying broad specificities of the HLA-A locus. 
To achieve this objective, several key areas had to be resolved;
(i) To start, it was necessary to collect all available Class I sequences into one 
alignm ent database. This was the fundam ental inform ation required to 
begin designing the PCR-SSP reactions. As new alleles were described, their 
effect on the specificity of the PCR reactions in the typing panels had to be 
reviewed.
(ii) Primer pair combinations had to be devised which specifically am plified 
the required specificities such that no known alleles were missed.
(iii) It was necessary to determine the correct stringency of the PCR to 
exclude both false positive and negative amplification.
(iv) Conditions had to determined which allowed a panel of PCR reactions, 
each defining a different specificity, to be performed simultaneously, under a 
standard set of conditions.
(v) The success of the PCR reaction was confirmed through the 
incorporation of an internal control PCR reaction.
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(vi) The PCR-SSP reactions were validated against DNA obtained from a 
panel of well characterised or preferably sequenced cell lines.
As described below, establishing the general conditions for the specific 
amplification of HLA specificities provided the means for design of 
additional SSP combinations, allowing increasing resolution at the HLA-A 
locus. Some of the PCR-SSP reactions in the typing panels required 
alteration over time, in response to new HLA-A alleles found. Param eters 
within the PCR were also altered, to increase stringency and to accommodate 
changes in PCR machines.
3.2 Establishing the parameters.
3.2.1 Sequence alignments.
One im portant prerequisite for designing a PCR based typing system is first 
to have access to a substantial alignment of the available HLA class I 
sequences. In designing specific PCR reactions for HLA-A specificities, 
because of the great am ount of shared polym orphism  between many class I 
alleles, not only must other allelic sequences within the locus be considered, 
but so m ust HLA-B, -C, and Class I psuedogene sequences (see Chapter 1). 
This thesis was initiated at a time when the num ber of published HLA class 
I sequences (Zemmour and Parham, 1991), was sufficient to begin design of a 
DNA based HLA-A locus typing system.
Sequence alignments (Zemmour and Parham, 1991; Zem mour and Parham , 
1992; Arnett and Parham, 1995) published in conjunction w ith  
Nom enclature reports, provided a list of known HLA Class I alleles in a 
form which allowed polymorphic differences to be readily distinguished. 
Being able to compare nucleotide sequences in this fashion, allowed 
sequence specific primers (SSP) to be designed, which when used in  
combination, allowed specific amplification of a particular sequence.
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3.2.2 The use of ARMS; designing SSP combinations.
The basis of PCR-SSP for HLA typing, is specifically to amplify a particular 
HLA specificity, so distinguishing it from other specificities. There are two 
major considerations; firstly how to make SSPs specific for the 
polymorphism they are to detect, and secondly how to combine SSPs in PCR 
reactions that amplify only the required alleles.
The basis of primer design in this study was the amplification refractory 
m utation system (ARMS) (Newton, et al 1989). This system inhibits 
nonspecific PCR amplification when a mismatch exists between tem plate 
DNA and the 3' residue of one of the primers in the PCR reaction (see figure 
1.9), under the correct conditions of stringency. This potentially allows 
discrim ination between two sequences on the basis of a single base pair 
difference (Newton, et al 1989).
For the definitive amplification of a particular HLA-A specificity, two SSP's 
were designed, each to identify a point of polymorphism , both of w hich 
were found together in the target sequence and not in any other specificities. 
In other words, the SSP combination had to be unique to the target 
sequences, with at least one designated polym orphism  defined by the SSP's 
missing in all other sequences. A PCR using this combination of two ARMS 
designed SSP's under the correct stringency should amplify only the target 
specificities.
The identification of a particular HLA type in a PCR reaction requires a 
combination of SSPs that amplify only those alleles containing both 
polym orphism s along the length of their sequence, as defined by the 
primers. If a unique polymorphism  exists w ithin a sequence, then this 
provides a good site to which an SSP could be designed. However, such 
unique sites are not always present, particularly in Class I alleles. The 
required specificity is then reached through the combination of SSPs, 
defining two points of polymorphism  in a sequence which differentiate it 
from other HLA types. In designing SSP, it is im portant to look at other 
available HLA sequences and pseudogenes, since certain polym orphic 
combinations may not be confined to a particular locus.
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The majority of polymorphisms in HLA-A and other Class I alleles lie 
within exons 2 and 3 of the gene, and this therefore dictates the positioning 
of the SSP's. Generally w ithin this protocol, each specific PCR reaction used 
a prim er which identifies a polymorphism in exon 2 in combination with a 
prim er identifying a polymorphism  in exon 3. The exon 2 prim er extended 
to become the cis strand, while the exon 3 prim er extended to become the 
trans strand of the PCR product. Usually, PCR reactions were perform ed 
from genomic DNA, and amplification therefore included a 240bp intronic 
region between the exons 2 and 3. Knowing the distance between prim ing  
sites allowed a defined product size to be expected, so allowing greater 
confidence in interpretation. PCR-SSP reactions were also performed on  
cDNA with the loss of intronic sequence reducing the size of expected 
product.
An initial exploratory PCR-SSP reaction attempted amplification of HLA- 
A’^ 01. Two cis SSP in exon 2 were tested in combination with two trans SSP 
in exon 3. Combinations of either AL#1 or AL#2 with AL#A (chapter 2, table 
2.2 & 2.3) seemed to be specific for HLA-Al. Combinations with the second 
trans SSP failed, and this was found to be due to a sequence error made in  
the design of the primer. The components of the PCR were as stated in  
Chapter 2 including the incorporation of internal control primers in the 
reaction (chapter 2 table 2.4). The cycling parameters used at this time on a 
Hybaid Thermal Cycler were;
(95°C-lmin, 55°C-lmin, 72°C-2min)30 cycles.
Although conditions were not always optimal due to the occasional 
presence of nonspecific PCR products, the ability specifically to amplify HLA- 
A*01 provided the ground rules for the design of a basic panel of reactions. 
The reaction panel covered all the HLA-A locus alleles known at that tim e, 
in a generic m anner based on broad serological specificities. This initial 
panel is depicted in Table 3.1, which also shows the perceived specificity of 
each SSP based on the published HLA-Class I sequences at that time. The 
observations made with this initial set of reagents provided the basis upon  
which the general parameters of the method were defined making possible 
further development.
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HLA-A locus 
Specificity
coding
primer
non­
coding
primer
Specificity of
coding
primer
Specificity of non­
coding primer
band
size
(bp)
A1 AL#2 AL#A A I A26 A29 A I 510
A2 AL#3 AL#B A 2 A9 A 2 A6802 A69 413
A3 AL#6 AL#D All A3 A28 A29 A30 A 3 547
A9 AL#5 AL#B AS HLA-G AS A2 A6802 A69 589
AlO AL#4 AL#C A28 A lO A33 A lO 436
All AL#6 AL#E À 11 A3 A28 A29 A30 A l l 574
A28 AL#4 AL#H A 28 AlO A33 A9 A2 Â 28 466
A19(not A30) CLI5' AL#F HLA CLASS I A 2S  A 3 1  A 3 2  A 3 3 626
A30 AL#6 AL#G All A3 A28 A29 A30 A 30 HLA-H 406
Table 3.1 Initial low resolution HLA-A locus typing panel, using a panel of nine PCR-SSP 
reactions defining eight broad serologically defined specificities (HLA-A30 could not be 
included in the A19 reaction). The specificity of each SSP is shown with those in bold 
denoting the specificity common to both primers and so amplified in the PCR reaction. The 
primer sequences are given in Table 2.2 and Table 2.3.
Internal Control PCR.
To ensure that conditions were complete for PCR to work, an internal 
control was included in each of the panel reactions. Primers specific ïor a 
region of the p-2microglobulin gene (Table 2.4) produced a 330bp product in  
each of the panel reactions, therefore validating conditions for the PCR. Any 
reaction whicli failed to produce either a specific or internal control product, 
was deemed to have failed. In this protocol, the internal control primers'^had 
melting temperatures of around 52°C. This discouraged the internal control 
reaction out-competing the specific amplification under annealing 
temperatures of 55°C or above in the PCR. Conversely, any specific HLA 
amplification would hold advantage and out-compete the internal control 
amplification under the given conditions. Other methods of PCR-SSP 
avoided competition from the internal control reaction by lowering the 
control primer concentration in relation to the specific SSP's (Olerup and 
Zetterquist 1991; Olerup, et al 1992). The SSP combinations amplified 
products of a size easily distinguished from the 330bp internal control band.
3.2.3 PCR stringency and conditions for simultaneous amplification.
Initially, each of the primers were designed to be 18 nucleotides in length. 
Each of the reactions was tested individually with a number of positive and
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negative control DNA. Using this initial panel, it became apparent that 
certain reactions were failing to work under uniform conditions of 
amplification. This was attributed to the primers not being matched in terms 
of melting temperature. Certain primers (AL#5, CLI5', AL#C) were therefore 
extended so that all the SSP had compatible melting temperatures (Thein, et 
al 1986) of between 56-60°C. In the case of the HLA-Al 1 reaction, the primer 
combination of AL#6 /AL#E continually faded. This was later attributed to 
an error in the published sequence. Other combinations were occasionally 
prone to false positive amplification, and new reactions were designed. 
Newly published aUeles also necessitated the redesign of certain panel 
reactions to maintain broad specificity, and to ensure no aUeles were missed.
The SSP combinations were tested against well characterised control DNA  
samples (from cell lines with sequenced HLA genes were possible), to 
validate specificity. Testing each reaction individually against a panel of 
control DNA identified those reactions prone to cross-reactivity or failure. A 
number of alternative PCR-SSP combinations were designed for these 
problem specificities, and alternative reactions were defined.
However, general problems still existed, particularly with the presence of 
occasional non-specific extra bands, due probably to mispriming within the 
PCR. The conditions which determined the success of the PCR were m ulti­
factorial. To see if specificity could be improved, alternative conditions 
within the PCR reaction were investigated. These included;
(i). The use of alternative PCR buffers.
A number of different PCR buffers were tried with HLA-A locus specific 
PCR-SSP reactions. These included both Potassium Chloride based and 
Ammonium Sulphate based buffers obtained from different sources, as 
listed in Table 3.2. The result of using different buffers showed a general loss 
of amplification with the KCl based buffer while the Biotaq NH 4 buffer 
tended to slightly increase the amount of nonspecific amplification. 
However no improvement was noted over the 'in house' lOx buffer.
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(A). Perkin Elmer buffer lOOmM Tris-HQ pH8.3,500mM KCl, 15mM MgCl2 / 0.01% w /v  
gelatin.
(B). Biotaq KCl buffer lOOmM Tris-HQ pH8.8,500mM KQ, 15mM MgCl2 , 1% Triton 
X-100.
(C).* Biotaq NH^ buffer 160mM (NH4  )2 SO4 , 670mM Tris-HQ pH8 .8 , 0.1% Tween-20.
(D).* In house buffer 166mM (NH 4  ) 2  SO4 , 67DmM Tris-HQ pH8.4, 6.7mM EDTA 
pH8.0, 0.17% BSA.
Table 3.2. lOX PCR buffers tested for use with HLA-A PCR-SSP typing. * MgCl2  not included
in these buffers and therefore added separately to final concentration of 2mM in the PCR 
reaction.
(ii). Magnesium Chloride concentration
The Mg2+ concentration in the PCR reaction is important for primer 
annealing and specificity, strand dissociation, enzyme activity and formation 
of artifacts. Identifying the correct concentration of Mg^ '*' in the PCR is 
therefore integral to specific amplification of target sequences. Several titres 
of Mg^ '*' concentrations were performed (0.0 - 6.0mM) using standard PCR 
conditions.
It was noted that loss of both specific and internal control amplification was 
observed at final Mg^  ^ concentrations below 1.5mM, while concentrations 
above 3mM caused the specific amplification to be reduced in favour of the 
internal control amplification. In a number of Mg^ "*" titrations performed 
during the course of this study, a final concentration of 2mM consistently 
gave the best results in terms of presence of both specific and internal 
control amplification with reduced (data not shown).
(iii). dNTP , Taq polymerase, and primer concentration.
The final concentration of dNTP's, Taq polymerase, and primer 
concentrations used in HLA specific PCR reactions has in general remained 
constant throughout this thesis. All primers were used at a final 
concentration of 0.2|nM, 1 unit of Taq polymerase was used per 50)li1 PCR 
reaction. Each dNTP was used at a final concentration of 200pM, with a 
slight loss of amplification noted at a concentration of lOOpM. These
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conditions were used standardly in the PCR reactions.
(iv). PCR temperature cycling parameters.
Adjustment of the PCR cycling parameters provided the major means of 
altering stringency within the PCR reactions. All the SSP were designed to 
have similar annealing temperatures in an attempt to allow all the typing 
reactions to be performed under the same amplification conditions. A n  
increase in stringency within the reaction could be achieved by raising the 
annealing temperature in the PCR, while lowering the annealing 
temperature would decrease stringency.
Problems were encountered in terms of both false positive and negative 
amplification at different annealing temperatures. False positives tended to 
present either as products of the correct size or incorrect size. The correct size 
product usually indicated a lack of stringency leading to cross-reactive 
amplification of HLA specificities (i.e. failure of the ARMS principle). 
Products of incorrect size indicated low stringency or primers annealing to 
sites different to that intended. If altering stringency had no effect on  
abolishing false positives, then alternative SSP sites or combinations were 
considered.
Lack of stringency was associated with false positive amplification. If the 
situation was general across many of the reactions, an increase in the 
annealing temperature generally improved specificity. If the problem is 
limited to one reaction or SSP, then titration of this SSP should be 
investigated. Also inclusion of a deliberate mismatch in the SSP, near the 3 ' 
residue was found to enhance specificity when cross-reactivity was a 
problem.
The inclusion of step-down PCR enhanced the specificity of the PCR 
reaction. Step-down PCR involves the alteration of the annealing 
temperature through the course of PCR cycling. The initial annealing 
temperature is set high for the first set of PCR cycles before being lowered (or 
stepped down') one or more times in the subsequent cycles. This in effect 
means that the PCR reaction starts at high stringency which is lowered as 
the PCR progresses. High stringency improves the accuracy of primer
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annealing and so enhances the specificity of the PCR reaction. However, the 
use of high stringency alone reduces the amount of PCR amplification, 
making it difficult to detect product. For this reason, the subsequent cycles in  
the step-down PCR are performed at lower stringency, at which the 
amplification is more efficient. Creating highly specific PCR product in the 
first rounds of PCR ensures that when the stringency is lowered, this 
product will form the basis of further amplification, so reducing the am ount 
of crossreaction and generation of false positives.
False negatives also appeared under conditions that favoured the internal 
control reaction at the expense of the specific reaction. It was therefore 
necessary to find the correct window of stringency within the PCR that 
allowed specific amplification without the presence of false positives or 
negatives.
As mentioned above, a step-down approach was adopted for enhancing 
specificity within the panel of PCR-SSP reactions. It also allowed for 
stringency without the loss of the internal control amplification. Due to the 
disparity in annealing temperature between the SSP's and the internal 
control primers, increasing the PCR annealing temperatures caused loss of 
internal control amplification. Decreasing the annealing temperature caused 
either an increase of non-specific amplification or false negatives though the 
internal control reaction competing out the specific reaction. A compromise 
PCR cycling program was determined, in which the initial PCR cycles were 
performed at high annealing stringency (65°C) followed by the remainder of 
PCR cycles performed at a lower annealing stringency (55°C). This step-down 
PCR enhanced the specificity of the HLA-A SSP combinations while also 
permitting amplification of the internal control reaction. Additional steps' 
down can be introduced within the PCR program to fine-tune stringency.
Step down PCR; (95°C-lmin, 65°C -Imin, 72°C-2min)5 cycles +
(95°C-lmin, 55°C-lmin, 72°C-2min)25 cycles
The use of step-down PCR provided the required stringency to control for 
false positive and negative amplification. The above step-down PCR was as 
used for much of the early work in the initial panels using the Hybaid 
thermal cycler. Another PCR cycling program was determined for use with
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MJ Research Thermal cyclers in which PCR was performed in 96 or 192 well 
plates in reduced volumes;
96 well plate step down ; (96°C-50s, 70°C-50s, 72°C-50s)5 cycles + .
(96°C-50s, ôl^C-SOs, 72°C-50s)15 cycles +
(96°C-50s, 55“C-50s, 72‘’C-lmin)10 cycles
Performance of typing reactions in microtitre plates rather than 0.65ml 
eppendorf tubes, allowed a larger throughput of samples and reduced 
reaction volumes (from 50|il to 25p,l or 13fxl). The change in PCR machines 
and small reaction volumes also reduced cycling times from 4 hours to 2 
hours for the 30 cycle PCR's described above.
(v). Preparation of reagents - consistent typing performance.
A  key factor in performing PCR-SSP HLA typing is consistency in  
performance and results. In establishing the basic method, assembly of the 
PCR reaction was initially performed on an individual basis, to test for a 
particular SSP combination or other parameter. Results improved as the 
conditions for PCR became optimised. However occasional variation was 
noted on repetition of a typing, which could be attributed to a lack of 
consistency in preparing each PCR typing individually. To abrogate this 
problem, once the basic PCR conditions were established, large batches of 
PCR mixes (containing dNTPs, PCR buffer, MgCl2) were made and aliquoted. 
Preparing such batches of PCR mixes reduced the problem of variation 
between each PCR amplification. Also the preparation of larger volumes of 
PCR mix reduced the variation between batches contributing to a more 
standardised assay. Incorporating such standardisation of reagents allowed 
for a more straightforward development of PCR protocols for HLA-A typing.
3.2.4 Validation of the FCR-SSP Low Resolution HLA-A typing panel.
Each of the reactions in the initial low resolution typing panel (LRT) in  
Table 3.1 was tested individually, to determine specificity. Several SSP 
combinations required alteration or replacement through the influence of 
newly identified alleles, cross-reactivity with pseudogenes or other class I 
alleles, or simply because better SSP combinations existed than those first
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considered. The continuous reassessment of the typing panel in response to 
newly identified specificities was a requirement throughout this thesis.
HLA-A locus 
Specificity
coding
primer
non­
coding
primer
Specificity of coding 
primer
Specificity of 
non-coding primer
band
size
(bp)
A1 AL#2 AL#A A1 A26 A29 A 1 510
A2 AL#3 AL#H A 2 A9 A 2 A28 453
A3 AL#6 AL#D All A3 A28 A29 A30 A 3 547
A9 AL#5 AL#H A9 A3002 HLA-G AS A2 A28 633
AlO AL#7 AL#C HLA-A except A202 A205 A lO 440
All AL#6 AL#I A l l A3 A28 A29 A30 A1 A l l 518
A28 AL#6 AL#H All A3 A 28 A29 A30 A9 A2 A 28 445
AID(not A30) AL#7 AL#F HLA A except A202 A205 A 2S  A 3 1  A 3 2  A 33 520
A30 AL#10 AL#G A 30 A31 A 30 HLA-H 446
Table 3.3. The first LRT panel following modification from pilot panel listed in Table 3.1
The first panel to be used for PCR-SSP typing at the HLA-A locus was as 
described in Table 3.3. To validate the performance of the LRT panel, a small 
number of DNA samples covering most of the specificities identified in the 
typing panel was tested blind. The results as compared to serology are shown  
in Table 3.4 below. The results were highly encouraging with agreement in  
all but one of the samples. The one discordant result was later found to be 
due to a wrongly labeled sample and not a problem with reaction specificity.
The LRT panel was further used to type genomic DNA extracted from  
peripheral blood mononuclear cells (PBMC) and EBV transformed B cell 
lines. Examples of typings using an LRT panel are given in figure 3.1. 
Additional validation was achieved through typing DNA obtained from  
serologically  w ell characterised sam ples and w here p ossib le  cell lin es that 
had been sequenced for HLA-A locus alleles. Continual use of the panel for 
typing of samples provided a constant if limited means of validation of the 
methods performance, since many samples had already been typed 
serologically. This continual assessment of performance allowed improved  
SSP combinations to be designed.
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CELL LINE
SSP-PCR HLA-A 
LOCUS TYPING.
SEROLOGICAL HLA-A 
LOCUS TYPING.
HRC.l 1 3 1 3
HRC.4 1 2 1 2
HRC. 6 1 9 1 9
HRC.7 1 0 28 26(10) 28
HRC.23 2 2
HRC.30 2 19 2 29 (19)
HRC.300* 2 9 1 28
HRC.302 2 19 2 29 (19)
HRC.304 2 19 2 31(19)
HRC.305 2 1 1 2 1 1
HRC.309 2 3 2 3
HRC.314 2 19 2 31(19)
Table 3.4. A panel of DNA tested blind by the PCR-SSP LRT reaction panel and compared to 
their serological typing. Concordance between PCR-SSP and serology was noted in all samples 
except *HRC.300, which was later shown to be a wrongly labeled sample.
The typing panel for low resolution typing listed in Table 3.5 provides a 
more current list of reactions for this level of resolution. An additional 
reaction has been added to the nine broad reactions to define HLA-A*80, 
which is a distinct specificity not identified in the other reaction groups.
The basic panel of the ten reactions listed in Table 3.5 was supplemented by 
two control reactions which divide the HLA-A locus specificities into two. 
Amplification with reaction 11 and or 12 can be used to confirm the 
observation made in the basic panel in a manner similar to using Bw4, Bw6 
assignment at B locus. The combined use of SSP's AL#30 and AL#31, specific 
for HLA-A was necessitated through observations made with the initial 
choice of coding SSP, AL#7 for these reactions, a cautionary tale with regard 
to the amplification of pseudogenes. The combination AL#7/AL#L 
potentially amplifies certain HLA-H alleles, which has resulted in false 
positive amplifications on several occasions. Interestingly, the presence of 
these false positives has coincided with HLA-A2 being present in the
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haplotype, suggesting potential linkage disequilibrium between HLA-A2 and 
the relevant HLA-H alleles. The important point to note from this is that 
not only must other Class I genes be considered in primer design, but also 
any Class I pseudogenes. An additional general HLA-A locus specific PCR 
(AL in Table 3.5), amplifying the majority of exons 2 and 3 can be used for 
additional typing through a nested approach, as discussed in the following 
chapter.
HLA-A locus Low Resolution Typing,
AI A2
AI9
Figure 3.1. Five examples of low 
resolution typing at HLA-A locus. 
A panel of nine reactions define as 
follows;
Lane A; A1 (AL#16/AT)
Lane B; A2 (AL#13/H)
Lane C; A3 (AL#7/D)
Lane D; A9 (AL#8/H)
Lane E; AlO (AL#7/C)
Lane F; A ll (AL#6/I)
Lane G; A28 (AL#6/H)
Lane H; A19(not A30) (AL#7/F) 
Lane I; A30 (AL#12/G)
A2AÎ0 / " Reaction J and K act as controls 
J with reaction J (AL#30.31/H) 
amplifying A2,A9,A28 and 
reaction K (AL#30.31/L) 
amplifying Al, A3, AlO, A ll, A19. 
Lane M is a size marker.
M ABCDEFGHI JK
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Tube No. Specificity Coding Primer Non-coding Primer size
1 Al/36 AL#16 AL#AT 527
2 A2 AL#13 AL#H 487
3 A3 AL#7 AL#D 626
4 A9 AL#8 AL#H 470
5 AlO AL#38 AL#AE 649
6 A ll AL#6 AL#1 518
7 A28 AL#6 AL#H 445
8 A19(notA30) AL#38 AL#F 580
9 A30 AL#12 AL#G 560
10 A80 AL#54 AL#BK 543
11 A2A9A28 AL#30&31 AL#H 446
12 A l/36 A3 AlO A ll A19 A80 AL#30&31 AL#L 446
AL A locus CL15' AL#AW 780
Table 3.5. A low resolution typing panel in the context oi recently identified alleles
Additional control reactions 11 & 12 provide validation of the typing result.
3.3. Discussion.
In this chapter, the development of a fundamental system for analysis of 
HLA-A polymorphism has been described. The determination of a workable 
system identified certain key factors which provided points of adjustment to 
the specificity of the system and also enabled the simultaneous performance 
of a series of PCR reactions each defining a different HLA-A specificity. 
Designing primers on the basis of ARMS (Newton et al, 1989) provided 
amplification specificity under the correct conditions of stringency achieved 
through the PCR cycling profile, as enhanced through the use of 'step-down' 
PCR. The ability to simultaneously amplify several different PCR reactions 
under a standard set of conditions was achieved through assuring all SSP 
had compatible annealing temperatures. A further important parameter was 
the 'batch' preparation of reagents to allow for consistency between typing 
results.
The advantage of using such a system became apparent at even this point. 
Typing from DNA rescinded the need for viable cells as required in serology.
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which in turn facilitated easier storage of samples. There was no reliance on  
non-renewable stocks of antisera, nor the problems of their cross-reactivity. 
The PCR-SSP system provided the opportunity for a standardised yet flexible 
system using standard laboratory equipment and renewable reagents.
Having been successful at a low level of typing resolution and having  
ascertained the relevant parameters to type reliably by PCR-SSP for HLA-A 
broad specificities, new SSP combinations were developed which increased 
the resolution offered by this typing approach. The increase in resolution  
and the approaches taken to acquire allelic definition are discussed in the 
following chapter.
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Subtyping and allelic definition.
4.1 Introduction.
The basic parameters for defining broad HLA-A locus specificities had been 
determined in Chapter 3. However the level of resolution offered by the 
basic low resolution panel was well below that possible through serological 
determination. Although the PCR-SSP approach at the HLA-A locus already 
held some advantages over serology in terms of ease of interpretation, 
standardised methodology and wide array of source material that could be 
utilised, the degree of resolution offered clearly needed improvement.
It became apparent through the development of the initial typing panel, that 
additional PCR-SSP reactions could be readily designed, offering subtyping of 
the broad serological specificities in the basic LRT typing panel. Because of 
the shared nature of polymorphism present amongst HLA-A specificities, 
some of the subtyping reactions could simply be designed using new  
combinations of SSP's already used or tested for the LRT panel. The first aim  
was to extend the number of specific reactions to attain a level of resolution  
comparable with that attainable by good serology at the HLA-A locus. It then  
remained to design additional SSP combinations and develop approaches 
which would allow allelic discrimination at the HLA-A locus. This chapter 
covers the developments made in protocols for achieving increasing 
resolution at the HLA-A locus to the point of defining the allele.
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4.2 Determining the common subtypes of HLA-A9, -10, -28 
and -A19.
The described low resolution typing system for the Class I HLA-A locus 
assigns HLA Class I specificities A*01, A*02, A*03, A9, AlO, A *ll, A28, A19 
(except A*30) A*30 and A*80 from genomic DNA. At this level, serology 
remains more definitive. Expansion of the initial reaction panel has allowed 
a higher resolution HLA-A locus typing, which for some alleles gives clearer 
definition than serology. This section describes this extension to the low  
resolution typing, by defining the common subtypes of A9, AlO, A28, and 
A19.
The design of additional SSP combinalioiis enables Qie identification of 
subtypes of the group specific reactions from the low resolution typing. For 
example, A9 can be split into A*23 and A*24 and A28 splits into A*6801, 
A*6802 and A*6901. One of the more challenging groups to assign subtypes 
for was the A19's. Out of necessity, the method already splits A*30 from the 
other A19's in the low resolution panel (chapter 3), due to a scarcity of 
shared polymorphism between A*30 and the other members of the A19 
group. However, further SSP combinations were created to distinguish 
between A*29, A*31, A*32 and A*33. This initial exercise in subtyping at the 
HLA-A locus also described primer combinations that differentiate between 
three allelic variants of A*30, (A*3001, A*3002 and A*3002) and two A*29 
allelic variants (A*2901 and A*2902).
4.2.1 HLA-A9 Subtyping.
Table 4.1 shows the subtyping reactions which define A*23 and A*24, the 
serological 'splits' of HLA-A9. An A*23 sample would amplify with  
reactions (a) and (b), while an A*24 would be positive with reactions (a) and 
(c).
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Reaction specificity coding SSP non-coding
SSP
size (bp)
(a). A9 AL#8 AL#H 470
(b). A*23 AL#8 AL#Q 555
(c). A*24 AL#8 AL#R 555
Table 4.1 Subtyping reactions defining A*23 and A"^ 24.
4.2.2 HLA-AIO Subtyping.
HLA-Al0 subtyping was performed by a pattern of reactions, as the SSP 
combination designed to identify A"^ 26 also amplified the rare A*43 allele 
(Table 4.2). The SSP combination (c) distinguished A*26 and A*43, 
perm itting the differentiation of these alleles. Three SSP combinations were 
required to define A*25 and A*26, and a further combination confirms HLA- 
AIO. The inclusion of the HLA-AIO SSP combination enabled this panel to 
identify the specificities A*25, A*26, A*43, and A*34/A*66. Figure 4.1 shows 
results from AlO subtyping with this panel, in which sample 1 types as an 
A*25, having positive reactions with (a), (c) and (d), sample 2 types as an 
A*26, being positive reactions with (b), (c) and (d), and sample 3 types as an 
A*43, being positive with reactions (b) and (d), but negative for reaction (c). 
An A*34 or A*66 DNA sample would be positive with reactions (c) and (d), 
(not shown in figure 4.1).
m m  m m
u A25 
b A2G A43 
V A 2 5  A 2 6  A 3 4  A(>C> 
d A25 A2() A34 A()() A43
m.-.abcü
1
.abed, .abed
7 3
Figure 4.1. Examples of AlO subtyping. Sample 1 types as A*25, sample 2 types 
as A*26 and sample 3 types as A*43. The constant lower band corresponds to 
the internal control. SSP combinations are given in Table 4.2
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Reaction specificity coding SSP non-coding
SSP
size (bp)
(a). A*25 AL#11 AL#C 398
(b). A*26 A*43 AL#2 AL#C 397
(c). A*25A*26A*34 A*66 AL#4 AL#C 438
(d). AlO AL#7 AL#C 497
Table 4.2 Subtyping reactions defining A'^ 25, A*26, AM3, A*34/66.
4.2.3 HLA-A28 Subtyping.
As with the AlO splits, the HLA-A28's were subtyped by reaction pattern. 
Table 4.3 shows the three SSP combinations, (a) being A*6901 specific, (b) 
being A*6802 and A*6901 specific while (c) amplifies A*6801, A*6802 and 
A*6901. A fourth specific combination (d) is also included, to differentiate 
between A*68 and A69. Reaction (d) also amplifies A*3401 and A*66 and so 
may not be informative in the presence of these alleles. Although this panel 
does not include a specific combinations for either A*6801 or A*6802, 
different patterns of reaction are obtained with the three prim er 
combinations. Thus A*6801 amplifies with primer combination (c) only, 
A*6802 amplifies with primer combinations (b) and (c), while A*6901 
amplifies with all three SSP combinations.
Reaction specificity coding SSP non-coding size (bp) 
SSP
(a). A%901 AL#6 AL#Y 382
(b). A*6802 A*6901 AL#6 AL#B 405
(c). A28 AL#6 AL#H 445
(d). A%8 A*3401 A%6 AL#6 AL#U 530
Table 4.3 Subtyping reactions defining A*6801, A*6802 and A*6901.
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4.2.4 HLA-A19 Subtyping.
Subtyping the HLA-A19 family of alleles has proved to be one of the 
problem areas for serology. SSP combinations which allow clear distinction 
between the major HLA-A19 subtypes are shown in Table 4.4. As described 
previously, HLA-A*30 could not be included in the A19 group specific 
reaction by PCR-SSP, and requires a separate reaction in the low resolution 
panel. Therefore, if a low resolution typing panel is performed initially on  
an A*30 sample, it is not necessary to further subtype for A19 unless the A19 
(not A*30) reaction appears positive indicating the presence of another A19 
allele.
in.'.abcdef. .abcdef
1 2
m.-.abcdef. .abcdef 
3 4
.abcdef. .abcdef
5^* ,
Figure 4.2. Examples of HLA-A19 
subtyping to identify
specificities; A’*'29 (sample 1), 
A*30 (sample 2), A'^ 31 (sample 
3), A*32 (sample 4), A’*'33
(sample 5) and A’^ 30, A'^31
(sample 6). The reaction panel 
consists;
Lane a; A*29 
Lane b; A*30 
Lane c; A*31 
Lane d; A*32 
Lane e; A"^ 33 
Lane f; A19 (not A*30)
SSP combinations are given in 
Table 4.4.
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Reaction specificity coding SSP non-coding
SSP
size (bp)
(a). A*29 AL#2 AL#F 420
(b). A*30 AL#12 AL#G 560
(c). A*31 AL#10 AL#F 480
(d). A*32 AL#11 AL#F 421
(e). A*33 AL#4 AL#F 461
(f). A19(not A*30) AL#7 AL#F 520
Table 4.4 Subtyping reactions defining A*29, A*30, A*31, A*32, A*33 and A*74 by exclusion.
A19 A30
Figure 4.3a. Low resolution typing of 
an individual with a serologically 
problematic combination of A19 
specificities, (A*30, A*31). The
A*31 in this panel types as an A19 
(not A*30). The primer combinations 
used in this typing panel are listed 
in chapter 3, Table 3.3.
m ."
Figure 4.3b. A19 subtyping of the 
individual identifying both A*30 
and A*31. The SSP combinations of 
panel are are listed in Table 4.4.
Figure 4.2 shows six examples of A19 subtypings using a panel of 
combinations to type for specificities A*29, A*30, A*31, A*32, and A*33, 
together with the group specific reaction for A19 (except A30). A lthough no t 
ideal, the A19 split FfLA-A*74 can also be determined by amplification w ith
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reaction (f) and exclusion of A*29, A*31, A*32 A*33. A specific PCR reaction 
is required to identify A*74 with confidence. In figure 4.2, samples 1 to 5 
typed as A*29 to A*33 respectively.
Sample 6 typed as an A*30, A*31. Individuals who are A*30, A*31 are 
extremely difficult to type by serology, due to cross reactivity w ithin the 
typing sera. This individual was initially typed by serology, th rough  
segregation of the two antigens in a family study. Figure 4.3 shows the ease 
of discrim ination of HLA-A*30 and -A*31. Firstly in the low resolu tion  
typing panel (top panel in figure 4.3a) in which the A31 is identified as A19 
and in subsequent A19 subtyping (bottom panel in figure 4.3b), in w hich 
both A30 and A31 are definitively identified. This example demonstrates the 
virtues of this PCR approach in defining serologically problematic 
specificities.
4.2.5 HLA-A*30 subtyping.
The typing panel listed in Table 4.5 was primarily designed to discrim inate 
between the common allelic variants of HLA-A*30, A*3001 and A*3002. The 
results from figure 4.4 show sample 1 typing as an A*3001, being positive 
with the A*3001 specific primer combinations, (a) and (b), while sample 2 
typed as an A*3002, being positive with primer combinations, (c) and (d). 
Both samples were positive with the additional HLA-A*30 combinations (e) 
and (f). At the time of design of the initial subtyping panel, only A*3001 and 
A*3002 had been described, and A*3003 and A*3004 were not considered. 
The influence of A*3003 and A*3004 on the specificity of the sub typing panel 
is included in Table 4.5. It would have been possible to determine A*3003 
and A*3004 since A*3003 would have presented by amplification w ith  
reactions (d) and (f) and A*3004 would have amplified with reactions (e) and 
(f). Allele specific discrimination of the A*30 group of specificities is 
described later in this chapter (section 4.4.3).
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m.-.abcdef, .abcdef 
1 2
Figure 4.4. A*30 subtyping by a panel of six 
reactions as listed in Table 4.5. Sample 1 types 
as A’^ 3001 and sample 2 types as A*3002.
Reaction specificity coding SSP non-coding
SSP
size (bp)
(a). A*3001 AL#6 AL#K 518
(b). A*3001 AL#12 AL#K 672
(c). A*3002 AL#10 AL#T 557
(d). A*3002, A*3003 AL#12 AL#T 671
(e). A*3001 A*3002 A*3004 AL*10 AL#G 446
(f). A*3001 A*3002 A*3003 A*3004 AL#12 AL#G 560
Table 4.5 HLA-A*30 subtyping reactions defining the alleles A*3001, A*3002 , A*3003, 
A*3004.
4.2.6 HLA-A29 Subtyping.
Two variants of HLA-A'^29 have been sequenced so far. The variants differ 
by only one base pair in the whole of exons 2 and 3. The '2901' SSP has been 
designed to detect this one base pair difference, which when used in the 
given combination (Table 4.6), produces a specific amplification for A*2901. 
The SSP combinations were used to screen known A29 samples in an 
attem pt to locate an A*2901 variant. In figure 4.5, samples 2 and 5, were both 
positive with the A*2901 specific primer combination, whilst samples 1, 3 
and 4 failed to amplify with this primer pair, typing these cell lines as 
A'^2902.
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Figure 4.5. Examples of 
subtyping for A*2901 and 
A*2902 using SSP
combinations listed in 
Table 4.6. Samples 2 and 
5 type as A*2901 and 
samples 1, 3 and 4 type 
as A*2902. The lower 
band present in each 
typing reaction
corresponds to the 
internal control at 330bp.
1 2  3 4
Reaction specificity coding SSP non-coding
SSP
size (bp)
(a). A*29 AL#2 AL#F 420
(b). A*2901 AL#6 2901 367
Table 4.6 HLA-A*29 sub typing reactions defining the alleles A*2901 and A*2902.
The above typings clearly illustrate the ability of ARMS-PCR to differentiate 
between alleles that differ from each other by a single base pair.
4.2.7 Conclusions to the primary HLA-A subtyping study.
Section 4.2 investigates the possibility of increasing the resolution of the 
PCR-SSP HLA-A locus typing system from that initially achieved in defining 
broad specificities. By using the PCR-SSP approach to identify of the 
common subtypes HLA-A9, -AlO, -A28 and -A19, an alternative method to 
serological definition has been demonstrated at the HLA-A locus.
In designing SSP combinations to define subtypes, there exists a certain level 
of flexibility as to the choice of primers as determined by the available 
polymorphism. Hence, a number of different SSP combinations may be used 
to define a single specificity. The level of resolution is another point of 
flexibility. The method had at this point already shown definition at a broad 
generic serological level to one well beyond serology with the allelic 
definition of A*2901, A*2902, A3001, A*3002, A*3003. Subtyping has also
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demonstrated that PCR-SSP can discriminate specificities on the basis of a 
single base pair difference as demonstrated on the A’^ 2901 C ^ G  A ’^ 2902 
substitution found at nucleotide position 33 in exon 3.
Many of the HLA-A locus alleles common in Caucasoids will be detectable 
by this protocol. However, instances have occured, especially when typing 
other ethnic groups, when the presence of a novel sequence may cause a 
discrepancy in the typing result. Discrepancies between serological and PCR 
typings may point to the existence of a new allelic variant. Further 
investigation using different primer combinations for the relevant 
specificity, may offer a prediction of the site of polym orphism  in the new  
sequence with respect to the other variants. The developm ent of this 
approach in characterising new alleles is discussed elsewhere (chapter 6.2). 
Alternatively, inclusion of broad generic reactions in addition to the 
subtyping reactions may indicate discrepancies (e.g. a positive am plification 
with the generic reaction but all the subtyping reactions type negative). Such 
examples emphasize the need to be constantly aware of new sequence data to 
ensure that the typing panel has valid specificity and covers all HLA-A locus 
alleles. The use of the additional SSP combinations AL#30.31/AL#H and 
AL#30.31/AL#L contribute a partial level of control in such situations.
The ability of the PCR-SSP approach to distinguish HLA-A locus alleles in  
different heterozygous combination is a significant attribute of this tissue 
typing system. However, using the SSP combinations described in this 
section, there remain some instances in which a definitive typing would no t 
be possible in defining certain heterozygous combinations. In subtyping for 
A28, A*6801 could not be distinguished from A*6802 if present together in a 
heterozygote. The described AlO subtyping panel would not be able produce 
a definitive typing if combinations of A*26 and A*43, or A*43 and 
A’^ 34/A'^66 were present together in a heterozygote. Also, in splitting A*29, 
the given SSP combinations would not distinguish A*2901 if present 
together with A'^2902 in the same individual. A lthough such antigen 
combinations will be rare in the general Caucasoid population, it rem ains 
im portant to be aware of their existance. The design of SSP com binations 
which offer a more concise typing without ambiguity provided the next area 
for improvement of the PCR-SSP method.
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This section has concentrated on defining the main variants or 'splits' of the 
broad specificities identified by the low resolution typing panel w ith  
emphasis placed on specificities present w ithin the Caucasoid population. 
However, it is also im portant to be aware of alleles found in other ethnic 
groups. A subsequent objective was the extension of the m ethod to cover 
alleles found in black and oriental populations.
4.3. V a lid a tion  o f an extend ed  H LA-A locu s PCR-SSP p an el through  
typ in g  D N A  from  the 4A O H  cell panel.
To further verify the fidelity of the HLA-A locus PCR-SSP typing system, the 
m ethod was applied to DNA samples in the Fourth Asia-Oceania 
Histocompatibility (4AOH) Workshop. The panel of SSP combinations used 
provided an equivalent, and in some instances superior level of resolution 
to that attainable to serology. The study was carried out blind under 
W orkshop conditions and the results confirm the m ethod as an accurate 
means of determining HLA-A locus tissue types.
The 4th Asia Oceania Histocompatibility W orkshop (4AOH) typing 
component offered the opportunity of DNA typing the HLA-A locus of 
workshop cell lines in a blind study. This study represents the first 
comparison of DNA based and serological typing methods for Class I alleles 
to be carried out under the controlled conditions of an HLA workshop. Cells 
grown from frozen stocks were used to extract genomic DNA using an 
Applied Biosystems 340A nucleic acid extractor and standard protocols. 48 
samples were typed by an initial low resolution panel of 9 reactions, (A l/36, 
A2, A3, A9, AlO, A ll , A28, A19(not A30) and A30) w ith subsequent 
sub typing of A9, AlO, A28 and A19; the method being as described 
previously in both this chapter and chapter 3. The SSP combinations used 
were capable of determining specificities as listed in Table 4.7. Following 
PCR, a sample of each reaction was run out on an agarose gel and the typing 
result determined by the presence or absence of the appropriate sized 
product.
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LOW RESOLUTION 
TYPING SPECIFICITIES
SUBTYPING
PERFORMED
A1/A36 -
A2 -
A3 -
A9 A*23
A*24
AlO A*25
A*26
A*43
A*34/A*66
A*3401
A ll -
A28 A*6801
A*6802
A*6901
A19(not A30) A*2901
A*2902
A*31
A*32
A*33
A30 A*3001
A*3002
A*3003
Table 4.7. List of HLA-A locus specificities tested for in both the Low Resolution Panel and 
subsequent subtyping panels.
Examples of low resolution HLA-A locus typings are given in figure 4.6. 
Sample 003 typed as A*01, sample Oil typed as an A’^ 02, A19(not A'^OO), 
sample 012 typed as an A*02, A^^ll, and sample 026 typed as A*03, A9. Each 
reaction also included a positive internal control primer set, amplifying a 
330bp region of the p-2 microglobulin gene. This product can be seen as the 
lower band present in each of the panel of nine reactions of the four typings 
shown in figure 4.6.
Results of the HLA-A locus typings in the 48 workshop samples (containing 
subtypings) are given in Table 4.8, which also compares data obtained by the 
PCR-SSP m ethod with the W orkshop "Best characterisation of 4AOH cell
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panel" (Degli-Esposti, et al 1993). This allowed the determ ination of the best 
allele assignment as typed by the most discriminating technique for that 
specificity and includes typing designations reached by this PCR-SSP 
method. Agreement was reached between PCR-SSP typings and the 
W orkshop results in 43 of the samples. The rem aining 5 samples produced 
results that did not concur with the workshop designation. Sample 013 was 
typed by PCR-SSP as an A*02, A'^ll, but only as an A*02 in the w orkshop 
results. Following the release of the W orkshop results, the cell was typed 
retrospectively by serology and the typing suggested the presence of a weak 
A *ll, but the results were not conclusive. Sample 021 was typed from DNA 
as an A^^ll A*6801 as compared to the W orkshop result of A“^02, A’*’l l .  The 
sample was retrospectively typed by serology, confirming the PCR-SSP 
A"^6801 designation.
4AOH.003
4AOH.011  ^ ^ ^ .
Figure 4.6. Four examples 
of HLA-A locus low 
resolution typing of DNA 
samples from the 4AOH 
workshop panel. The 
typing panel consists of;
Lane 1; A1
Lane 2; A2
Lane 3; A3
Lane 4; A9
Lane 5; AlO
Lane 6; A ll
Lane 7; A28
Lane 8; A19 (not A30)
Lane 9; A30
The panel is as described 
in figure 3.1 in chapter 3.
4AOH.003 types as A l, 
4AOH.011 types as A2, 
A19(not A30), 4AOH.012 
types as A2, A ll and 
4AOH.026 types as A3, 
A9. Additional subtyping 
was performed to 
identify the specificities 
listed in Table 4.8.
90
4A0H 
SAMPLE No. A
SSP TYPINGS
A
4AOH TYPINGS 
A A
001 2 2
002 19 (33) 19 (33.1)
003 1 1
004 2 2
005 11 19 (33) 1 1 19 (33)
006 3 9 (24) 3 9 (24)
008 2 3 2 3
009 10 (26) 10 (26.1)
010 2 19 (2902) 2 19 (2902)
Oil 2 19 (31) 2 19 (31)
012 2 1 1 2.2 1 1.2
013 2 1 1 2
014 2 19 (31) 2 19 (31)
015 2 9 (24) 2 9 # 4
017 2 19 (31) 2 19 (31)
018 9(24) 9(24)
019 1 1
020 2 2.2
021 1 1 28 (6801) 2 1 1
022 1 1
024 2 2.4
026 3 9(24) 3 9(24)
027 9(24 9(24)
028 2 10 (3401) 2 34
029 2 2
030 19 (3U 19 (31)
031 2 2
033 2 2
037 3 3
038 3 3
039 1 1
040 3 3
045 1 1
052 1 1 11.2
059 2 2.2
068 19 (31) 19 (31)
070 2 2.2 3
072 2 2.2
073 2 2
077 2 2.2 3.2
141 1 1
200 2 2.4
204 2 2
208 1 1
211 3002 30
016* 11 19 (2902, 33) 1 1
032* 1, 2 9(24) 9 (24.1)
036* 3,9(24) 10 (26), 30 3.2 9 (24.1)
typing results for HLA-A locus. * Indicates DNA samples with contamination.
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In the remaining three samples (016, 032, 036), more than two HLA-A locus 
alleles were identified in each sample. These typing differences were show n 
to be a result of DNA contamination and not an intrinsic problem of the 
PCR. PCR-SSP typings of these samples consistently identified additional 
HLA-A locus alleles. Sample 016 was typed in the W orkshop as A *ll. The 
results revealed the additional presence of A“^2902 and A33. Serology could 
only confirm the additional presence of A*29 in this cell line. Sample 032 
was reported in the W orkshop as an A24.1. Typing by PCR-SSP found a 
further two alleles (A'^Ol A*02). Subsequent serology found A*01 A*^ 02 but 
failed to see A24. Following disclosure of the results it was noted that 
Sample 032 corresponded to the well defined cell line DKB (A24). Typing a 
separate source of this DNA from our own stocks confirmed the Workshop 
result, indicating that the sample typed initially in the study was 
contaminated. Sample 036 (known better as L0081785), typed as A^ 2^6 A“^30 in  
addition to the reported typing of A*^ 03 A24.1. Serology confirmed the 
workshop result. Repeating the typing with DNA obtained from an 
independent source, also confirmed the workshop result, whilst the 
anomalous DNA sample reproducibly gave the additional specificities. 
Similar instances of contamination have been previously observed, and this 
highlights the need for extreme care in the preparation of DNA samples.
In this blind study, the degree of concurrence between the ARMS PCR-SSP 
typings and Workshop results confirms that HLA Class 1 DNA typing is both 
feasible and reliable. Even in the instances where disagreement existed, this 
could be explained by sample contamination or serological mistyping. The 
lEF data included in the Workshop results (Degli-Esposti, et al 1993), 
identified some specificities additional to our own, namely A2.2, A2.4, A3.2 
A24.1, A26.1, A33.1 in the panel tested. The ARMS PCR-SSP m ethod, 
however, is capable of typing at an allelic level as shown in identifying 
A*2902, A*3002 A*3401 and A*6801 in the DNA's tested, so producing far 
more definitive typings than serology. The full potential of the technique in  
producing Class 1 allelic typing was not realised in this study. Further 
development was therefore necessary to extend this level of allelic typing to 
all Class 1 specificities.
As with other DNA based typing methods, ARMS PCR-SSP can only assign 
allele specificity based on known DNA sequences. The use of group specific
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reactions in the low resolution panel minimises the chance that 'n ew ' 
alleles will be missed by the technique. But new sequences need to be 
examined to ensure they are detectable correctly by the current panel of SSP 
combinations, and if not, new SSP combinations have to be designed. The 
flexibility of the method usually means that more than one SSP 
combination exists for each specificity or broad group specific reaction, 
enabling a replacement combination to be found.
In conclusion, the potential of the ARMS PCR technique as dem onstrated 
under W orkshop conditions, clearly showed it to be an accurate means of 
determining the HLA-A locus tissue type from DNA. The successful typing 
of 4AOH DNA provided the confidence for further developm ent of the 
method in search of increasing resolution at HLA-A and also the application 
of a similar approach to HLA-B (Sadler, et al 1994). The use of PCR-SSP for 
HLA-A locus typing provided future W orkshops and studies an additional 
technique for Class I DNA typing, with a potential well beyond that of 
serology.
4.4 N ested  PCR-SSP for a lle lic  H LA -A  typ ing.
4.4.1 Introduction.
The nature of polymorphism found amongst HLA alleles occurs mainly as a 
result of different combinations of sequence motifs shared with other HLA 
alleles at hypervariable regions w ithin the gene. To type at a level of allelic 
definition is difficult due to a relative absence of unique sequence 
polym orphism s which would allows for their specific identification in a 
PCR-SSP system. The lack of unique polymorphism  and the prevalence of 
shared sequence polymorphism  amongst HLA Class I genes, increases the 
complexity for specifically amplifying and identifying a particular allele. One 
approach to increase the polymorphism  available for allelic definition of 
HLA Class I alleles is the use of nested PCR. The use of nested PCR for HLA 
typing was first described in relation to class II DNA typing, th rough  
definition of DRBl specificities (Bein, et al 1992).
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The general principal of nested PCR-SSP in the context of this study, is the 
primary amplification of the desired group of specificities using prim er sites 
which flank the polymorphic regions required to distinguish the alleles of 
interest. This specific first round PCR is then used as template for 
subsequent PCR-SSP reactions using prim er sites found within the initial 
amplification. The use of a specific first round PCR excludes the interference 
of other class I alleles which would compromise the integrity of the 
subtyping reactions. The 'filtering out' of unw anted HLA alleles increases 
the available polymorphisms from which SSP combinations can be designed 
which allow differentiation between alleles of highly similar sequence.
The use of nested PCR is also useful in situations where DNA quantity is 
limiting. As described in Table 3.5 (Chapter 3), the SSP com bination 
CLI5'/AL#AW specifically amplifies the majority of exons 2 and 3 of all 
HLA-A locus alleles. This PCR product can then be used with the majority of 
specific SSP combinations used for typing at HLA-A.
The use of nested PCR for subtyping in this thesis, was initially established 
for defining the allelic variants of HLA-A"^03. Further application of the 
nested approach was used for allelic definition of HLA-A’^ 30 and HLA-A’^ 02. 
W here required, nested typing was used to define specificities difficult to 
identify through a one step PCR-SSP approach. This section will describe the 
developm ent of nested approaches for the discrim ination of HLA-A 
specificities to the allelic level.
4.4.2 Establishing the parameters for nested PCR.
The general parameters for the use of nested PCR in application to PCR-SSP 
typing at the HLA-A locus was established in relation to A*03 subtyping. 
Two allelic variants of HLA-A’^ 03 had been sequenced (Bodmer, J.G. et al 
1995). As an exercise in screening for A*03 subtypes, it was decided to 
attem pt definition of A*0301 and A"^0302.
Definition of these alleles through a one step PCR-SSP proved difficult, since 
their differentiation relies on identifying polym orphism s found in o ther 
class I alleles. The main polymorphisms that discriminate between the two 
A"^ 03 alleles are found in exon 3 at nucleotide positions 195/6. A"^ 0301 has
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nucleotides 'TT' at this site while A"^0302 has 'CA'. To define either A*03 
variant, it was necessary to combine the discriminatory SSP's with a fairly 
specific A*03 SSP. The only polymorphic site which has this specificity is as 
defined by prim er AL#D, located some 18 nucleotides 3' of the 195/6 
polym orphism  in exon 3 and too close to be of use in a one-steps PCR 
system.
To remove the influence of the potential cross-reactivity from other class I 
alleles, a nested approach was considered. This would use the A’*'03 specific 
SSP combination AL#7/AL#D which flanks the sites of polym orphism  
which distinguish A’^ OSOl and A’*’0302. The parameters for PCR-SSP using 
PCR product as template needed to be determined in the context of the HLA- 
A locus typing approach established so far.
An approach was investigated whereby the first round A*03 am plification 
was performed through the standard 30 cycle step-down PCR. A titration of 
this first round product comprising tenfold dilutions (1:10^ to 1:10^ final 
dilution in the PCR), were then tested in a further 30 cycle step down PCR 
using nested SSP combination AL#6/AL#Q, specific for A'^OSOl. Using the 
nested SSP combination, specific amplifications were present at all the 
dilutions. An A*03 negative DNA was also tested. No specific product was 
seen and only the internal control was amplified at all the dilutions.
Reaction specificity coding SSP non-coding
SSP
size (bp)
(a) A*0301 AL#6 AL#Q 530
(b) A*0301 AL#6 AL#AA 519
(c) A*0302 AL#6 AL#R 530
Table 4.9 Screening panel for identifying A*03 subtyping performed nested from AL#7/AL#D.
A*03 subtyping was performed on a 1:500,000 final dilution of first round  
product obtained from thirteen A*03 DNA samples, through a 30 cycle step- 
down PCR using the typing panel given in Table 4.9. Two A*03 negative 
DNA samples were also included as controls. All thirteen A’^OO samples 
typed as A W O l, and no A^^0302 DNA was identified. Neither non A ’^OO
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samples gave a positive amplification (data not shown). U nfortunately, 
sequenced controls were not available for both A*03 subtypes. However, 
later in this chapter (section 4.5), an A*0302 sample was identified using a 
similar sub typing panel.
The extent of dilution of the first round product was not really practical for 
this system. To circumvent this problem, the first round PCR was used at a 
lesser dilution and the number of PCR cycles reduced. A 1:10^ and 1:10^ final 
dilution of A“^03 first round product in the PCR were tested with controls 
against a 20 and 25 cycle A*0301 specific nested step-down PCR using SSP 
combination AL#6/AL#Q. All of the combinations of PCR cycle num ber and 
dilution factor produced clean specific amplifcation. Initially, based on this 
result, it was decided that a 1:10^ final dilution of first round product in  
combination with 20 cycle PCR would be appropriate for this system. 
However, in extending this approach to AlO and A19 sub typing, occasional 
non-specific amplification was observed (data not shown). To counter this 
problem, the num ber of cycles within the PCR was reduced to 15. The final 
conditions used for nested PCR were therefore a final 1:10^ dilution of first 
round PCR product in a 15 cycle amplification. The cycling parameters as 
used on the Hybaid thermal cycler were;
(95°C-lmin, 65°C-lmin, 72°C-2mm)5 cycles + (95°C-lmm, 55°C-lmin, 72°C-2mm)10 cycles.
Another approach to reduce non-specific amplification was to increase the 
dilution factor of the first round product. Variation in the dilution factor has 
proved useful when the first round amplification has been above or below 
that expected. For example, in the event of a weak first round amplification, 
a smaller dilution can be used in the subtyping reactions.
The following sections describe the use of nested subtyping with particular 
analysis of HLA-A"^ 02 and A*30. Finally, the last section describes a 
com prehensive system for discrimination of HLA-A locus alleles, 
sum m arising the previous developments made in this chapter.
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4.4.3. Nested PCR-SSP to identify the allelic subtypes of HLA-A"^ 30.
This section describes a nested PCR method to distinguish the allelic 
variants of HLA-A*30 alleles. This approach was adopted to facilitate easier 
identification of these alleles without the interference of cross-reactivity 
from other HLA class 1 alleles. A first round amplification was used to 
generate an HLA-A'^30/A’^ 3302 specific ARMS/PCR product. At the tim e 
this reaction was designed, A*3302 had not been described. The co­
amplification of A*3302 would however not interfere in the specificity of the 
subtyping reactions. This is then used as template for a second round of 
amplifications in which the different A*30 alleles can each be specifically 
identified.
Although the A*30 subtyping SSP combinations described earlier in this 
chapter (Table 4.5), could discriminate between A*30 variants, this was 
achieved through interpretation of reaction patterns. Typing th rough  
reaction pattern may fail to identify certain heterozygous combinations, as 
indeed is seen in Table 4.5, where an A*3002/A*3003 heterozygote w ould 
produce the same reaction pattern as an A*3002 homozygote. To address this 
situation, it was decided that where possible, specific SSP combinations for 
each allele or specificity would be incorporated into typing panels, w hich 
may require the application of nested PCR.
The initial nested protocol was devised to identify the three variants of 
HLA-A*30 known at that time. DNA from A*30 sequenced B cell lines were 
available for each of these three variants and used for verification of the 
sub typing panel. These included LBF, RSH (A*3001), EJ32B, CR-B (A*3002), 
and JS (A*3003), with additional local DNA samples com plem enting the 
controls. All DNA's were used at 500ng/50pl for the first round PCR 
reaction.
Reagents and primer concentrations were as described in chapter 2 (Section 
2.1.2). The SSP combination used (Table 4.10, SSP sequences in Tables 2.2. & 
2.3) for the first round HLA-A*30 A*3302 specific amplification was initially 
AL#12/AL#Q. This was later modified to AL#12/AL#W to accommodate 
and characterise a variant A*30 allele, A*3004. These prim er pairs are 
different to the combinations used for identification of A*30 (AL#12/AL#G)
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in the low resolution panel (see chapter 3), which does not amplify a 
sufficient region of exons 2 and 3 for subsequent nested subtyping. The 
possible co-amplification of A*3302 with SSP combinations AL#12/AL#Q 
and AL#12/AL#W should not interfere with the A*30 nested subtyping 
panel of reactions, as all the nested PCR reactions used in the subtyping 
panel were specific for A*30 alleles. An A*3302 cell line was not available, 
and so it was not possible to verify its reactivity with the above SSP 
combinations. The first round amplification consisted of (95°C-lmin, 65°C- 
Im in, 72°C-2min) for 5 cycles followed by (95°C-lmin, 55°C-lmin, 72°C- 
2min) for 25 cycles. Following the first round amplification, lOgl of PCR 
product was checked on a gel to identify the presence of a PCR product and 
confirm the sample as HLA-A*30. The PCR product was diluted 1:100 in  
dH20. 5pl of the dilution was then used in each of the 50gl second round 
amplifications with the appropriate SSP combinations (Table 4.10). The 
second round PCR was run on the shortened program consisting of (95°C- 
Im in, 65°C-lmin, 72°C-2min) for 5 cycles followed by (95°C-lmin, 55°C- 
Im in, 72°C-2min) for 10 cycles. The final PCR product was visualised on an 
ethidium  bromide stained agarose gel, and the result interpreted th rough  
the presence or absence of the appropriately sized PCR products.
As part of these studies, a serologically defined A*30 sample was tested and 
failed to amplify with the initial first round PCR-SSP com bination 
(AL#12/AL#Q). This discrepancy between the serological definition and the 
DNA suggested the presence of a novel variant of HLA-A*30. Failure to 
amplify with A*30 PCR-SSP combinations utilising prim er AL#Q, provided 
insight that a polymorphism  existed at this site. Further characterisation of 
this sample by PCR gene-mapping' and DNA sequencing (discussed in  
Chapter 6), defined this A*30 as a new variant and it was subsequently 
cloned, sequenced and named A*3004 by the WHO nom enclature 
committee. As mentioned in the Table 4.10, PCR-SSP combinations exist for 
specific amplification of A*3004, and one of these was included in  
subsequent panels (see Table 4.13).
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Reaction specificity coding SSP n o n ­
coding SSP
size (bp)
1st round A*30 A*3001, A*3002 AL#12 AL#W 719A*3003, A*3004
PCR A*3302
A*3001, A*3002 AL#12 AL#Q 687
A*3003, A*3302
2nd round (1)
A*3001 AL#6 AL#K 518
subtyping (2)
A*3002 AL#10 AL#T 557
PCR (3) A*3001, A*3002 A*3004
AL#10 AL#0 444
(4) A*3002, A*3003 AL#12 AL#T 671
(5) A*3003 AL#36 AL#T 557
Table 4.10. SSP combinations for HLA-A*30 subtyping by nested PCR. A first round 
amplification (AL#12/AL#W) is used as template for a second round of subtyping reactions. 
AL#12/AL#Q was found to not amplify an A*30 variant (A*3004). A specific reaction for the 
A*3004 can be obtained using any combination of AL#10 with AL#AX, AL#AY, AL#AO, 
AL#AV or AL#AU as shown in the PCR gene mapping' characterisation (Figure 6.1 Table 6.1)
Examples of typing the four variants of HLA-A*30 by nested PCR-SSP, is 
given in Figure 4.7. Hence, with the panel, A*3001 is identified by 
amplification with reactions 1 and 3, A*3002 with reactions 2, 3 and 4, 
A*3003 amplifies with reactions 4 and 5 and the new A*30 variant (A*3004) 
identified by reaction 3 and failure to amplify with the original first round  
amplification, AL#12/AL#Q. All four variants can be distinguished and the 
addition of an A*3004 specific nested PCR-SSP combination to the panel, 
removes any possible ambiguity in definition of A*30 heterozygous 
combinations. The four A*30 variants can be defined by four allele specific 
SSP combinations, however the additional reaction can prove useful for 
subtype verification.
The identification of new HLA class I alleles provides a constant reason for 
vigilance in terms of how new sequences may affect the specificity of existing 
ARMS/PCR reactions. For typing A*30 alleles, we are now aware of two 
recently identified alleles, A*0102 (Browning, et al 1995) and A*3302 (Kato, et 
al 1993), for which SSP AL#12 (previously thought to be A*30 specific) also 
has specificity. Of these two alleles, A*3302 can potentially be co-amplified by
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the first round primer combination of AL#12/AL#W. In this study, the 
subtyping reactions exclude the presence of A*3302, since they identify 
motifs not seen in this allele. Co-amplification of A*3302 would therefore 
not affect A*30 subtyping in the methods described. It would however be 
potentially be misleading to use the SSP combination AL#12/AL#W as A*30 
specific, in the low resolution HLA-A locus typing panel as it is in fact A*30 
plus A*3302 specific. For this reason we continue to use prim er com bination 
AL#12/AL#G, which specifically amplifies all four HLA-A*30 variants, as 
the generic A*30 SSP combination in the low resolution typing panel 
(Chapter 3, Table 3.5).
1 2 3 4 5 2 3 4 5
m - 1 2 3 4 5 - 1 2 3 4 5
C D
Figure 4.7. Four 
examples of A*30
subtyping by nested
PCR. The panel of 5 
subtyping reactions, 
listed in Table 4.10, are 
performed nested from 
1st round PCR 
AL#12/AL#W.
Sample A types as an 
A*3001 being positive 
with reactions 1 and 3. 
Sample B types as an 
A*3002, being positive 
with reactions 2, 3, 4. 
Sample C types as an 
A*3003 being positive 
with reactions 4 and 5. 
Sample D types as an 
A*3001, A*3002 being 
positive with reactions 
1,2,3 and 4. An A*3004 
sample would be 
amplified by reaction 3 
alone (not shown).
4.4.4. Nested PCR-SSP to identify the allelic subtypes of HLA-A*02.
HLA-A*02 is present at high frequency in most populations. Seventeen 
allelic HLA-A*02 variants have been identified at the time of writing. The 
great majority of genetic polymorphism which defines the allelic variants is
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found in exons 2 and 3 of the A*02 genes. These exons encode the a-1 and a- 
2 domains of the HLA Class I molecules, and variation within the genes 
may influence the peptide binding specificity of the gene products of each 
allele. This section describes a method for determining the different HLA- 
A*02 alleles by use of a nested PCR-SSP approach. This method of HLA-A*02 
subtyping permits a more detailed and discriminating study of allelic 
variation between different population groups as discussed in Chapter 5.
This inability of serology to define adequately functionally distinct allelic 
variants render it redundant for typing to the T cell level of d iscrim ination 
Serology can at best identify three A2 specificities (Marsh, et al 1992), and five 
ID-IEF (Guttridge, et al 1992). But through DNA sequencing. Sixteen of the 
seventeen then known A*02 alleles, encode molecules which have different 
amino-acid sequences and potentially different profiles of im m unological 
function (reviewed in chapter 8). A*0215N is not expressed and is truncated 
prem aturely in exon 4 through a point mutation encoding a stop codon. The 
relevance of the polymorphic differences that exist between the HLA allelic 
variants makes their identification desirable. This is particularly true for 
HLA-A*02, which is found at high frequency in nearly all populations 
studied.
The HLA-A*02 alleles vary in the main part in exons two and three. Of the 
16 expressed HLA-A*02 alleles, only A*0201 and A*0209 are identical in  
exons 2 and 3, differing only in exon 4 by a single amino acid. All the A*02 
alleles show a high level of sequence similarity, containing motifs shared 
with other A*02 variants as well as other A locus and Class I alleles. The 
high degree of sequence homology between the HLA-A*02 alleles and the 
relative lack of unique polymorphisms make identification of the 
individual alleles potentially difficult. Figure 8.2 (chapter 8) describes the 
polymorphic differences between the A*02 allelic variants.
A panel of subtyping reactions using SSP designed on the ARMS principle 
was used to achieve the high level discrim ination required to distinguish 
between the A*02 alleles. These subtyping reactions were run nested from a 
initial flanking ARMS-PCR which specifically amplifies essentially all of 
exons 2 and 3 of all A*02 alleles as demonstrated in figure 4.8. The use of an 
A*02 specific first round reaction excludes the interference of other Class I
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alleles in the subtyping reactions. This addition of specificity through a first 
round reaction enables high resolution typing and discrim ination between 
alleles of highly similar sequence. The system was validated using DNA 
from sequenced cell lines, and shown capable of distinguishing between all 
known A*02 alleles.
EXON 2
A2 specific 
first round 
primer
intron EXON 3
A locus specific 
first round 
primer
5' A2 nested 3' A2 nested
subtyping subtyping
primers primers
Figure 4.8. Representation of the nested PCR-SSP approach to subtyping the HLA-A*02 
specificity. An initial flanking reaction comprising an A*02 specific primer at the 5' end of 
exon 2 is combined with an A locus specific primer at the 3' end of exon 3. This PCR product 
which contains many of the polymorphic differences between the A*02 alleles is then used as 
template for a further round of PCR reactions using primer sites within the initial flanking 
reaction which determine the A*02 subtype.
Control DNA's representing many of the known A*02 alleles, were obtained 
from B cell lymphoblastoid lines including JY (A*0201), M7 (A*0202), DKl 
(A*0203), RML (A*0204), WT49 (A*0205), CLA (A*0206), KNE (A*0207), KLO 
(A*0208), OZB (A*0209), XLI.ND (A*0210), KIM.ND (A*0211), KRC033 
(A*0212), SLUGEO (A*0213), TUBO (A*0216) and AMALA (A*0217). A*0214 
(Krausa, et al 1995) genomic DNA was provided from peripheral blood 
m ononuclear cells (PBMC), from the individual in whom the allele was 
identified. No DNA was available for the non-expressed A*02 variant, 
A*0215N.
The identification of HLA-A*02 alleles was achieved in two steps. Firstly a 
generic 813bp HLA-A*02 specific flanking reaction, using SSP com bination 
AL#37 and AL#AW, amplified all of exons 2 and 3 together w ith the 
intervening intron (figure 4.8). Secondly, a panel of SSP combinations lying 
nested within the first round amplification were used against the A*02
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specific PCR product. Initially, only 14 A*02 variants had been identified, 
which were discriminated by the panel of 13 sub typing reactions given in  
Table 4.11. SSP sequences are given in Chapter 2, Table 2.2 and 2.3. A*0201 
and A*0209, together with A*0207 and A*0215N were not distinguished by 
nested PCR since the defining polymorphisms are located in exon 4. SSP 
AL#BJ, used for identification of A*0207, has a melting tem perature of 72°C 
as compared to the standard 58-60°C used in these protocols. The initial SSP 
used to identify this allele consistently gave weak false positive bands. W e 
overcame this problem by extending the prim er to a 21mer, and 
incorporating a deliberate mismatch (Newton, et al 1989) four nucleotides 
from the 3' end. This SSP was still compatible with the conditions used for 
the other SSP's.
A*0207, A*0208 and A*0209 were initially only described as amino acid 
sequences (Lopez de Castro, 1989). To design SSP's which could be used to 
identify these alleles, the amino acid sequence was conservatively translated 
into nucleotide sequence, within the context of other known HLA-A locus 
alleles. The validity of these SSP sites was then tested in the appropriate PCR 
combinations against DNA obtained from the sequenced cell lines KNE 
(A*0207), KLO (A*0208) and OZB (A*0209). In the absence of nucleotide 
sequence, others have also successfully taken this approach to identify these 
three alleles by oligonucleotide probing (Fernandez-Vina, et al 1992). The 
SSP's designed on this basis together with the other SSP's used in the 
subtyping panel, provided the required specificity in determ ining the A*02 
subtype for these three alleles.
In the initial A*02 subtyping panel described in Table 4.11, identification of 
the A*02 alleles was achieved by SSP combinations specific for a particular 
allele or pattern of reactivity. A*0202, A*0203, A*0204, A*0207, A*0208, 
A*0209, A*0210, and A*0211, were identified by specific PCR reactions. 
Identification of A*0201, A*0205, A*0206, A*0212 A*0213 and A*0214 relied 
on interpretation of reaction patterns (e.g. A*0205 was identified by positive 
reactivity with reactions 'e' and 'f  in Table 4.11). A*0201 and A*0209 were 
distinguished by an additional reaction from genomic DNA, using an SSP 
combination amplifying from exon 3 (AL#29) to an A*0209 specific site in  
exon 4 (AL#AL).
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In situations where A*0204 or A*0207 or A*0211 were identified, and no  
other A locus allele was observed, the additional presence of A*0201 in an 
A*02 heterozygous combination, could not be discounted by the panel 
described above. To verify whether A*0201 is present in such situations, 
additional reactions were required as listed in Table 4.12. Similarly, reactions 
that detected A*0206 in an A*0206/A*0210 heterozygous sample and A*0212 
in an A*0212/A*0213 heterozygous sample were also required. The reactions 
listed in Table 4.12 were validated against a panel of sequenced A*02 DNA's. 
Because A*02 is present at high frequencies within m any populations, the 
possibility of A*02 allelic heterozygotes cannot be ignored, and where the 
situation dictates, these additional reactions must be pursued.
The component reagents of the PCR were basically as described elsewhere in  
this Chapter and in Chapter 2. A negative control reaction, containing 
distilled water instead of DNA was included to ensure the PCR m ixture was 
not contaminated. The first round A*02 specific amplification was 
performed through a 30 cycle step-down PCR. lOpl of PCR product was 
screened on a 2% Agarose gel stained with ethidium  bromide to check for 
the A*02 specific amplification. A 1:100 dilution of the A*02 specific PCR 
product was made, and 5|il of this is added to a final 50|il volum e of each of 
the subtyping reactions. The panel of sub typing reactions was then ru n  
through a 15 cycle step-down PCR as previously described (section 4.3.3) The 
sub typing reactions were then visualised on a 2% agarose ethidium  brom ide 
stained gel, and the result interpreted by the presence or absence of the 
appropriately sized PCR products in each of the panel reactions.
The reaction panel was tested against genomic DNA derived from a panel of 
sequenced HLA-A*02 B cell lymphoid lines or PBMC, which covered all the 
known A*02 sequences at that time (Bodmer, J.G. et al 1994; Krausa, et al 
1995). The initial first round reaction (AL#37/AL#AW) was shown to 
specifically amplify all the known A*02 alleles. Using the A*02 specific PCR 
product as template DNA for the nested PCR, the subtyping reaction panel 
worked as expected, allowing identification of all the alleles tested. Figure 4.9 
shows the patterns of reactions obtained from A*02 sub typing the first 14 
A*02 alleles from the panel of control cells. Any sample typing as 
A*0201/A*0209 was further tested with an additional SSP com bination 
(Table 4.11), defining the A*0209 specific polymorphism in exon 4.
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No.
Coding SSP
Non-coding
SSP Specificity size
A2 FIRST ROUND
A2 AL#37 AL#AW A*0201-*0214 813
A2 NESTED SHORT SUBTYPING PANEL
a AL#22 AL#Q A*0201, *0204, *0207, *0209, *0211 715
b AL#22 AL#AK A*0202 579
c AL#22 AL#AE A*0203 694
d AL#22 AL#AF A*0204 540
e AL#3 AL#AK A*0202, *0205, A*0214 409
f AL#27 AL#AK A*0205, *0208, A*0214 579
g AL#22 AL#BJ A*0207 549
h AL#26 AL#AK A*0208 408
i AL#27 AL#Q A*0206, *0210, A*0214 715
j AL#27 AL#N A*0210 546
k AL#55 AL#Q A*0211 522
1 AL#22 AL#R A*0212 A*0213 705
m AL#22 AL#BL A*0203, A*0213 695
Distinguishing A*0209 from A*0201 (30 Cycle from genomic)
209 AL#29 AL#AL A*0209 907
subsequently typed by an additional panel of nested reactions (a-m). A*0209 is differentiated 
from A*0201 by a separate reaction (209) from genomic DNA.
Additional SSP combinations were added to the subtyping panel for the 
determination of new A*02 alleles (A*0215N-A*0217) (data not shown). The 
effects of the polymorphism present within newly identified A*02 alleles on 
the specificity of the sub typing panel were evaluated, and additional SSP 
combinations included to ensure allelic A*02 definition. Specific SSP 
combinations for A*0216 and A*0217 were added to the nested subtyping 
panel. As with A*0209, a separate amplification was required for A*0215N, 
which identified the specific polymorphism in exon 4, differentiating it from
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A*0207. An updated panel of A*02 subtyping reactions is included m Table 
4.13 (section 4.5 later in this chapter).
A®02C*3
aKKaet» fA’0?05
A*2206
A»0237
m m
mém
A“02H
A’020
A*C2Î3
KahedegçW. jklm
Figure 4.9. E xam ples of FiLA -A *02 
subtyping  14 sequenced D N A 's  
using a p an e l of SSP com binations 
(a-m ) as lis ted  in  T able 1. T h e  
330bp p roduct of th e  in te rn a l  
control p rim ers correspond to  th e  
low er b a n d  p resen t in  each  reac tio n  
lane (a-m ). M= size m ark er. C e ll  
lines used;JY=A*0201, M7=A*0202, 
DK1=A*0203, RM L=A*0204,
W T49=A*0205, CLA=A*0206,
KNE=A*0207, KLO =A *0208,
OZB=A*0209, X LI.N D =A *0210,
K IM E.N D =A *0211, 
KRC033=A*0212,
SLUGEO=A*0213, 1S=A*0214. 
A*0201 an d  A*0209 w ere
indistinguishable with this panel 
of nested PCR reactions but were 
discriminated by an additional 
reaction given in Table 4.11.
Reaction Coding
SSP
Non­
coding
SSP
a AL#22 AL#BG
b AL#22 AL#BF
c AL#14 AL#H
d AL#27 AL#BF
e AL#22 AL#AO
f AL#27 AL#U
g AL#7 AL#0
Table 4.12. Further reactions aesigneu
Specificity size
A*0201/2/3/7/9/1 1/12/13 not A*0204 
A*0201/2/3/4/9/11/12/13 not A*0207 
A*02 not A*0211 
A*0205/6/8/14 not A*0210 
A*0201/2/4/7/9/l 1/12 not A*0213/03 
A*0205/A*0208 not A*0214
A*0201/4/6/7/9/10/11 n o tA ^;021^
-------------------------   1 • 7 l  A ik /Y O  ^ 1 1 i= k 1 o C  I t !  C l
540
549
437
549
705
716
614
reaction T in the subtyping panel (Table 4.11).
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The nature of polymorphism  amongst the HLA-A*02 variants occurs 
mainly as a result of different combinations of sequence motifs shared w ith  
other A*02 and Class I alleles at hypervariable regions within the gene. Only 
a few A*02 alleles contain unique sequence motifs. The lack of allele specific 
motifs makes the use of a nested PCR, in which the first round reaction 
excludes all non A*02 Class I alleles, a powerful approach for differentiating 
between this group of highly similar alleles. The different possible 
combinations of A*02 polymorphic motifs generates a potentially large 
num ber of HLA-A*02 subtypes in excess of alleles presently identified. N ot 
all of these potential combinations of motifs will generate new alleles w hich 
offer a selective advantage to the host and result in selection of the varian t 
within the gene pool of a given population. There remains a possibility, 
however, that new variants of A*02 will be found through the 
discrim ination offered by DNA based methods of tissue typing. This is 
demonstrated in the characterisation of A*0214 and A*0216 discussed in  
Chapter 6.
The ability to identify the allelic variants of HLA-A*02 allows the potential 
for determination of the functional relevance of polymorphic differences, in  
terms of peptide binding and T cell recognition. Reports have already been 
made identifying different A*02 variants eliciting different profiles of T cell 
response (Biddison, et al 1980; Latron, et al 1991; Rotzschke, et al 1992; Utz, et 
al 1992; Tussey, et al 1994). It is therefore expedient to type at the highest 
possible level of discrimination, which in the first instance requires allelic 
typing to identify which sequences are immunologically relevant. Previous 
reports have described limited sub typing of HLA-A2 variants based on  
biochemical (Guttridge, et al 1992) or molecular biological approaches 
(Fernandez-Viûa, et al 1992; Allen, et al 1994; Tiercy, et al 1994). This section 
represents a definitive report of the discrimination of all known HLA-A*02 
alleles at the time of writing, and all possible heterozygous combinations of 
these alleles. Many reports have been made with regard to HLA-A2 
restricted CTL responses, w ithout identification of the A*02 allelic variant. 
Even in a small group of Caucasians, biochemical definition of HLA-A2 m ay 
not reflect the level of discrimination of HLA-A*02 variants recognised by T 
lymphocytes (Gotch, et al 1985).
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As discussed in Chapter 5, the diversity of A*02 alleles varies greatly in  
different population groups. With HLA-A*02 present at high frequencies in  
most populations, the method described offers the capacity to identify A*02 
at an allelic level, providing cellular immunological studies with greater 
m eaning and definition by appropriate matching of T cell and antigen 
presenting cell. This is particularly im portant when performing CTL assays 
in matched rather than autologous target cell lines. The capacity to identify 
HLA class I genes at an allelic level elucidates further population differences 
in HLA structure and diversity, and may increase disease associations w ith  
particular subtypes, so extending the understanding of why such differences 
exist.
4.5 A comprehensive PCR-SSP typing system for identification of 
HLA-A locus alleles.
This section concludes Chapter 4 and provides a sum m ary of SSP 
combinations used either in one-step or nested PCR to achieve allelic 
definition at the HLA-A locus. The majority of reactions required have been 
described previously in this and the preceding chapters. Where appropriate, 
new SSP combinations acknowledge recently identified alleles, and the 
specificity of existing SSP combinations are modified accordingly. As m any 
allele-specific polymorphism s have potential functional significance in  
terms of cellular responses (Gotch, et al 1985; van der Poel, et al 1986; Tussey, 
et al 1994), it becomes im portant to type at a level of resolution sufficient to 
identify these differences. The ability of PCR-SSP protocols to define HLA-A 
locus specificities to an allelic level holds precedent for allelic typing at o ther 
HLA loci.
The reaction combinations described in Table 4.13, are the result of 
developm ent of the method through the course of this thesis. The SSP 
combinations listed provide the means for high resolution typing in the 
context of the currently identified HLA-A locus alleles (Bodmer, et al 1995). 
W here possible, the reactions have been screened against DNA obtained 
from cell lines sequenced for the relevant allele. A list of control cell line 
DNA tested is given in chapter 2, Table 2.1. If sequenced cell line DNA was 
not available, then DNA obtained from serologically well characterised cell
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lines was used. In some instances, control DNA has not been available from  
certain recently identified HLA-A locus alleles, namely for A*0215N, 
A*2404, A*2405, A*2406, A*2602, A*2603, A*2604, A*1102, A*3302. The 
reactions identifying these alleles have therefore not been positively tested, 
however, they should provide the appropriate specific reaction based on the 
published gene sequence. Certain allele specificities are determined th rough  
reaction pattern. This has been kept to a m inim um  by using allele specific 
reactions where possible, and by the inclusion of additional reactions to 
ensure that certain alleles will not be hidden in particular heterozygous 
combinations. However, the reaction panel in Table 4.13 would no t 
determine A*3303 in the presence of A*3301, A*1101 in the presence of
A*1102, A*0204 in the presence of A*0217 and A*0207 in the presence of
A*0215N.
The SSP sequences are provided in Table 2.2 and 2.3. However, to 
accommodate new sequence data and higher resolution typing, several of 
the SSP combinations listed in Table 4.13 have been altered from those 
previously described in this chapter and chapter 3. All SSP's have been 
designed to have annealing tem peratures in the range of 56°C to 60°C, as a 
means of ensuring that all the SSP combinations work under the same 
conditions. These SSP's can be modified to work under conditions described 
by others (Olerup, et al 1993; Bunce, et al 1995a). This is can be achieved by 
extending the SSP sequence at the 5' end by the appropriate num ber of
nucleotides based on the allele sequence, such that the annealing
tem perature of the SSP is increased to 58-62°C.
Many of the reactions can be performed in one step from genomic DNA, as 
shown in the subtyping of A*10 variants in figure 4.10. Typing is also 
possible through at least two sequential rounds of nested am plification 
w ithout false positive amplification. For example, in typing A*3401 and 
A*3402 in sequential rounds of PCR, genomic DNA was specifically 
amplified with the general A locus SSP combination (CLI5'/AL#AW). This 
PCR product was diluted and used for a nested low resolution typing. The 
AlO positive PCR product (AL#38/AL#AE) from the low resolution typing 
was then diluted and used in a further round of nested AlO subtyping 
reactions.
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Amplification was either directly from genomic DNA and through 30 step- 
down PCR cycles, or nested from a diluted first round PCR product, th rough  
15 step-down cycles. These parameters may require alteration for use in  
different PCR machines. In general terms, raising or reducing the annealing 
tem perature increases or decreases the stringency of the PCR respectively.
Amplification in 0.5ml tubes was carried out in a Hybaid Thermal Cycler, 
but recently PCR has been performed in the PTC-200™ therm al engine (MJ 
Research Inc.) which accommodates a 96 or 192 well Thermowell th in  
walled plate (Costar). The reaction volume used in the 96 well plate was 25pl 
and a 13pl reaction volume was used in the 192 plate. The use of plates 
increases the throughput of samples, especially when used in com bination 
with a m ultitrack pipette and dedicated gel apparatus (Flowgen). As w ith  
tubes, plates containing all the reaction components except target DNA, can 
be stored frozen at -20°C, and thawed prior to use. Typings have been 
successfully performed using plates which have been stored frozen in excess 
of 6 months.
The use of nested PCR has proved advantageous in four main applications. 
Firstly, a group specific first round amplification can be used to exclude the 
presence of unwanted, potentially cross reactive specificities from the DNA 
for the nested PCR, so increasing the specificity of the second round PCR to 
allow for allele specific HLA gene detection. Secondly, where DNA is 
limiting, the use of a first round flanking PCR effectively amplifies and 
creates more template DNA. In this way, a full HLA-A locus typing can be 
performed on DNA samples as small as lOOng. In both these applications of 
nested PCR, first round PCR product was diluted (normally 1:100), and Ip l 
added per lOpl of reaction volume in the nested second round PCR. Thirdly, 
with the correct stringency, the first round amplification produces a highly 
pure template DNA, contributing to a cleaner amplification in the nested 
PCR. This may be advantageous for DNA samples from which one-step PCR 
gives relatively poor yields of specific PCR product. Finally, the use of nested 
PCR enables a higher resolution of typing, enabling allelic definition. Details 
of which subtyping reactions can be amplified from which specific first 
round flanking reaction are given in Table 4.13. It is important to note that a 
balance needs to be struck between dilution of the first round product and 
the num ber of cycles in the nested PCR amplification. Insufficient d ilu tion
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of product or too many cycles in the PCR may generate false positive 
amplification.
n
A 3402
A/6601
M A B C D E F G E
Figure 4.10. An example of 
one step HLA-AIO 
subtyping from genomic 
DNA, using a panel of 
reactions drawn from 
Table 4.13;
Lane A = A*25
Lane B = A*2601/2/4,
AM301
Lane C = AID not AM301 
Lane D = A*4301 
Lane E = A*34, A*66 
Lane F = A*3401 
Lane G = A’^ 3402 
Lane H = AID not A*6602.
Hence, A*2501 is defined 
by postives with reactions 
A,C,H, A*3401 is defined 
by positives w ith  
reactions C,E,F,H, A*3402 
is defined by positives 
with C,E,G,H and A*6601 
is positive with C,E,H. M 
is the size marker and the 
lower band present in 
each reaction is the 
internal control.
One significant advantage of the PCR-SSP approach to HLA typing is that it 
is relatively simple to change the level of resolution by selection of SSP 
combinations which specifically amplify broad or narrow allele groups, 
making the system readily adaptable to give levels of resolution of HLA 
specificity to suit the application. The approach generally followed for HLA 
typing in studies performed in this thesis, has been to perform an initial low 
resolution typing (Chapter 3.2). Following this low resolution typing, further 
sub typing reactions were pursued as dictated by the initial result. Sub typing 
can be carried out nested from either first round broad specific
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1st round 
PCR Template Reaction Specificity
coding
SSP
non-coding
SSP
band size 
(base pairs)
1 G • HLA-A CLI5' AL#AW 795
G,1 A*01/A*36 AL# 16 AL#AT 526
G,1 • A*01 AL# 16 AL#Z 574
G,1 A*0101 AL#22 AL#X 737
G,1 A*0102 AL# 12 AL#AT 671
G,1 • A*3601 AL# 16 AL#V 563
2 G • A*02 AL#37 AL#AW 813
G,1,2 A*02 AL#13 AL#H 487
2 A*0201, A*0204, A*0207, AL#22 AL#Q 715
A*0209, A*0211, A*0215N
A*0216 A*0217
2 A*0202 AL#22 AL#AK 579
2 A*0203 AL#22 AL#AE 694
2 A*0204, A*0217 AL#22 AL#AF 540
2 A*0202, A*0205, A*0214 AL#3 AL#AK 409
2 A*0205, A*0208 AL#27 AL#U 716
2 A*0205, A*0208, A*0214 AL#27 AL#AK 579
2 A*0207 A*0215N AL#22 AL#BJ 549
2 A*0208 AL#26 AL#AK 408
2 A*0206, *0210, A*0214 AL#27 AL#Q 715
2 A*0210 AL#27 AL#N 546
2 A*0211 AL#55 AL#Q 522
2 A*0212 A*0213 AL#22 AL#R 705
2 A*0203, A*0213 AL#22 AL#BL 695
2 A*0216 AL# 13 AL#AD 595
2 A*0217 AL#22 AL#BQ 533
2 A*0201/2/3/7/9/ll/12/ AL#22 AL#BG 540
13/16 not A*0204/17
2 A*0201/2/3/4/9/ll/12/ AL#22 AL#BF 549
13/16 not A*0207/15N/17
2 A*02 not A*0211 AL# 14 AL#H 437
2 A*0205/6/8/14 not A*0210 AL#27 AL#BF 549
2 A*0201/2/4/7/9/l 1/12/ AL#22 AL#AO 705
15N/16/17 not A*0213/03
2 A*0201/4/6/7/9/10/l 1/ AL#7 AL#Q 614
15N/16/17 not A*0214
2 A*02 not A*0216 AL# 13 AL#V 595
G A*0209 AL#29 AL#AL 907
G A*0215N AL#29 AL#BS 971
3 G,1 • A*03 AL#7 AL#D 626
3 A*0301 AL#6 AL#AP 532
3 A*0302 AL#6 AL#AQ 532
G,1 A9 AL#8 AL#H 470
G,1 • A*2301 AL#8 AL#Q 555
G,1 • A*24 AL#8 AL#R 555
G,1 A*2301/A*2402/4/5/6 AL#9 AL#Z 581
G,1 A*2403 AL#8 AL#W 589
G,1 A*2404 AL#2 AL#R 516
G,1 A*2301 A*2405 AL#8 AL#P 521
G,1 A*2406 AL#8 AL#U 558
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1st round 
PCR Template Reaction Specificity
coding
SSP
non-coding
SSP
band size
(base
pairs)
G,1 • AlO AL#38 AL#AE 649
G,l,4 • A*2501 AL#11 AL#C 398
G,l,4 • A*2601/2/4A*4301 AL#34 AL#C 400
G,l,4 A*2602 AL#34 AL#BN 395
G,l,4 A*2603 AL#14 AL#C 407
G,1 A*2604 AL#34 AL#BO 535
G,l,4 • AlO not A*4301 AL#4 AL#C 438
G,l,4 • A*4301 AL#17 AL#C 440
G,l,4 • A*34/A*66 AL#6 AL#C 417
4 A*3401 AL#18 AL#C 432
4 A*3402 AL#19 AL#AB 440
4 A*3402 AL#4 AL#AM 426
G,l,4 AlO not A*6602 AL#21 AL#C 362
G,1 A*6602 AL#6 AL#AD 553
G,1 • AHlOl, A*1102 AL#6 AL#I 518
G,1 A*1102 AL#23 AL#I 675
G,1 • A*ll, A*6601 AL#6 AL#AC 553
G,1 • A28 AL#6 AL#H 445
G,1 • A*6801 A*3402 AL#4 AL#AM 426
G,1 • A*6802 AL#25 AL#H 623
G,1 • A*6901 AL#6 AL#Y 405
G,1 • A19[not A*30] AL#38 AL#F 580
G,1 • A»29 AL#35 AL#F 515
6 A*2901 AL#17 2901 394
6 A*2902 AL#17 AL#AS 394
G,1 • A*30 AL#12 AL#G 560
G,1 • A*30/A*3302 AL#12 AL#W 720
7 A*3001 AL#6 AL#K 518
7 A*3002 AL#10 AL#T 557
7 A*3003 AL#36 AL#T 557
7 A*3004 AL#10 AL#U 572
G,l,5 • A+3101 AL#10 AL#F 481
G,l,5 • A*3201 AL#11 AL#F 421
G,l,5 • A*33 AL#4 AL#F 461
G,1 A*3301 AL#4 AL#AG 598
G,l,5 A*3302 AL#12 AL#F 598
G,l,5 • A*3201/A*7401 AL#24 AL#AR 494
G,l,5 • A19[not A32/A30] AL#32 AL#F 414
G,1 • A*8001 AL#54 AL#BK 543
G,1 • A2/A9/A28 AL#30/31 AL#H 446
G,1 • A1/A36/A3/A10/A11/
A19/A80
AL#30/31 AL#L 446
Table 4.13. SSP combinations for determination of HLA-A locus alleles. Reactions listed in the 
'1st round PCR' column can be used as template for the appropriate subtyping reactions. The 
letter G in the template column denotes genomic DNA. Hence, the allele A*0101 can be 
amplified using SSP combination AL#22/AL#X from genomic DNA or 1st round reaction 1 
product (CLI5'/AL#AW) to give a band 737 base pairs in size. A suggested HLA-A locus typing 
panel of reactions which can be performed directly from genomic DNA is denoted by (•). 
Alleles denoted in bold have not been tested.
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reactions where possible (A’^ 02 - AL#37/AL#AW, A*03 - AL#7/AL#D, AlO - 
AL#38/AL#AE, A19{not A3Ü} - AL#38/AL#F), or from the A locus specific 
general amplification. This approach does not suit all applications, and for a 
more routine typing at the HLA-A locus, a panel of 31 reactions is suggested 
(identified in Table 4.13), which provide a level of resolution which exceeds 
that achievable by serology in a single round of PCR.
At the time of development, the reaction panel listed in Table 4.13 provides 
definition of all published A locus alleles (Bodmer, et al 1995). However, the 
current activity of DNA sequencing has generated a constant stream of new  
alleles both for class I and class II specificities. Many recently identified HLA 
Class I alleles appear to have arisen as the result of gene conversion events, 
which implies that many polymorphisms in a newly identified allele may be 
shared with others. This will increase the possibility that a recently 
identified allele will be amplified by an existing amplification, so altering the 
specificity of one or more reactions. The integrity of the reaction panel has 
therefore to be validated within the context of newly identified allelic 
sequences. If the specificity of an established reaction is altered by a newly 
identified allele, then it may be necessary to find an additional or alternative 
SSP combination.
The capability for such high resolution definition opens the way for an 
increased understanding of anthropological differences, the functional 
significance of allelic differences to aspects of T cell responses, their 
relevance to transplantation and insight into the functioning of the HLA 
restricted cellular immune response.
4.6 D iscu ssio n .
This chapter charts the development of PCR-SSP subtyping at the HLA-A 
locus from the level of resolution obtainable with serology to a level 
achieving allelic definition. The methods described provided the means of 
discrim ination of all the HLA-A locus alleles known at that time. High 
resolution was possible through a combination of ARMS designed SSPs, 
stringency w ithin the PCR, validation with analysis of control DNA, and
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where appropriate, the introduction of additional specificity in the PCR 
through nested approaches.
The developments described in this and the previous chapter formed the 
basis of the A locus component of a class I PCR-SSP DNA typing kit and an 
A "^ 02 sub typing kit, which was used in the recent 12th International 
Histocompatibility W orkshop. Additionally, certain of the A locus SSP 
combinations have been incorporated into a class I and II PCR-SSP 
'Phototyping' technique described by Bunce et al (Bunce, et al 1995b). The 
ability to type sim ultaneously for both class I and II in one procedure, w ith  
resolution beyond that determined through serology, foretell the increased 
use of standardised PCR-SSP and other DNA techniques in the field of 
histocompatibility testing.
PCR-SSP tissue typing realises specificity through the identification of two 
points of cross-dependent sequence polymorphisms, as determined by the 
specificity of each SSP in the PCR reaction. Hence, for a particular allele to be 
amplified, it m ust contain two particular polymorphic sequence m otifs 
along the length of its sequence, for which each SSP has relevant specificity. 
The resulting PCR product must then be of expected length, as determ ined 
by the sites of specificity of each SSP. However, as more alleles are identified, 
and the complexity of the HLA system increases, it is increasingly difficult to 
identify allele specific reactions using one-step PCR. Nesting allows 
additional levels of specificity. The specificity of the first round allows the 
possibility of greater resolution in subsequent nested subtyping reactions. 
This is achieved through the specificity of the initial flanking reaction 
removing the presence of sequences which may interfere in determ ination  
of the allele-specific tissue-type in the subsequent sub typing reactions. 
Furthermore, sequential nesting can be used in determ ining allelic 
definition for certain groups of alleles. Table 4.13 outlines the possible 
different routes to obtaining typing at the appropriate resolution.
The ability to HLA type with increased discrimination offers the opportunity 
to better characterise population groups, show more precise linkage 
disequilibrium between HLA specificities, and better correlate HLA in  
disease association. The improved resolution of PCR-SSP over serology also 
allows improved matching in cellular assays providing more m eaningful
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results. Accurate determ ination of the tissue type, and examining the 
difference in function between alleles of similar sequence, may provide a 
better understanding of the role of polymorphism in the mechanisms of the 
HLA restricted immune response.
The following chapters will explore some of the above applications of this 
improved approach for HLA typing, with particular reference to population 
studies, characterisation of new alleles and studying the effects of 
polym orphism  with regard to the functioning of the T cell m ediated 
im m une response.
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Analysis of HLA in populations by PCR-SSP.
5.1 Introduction .
The ability to tissue type for A locus specificities can be applied to the 
characterisation of HLA in different population groups. The identification of 
HLA polymorphism at a resolution beyond that possible through serological 
discrim ination can increase the definition with respect to the structure of 
HLA gene frequencies between populations, and strengthen observations of 
HLA haplotype associations or linkage disequilibrium.
The highly polymorphic nature of the HLA system has provided a genetic 
basis for comparing different population groups. Through past workshops, 
based mainly on serological data (Imanishi, et al 1992a), the prevalence of 
HLA specificities was shown to vary considerably between different 
population groups. Hence HLA specificities common in one population may 
be rare or absent in another. The comparison of the HLA composition in  
different population groups may provide an understanding of how HLA 
polym orphism s may have evolved. The geographical distribution of 
populations in relation to HLA frequencies can also elucidate the origins 
and relationship between different populations. The presence or abundance 
of certain HLA specificities w ithin a population may be in consequence to 
the local pathogenic pressures.
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It is known through recent sequencing as reported in nom enclature reports 
(Bodmer, J.G. et al 1995), that a level of polym orphism  exists beyond that 
detectable through serological characterisation. Although serology has 
identified clear differences between population groups, the prospect of 
examining differences between populations based on allelic HLA definition 
may emphasize the singularity of an ethnic group in comparison to the 
generality of serological observation. Accurate HLA characterisation of a 
population is also an important prerequisite for CTL based vaccine trials.
The characterisation of population groups in terms of HLA differences based 
on allelic differences may elucidate differences not identified previously. In 
this chapter, HLA-A specificities in populations will be characterised to 
determine which allelic subtypes are prevalent, and if this inform ation  
strengthens any linkage disequilibrium. On a practical note, these exercises 
advocate the use of DNA methodology over serology, since exotic 
populations can be collected distant to the site of typing w ithout the 
requirement for separating lymphocytes and keeping them viable for testing.
The studies included w ithin this chapter involve the characterisation of 
HLA-A’^SO subtypes in the Sardinian population, comparing the prevalence 
of A"^ 02 subtypes in a num ber of different populations, and the use of PCR- 
SSP 'phototyping' (Bunce, et al 1995b) with additional allelic subtyping for 
characterising a Ugandan population.
5 .2 . C haracterising  the allelic variants o f H L A -A "^ 30 in a Sard in ian  
p op u la tion .
5.2.1 Introduction .
The origins of the Sardinian population, are far from clear, but the first 
hum an settlement is estimated in the Paleolithic period, at around 15,000- 
10,000 BC. A succession of settlements ensued during the following ages, 
including those from South West Europe, Asia Minor, the Aegean and 
Balkan regions reflecting the trade links taking place in the M editeranean. 
The inclusion of several ethnic groups, such as Corsican, Balearic, Iberian, 
Central European, Libyan, and Estruscan has also been made into the
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Sardinian population. The impact of this on the native population is no t 
readily apparent. Also, a major civilisation was present between 2000BC - 
300BC, prior to a succession of invasions, starting with the Phoenicians at 
around 500BC (Contu, et al 1992).
HLA characterisation therefore invited an interesting perspective upon the 
anthropology of the Sardininian population. This was approached in an 
extensive study of some 551 families, generating interesting data on the HLA 
structure of the population (Contu, et al 1992). The HLA analysis was 
performed by serological typing. As described in chapter 4, PCR-SSP offered a 
more discriminatory method of HLA typing, revealing polym orphism  no t 
determined through serological testing. To demonstrate this, indiv iduals 
serologically identified as HLA-A30 were subtyped for this allele by nested 
PCR-SSP.
This initial HLA characterisation (Contu, et al 1992) observed the presence of 
certain haplotypes, characteristic of the Sardinian population and also 
showed a high incidence of HLA-A30 (23.02% frequency), mainly as part of 
an A30 Cw5 B18 DR3 haplotype. HLA-A’^ 30 is one of the specificities 
included in the HLA-A19 serologically cross reactive group. But at a 
nucleotide level, HLA-A*30 seems distinct from the A19 group, and 
probably belongs within an A1/A3/A11 allele group (Kato, et al 1989). Prior 
to characterising this population, three allelic variants had been identified in 
the contemporary nom enclature report (Bodmer, J.G. et al 1994), with a 
fourth identified as a consequence of this study. These variants can be 
differentiated by one-dimensional isoelectric focusing (lEF) (Yang, 1989a; 
Choo, et al 1993), but are difficult to distinguish by serology. Hence, this 
study describes the use of PCR-SSP in application to A*30 subtyping. The 
increased level of typing definition which can be achieved using m olecular 
techniques contributes additional information to the understanding of the 
HLA composition in population studies.
PCR-SSP approaches for identification of A*30 subtypes have been described 
in Chapter 4 (sections 4.2.5, 4.4.3 and 4.3). In this study, a nested approach 
was pursued as outlined in Chapter 4.4.3. The use of a nested typing offers a 
highly discriminatory approach to defining alleles of very similar sequence, 
even when they are present in heterozygous combination.
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As described below, this approach has been used to subtype DNA from a 
panel of unrelated Sardinian individuals who had been typed by serology as 
HLA-A30.
5.2.2 M aterials and m ethods.
Thirty-five serologically characterised HLA-A30 DNA samples were taken 
from unrelated members of the Sardinian Population study panel (Contu, et 
al 1992) and HLA haplotype information was available on twenty-nine of 
these individuals. The Sardinian samples were all at lOOng DNA per pi TE 
buffer. DNA samples from well characterised B cell lines, including LBF, 
RSH (A*3001), EJ32B, CR-B (A*3002), and JS (A*3003), were used as controls, 
and were at varying concentrations diluted in dH20. All DNA's were used at 
500ng/50pl for the first round PCR reaction. The PCR-SSP nested subtyping 
was generally performed as previously described in Chapter 4.4.3
5.2.3 R esults.
Thirty-five HLA-A'^30 samples of which twenty-nine had haplotype 
inform ation were subtyped to identify alleles A"^ 3001, A'*'3002, and a new  
A*30 variant, A*3004. A*3003 was not found in the sample population. In 
chapter 4, Figure 4.7 shows typing results representing HLA-A*30 alleles, 
A*3001, A*3002, and A*3003 amplified by nested ARMS/PCR following first 
round amplification with primers AL#12/AL#W. A*3004 only amplified in  
this nested subtyping PCR panel with SSP pair AL#10/AL#O (not show n) 
(Table 4.10), distinguishing it from the other known A*30 alleles. This 
observation can be explained by the results obtained in the series of PCR 
gene mapping reactions discussed in chapter 6.
The haplotype results in terms of HLA-B locus, based on gene segregation in  
family studies, are given in Table 5.1. Additionally, six HLA-A*30 samples in 
which HLA gene segregation studies had not been performed, were also 
subtyped (not included in Table 5.1). Two of these samples typed as A*3001, 
and four typed as A*3002. All four A*3002 samples from this group 
contained HLA-B18 in their B locus assignment. Counting HLA-A*30 
homozygotes as two alleles, the sample group contained thirty-three A*3002
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alleles, four A*3001 alleles and one A*3004. In all, twenty-six out of thirty- 
three A*3002 alleles were associated with B18.
HAPLOTYPE NUMBER
.A*3002 -B18 22
-B50 2
- B41 1
-B8 1
-B49 1
-B27 1
-B35 1
total 29
A*3001 - B50 1
- B22 1
A*3004 -B49 1
total 3
Table 5.1. HLA-A*30 h a p lo ty p e s  in a S a rd in ia n  
p opu la tion . In 32 HLA-A*30 hap lo ty p es, 2 su b ty p ed  
as A *3001,1 sub typed  as A*3004 and  29 sub typed  as 
A*3002. 22 of the 29 A*3002 types w ere a s so c ia te d  
w ith  B18.
5.2.4 D iscu ssion .
This study has demonstrated that the use of nested PCR-SSP can be applied 
to defining the allelic variants of HLA-A*30 in a Sardinian population. The 
high frequency of HLA-A*30 in Sardinia, particularly in linkage 
disequilibrium with B*18, provided an interesting group in which to define 
the A*30 allelic subtypes. The data shows that of thirty-eight Sardinian HLA- 
A*30 alleles typed, thirty-three were A*3002, four were A*3001 and one a 
new variant, A*3004 (chapter 6.3). No A*3003 alleles were identified. Further 
to this, linkage disequilibrium was demonstrated between A*3002 and B18 
in Sardinia, (twenty-two out of twenty-nine A*3002 haplotypes tested in this 
study). The A*3002, B18, Cw5, DR3 represents the most common haplotype 
in the Sardinian population. Linkage disequilibrium between HLA-A30 and 
B18 has been reported in other population groups (Contu, et al 1992), namely 
Basques, Spanish, Catalan and Berber populations, but no A*30 sub typing 
data exists for these population groups. These results do confirm previous
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lEF data which suggests linkage disequilibrium between A30.1 (A*3002) and 
B18 (Yang, 1989a). The prevalence of A*3002 in Sardinia, contrasts w ith  
frequencies observed in other population groups. Data from another study 
in three African Black population groups found that in twenty-nine HLA- 
A*30 alleles typed, twelve were A*3001, sixteen were A*3002 and one allele 
typed as A*3004. As discussed in chapter 6, the characterisation of A*3004 
shows that it represents the IFF variant A30.2 which has been found in low 
frequencies in both Caucasian and Black populations (Yang, 1989a).
In conclusion, nested PCR-SSP was used to type further serologically defined 
HLA-A30 samples to achieve an allelic level of discrimination. Exam ining 
the allelic nature of A*30, present in the Sardinian population at high gene 
frequency (23%), it can be seen that 91% of the A*30's type as A*3002 of 
which 69% are associated with B*18. The data obtained demonstrated the 
potential benefits of high resolution DNA typing in elucidating the allelic 
HLA structure of a population and strengthening serologically perceived 
linkage disequilibria. The high resolution of this typing method has given 
further insight into the structure of HLA amongst the Sardinian population.
5.3 T he a lle lic  variation  o f HLA-A"^02 in  d ifferen t p op u la tion s.
5.3.1 In troduction .
HLA-A*02 is found at high frequency in the majority of populations 
investigated. The gene frequency of HLA-A*02 has been defined by serology 
in a British population at 24%, in Black populations at 18% and in Singapore 
Chinese at 37% (Imanishi, et al 1992a). The prevalence of A*02 in so m any 
populations may be explained by its capability to present a peptide m otif 
(Falk, et al 1991) using anchor residues commonly found in many protein  
sequences.
The first PCR-SSP HLA-A*02 analysis of population groups was in the 
context of the 14 alleles then known. The num ber of published A*02 alleles 
has increased to seventeen at the time of writing (Bodmer, J.C. et al 1995). 
Identification of many of the A*02 variants was not supported by frequency 
data concerning their prevalence within the population they were identified
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nor any other population group. In this study, the nested subtyping 
approach described in chapter 4.4.4 and 4.5 provided the means for 
identifying the A*02 allelic variants in a num ber of different populations. 
This involved the performance of an initial A*02 specific am plification 
which was used as template for a panel of PCR reactions using prim ing sites 
nested to the initial PCR.
A nested subtyping reaction panel has been used to identify the relative 
frequencies of A*02 alleles in a num ber of different ethnic groups, nam ely 
Caucasoid, African black and a Singapore Chinese population. Each of the 
populations showed a distinct distribution of A*02 alleles amongst the HLA- 
A*02 individuals investigated.
Discrimination between HLA-A*02 allelic variants allows differentiation 
between potentially functionally different HLA Class I molecules. This has 
implications for organ transplantation, in studies of T lymphocyte responses 
in HLA-A*02 individuals, particularly in non-Caucasoid populations, and in 
population genetics and disease association studies.
5.3.2 M aterial and M ethods.
Cenomic DNA samples were obtained from a num ber of different 
population groups. The HLA-A*02 populations studied included 63 D N A 's 
from random  cadaver donors from Oxford England, 55 random  ind iv iduals 
from the Chinese Singapore population and 40 random, and 19 selected 
Sardinian individuals. A number of different African populations were also 
investigated for A*02 heterogeneity. These included 45 random  indiv iduals 
from The Cambia, 73 individuals from Nairobi, and 27 from Uganda. 
Additionally, 7 individuals from west Central Africa and 10 indiv iduals 
from elsewhere in Kenya were also A*02 subtyped.
The studies were performed at different times, and the A*02 specificity in  
the subtyping panel reflects the known A*02 variants at the time of 
investigation. The reaction panels used for typing all except the U gandan 
population was as described in Table 4.11 (Chapter 4). The U gandan 
population was typed with a reaction panel specific for the 17 A*02 allelic 
variants as described in Table 4.13 (Chapter 4).
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The use of the subtyping reaction panel as described in Table 4.11 may m ean  
that examples of A*0216 may have been missed in populations typed w ith  
this reaction panel. Additionally, A*0215N may have been missed in  
samples typing as A*0207. A*0217 may have been missed in samples typing 
as A*0204, but this allele was not identified in any of the studies.
The Singapore Chinese population was also typed for HLA-B*46, to 
investigate if linkage disequilibrium existed with a particular A*02 allelic 
variant. HLA-B*4601 was identified using primer combination BL#46 (5' 
CACACACACAACTACAACCC 3' specific for BM601 and all HLA-C 
alleles) and BL#D1 ((Sadler, et al 1994); specific for a subset of HLA-B alleles 
including B*4601).
5.3.3 R esults
O x f o r d  C a u c a s o i d  p o p u l a t i o n .
63 random  DNA samples were obtained from serologically identified HLA- 
A2 donors in Oxford. 13 individuals were identified as being HLA-A2 
homozygous by serology and this was confirmed by a generic ARMS-PCR 
low resolution HLA-A locus typing (chapter 3, Table 3.5). The samples were 
A*02 sub typed by nested ARMS-PCR as described above and the results are 
shown in Table 5.2. This population predom inantly contained A*0201 
(96.1%), although one allele was identified as A*0205 (1.3%), one as A*0211 
(1.3%) and one as A*0213 (1.3%). The A*0205 sample and one A*0211 sam ple 
were found in heterozygous combination with A*0201 and this result was 
validated by the presence of only HLA-A*02 in the generic low resolution 
HLA-A locus typing.
S i n g a p o r e  C h i n e s e  p o p u l a t i o n .
55 Singapore Chinese DNA samples from individuals who had been 
identified HLA-A2 by serology, were A*02 subtyped. The sample population 
contained six HLA-A*02 homozygotes and five HLA-A*02 heterozygotes, 
which again were verified by an ARMS-PCR low resolution typing (chapter 
3, Table 3.5). The profile of A*02 allelic frequency amongst this population
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varied considerably from the other populations studied (Table 5.2). As a 
percentage of the A*02 alleles tested, A*0207 was the most frequent (45.0%), 
with A*0203 (23.0%), A*0201 (23.0%) and A*0206 (7.5%) also significantly 
represented. A single example of A*0210 (1.5%) was found in this 
population. Any sample which typed as A*0207 was tested for the presence 
of A*0201 using SSP combination AL#22/AL#BF (A*02 but not A*0207). 
Two A*0201/A*0207 heterozygous samples were also found. The study 
group also contained one A*0201/A*0210 heterozygous sample, one 
A*0201/A*0203 heterozygous sample, and one A*0203/A*0206 heterozygous 
sample.
A significant association has been described between HLA-A*02 and -B*46 in  
Singapore Chinese, with a haplotype frequency of 11.4% and a linkage 
disequilibrium value of 5.8 (Imanishi, et al 1992a). It was of interest to 
determine whether this linkage disequilibrium occurred with any particular 
A*02 allele found in the Singapore Chinese population. Of the 66 A*02 DNA 
alleles identified, 19 were B*46 positive when typed by ARMS PCR-SSP. Of 
these 19 B*46 alleles, 17 typed as A*0207 (one B*46 sample was an  
A*0201/A*0207 heterozygous sample). Using these data in conjunction w ith 
previously published frequency figures for HLA-A*02 in Singapore Chinese 
(Imanishi, et al 1992a), it would be expected that A*0207 would be found at a 
gene frequency of 16.7% in the Singapore Chinese population. With B*46 at 
a gene frequency of 15.1%, then a A*0207/B*46 haplotype would be expected 
at a frequency of 2.5%, if no linkage disequilibrium existed. The observation 
in this study was a frequency of 9.6%, suggesting a linkage disequilibrium  
value of 7.1 (observed - expected). This suggests that in the Singapore 
Chinese population, A*0207 is the main A*02 allele in linkage 
disequilibrium  with B*46. The frequency data generated for the population  
in these studies are limited by the number of samples investigated and need 
confirmation through larger investigations.
S a r d i n i a n  p o p u l a t i o n .
As with the study of A*30 allelic variants (section 5.2), DNA was obtained 
from a well characterised Sardinian population (Contu, et al 1992). The DNA 
cohort, consisted of 40 random  individuals, serologically defined as A*02. 
This groups contained 4 A*02 homozygotes individuals. 19 selected A*02
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subjects were also investigated, and this group contained 5 individuals w ho 
were A*02 homozygous. The 19 selected individuals contained an A*02 B17 
haplotype, commonly found in the Sardinian population. The results 
obtained with the randomly selected A*02 individuals, indicated the 
presence of two A*02 subtypes in the Sardinian population, namely A*0201 
and A*0205 (Table 5.3). Of the 44 random  haplotypes tested, 26 (59.1%) typed 
as A*0201 and 18 (40.9%) typed as A*0205. As shown in Table 5.2, this is in  
marked contrast to the Oxford Caucasoid population, in which A*0201 
represented 96.1% of the A*02 alleles and A*0205 was rare (1.3% of A*02's 
tested).
HLA-A*02 individuals Selected A*02-B17 haplotypes
Alleles N° Frequency Haplotype Frequency
A *0201 26 59.1% A*0205-B58 20 83.3%
A*0201-B58 3 12.5%
A*0205 18 40.9% A*0201-B57 1 4.1%
Table 5.3. Results obtained in subtyping 44 A*02 alleles from 40 individuals and 24 selected 
A2-B17 haplotypes from the Sardinian population.
Because the Sardinian population was well characterised through family 
studies, in which the haplotype could be determined, the associations 
between the A*02 allele identified and the B locus allele was known and is 
shown in Table 5.4. The most frequent association with A*0201 at the B 
locus was HLA-B*18, observed in 7 of the 26 A*0201 haplotypes identified. 
The association at the B locus with the other A*02 allele, A*0205, was m uch  
more marked. Of the 18 alleles identified as A*0205, 13 were in linkage 
disequilibrium with B17. This observation is confirmed in examining the 24 
selected A*02-B17 haplotypes shown in Table 5.3. Subtyping of these selected 
samples shows that 20 of the 24 A*02 alleles type as A*0205. All of the 20 
A*0205 were associated with B*58, whilst 4 A*02's subtyped as A*0201, 3 
being associated with B*58 and one associated with B*57.
If the data from the 40 random individuals is combined with the selected set, 
out of 40 A*02-B17 haplotypes tested, 33 (82.5%) were A*0205 and only 7 
(17.5%) typed as A*0201. This shows that there is strong linkage 
disequilibrium  between A*0205 and B17. It has previously been observed
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that A2 is associated with B58 in an extended haplotype also containing Cw7, 
DRB1*1601, DQA1*0102, DQB1*0502 present at a frequency of 5.99% in the 
Sardinian population. It seems from the observations made in this study, 
that A*0205 is a constituent component of this haplotype.
HLA-A*0201-B haplotypes HLA-A*0205-B haplotypes
Haplotype Frequency Haplotype NO Frequency
A*0201-B18 7 15.9% A*0205-B17 13 29%
A*0201-B35 4 9% A*0205-B21 2 4%
A*0201-B51 4 9% A*0205-B35 1 2%
A*0201-B17 1 2% A*0205-B13 1 2%
A*0201-B21 1 2% A*0205-B39 1 2%
A*0201-B14 1 2%
A*0201-B52 1 2%
A*0201-B37 1 2%
A*0201-B45 1 2%
A*0201-B44 1 2%
A*0201-Bbl 2 4%
5.4 . Frequency of A*02-B haplotypes obtained from 40 random A*02 Sardinia
individuals.
A * 0 2  s l i b t y p i n g  in A f r i c a n  p o p u l a t i o n s .
Having analysed HLA-A*02 in both oriental and Caucasoid populations, the 
next major ethnic group that was examined was from Africa. Three 
populations were subtyped for HLA-A*02. The populations in this study 
were from The Gambia, Uganda and Nairobi in Kenya. The Gambia is 
geographically distinct from the other two populations being located in West 
Africa as opposed to the Uganda and Kenya, which are in East Africa.
The individuals typed were taken from cohorts being used in disease 
studies. The Gambian DNA was drawn from individuals taking part in  
either malaria (Allsopp, et al 1992; Aidoo, et al 1995), or HIV studies 
(Ariyoshi, et al 1996). The Nairobi DNA was taken from a study of sexually 
transm itted diseases in commercial sex workers (Plourde, et al 1992). The
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DNA from Uganda was taken from a random  HIV cohort used to 
characterise the HLA structure of the population. This information from the 
Ugandan study will be used in the design and im plem entation of a future 
cellular based vaccine trial. The typing of this cohort is discussed m ore 
extensively in section 5.4 of this chapter.
The results as indicated in Table 5.2 show a considerable similarity in the 
three African populations typed. All three have A*0201 as the prevalent 
A*02 allele (56.8-63.3%), with A*0202 also present in significant num bers 
(23.3-31.9%). A*0205 is again found in all three populations, but represents 
only a smaller proportion of A*02 population (6.7-10.6%). From the 
observation made in these three African populations, it seems that A*0214 is 
found in low numbers in East Africa (5.7-6.7%) but is absent in the Gam bian 
population. It would be interesting to investigate the extent of A*0214 
distribution, and confirm its absence in West Africa. This observation has 
limitations in the num ber of individuals typed. Both A*0202 and A*0214 
seem to be restricted to the African population groups.
In addition 7 A*02 samples were typed from a West Central African 
population and 11 A*02 samples were typed from a study on a series of 
unrelated adults living in the north-western region of Kenya, in Saradidi, a 
town on the shores of lake Victoria. The West Central African population  
yielded five A*0201, and one of A*0202 and A*0205. The Saradidi population 
produced nine A*0201 and one A*0202 individuals, and one new A*02 
variant which was sequenced and named A*0214. The characterisation of 
this new variant is described in the following chapter (chapter 6.3.2).
5.3.4 D iscu ssion .
Section 5.3 describes the definition of genetic polym orphism  within HLA- 
A*02, and the relative frequencies of individual A*02 alleles in a num ber of 
different ethnic populations. Significant differences in the range and relative 
frequencies of individual A*02 alleles were observed both between and 
within the Caucasoid, Oriental and African populations. In the African 
population groups and more so in the Singapore Chinese population, the 
diversity of A*02 alleles is more pronounced as compared to the Caucasoid 
group studied. A*02 heterogeneity is also observed between more closely
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related populations. This is exemplified by the absence of A*0214 in the 
Gambian population as compared to the Ugandan and Kenyan populations 
and more markedly, the high frequency of A*0205 in the Sardinian 
population in contrast to the Oxford Caucasoid population. With HLA-A*02 
present at high frequencies in most populations, application of nested PCR- 
SSP subtyping offers the capacity to identify A*02 at an allelic level, 
providing cellular immunological studies with greater m eaning and 
definition by appropriate matching of T cell and antigen presenting cell. This 
is particularly im portant when performing CTL assays in matched rather 
than autologous target cell lines.
The polymorphism s described encode genetic substitutions in amino acid 
residues in and around the peptide binding groove of the HLA-A2 molecule. 
The selection and maintenance in different populations of polym orphic 
variants may reflect m utations which confer a selective advantage on the 
individual in terms of protective im m unity against potentially lethal 
pathogens. Such a mechanism has been proposed to account for the h igh  
incidence of HLA-B53 in African populations, as this specificity has been 
associated with protection from severe malaria (Hill, et al 1991b) and a 
cytotoxic T cell response to the malaria parasite, restricted by HLA-B53 (Hill, 
et al 1992).
Several studies have confirmed that polymorphism  between A*02 alleles is 
relevant for peptide presentation. Recently, the peptide motif has been 
determ ined for A*0207 (Sudo, T. et al., 1995) and the presence of an Asp P3 
anchor residue makes it distinct from the other A*02 peptide m otifs 
identified (Rotzschke, et al 1992; Barouch, et al 1995; Sudo, et al 1995). This 
may hold relevance for understanding the prevalence of A*0207 over 
A*0201 in the Singapore Chinese, which may have arisen th rough  
pathogenic pressure (Lawlor, et al 1990), such that A*0207 individuals may 
have obtained a selective advantage w ithin the Singapore Chinese 
population. Hence the heterogeneity of HLA-A*02 variants across different 
ethnic groups may be a consequence of the variation of pathogenic pressures 
acting upon those populations.
The polym orphism  present w ithin different A*G2 variants have  
implications for matching donor and recipient for transplantation. As
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different population groups contain different A*02 variants, which elicit 
different im m une responses, then it would be prudent to know to w hich 
ethnic group recipient and donor belong. As can be seen in the data 
generated in this study, trying to match A*02 between a Caucasoid and a 
Singapore Chinese individual cannot rely on serological or biochemical 
definition. Preliminary evidence from allelic typing in unrelated bone 
m arrow transplant screening show a significant incidence of mismatch for 
HLA-A*02 alleles between potential donors and recipients which have been 
typed by serology an d /o r one dimensional isoelectric focusing (Anholts et al, 
personal communication). For this reason, FILA population studies w hich 
can identify allelic frequencies, may prove essential for recognising w hich 
variants to match for in a given ethnic group. Also, linkage disequilibrium , 
as described between B*46 and A*0207 in the Singapore Chinese A*02 
samples and A*0205 and B*58 in the Sardinian population, becomes m uch  
more apparent with a high resolution typing method, and may provide 
useful information through haplotype association in situations where high  
resolution typing is not available. With PCR-SSP offering allelic typing, 
further cases of linkage disequilibrium may be found, which rem ain  
obscured or diluted by the relatively poor level of resolution offered by 
serology.
This study shows a marked variation in the relative frequencies of A*02 
alleles in different populations. It also reveals a difference in A*02 allelic 
diversity w ithin each population. This diversity may reflect the pathogenic 
pressures each population has been subjected to. As the capability to 
determine the allelic composition is applied to an increasing num ber of 
population groups, so a better understanding of the structure and diversity 
of HLA polym orphism  will follow. This may determine more succinct 
characterisation of ethnicity which in turn may better chart the evolution of 
HLA polymorphism through the study of different populations. The ability 
to define allelic variants could strengthen disease associations w ith  
particular subtypes and extend our understanding of why such differences 
exist.
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5.4 H LA C lass I & II p o lym orph ism  detected b y  PCR-SSP in  a sem i-  
urban H IV  p ositive  U gandan popu lation .
5.4.1 In troduction
The study of HLA polymorphism with regard to different population groups 
has revealed widely disparate results in terms of the HLA specificities found 
and their relative frequencies (Imanishi, et al 1992a). Until recently, 
determ ination of tissue types in population studies has mainly relied on  
serology for Class I (Ferrone, et al 1973) and a num ber of DNA based 
approaches for Class II (Erlich, et al 1991a; Vaughan, 1991; Olerup, et al 1992). 
In characterisation of certain populations, particular HLA specificities prove 
difficult to identify by serology, due to a lack of relevant specific antisera or 
misleading crossreactivity. Alternative DNA based m ethods now exist, 
which provide an accurate and easily interpreted approach to HLA Class I 
and Class II typing (Bunce, et al 1995b).
The purpose of this study was to identify the HLA Class I and Class II 
polym orphism  in a typical group of HIV infected Ugandans. These 
individuals will be used to identify the characteristic HLA restricted cytotoxic 
T lymphocytes (CTL) directed against HIV viral epitopes present in the 
population. Similar individuals will be participating in a forthcoming HIV 
vaccine trial, based upon the initial CTL work. Reports have suggested that 
some individuals have developed partial or complete protection against the 
HIV virus and this may in part be afforded to HIV specific T cells (Rowland- 
Jones, et al 1993; Callimore, et al 1995; Rowland-}ones, et al 1995). Such 
reports provide the rationale for the developm ent of a possible prophylactic 
vaccine which could stimulate cellular immune responses and in particular 
virus specific CTL, thus protecting the individual against HIV infection 
(McMichael, et al 1994).
CTL exhibit specificity through HLA Class I restriction and the sequence and 
orientation of foreign peptide bound by the HLA molecule (McMichael, et al 
1988; Madden, et al 1993; Rammensee, et al 1995). The HLA restriction of 
CTL clones has been demonstrated to differentiate beyond that determ ined 
by serology (Cotch, et al 1987; Tussey, et al 1994; Barouch, et al 1995). 
Therefore, in contemplating such a vaccine trial study, it is im portant to 
know the frequency and fine specificity of HLA alleles w ithin a particular
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population, in conjunction with the clades of virus circulating within that 
population. Certain CTL will exhibit cross reactivity between viral strains, 
however differences in viral sequence known to exist in Uganda could 
mean that CTL responses in Sub-Saharan Africa will be to totally different to 
those already identified in Caucasoid populations, even if restricted by the 
same HLA specificity.
In comparisons between African and Caucasoid populations, it is 
immediately apparent that major differences exist in terms of the gene 
frequencies found between both groups (Figure 5.1). Differences can be seen 
even between different African populations (Figure 5.2) and tribal groups, 
(duToit, et al 1988; duToit, et al 1990; Allsopp, et al 1992; Imanishi, et al 
1992a; Halle, et al 1994; Dieye, et al 1996). For the purpose of a vaccine trial, it 
becomes implicit to accurately characterise the HLA polym orphism  within a 
population. Identifying those common alleles which cover in excess of 90% 
of the population, provides the necessary information from which the 
appropriate viral epitopes can be incorporated into a vaccine inducing HLA 
restricted CTL.
5.4.2 M aterials & Methods.
With the above considerations, 3ml of EDTA blood was collected from 90 
HIV seropositive individuals attending the TASO and UVRI clinics in a 
relatively high prevalence area around Entebbe. Using a Puregene™ DNA 
Isolation kit (Centra Systems Inc), genomic DNA was extracted from this 
blood using a simple salting out technique (Buffone, et al 1985; Miller, et al 
1988). This yielded approximately 50-150pg DNA per 3ml whole blood. This 
genomic DNA was initially tested by a PCR-SSP panel of 144 'Phototype' 
reactions (Bunce, et al 1995b) which identifies specificities at HLA-A, -B, -C, - 
DRBl, DRB3, DRB4, DRB5 and DQBl loci. Details of the Phototyping 
protocol is given in chapter 2 (2.1.4).
The level of resolution of the 'phototyping' panel was equivalent and in  
areas superior to that offered by serology, w ithout the problems of 
crossreactivity, difficult heterozygous combinations or detection of HLA-Cw 
specificities. It also permitted the sim ultaneous typing for both HLA class I 
and class II under a standard set of conditions in a relatively short period of
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time. In application to a non-Caucasoid population, this PCR-SSP allowed 
clear identification of certain HLA specificities to which serological reagents 
may be rare or ambiguous.
In view of the population group studied, additional allele specific PCR-SSP 
sub typing was performed for certain prevalent HLA group specificities. 
Hence, HLA sub typing was performed on samples identified as HLA-A*02, - 
A*29, -A*30. -A*68 (chapter 4, Table 4.13) and B*58 (Browning, et al 1995). 
The results of the A*02 subtyping are described in chapter 5.3.4 of this 
chapter. B*5801 and B*5802 could be discriminated in the Phototyping panel 
except when in the presence of B*5301. It was im portant to identify these 
subtypes correctly since they are prevalent in this population and can 
potentially elicit functionally distinct cytotoxic T cell responses (Barouch, et 
al 1995). Determining allelic subtypes involved the use of nested PCR 
(chapter 4.4). This required amplifying an initial flanking PCR reaction 
which contained the relevant sites of polym orphism  necessary for 
discrim inating the allelic group of interest. This first round product was 
then used as template DNA for a subsequent nested panel of PCR reactions 
which define the relevant subtypes (chapter 4).
5.4.3 Results.
Table 5.5 shows the gene frequencies defined by 'Phototyping' in this 
Ugandan population with those alleles derived by additional subtyping 
reactions highlighted. In the Ugandan population, of the 90 individuals, 27 
typed as HLA-A*02 and following nested subtyping (chapter 4.4.4 & 4.5), it 
was revealed that the gene frequencies (gf) of each variant was A*0201 
(9.94%), A*0202 (3.41%), A*0205 (1.11%) and A*0214 (1.11%). Gene
frequencies (gf) were determined by the maximum likelihood m ethod 
(Imanishi, et al 1991a). These data again shows differences in frequency 
profiles as compared to other population groups in previous studies (section 
5.3). HLA-A*30 proved the most frequent HLA-A locus specificity detected 
amongst the Ugandans typed. Nested subtyping (chapter 4.4.3 & 4.5) of this 
group of 31 HLA-A*30 individuals, found gene frequencies of A*3002 
(9.94%), A*3001 (8.13%) and A*3004 (1.66%). In subtyping the sixteen A28 
and fifteen A*29 positive individuals, all were found to be A*6802 and 
A*2902 respectively.
134
O  O  O  o  O  *  ★ *  ^  *  orH rH  rH  q  rH *CÛ CÛ CÛ * CÛ ^
g g g g g g
N \0 0\ G\ \0in oq in lo p
o6 in ni cnI o
1—I CO in o  IX CM 00 O n OCOOOO’^ OOO
CÛ PÛ CO r-< CÛ CÛCsi ^ pïi Csi CO CO CO CÛ CO CÛ 0<P<D<P<P<0<
Q D D g D D § D Q D Q Q O  
D
1-H VO CM
CM 'Tf CO
IX rH t-H
CO CO CO
C£5 c<  P i
O D D
CD t o  CM I—I ON VD fO  IN CnI fS
-f  \o N  o  N cs N D O o o o - ^ t n t N  r o o
' a 5 * a
stns -Q
R "3if!s
t î î
V. X!
y
M -S « S u &
l i
ÎÎÎ!
iiH 1 ^0) nj T3
g; gpti
lill 
i l f l .
o  
s S  ° o CO T-. col 00 CM VO VO VO 1-H T-t i nN IX o \ CM p
o6 GO K i n i n i n m CO CO CO CO n i CM CM CM 1—< t-H 1—t 1-H d d
IX
CO CM
CO o CM O IX IX GO t x N > o
< i n 00 i n Tfi CM T f p N i n
i P IXCO CO CO CO CO CO CO CO CO CO CO 00 CO CO CO i n CO CO 00 CO CO CO CO CO DO
DC CO CO CQ CO CO CO CO CO
CO DO
: ^  ^  
 ^ col COv£) \o m m m
T f CO O  O  VO CM
CM CM w |  t-h 1—1
IP"
< <
At the HLA-B locus, certain key prevalent were again identified specificities 
in this population, namely B*58 (12.61%), B*5301 (11.17%) and B*1503 
(8.73%). Subtyping was performed on the B*58 samples (Browning, et al 
1995) to reveal that B*5802 gene frequency (7.48%) was slightly m ore 
frequent as compared to B*5801 (5.13%). The advantage of a PCR-SSP 
approach was underlined at the C locus, in which typing was clear and 
unam biguous, with serological C locus blanks (Cw*12-Cw’^ 17) easily 
determined. The main HLA-C specificities identified were HLA-Cw’^ 04 
(23.97%), -Cw*06 (15.68%), -Cw*17 (12.42%) and -Cw'^0701 (11.80%). The 
prevalent HLA Class II gene frequencies for this Ugandan population were 
D R B in i (18.57%), DRB1U3 (15.86%), DRB1U5 (12.59%) and DRB1*0302 
(12.59%). At HLA-DQ, we found DQBU06 (25.37%), DQBU05 (21.64%), 
DQB1*02 (19.50%) and DQBl*0301/4 (16.04%).
5.4.4 Discussion
A comparison of broad specificities at HLA-A and -B between the U gandan 
population characterised by PCR-SSP and several other serologically typed 
population groups is depicted in Figures 5.1 and 5.2. In figure 5.1, the 
Ugandan population is compared to a British and a Singapore Chinese 
population (Imanishi, 1992). It is clear that the prevalence and gene 
frequency profile of HLA specificities varies greatly between the three 
population groups. At HLA-A (Figure 5.1a), HLA-A'^SO is the most prevalent 
specificity in the Ugandan population, but relatively infrequent in the 
British and Singapore Chinese population groups. HLA-A"^02 is present at 
high frequencies in all three populations, however previous studies have 
shown that the allelic composition varies in each of the population groups 
(chapter 5.3). The British population is characterised by the prevalence of 
HLA-A’^ 01 and -A"^03, whilst the Singapore Chinese contain HLA-A^^ll and - 
A"^ 24 at high gene frequency.
At HLA-B (Figure 5.1b), the gene frequency profiles in the three populations 
were clearly different. The Ugandan population contained a high proportion 
of HLA-B70 (B*1503, B*1510), -B*58 and -B*5301. This is in contrast to the 
British population, in which HLA-B’^ 08, -B*44 and -B*35 were the 
predom inant specificities. The Singapore Chinese population is again 
different containing a high number of HLA-BM6, -B*40 and -B5 (B*51, B*52)
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specificities. Many other differences exist between the three populations at 
HLA-A and -B, and these are represented in Figure 5.1.
Figure 5.1a
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Figure 5.1b
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Figure 5.1. Gene frequencies observed in serologically characterised British and Singapore 
Chinese populations (Imanishi, 1992) in comparison with the PCR-SSP typed Ugandan study 
population. Frequencies were compared on the basis of serological specificities; (a) represents 
a comparison at HLA-A and (b) a comparison at HLA-B.
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Figure 5.2. Gene frequencies observed in serologically characterised Zimbabwean and Zairean 
populations (Allsopp, 1992; Imanishi, 1992; Halle, 1994) in comparison to the PCR-SSP typed 
Ugandan study population. Frequencies were compared on the basis of serological 
specificities; (a) represents a comparison at HLA-A and (b) a comparison at HLA-B.
Figure 5.2 represents a comparison of the PCR-SSP typed U gandan 
population in this study w ith serologically determined gene frequencies 
observed in two other African populations (Allsopp, 1992; Imanishi, 1992; 
Halle, 1994). Although the Ugandan population shows similarities w ith the 
two African populations as compared to the British or Singapore Chinese
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populations (Figure 5.1), distinctions can still be made. Hence in both 
Uganda and Zimbabwe, HLA-A*30 followed by -A*02 represent the m ost 
prevalent specificities. This is reversed in the Zaire population. The 
prevalence of HLA-A’^ 23 and -A*33 in both Zimbabwe and Zaire is in  
contrast to the lower frequency observed in the Ugandan population. At 
HLA-B, similarities were seen between the three populations, through the 
prevalence of B70 (B*1503, B*1510). However differences were also observed, 
as illustrated by the high gene frequency of HLA-B"^58 and B*5301 in the 
Ugandan and Zimbabwean populations as compared to the Zairean 
population. It was also noted that HLA-B"^57 and -B*18 were more prevalent 
in Zimbabwe than in the other two populations, whilst HLA-B*07 and -B’^ 44 
were found at a higher gene frequency in Zimbabwe and Zaire as compared 
to Uganda. Certain recently identified specificities (HLA-A’^ 8001, HLA- 
B*8101) were not tested for in population groups used for comparison. It is 
probable that re-screening would identify HLA-A’^ 8001 and B*8101 in som e 
of the population groups considered. It must also be acknowledged that this 
population may not prove wholly typical of a general Ugandan population  
since it has been selected from HIV positive individuals attending two 
clinics.
The results generated through this PCR-SSP approach, represent a m ore 
comprehensive description of HLA in an African population than  
previously described. The observations in general are in concordance w ith  
those reported in a general Black population (Imanishi, et al 1992a). It 
should be noted that substantive differences exist between this population 
and Caucasoid populations in which immunological responses to HIV have 
been investigated. Thus in the Caucasoid population >90% of the population 
may be represented as having A’^ OlOl, A’*'0201, A*03, B*07, B*08 or B*44, 
whilst a different set of specificities represents >90% of the U gandan 
population studied (A*0201, A3001, A3002, B*5301, B*5802 or BH503). This 
emphasises that the main HLA restrictive elements for HIV specific CTL are 
in the most part likely to be different for each population. It was also noted 
that the frequency of B*35 which has been associated with bad prognosis in  
HIV infection (Itescu, et al 1995), was much lower in the U gandan 
population (2.2%) as compared to West African populations (Gambia 16.1%, 
Senegal 13.1%) (Allsopp, et al 1992; Imanishi, et al 1992a; Dieye, et al 1996).
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With the key HLA specificities identified in this study, putative CTL 
epitopes can be ascertained from the predom inant HIV circulating gag, pol 
and nef proteins. The preferred peptide binding motifs of certain HLA 
specificities (e.g. A*3001 and A’^ 3002) had not been demonstrated at the tim e 
of this population study. Because of their prevalence in this and other 
populations, the peptide motifs of the allelic variants of A ’^ 30 was 
determined as described in chapter 7. Identifying peptide epitopes for all the 
major HLA specificities in the Ugandan population, will allow strategies to 
be designed for the pursuit of possible HIV vaccines.
It therefore seems probable that a prophylactic vaccine, designed to stim ulate 
potentially protective cellular immune responses, specifically in an African 
population will contain a totally different profile of viral peptide epitopes as 
compared to a vaccine specifically designed for an at risk Caucasoid 
population. This does not necessarily imply that a vaccine will have to be 
'tailor made' for an Ugandan population, but rather a vaccine designed for 
global use should take into account the very different genetic background of 
different populations, in addition to the heterogeneity of the circulating HIV 
viruses.
This study therefore describes the use of PCR-SSP to HLA type a cohort of 
Ugandan HIV positive individuals. The level of resolution possible by this 
m ethod addresses the discrimination possible by the T cell in cellular 
im m une responses. This accurate determ ination of HLA types forms an 
im portant prerequisite to potential approaches in vaccine trials based on the 
HLA restricted immune response.
5.5 D isc u ss io n  on  app lication  o f PCR-SSP to p op u la tion  stu d ies.
This chapter describes studies in which the PCR-SSP approach to HLA typing 
has been applied to analysis of HLA-A allelic variants in a num ber of 
different population groups. Characterisation of HLA has been an im portan t 
aspect of anthropological studies by virtue of the polymorphic nature of the 
HLA system. Population analysis has also provided a certain am ount of 
insight as to the evolution of HLA polymorphism  through geographical 
distribution.
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The 11th International Histocompatibility W orkshop included an 
anthropological component. This component analysed the relationship 
between different population groups on the basis of HLA polym orphism  
(Imanishi, et al 1992a). The relationship was explored through the 
generation of dendrograms; phylogenetic trees which show an estim ation of 
the genetic distance between different populations. Analysis revealed and 
confirmed the clustering of different populations into distinct ethnic 
groupings. However, this representation did have flaws as described in the 
characterisation of two Am erindian groups as being distantly related, w hen  
a good deal of other evidence shows the opposite. Further analysis was 
required to make a more valid judgem ent as to the relationship betw een 
different populations.
The analysis of genetic distance in the above workshop studies was based 
upon serological definition for class I specificities and some DNA based 
typing at class II. By including different subtypes found in different 
populations in one serologically defined basket, the similarities or 
differences between populations could be lost. This was demonstrated by the 
identification of B’^ 2703 in the Gambian population (Hill et al. 1991a). This 
allele is identified as the most common subtype in the Gambian population  
and absent in most non-black population groups. By not defining such 
differences, serology fails to provide a precise representation of a population 
that takes into account key allelic HLA markers. This is further revealed by 
the failure of serology in identifying HLA-C specificities, for which the 
application of DNA approaches has provided a highly definitive m ethod 
(Bunce, et al 1994a; Bunce, et al 1994b).
The application of DNA based typing technology has im proved the 
resolution of tissue-typing and so provided a more detailed account of 
populations in terms of their HLA composition. Because viable cells were 
not a requirem ent for DNA based methods of typing, more populations 
became accessible to HLA characterisation. This and the general activity in  
DNA sequencing has identified an ever increasing num ber of HLA alleles 
which in turn provide more definition of ethnic groups. As m ore 
populations are studied with the tools of DNA methodology, so it seems 
likely that new HLA alleles will be discovered.
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This has certainly been the case in the studies described in this chapter, w ith 
A*3004 being identified in the Sardinian population and A"^ 0214 being 
identified in the Kenyan population. Both of these alleles were discovered 
through anomalies observed in PCR-SSP typing, where the sequence 
polym orphism  they contained produced novel reaction patterns. Their 
characterisation will be discussed in the following chapter. The 
identification of A*0214 provided a marker for the East African populations, 
even though it was observed at relatively low frequency, since it appears 
absent in the West African Cambian population. It would also be interesting 
to examine a wider num ber of populations to see the true extent of the 
distribution of A W 14 and the other A“^02 alleles.
The characterisation of A"^ 02 in different populations, has provided a good 
example as to the importance of sub typing in uncovering significant 
differences between populations. Different alleles are present at different 
frequencies in different populations. Also certain alleles can be definitive of 
a particular ethnic group, such as A’*'0203, A*0206, A*0207, A"^0210 in the 
oriental populations, A’^ 0202 and A’^ 0214 in African populations. This 
information provides a better description of the population which would be 
missed through serology.
Allelic definition in populations also enables a better distinction of linkage 
disequilibrium. Hence, through these studies, it is clear that A’^ 3002 is in  
linkage disequilibrium with and A"^0205 is in linkage disequilibrium
with B"^ 58 in the Sardinian population, and A’^ 0207 is in linkage 
disequilibrium  with B*46 in the Singapore Chinese population. Linkage 
disequilibrium  had been noted though broad serological definition, but 
allelic definition both identified the precise nature of this association and so 
strengthened the observation. Identification of linkage disequilibria, w hich 
may vary in different populations, provides another index for 
characterisation of a population group.
The ability of PCR-SSP for typing a remote population is exemplified in the 
Ugandan study. The application of the 'Phototyping' panel (Bunce, 1995b), 
with additional subtyping provided a well characterised population. This 
information is not only useful for anthropology, but also for clinical studies.
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As m entioned in the Ugandan study, this inform ation is extremely 
im portant for the designing and implem enting of a cellular based vaccine 
trial, in which HLA restricted responses form a major consideration. In 
addition, disease association can be made more apparent when sub typing is 
performed. Reports have been made, as to the association of A*0206 w ith  
Graves' disease and A’^ 0207 with Hashimoto's thyroiditis, in the Japanese 
population. An association has also been recently established between 
A*6802 and susceptibility to scarring trachoma in a Gambian population 
(Conway, et al 1996).
PCR-SSP is therefore a powerful means of characterising a population in  
terms of its HLA polymorphism. The application of such definitive typing 
will undoubtedly provide a great deal more information about populations 
and so increase understanding of the relationship between ethnic groups. 
The characterisation of populations may also clarify the nature of HLA 
evolution in terms of genetic drift and selective pressure. The precise 
characterisation of HLA polymorphism within different population groups 
has an im portant influence in the fields of transplantation and cellular base 
vaccine programs. These reasons validate the importance of accurate 
characterisation of HLA polymorphism in different populations
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Analysis and characterisation of new HLA alleles.
6.1 Introduction.
Through the course of this thesis, novel HLA-A specificities have been 
identified either through anomalies observed in PCR-SSP typing, or 
discrepancies between different typing approaches. The application of a new  
typing approach produces a novel perspective from which the HLA alleles 
can be defined. By altering the means of definition, there remains a 
possibility that this will expose new polymorphic differences between alleles 
previously considered to be identical. However, PCR-SSP does not define all 
the polym orphism  within an allele, and so there remains that possibility 
that new alleles will not be discriminated.
The characterisation of HLA polym orphism  has relied on such 
discriminatory observations, be it through the differing specificity of sera or 
T cells, lEF and RELP analysis, or more recently through PCR based analysis 
of DNA. The observation and discovery of the highly polymorphic nature of 
HLA specificities has been possible through the use of increasingly specific 
reagents, or the contradictory results obtained by two or more m ethods of 
analysis. Indeed, the development and application of new technology over 
the years has been instrumental in the definition of the nature and level of 
polymorphism  within the HLA system.
The characterisation of HLA polymorphism  has been further enhanced
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through the comparison of different population groups. The application of 
m ethods designed for analysis of HLA polym orphism  in one population 
may produce unexpected results when applied to different population  
groups. This is due to the potential presence of as yet unknow n HLA 
specificities in uncharacterised populations. As m entioned in Chapter 5, 
HLA polym orphism  in different populations may be driven by different 
pressures, which may not only shape the frequency of HLA specificities, but 
may also determine novel specificities unique to that particular ethnic 
group.
The ability to analyse HLA in different populations has increased as the 
restrictions of serological typing have been replaced by the more convenient 
and practical PCR based DNA analysis. The combination of HLA typing in  
different population groups together with the application of definitive DNA 
based typing approaches has extended the num ber of known alleles 
(Domena, et al 1993; Hildebrand, et al 1994a; Hildebrand, et al 1994b; 
Selvakumar, et al 1995; Date, et al 1996). This has been the case in the 
application of methods developed in this thesis to the study of HLA-A 
specificities in different populations. The study of Caucasoid and African 
populations has yielded a num ber of newly identified HLA-A alleles, 
identified through discrepencies in the PCR-SSP typing approaches described 
in previous chapters. A new HLA specificity was also identified through a 
discrepancy between lEF data and the PCR-SSP typing result.
To define accurately the sequence polymorphism defining these new alleles, 
it is necessary to characterise them by DNA cloning and sequencing. As an 
interim  measure, to determine quickly the composition of polym orphism  
found w ithin an allele, panels of ARMS designed SSP can be used to define 
the presence or absence of specific polymorphic residues or motifs at 
particular sites within the allelic sequence. This developm ent of this PCR 
approach of 'gene mapping' (see section 6.2), has proved useful on a num ber 
of occasions in characterising and confirming the combinations of 
polymorphism denoting a new allele. This approach has also been useful in  
providing a quick and easy method of confirming the presence of absence of 
specific polymorphic motifs at specific locations within the HLA sequence. It 
does not represent an alternative to DNA sequencing which is still necessary 
for characterisation of new HLA alleles.
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This chapter describes the circumstances under which new alleles were 
identified in this project, and the approaches taken for their further 
characterisation. The application of DNA based methods to HLA typing has 
shown a larger level of polymorphism  than observed through previous 
serological approaches. This chapter will also discuss the relevance of 
polymorphism s found within the newly identified alleles, not only on the 
interpretation of the PCR-SSP typing approach at HLA-A locus, but also on  
the possible effects on immunological function. In addition, this chapter will 
describe the use of PCR-SSP as a means of characterising HLA sequences, 
either to confirm the polymorphism  found w ithin a sequence, or to 
ascertain the polymorphic content of a new allele. Studies are also described 
in which the nature of serological HLA-A 'blank' specificities are 
investigated. The use of PCR-SSP not only contributes to the detection of 
new HLA specificities, but provides the means for their characterisation.
6.2  PCR 'gen e-m ap p in g .'
As an extension of the PCR-SSP method, a technique of PCR 'gene-mapping' 
has been developed (Krausa, et al. 1995d) for the definition of sequence 
polym orphism  found within HLA alleles. PCR 'gene-m apping' uses the 
specificity of a panel of SSP's, based on the known polymorphic motifs at 
specific sites w ithin the HLA class I genes, to define the sequence 
polym orphism s found within a particular allele. This has proved highly 
useful in the evaluation of sequence polym orphism  in HLA alleles. This 
approach of using PCR-SSP to ascertain the polymorphic 'content' of HLA 
specificities has been beneficial in both confirmation of known alleles, as 
well as the characterisation of new allelic sequences. This m ethod of 
sequence characterisation is made possible through the specificity of ARMS 
PCR (Newton, et al 1989). ARMS PCR under the correct conditions of 
stringency, has the ability of discriminating between sequences on the basis 
of a single base-pair difference. This approach provides a highly powerful 
analytical tool for the detection of sequence polymorphism.
The nature of polymorphism  found amongst HLA alleles provides another 
consideration in their identification. Very few HLA sequence
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polymorphisms are unique to a particular allele, rather they are shared w ith  
other specificities not only within the same locus, but on occasions w ith  
alleles of other loci. The definition of a HLA allele is therefore m ainly 
through the unique combination of these sequence polym orphism s along 
the length of the gene. By having a substantive panel of SSP defining the 
major sequence polymorphisms found amongst HLA alleles, it is possible to 
identify the key polymorphisms present w ithin a particular HLA specificity. 
This information can then be extrapolated to predict the DNA sequence of a 
newly identified allele, prior to its characterisation by formal sequencing 
methods (Sanger, et al 1977).
In HLA class I, the majority of sequence polym orphism s are found w ith in  
exons 2 and 3 of the HLA genes, which code for the domains which form the 
the peptide binding groove of the molecule. This part of the molecule plays 
an im portant role in antigen presentation and interaction with the T cell. In 
developing the PCR-SSP for HLA typing at A locus, a panel of SSPs were 
assembled which defined many of the polymorphism s found w ithin these 
exons. These SSP have proved useful reagents for the characterisation of 
new allelic sequences. The approach of PCR 'gene-mapping' for definition of 
polym orphism  in exons 2 and 3, is to combine a fixed specific SSP in one 
exon with a panel of SSPs defining polymorphism s in the other exon. The 
polym orphism  defined by the fixed SSP provides the context w ithin w hich 
the sequence is characterised. It allows a single allele to be analysed as 
opposed to SSOP in which the PCR generally amplifies both alleles. The use 
of nested PCR can be used to increase specificity of the SSPs in the 
performance of PCR gene-mapping, so providing a more definitive 
characterisation.
6.3 N e w  a lle les id en tified  during the w ork  for th is thesis.
6.3.1 HLA-A^3004
HLA typing for the allelic variants of HLA-A*30 in the Sardinian population 
(Chapter 5.2) identified an individual, who although serologically typed as 
A*30, A'^ll, failed to amplify with a putative A*30, A’^ 3302 specific SSP 
combination (AL#12/AL#Q), which had already been positively tested
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against the known A’*'3001, A*3002 and A*3003 alleles. A lthough this 
individual was shown to be negative with the AL#12/AL#Q com bination, 
typing with the AL#12/AL#G SSP pair confirmed the presence of an A*30 
gene. The discrepant results with the serological typing, and the PCR-SSP 
observations, indicated the presence of a new A"^ 30 allele.
The above observations already provided some information on the natu re  
of the polymorphic difference between this A*30 and the other sequenced 
A*30 alleles. The failure to amplify with SSP combination AL#12/AL#Q, but 
positive amplification with AL#12/AL#G, indicated this new varian t 
contained the polymorphisms defined by SSP AL#12 and AL#G, but not that 
defined by SSP AL#Q. To investigate these observations further, this varian t 
of A*30 was characterised through PCR 'gene-m apping', w ith particular 
emphasis on the region identified by SSP AL#Q.
The A*30 variant allele (A*3004) was characterised by PCR 'gene-m apping ' 
through a nested PCR approach using a first round product obtained w ith  
SSP pair AL#12/AL#W (specific for A*30 A*3302), which gave a PCR 
product of 719bp. The SSP listed in Table 6.1, in their appropriate 
combinations, were used to identify the sequence motifs present in the 
known HLA-A*30 alleles and those in the variant, A*3004, in a nested PCR 
system using template generated by the first round reaction using p rim er 
combination AL#12/AL#W. An initial screen showed the sequence of 
A*3004 differed from the other A*30 alleles in a region roughly between 
nucleotide positions 170-200 of exon 3. Using a panel of SSPs in a nested 
PCR, a fine map of the sequence motifs present in A*3004 were defined, in  
comparison to A*3001 and A*3002 in this region. Exon 2 was characterised 
using a panel of seven motif specific SSPs run off an SSP (AL#G) com m on 
to all A*30's in exon 3. Exon 3 was more extensively characterised using a 
panel of twenty-seven motif specific SSPs run off a fixed prim er common to 
A*3001 and A*3002 (AL#10) in exon 2.
Results of PCR 'gene-mapping' of HLA-A*3004, at the SSP sites tested, 
revealed that the sequence of the allele resembled A*3002 except for a region 
between nucleotides position 180-195 in exon 3. The m apping data are 
shown in Table 6.1, and sum m arised on a gel in figure 6.1. This figure 
identifies the different motifs distinguishing A*3001 and A*3002 from
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A*3004, at prim er sites AL#AX to AL#U. The figure also shows the 
difference in exon 3 between A*3001 and A*3002 at prim er sites AL#K and 
AL#T. A more extensive results panel is given in Table 6.1. The sequence 
polymorphism s identified in A*3004 between nucleotide positions 180-195 
are similar to those of A*0202, A*0205, and the A*68 sequences. The 
sequences of the A*30 allelic group and the A*0202, A*0205 A*68 sequence 
group are identical in the region 3' of position 195 in exon 3. This finding 
suggests a gene conversion event in exon 3. The proposed sequence of 
A*3004 in this region based on PCR 'gene-mapping' of polymorphic m otifs 
is given in figure 6.2, and has been confirmed by DNA sequencing as part of 
this study.
In addition, observations obtained by PCR 'gene-mapping' (Table 6.1a), made 
it clear that the cell line LBF, from which the A*3001 allele was sequenced 
(Kato, et al 1989), has a cytosine and not a thymidine at nucleotide position 
25 in exon 2, as previously reported. This has been substantiated by 
sequencing LBF in the 5' region of exon 2, and confirmed by others (Olerup, 
et al 1994). The correct polymorphism  at position 25 is present in the other 
A*30 alleles together with the A9 group specificity, all of which share a 
Serine at position 9 in the alpha-1 domain of the class I molecule. PCR 
'gene-mapping' therefore has a particular application in rapid confirm ation 
of published sequences.
Table 6.1a. Exon 2 gene mapping (for table legend, see following page)
SSP position of 
SSP 3' 
nucleotide
Sequence
m otif
identified
A*3001 A*3002 A*3004
AL#5 25 e tc + + +
AL#22 25 CtT - - -
AL#12 53 AgTggA + + +
AL#10 169 AggccT + + +
AL#6 208 caG + - -
AL#44 227 TgG 4- - -
AL#45 227 aga - -1- +
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Table 6.1b. Exon 3 PCR gene mapping
SSP position of 
SSP 3' 
nucleotide
Sequence
m otif
identified
A 3001 A*3002 A*3004
AL#AB 18 TAa + + +
AL#Y 48 Tgg - - -
AL#AK 58 Gcg - - -
AL#0 68 tGaA + + +
AL#G 71 AcagC + + +
AL#C 80 Tta - - -
AL#F 104 Ttg - - -
AL#H 109 Aga - - -
AL#L 109 cga + + +
AL#AU 145 Age - - -
AL#AJ 153 Cca - - -
AL#P 158 cag + + +
AL#S 158 Aag - - -
AL#AZ 162 Ac a - - -
AL#AE 173 Ac g - - -
AL#AX 180 Atgt - - +
AL#J 180 gtg - - -
AL#AY 182 gtg - - +
AL#K 182 TGg + - -
AL#T 182 CGg - + -
AL#AO 183 tgg - - +
AL#I 183 Cgg - - -
AL#AN 183 Agg - - -
AL#AA 183 Agg - - -
AL#Q 194 Ttg + + -
AL#AV 194 TGg - - +
AL#U 195 Gga - - +
AL#W 226 g tg + + +
Table 6.1. showing details of PCR gene mapping of HLA-A*30 alleles in exons 2 (Table 6.1a) 
and 3 (Table 6.1b). Uppercase letters denote polymorphisms from the consensus sequence as 
detailed in the 1995 sequence alignments (Arnett, K.L. et al., 1995). Sequence motifs as 
identified by the 3' residues of SSP's listed and sequences given at positions as denoted in the 
1992 sequence alignments. Reaction patterns of the SSP's against A*3001, A’^ 3002 and A*3004 
are given when combined with AL#G to map exon 2 and AL#10 to map exon 3 in a nested PCR 
from first round product amplified with SSP combination AL#12/AL#W.
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Summary gels of 
'gene mapping' in Exon 3 for A*3001, 
A*3C02, and the A30 variant.
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Figure 6.1. Examples of reactions for PCR gene mapping A*3001, A*3002 and the A’^ 30 variant 
(A*3004) in exon 3. SSP's (a-m) defining motifs were combined with an exon 2 A*3001 A*3002 
A*3004 specific SSP (AL#10) in a series of nested reactions against the AL#12/AL#W first 
round PCR product. A*3001 and A*3002 differ in sequence as defined by their respective 
reactions with SSP AL#K (h) and AL#T (i). A*3004 differs from A*3001 and A*3002 as 
defined with SSPs AL#AX to AL#U (f-m). A more comprehensive list of motif defining 
reactions is given in Table 6.1.
Sequencing A’^ 3004 (single stranded method as described in chapter 2.2), 
confirmed the predictions made by 'PCR gene mapping'. In exon 2, the 
sequence of A ’^ 3004 is shown to be identical to alleles A’^ 3002 and A*3003.
Piowever, in exon 3, A*3004 is the same as PTLA-A*3002 except for a region 
between nucleotide positions 180 and 196. At position 180, the A*3004 
sequence substitutes an A for G as compared to the other A*30 alleles. At 
nucleotide position 182 and 183, A*3004 has bases GT as opposed to TG in  
A*3001 and CG in A*3002 and A*3003. At nucleotide position 196, A*3004 
differs from the other A*30 alleles by having a G in substitution for a T. 
Details of these nucleotide differences are shown in figure 6.2. The sequence 
polymorphisms observed cause amino acid substitutions as compared to the 
other A*30 alleles. In detail, these are a substitution of histidine for arginine 
at amino acid position 151, valine for tryptophan (A*3001) or arginine 
(A*3002/3) at position 152 and tryptophan for leucine at position 156. W hen
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these changes are viewed in terms of their location on the class I m olecule 
(Bjorkman, et al 1987), they are all found on one of the alpha helices, 
pointing into the peptide binding groove. These polym orphism s have 
probable implications as to the peptide motifs the A*3004 molecule will 
bind, and hence have relevance for transplantation matching. A report of a 
one amino acid difference between A*3002 and A*3003 has been implicated 
as causing GVHD in an unrelated donor m arrow transplant (Choo, et al 
1993).
(a)
Exon 3
140 160 180 200
A*3001 ----- T--------------------------------------------------------------------TG----------------T-------------------
A*3002 - - -T --------------------------------------------------------------------CG----------------T-------------------
A*3003 —-T--------------------------------------------------------------------CG----------------T-------------------
A* 3 004----- T----------------------------------------------------------------A--------------------- TG------------------
A* 02 02----- T---- A----------- C------ A---- A---------------------------- A--------------------- TG------------------
CONSENSUS ACACGGCGGCTCAGATCACCCAGCGCAAGTGGGAGGCGGCCCGTGTGGCGGAGCAGCTGAGAGCCTACC
(b)
a l  Domain
130 140 150 160 170 180
A* 3 001 -------------M---------------------W------------------------------------------------- T
A* 3002 -------------M---------------------R------------------------------------------------- T
A* 3 003 -------------M---------------------R------------------------------------------------- T
A* 0202 -------------M T“KH H W------------------------------------------ T
CONSENSUS LRSWTAADTAAQITQRKWEAARVAEQLRAYLEGTCVEWLRRYLENGKETLQRA
Figure 6.2. A comparison of the (a) nucleotide and (b) amino acid sequences of the variant A*30 
allele (A*3004) with the other A*30 alleles, and the A*0202 sequence, showing the 
polymorphic motifs in the 3' region of (a) exon 3 (b) alpha-2 domain. The A*3004 
polymorphisms were identified firstly by 'PCR gene mapping' and subsequently confirmed by 
DNA sequencing.
Further characterisation on a B cell line generated from the A*3004 
individual (provided by C.Carcassi), was performed by IFF. An A*30 IFF 
variant had previously been described, but not sequenced (Yang, 1989a). IFF 
analysis was performed on A*3004 to determine whether it was the 
equivalent to this unsequenced IFF variant A30.2. Analysis of sequenced 
A*30 cell lines (FBF, A*3001; CR-B, A*3002; JS, A*3003) together with the 
A*30 variant (W7), were carried out as previously described (Yang, 1989b) 
with details given in chapter 2. Unfortunately, it was not possible to obtain
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an A30.2 lEF variant control, which could provide a direct comparison w ith  
the A*3004.
Analysis of A*3004 by one dimensional lEF, as illustrated in figure 6.3, 
shows that the A*30 variant runs in the same position as the A30.2 IFF 
variant in relation to the other A*30 alleles, based on the published data of 
Yang et al (Yang, 1989). IFF variant A30.2 runs acidic to IFF variant A30.1 
(A*3002) and basic to A30.3 (A*3001). The only amino acid differences 
between A*3002 and A*3004, lie in the alpha 2 dom ain between positions 
151-156 (Figure 6.2). In this region, A*3002 has two basic residues (Arg-151, 
Arg-152) as compared to the aromatic and aliphatic residues (His-151, Val- 
152), in A*3004. This explains the relative IFF focusing of the two allele
products.
■s. ■ -
:___
Figure 63 A one dimensionsal IFF comparison of four different HLA-A30 subtypes. The four 
cell lines LBF (A*3001), CR-B (A*3002), JS (A*3003) and W7 (A*3004) produce different A30 
IFF bands. The results show LBF has an A30.3 IFF subtype and CR-B has an A30.1 IFF subtype. 
W7 produces an A30.2 equivalent IFF subtype. JS has an A30 IFF subtype different to A30.1,
A30.2 and A30.3.
The identification of new HLA Class I alleles provides a constant reason for 
vigilance in terms of how new sequences may affect the specificity of existing 
PCR-SSP reactions. For typing A*30 alleles, we are now aware of two recently
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identified alleles, A*0102 (Browning, et al 1995) and A*3302 (Kato, et al 1993), 
for which SSP AL#12 (previously thought to be A*30 specific) also has 
specificity. Of these two alleles, A*3302 can potentially be co-amplified by the 
first round prim er combination of AL#12/AL#W. In this study and in the 
A*30 subtyping reactions (chapter 4.4.3), the potential presence of A*3302 
does not compromise the specificity of the panel, as both HLA-A alleles were 
known and the presence of A*3302 excluded.
In conclusion, a presence of a novel HLA-A*30 specificity was identified 
through failure to amplify a serologically determined A*30 individual w ith  
SSP combinations specific for the then published A*30 alleles. The sam ple 
was typed as A*30 by PCR-SSP through the use of an alternative A*30 
specific SSP combination. Additional characterisation through PCR 'gene- 
m apping' identified polymorphic differences to the known A*30 alleles in  
the latter region of exon 3. This was confirmed by conventional DNA 
sequencing, with the polymorphic differences identified suggestive of a 
probable gene conversion event by virtue of their presence in the sequences 
of A*0202, A*0205 A*68 alleles.
Further characterisation by IFF analysis identified the new specificity as IFF 
variant A30.2. This new specificity has been observed at low frequency in  
other population groups (chapter 5.4). The sequence of A*3004 was officially 
assigned as A*3004 by the WHO nom enclature committee. The nucleotide 
sequence is reported in the FMBL database under accession num ber Z34921.
6.3.2. HLA-A*0214.
As with the identification of A*3004, A*0214 was determined through an 
anomaly in PCR-SSP typing. A Black Kenyan individual was typed at HLA- 
A locus by PCR-SSP, as previously described. Genomic DNA from this 
individual was analysed by PCR-SSP low resolution typing, high resolution 
sub typing, and PCR gene mapping. Low resolution typing identified the 
sample as HLA-A*02, A*33. High resolution HLA-A*02 subtyping (chapter 
4.4.4), suggested the individual was heterozygous for A*02, with both A*0205 
and A*0206 being identified. In view of the low resolution HLA-A locus 
typing, this raised the possibility that the A*02 gene was a new HLA-A*02
154
variant which contained sequence motifs characteristic of both the A*0205 
and A*0206 alleles.
PCR gene m apping of this A*02 allele (A*0214) was performed nested from  
the A*02 specific AL#37/AL#AW SSP combination used for nested A*02 
subtyping (chapter 4.4.4). Table 6.2 lists the primers used for the 
identification of sequence polymorphism present in exon 2 and exon 3 of the 
A*0214 allele. The PCR gene mapping result (Table 6.2 & Figure 6.4) shows 
A*0214 to be identical to A*0205 in exon 2, but varying in exon 3 as defined 
by primers AL#Q, AL#U, and AL#AV, suggesting a sequence difference of 
one nucleotide (G ^T ) at position 196 in exon 3, as compared to A*0205.
exon
2 primer primer sequence
exon
3 primer primer sequence
F i r s t R o u n d
AL#37
PCR
CCTCGTCCCCAGGCTCT AL#AW TGGCCCCTGGTACCCGT
a AL#22 CACTCCATGAGGTATTTCTT a AL#AF ACGTCGCAGCCATACATCA
b AL#27 CACTCCATGAGGTATTTCTA b AL#N CCCCACGTCGCAGCCAA
c AL#51 TCCATGAGGTATTTCTTCACA c AL#AK ACTGGTGGTACCCGCGC
d AL#38 AGCCCCGCTTCATCGCC d AL#B CGTCGTAGGCGTACTGGT
e AL#56 GACAGCGACGCCGCGACCCG e AL#AU GTGCTTGGTGGTCTGAGCT
f AL#40 GTCCGGAGTATTGGGACG f AL#AJ CCCACTTGTGCTTGGTGG
g AL#3 GACGGGGAGACACGGAAA g AL#AZ GGCCGCCTCCCACTTGT
h AL#26 GACGGGGAGACACGGAAT h AL#AE TCCGCCTCATGGGCCGT
i AL#6 CGGAATGTGAAGGCCCAG i AL#R CTCCAGGTAGGCTCTCTG
j AL#14 AGGCCCACTCACAGACTC J AL#Q CTCCAGGTAGGCTCTCAA
k AL#32 CGAGTGGACCTGGGGAC k AL#U CTCCAGGTAGGCTCTCC
1 AL#33 GACCTGGGGACCCTGCG 1 AL#AV CTCCAGGTAGGCTCTCCA
fixed AL#H CAAGAGCGCAGGTCCTCT fixed AL#13 TGGATAGAGCAGGAGGGT
Table 6.2. HLA specific oligonucleotide primers and sequences used to PCR 'gene-map' HLA- 
A*0214 in exons 2 and 3. A comparison of A*0201, A*0205 and A*0214 is shown in Figure 6.4
Confirmation of the predicted sequence (figure 6.5) was obtained by DNA 
DNA sequencing of exons 2-5 of the A*0214 allele as described in chapter 2.2. 
Single stranded DNA was prepared from single plaques of M13 phage and 
dideoxy sequencing (Sanger, et al 1977) was performed on both strands of 
three individual clones from three independent PCR amplifications.
The sequenced DNA indicated A*0214 to be identical to A*0205 in exons 2-5, 
except for a single base difference at position 196 in exon 3 (T instead of G), as 
seen in the A*0201, A*0204, A*0206-7, A*0209-ll and A*0215N-17 sequences 
(Arnett, 1995). In comparing A*0214 to A*0205, this causes a single am ino
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acid substitution of Trpis6 (A*0205 ) to Leui5 6  (A*0214 ) in the alpha 2 
domain of the molecule (Table 6.3). This change of aromatic to aliphatic side 
chain change at residue 156 has likely implications in the binding 
characteristics of the D and E pockets in the peptide binding groove (Saper, et 
al 1991).
Mabedei'ghi i kl 
* 2 '%  -
A*0201
A'^0205
A*0214
Mabcde.fghijkl
Figure 6.4. PCR gene maps of exons 2 and 3 of A*0201, A*0205, A*0214. Exon 2 gene maps were 
constructed using fixed primer AL#H in exon 3, and, in order, SSP AL#22, AL#27, AL#51, 
AL#38, AL#56, AL#40, AL#3, AL#26, AL#6, AL#14, AL#32, AL#33. Exon 3 gene maps were 
constructed using fixed primer AL#13 in exon 2, and, in order, AL#AF, AL#N, AL#AK, AL#B, 
AL#AU, AL#AJ, AL#AZ, AL#AE, AL#R, AL#Q, AL#U, AL#AV.
Exon 3
160 180 200
A* 02 05  A---------------------------- A---------------------- TG---------
CONSENSUS AGCGCAAGTGGGAGGC(2GCCCGTGTGGCGGAGCAGCTGAGAGC
Figure 6.5. Comparison of A*0201, A*0205 and A*0214 nucleotide sequence, showing the only 
nucleotide difference in exons 2-5 between A*0205 (G) and A*0214 (T) at position 196 in exon 3.
A*0214 has since been identified in other Kenyan individuals and also in  
Uganda (chapter 5.3). However, although identified in East Africa, its
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presence has so far not been noted in the West African population of 
Gambia, or indeed outside of the Africa. Additional A*02 subtyping of 
population groups may well reveal the true distribution of this A*02 
variant.
Residue
Position A*0201 A*0205 A*0214
9 Phe Tyr Tyr
43 Gin Arg Arg
95 Val Leu Leu
156 Leu Trp Leu
Table 6.3. Amino acid sequence differences between A*0201, A*0205, A*0214. Note that 
A*0205 has four differences from A*0201 and that A*0214 has three of these four differences.
The name A*0214 has been officially assigned by the WHO N om enclature 
Committee. The nucleotide sequence data reported appears in the EMBL 
Databases under the accession number Z30341.
6.3.3. HLA-A*0216.
The characterisation of A*0216 was possible through observations m ade 
with the B cell lymphoblastoid line TUBO (10th International 
Histocompatibility W orkshop ID 9045; HLA-A2, A3, B51, Bw4, Cw7, D R ll, 
DR12, DQ7, DR52, Caucasoid origin). As mentioned previously in this 
chapter, the discepancies observed between methods of HLA typing often 
highlight the presence of novel specificities. In the case of A*0216, the 
discrepancies presented as a difference on lEF analysis and molecular typing.
The evidence of this discrepancy exists in the initial DNA typing of TUBO by 
both PCR-SSOP (Fernandez-Viha, et al 1992) and nested A*02 PCR-SSP 
subtyping (chapter 4.4.4). Early versions of these typing approaches both 
typed TUBO as A*0201. However, this was at variance with the lEF analysis 
of the TUBO A*02. The isoelectric focal point of the TUBO A*02 was show n 
to be more acidic than A2.1 (A*0201), focusing at a point similar to A2.3 
(A*0203, A*0209) (Guttridge, et al 1992). PCR-SSP typing of TUBO had 
excluded A*0203 and A*0209. The difference in the observations made in lEF
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analysis and molecular typing suggested the presence of a new A*02 variant.
Verification of these observations was made in cloning and DNA 
sequencing (Sanger, et al 1977) of the A*02 cDNA obtained from TUBO, as 
described in chapter 2.2. As in the characterisation of all new HLA alleles, 
three clones obtained from three independent PCR amplifications were 
sequenced on both strands, to allow confidence in the sequence data 
generated. The DNA sequence data generated showed A*0216 to have a two 
base pair difference from A*0201, at nucleotide positions 216 and 217 in exon 
3 (A*0201 A C ^G A  A*0216). The sequence substition caused a single am ino  
acid change of glutamic acid instead of the threonine found at residue 163 in  
the alpha-2 domain of the A*0201 molecule.
The sequencing provided information for the design of an A*0216 specific 
PCR-SSP combination, as illustrated in figure 6.6. The observed 
polymorphism is not found in any other of the A*02 alleles so far described, 
which makes its definition by A*02 nested subtyping unequivocal, w ith in  
the context of the known A*02 alleles. The polym orphism  is seen in other 
HLA-A locus alleles, (A*6602, A*8001), in addition to a large num ber of B 
locus alleles (including B*27, B*07, B*4001-4, B*4006, B*1301-2, B*4701 & 
B*4801) and some C locus alleles (Cw*0201 and Cw*0202). The 
polym orphism  being present as two adjacent base pairs, found in m any 
other alleles, is suggestive of A*0216 arising through a gene conversion 
event (Parham, et al 1988). The single amino acid difference caused by this 
polymorphism in relation to A*0201 produces a substitution from a polar to 
acidic residue. This change explains previous lEF observations in that 
A*0216 focusing at a more acidic position in relation to A*0201.
The amino acid substitution also has implications for potential peptide 
binding characteristics of the A*0216 molecule. Residue position 163 of the 
class I molecule is known to have involvem ent in the binding 
characteristics of the 'A' pocket of the peptide binding groove (Bjorkman, et 
al 1987). Characterisation of this allele shows further evidence of the 
concentration of polymorphism around the peptide binding groove of HLA 
molecules, and suggests that A*0216 may be functionally distinct in terms of 
peptide presentation.
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Further subtyping studies for A’^ 02 has not revealed an additional example 
of A*0216. The name A*0216 was assigned by the WHO nom enclature 
committee, with the nucleotide sequence placed in the EMBL database under 
accession num ber Z46633.
Mab cde f ghi j kl
JY
TUBO
Figure 6.6 HLA-A*02 
subtyping DNA from JY 
(A*0201) and TUBO 
(A*0216) by ARMS-PCR. 
Reaction specificity;
a=A *0201 /4 /7 /9 / l  1, 
b=A*0202, c=A *0203,
d=A *0204, 
e=A *0202/5/14, 
f=A*0205/8/14, 
g=A*0207, h=A *0208,
i=A*0206/10/14 , 
j=A*0211, k=A *0212/13 , 
1=A*0203/13, m=A*02 not 
A*0216, n=A *0216.
M=size marker. Lower band 
present in each reaction 
lane is the internal control. 
The results show the 
difference between A*0201 
and A*0216 as determined 
by reactions (m) and (n) 
identifying the sequence 
polymorphism in exon 3 of 
the HLA-A locus gene.
6.3.4. HLA-A’^ 2502.
HLA-A’^ 2502 was determined through observing a novel pattern of 
reactivity when HLA typing a DNA sample by PCR-SSP. As discussed 
previously, new specificities may appear in typing, when a novel 
combination of polymorphism s in the allele, manifests as a new pattern of 
reactivity with the typing panel.
A Caucasian individual was HLA typed from genomic DNA th rough  
'Phototyping' (Bunce, et al 1995b). The result indicated a discrepancy at the 
HLA-A locus, with identification of three alleles (A*6601 A*2501, A*68). The 
rest of the genotype comprised B*0801, B*1402, Bw6; Cw"^0701, Cw’^ 0802; 
DRBH0301/4, DRB1H303, DRB3; DQBH02, D Q BlW O l/4. Both A*6601 and 
A"^2501 belong to a broad serological specificity, HLA-AIO. It was conceivable
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that the typing result represented a novel sequence recom bination 
involving elements of A*6601 and A"^2501.
To investigate further, the nature of the A’^ 2502 sequence polym orphism  
was determined through PCR 'gene-mapping' as illustrated in figure 6.7 and 
Table 6.4. This approach found that the new allele contains a combination of 
polym orphism s found in both A"^ 2501 and A"^6601. The variant resembles 
A"^2501 by containing the characteristic Bw4 motif (figure 6.8, nucleotide 
position 300-320), whilst it also contains a polym orphism  at nucleotide 
position 282 found in A%601 but not in A*2501. The combination of 
polymorphisms present within the sequence of A"^2502 explained the initial 
anomalous PCR-SSP HLA typing result.
A*2501
A/b601
A*2502
A*2502
repeat
M a b c d e f g h i j  k l
Figure 6.7 PCR gene-map of A’^ 2502 in the 3' region of exon 2. The pattern of reactivity 
is compared to A*2501 (FBll) and A*6601 (TEM). Details of the gene-map panel are 
given in Table 6.5. Reactions were run nested from AL#38/AL#AC and constructed 
with a fixed primer, AL#AE, in exon 3. The lower band present in each reaction lane 
represents the internal control amplification.
The FiLA-A’^ 2502 gene was then cloned and sequenced, as described in  
chapter 2.2. Cells were then transformed and clones picked and screened by 
specific HLA-A PCR-SSP reactions to identify vectors containing HLA- 
A’^ 2502. Four independent A*2502 clones were then sequenced on both 
strands. One clone was dideoxy sequenced using a standard approach 
(Sanger, et al 1977). Three other clones were full length sequenced on both 
strands using the ABI377 DNA Sequencer technology (Perkin-Elmer, USA).
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Autom ated sequencing was performed by Angela Ivison at the Advanced 
Biotechnology Centre, Charing Cross & W estminster Medical School, 
London. DNA sequencing verified the results observed in the initial PCR- 
SSP tissue-typing and 'gene-mapping'.
DNA sequencing of the A*2502 allele confirmed the polym orphism  at 
nucleotide position 282, distinguishing it from A’^ 2501 (figure 6.8). As w ith  
many other HLA alleles, the nature of sequence polym orphism  found 
w ithin this allele probably arose through a gene conversion or 
recombination event (Parham, et al 1988), since the defining polymorphisms 
found within A’^ 2502 are present in other HLA-A alleles. As with A*2501, 
this variant contains the Bw4 polymorphism. This is found between am ino 
acid positions 77-83, which is located at the top of the alpha helix of the 
alpha-1 domain of the class I molecule. Expression of the Bw4 motif has 
been shown to inhibit lysis by a subset of natural killer (NK) cells containing 
the NKBl receptor (Gumperz, et al 1995). Although slightly different to 
HLA-B molecules containing the Bw4 motif, HLA-A*2403 and A^^2501 have 
been shown to prevent lysis by the NKBl subset of natural killer (NK) T cell 
clones. It therefore seems likely that A’^ 2502 will also exhibit this NK 
inhibitory capability.
reaction SSP posn. size (bp) 1 2 3 4
1st #38
#AC
2.71C
3.216C
691 4- 4- 4- 4-
a #4 2.188C 532 + 4- 4- 4-
b #18 2.197A 523 - - - -
c #6 2.209G 511 - 4- 4- 4-
d #34 2.226C 494 + / - - - -
e #44 2.228G 492 - 4- - -
f #45 2.228A 492 + - 4- 4-
g #2 2.229A 491 - - - -
h #11 2.229G 491 4- - 4- 4-
i #32 2.238C 482 - 4- - -
j #33 2.244G 476 - 4- - -
k #15 2.246C 474 4- - 4- 4-
1 #21 2.268A 452 4- 4- 4- 4-
anchor #AE 3.174A 4- 4- 4- 4-
Table 6.4. PCR gene-map of A*2502 (3,4) in comparison to A*2501 (1) and A*6601 (2). A*2502 is 
identical to A*2501, except for the polymorphisms defined by AL#6. Some crossreactivity was 
noted with AL#34 and A*2501.
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The name A’*’2502 was officially assigned by the WHO N om enclature 
Committee and the nucleotide sequence data submitted to the GenBank 
EMBL database under the accession number X97802.
Exon 2- (3'region)
2 6 1  • • 2 9 1  • • 3 2 1
A* 2 5 0 1  C ----------G — ATG—G------- G ----------T ------------------------------------------------------------- T —GC —  T —C --------------------------
A* 6 6 0 1  C -------- G — A T G -G -----G  G T-----------------------------------T - G A -------- G  C ----------------------------------------------
A* 2 5 0 2  C ----------G - - A T G - G ------- G ------- G T ------------------------------------------------------------- T - G C - - T - C --------------------------
C o n s e n s u s  GACACAGATCTTCAAGACCCACACACAGACTGACCGAGAGAGCCTGCGGAACCTGCGCGGCTACTACAACCî
al Domain region
5 0  6 0  7 0
A * 2 5 0 1   N~RN------ H S ------------------ lA L R -
A * 6 6 0 1  ---------------------------- N —RN------ Q S ------
A * 2 5 0 2  ---------------------------- N —RN------ Q S ------------------ lA L R -
CONSENSUS PWIEQEGPEYWDRETQIVKANTQTDRESLRNLRGYYNQSEA
T
80 9 0
- I A ------ ------D
'- G T ------------- ------D
- I A ------ ------D
Figure 6.8. Sequence alignments stiowing both nucleotide and amino acid comparisons between 
HLA-A*2502 and A*2501, A*6601. Nucleotide sequence numbered from the first residue in exon 
1, protein sequence numbered from the first amino acid in the a-1 domain. HLA-A*2502 may 
have resulted from a gene conversion event introducing the polymorphism found at nucleotide 
position 282 in A*6601 (Î) into the A*2501 sequence.
6.4. PCR-SSP typ in g  H LA-A locu s ’blanks'.
The developm ent of PCR-SSP as applied to HLA analysis provided the 
opportunity to reassess the nature of HLA-A locus 'blank' specificities. 
Serological analysis in past workshops has revealed a significant num ber of 
HLA-A blanks (Imanishi, et al 1992a), which may reflect the inadequacy of 
serology for defining specificities in one population, when applied to 
another. This thesis has encountered two opportunities to characterise 
'blank' or non-expressed HLA-A specificities. One corresponded to a new  
allele (HLA-A’^ SOOl) recently identified, for which serological identification 
proved difficult. However, this A*8001 allele (Rosen-Bronson, et al 1992; 
Starling, et al 1994) is expressed and can be detected serologically (Rosen- 
Bronson, et al 1992) with the appropriate sera. The other study contained a 
num ber of individuals all determined as possessing an HLA-A locus blank 
through family studies. This latter group of individuals appears to carry a
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HLA-A allele which is not expressed.
6.4.1. HLA-A*8001 confirm ation  in  a M oroccan Fam ily.
HLA-A’^ 8001 was identified in a num ber of studies (Rosen-Bronson, et al 
1992; Domena, et al 1993; Starling, et al 1994). All of these studies identified 
this allele in black North Americans. The observed antigen frequency of this 
allele in the African-American population was estimated at 2% in a study of 
254 individuals tested, and shown to be absent in 305 Caucasians (Starling, et 
al 1994). It seems likely that this specificity is of African origin which did no t 
spread to Europe and Asia in early population migrations (Domena, et al 
1993). In examination of the sequence of A*8001, it seems likely that A*8001 
represents a separate sixth family of HLA-A specificities, in addition to the 
A3, A9, A2, AlO, A19 families (Domena, et al 1993).
The lack of available sera for definition of this allele potentially can result in  
it being identified as a HLA-A 'blank'. Such a situation arose in serological 
typing of a Moroccan family (for a matched bone marrow translplant), which 
seemingly contained a HLA-A locus blank in one paternal haplotype 
(personal com m unication from Dr I. Joosten, Academisch Z iekenhuis 
Nijmegen). Serological observations identified the presence of HLA-A30 
with some weak HLA-Al reactivity. The haplotypes determined in the 
paternal sample were Ax;B51;Bw4 and A30;B18;Bw6, with Ax denoting the 
'blank'. Dr. Joosten further typed this sample by PCR-SSP using a basic low 
resolution panel similar to that described in Table 3.2 in chapter 3.2.4. The 
observation made in this PCR-SSP typing, which did not include a reaction 
to A’*'8001, typed this sample as A’^ SO only. The failure to account for the 
weak A1 reactivity, suggested that a specificity was being missed in the PCR- 
SSP typing, and this may represent a novel allele.
At the time that these observations were made, the A"^8001 allele was 
described in the black North American population. In examination of the 
sequence of this allele, it was clear that it represented a specificity distinct 
from the other A locus specificities defined in the low resolution typing 
panel, and would not be amplified by any of the existing SSP combinations. 
However sequence similarities were present with other A locus alleles, in
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particular A ’^ 0101, although 34 nucleotide substitutions exist between the 
two alleles (Domena, et al 1993). The noted weak serological A1 
crossreactivity in the Moroccan sample, made A"^ 8001 a candidate for the 
observed blank specificity.
p rim er
exon 2 (primers
m otif 3' nucleotide A’^ SOOl 
position 
in combination with AL#Z)
Moroccan
A/BOOl
A 2 A19
(1) AL#51 TcacA 29 + + -
(2) AL#19 CcA 127 + + -
(3) AL#8 CA 184 + + -
(4) AL#49 TC 199 + + -
(5) AL#30 acT 210 + + -
(6) AL#32 GggaC 238 + + -
(7) AL#21 ggA 268 + + -
AL#53 gcA 103 + + -
AL#54 ctA 219 + + -
exon 2 (primers in combination with AL#54)
(a) AL#AB TA 20 + + -
(b) AL#AM CC 71 + + -
(c) AL#L eg 110 + + -
(d) AL#AI T 125 + + -
(e) AL#S A 159 + + -
(f) AL#T CC 184 + + -
(g) AL#BK CA 217 + + -
AL#Z CC 228 + + -
Table 6.5. Summary Table of A*8001 PCR gene mapping in the Moroccan family study. For the 
sequence motif column, lowercase denotes nucleotides identical to the consensus sequence, w ith  
uppercase showing polymorphism. Primer sites are shown in Figure 6.10.
With the sequence of A*8001 published (Domena, et al 1993), it was possible 
to design PCR-SSP combinations which would specifically amplify A'^SOOl. 
The Moroccan A locus blank DNA was tested against two A*8001 specific 
SSP combinations (AL#53/AL#BK and AL#54/AL#BK). In addition, an 
A'^SOOl control DNA was tested, together with the other members of the 
Moroccan family, none of which contained the blank. Both PCR-SSP 
reactions identified the A blank as A’^ SOOl, which was further verified by the
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A"^8001 control DNA.
Since A’^ SOOl seems to represent a novel specificity amongst HLA-A alleles, 
it is possible that variants could exist as amongst the other HLA-A families. 
To address this w ithin the context of this Moroccan A*8001, a limited PCR 
'gene-map' was performed, which identified key polym orphism s in both 
exon 2 and 3 of the A*8001 gene. An initial first round A locus specific PCR, 
amplifying the majority of exons 2 and 3 was used as template for a 
subsequent nested panel of 'gene-mapping' reactions identifying 
polymorphisms in this region of the A locus sequence. The PCR 'gene-m ap ' 
as shown in figure 6.9 and Table 6.5, shows that the A’^ 8001 characterised in  
this study is identical to the A’^ 8001 control DNA at the prim er sites tested 
(figure 6.10). It is possible that polymorphisms may exist at other locations 
w ithin the sequence not considered by this panel of primers, and DNA 
sequencing should be considered to investigate this further.
M M :
A*8001
moroccan
A*80
Exon 2
1. AL#51
2. AL#19
3. AL#8
4. AL#49
5. AL#30
6. AL#32
7. AL#21
Exon 3
a. AL#AB
b. AL#AM
c. AL#L
d. AL#AI
e. AL#S
f. AL#T
g. AL#BK
Exon 2 SSP in 
combination w ith
AL#Z, exon 3 w ith  
AL#54
Figure 6.9. Gel showing PCR gene-map to characterise A*8001 from a sequenced A*8001 DNA, 
a Moroccan A*8001 individual and an A*8001 negative DNA. The results are given in Table 
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In separate studies, we have noted the presence of A*^8001 at low gene 
frequency in typing Gambian and some Senegal individuals (data no t 
shown). A’^ 8001 was not identified in typing the 90 individuals in the 
Ugandan study (chapter 5.4, Table 5.5). Although num bers and populations 
studied are small, from current observations it seems likely that the 
distribution of this allele may vary between different parts of Africa. Future 
typing of presently untested populations may reveal its true distribution. 
Since the means for its identification now exist, future studies may resolve 
the presence of any additional polymorphism within the A'*'8001 specificity.
6.4.2. Characterisation of a HLA-A locus blank in three independent 
families.
During the course of this work, three independent cases of serological HLA- 
A locus 'blanks' have been characterised by the PCR-SSP based approach. In 
each case, the presence of a HLA-A locus blank was serologically determ ined 
through family studies. To achieve additional information as to the nature  
of the HLA-A serological blank, the use of PCR-SSP was applied to 
characterise these seemingly non-expressed specificities at the DNA level.
(i).  T h e  B - S  f a m i l y .
The B-S family was the first study in this project in which the nature of a 
serologically negative HLA-A specificity was investigated. The origin of the 
family was from Belfast. DNA from two members of the family were 
provided by D.Middleton, Belfast, N.Ireland. The serologically determ ined 
HLA types of the two individuals is given in Table 6.6.
Serological Class I type
Sample A A B B Bw4 Bw6 Cw Cw
JB A3 AX B7 B60 - Bw6 Cw7 CwlO
JS A3 AX B27 B60 Bw4 Bw6 Cwl CwlO
Table 6.6. Serological typing of two family members containing a HLA-A blank specificity.
The HLA-A locus was investigated by PCR-SSP using a low resolution 
typing panel as described in Table 3.4 in chapter 3. Both DNA samples typed 
as HLA-A3, A9. It was therefore apparent that the specificity whose
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expression was not detected was HLA-A9. Further analysis by additional 
reactions showed that the A 'blank' specificity was typing as A’^ 24. This was 
confirmed by a limited gene-mapping panel looking at four definitive sites 
of A24 sequence polym orphism  in exon 2 and three in exon 3 (data no t 
shown),
(i i).  T h e  A - E  F a m i l y .
In trying to find a match for a bone m arrow transplant patient, a Saudi 
family were serologically HLA typed. This exercise found a haplotype w ith in  
which the HLA-A specificity that was not detected. This haplotype was 
present in the patient's mother and two of his siblings. Details of the family 
and their serological types are given in figure 6.11. The four individuals in  
the family possessing the serological A locus blank were typed by PCR-SSP at 
the A locus. The typings showed, as with the B-S individuals, the A 'b lank ' 
typing as A'*'24. These samples were subtyped to determine whether the A 
locus blank was A'^2402 or A*2403. A panel of three reactions were used, 
which identified; A*24 (AL#8/AL#R), A*2403 (AL#8/AL#W) and A*2301, 
A'^2402, A'*"2404, A*2405 and A'^2406 (AL#9/AL#Z). These reactions are listed 
in Table 4.13. The results identified the presence of A'*'2402.
mother 
A B
I__
father
C D
B O
1
A D 
2
B D
3
A C
4
A D
5
B C
6
A C
7
Haplotype A; A28 B27 Cw2 D R 17 DQ2  
Haplotype B; A X' B58 Cw3 DR 17 DQ2  
Haplotype C; A3 B50 Cw6 DR 4 DQ8  
Haplotype D; A28 B50 Cw6 D R 1 1 DQ 7
Figure 6.11. Family tree of the A-F family showing HLA haplotypes. Haplotype B contains 
the serological HLA-A blank (A'X'), present in individuals 1,3,6 and their mother.
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(ni). The C-B family.
Three DNA samples obtained from an Israeli family had been serologically 
HLA typed to reveal the presence of an A locus blank. As with the other two 
families, these were investigated by PCR-SSP at the A locus with the blank 
specificity typing as HLA-A9. Further sub typing determined that the blank 
typed as A'*'2402 (data not shown).
The three above studies of serological HLA-A locus blanks found that at the 
DNA level, each blank could be identified as HLA-A'*'24. HLA-A'*'24 from the 
BS family and another HLA-A'*'24 blank sample (not included in this study) 
have recently been DNA sequenced (A'^2409N, A'^2411N (Marsh, et al 1996)). 
The exact sequence details remain as yet unpublished. However, each of the 
two non-expressed alleles contain a single base pair difference from the 
A'*'2402 (P.Parham, personal communication). It is interesting that in three 
different families, the A locus blank found was attributed to a non-expressed 
variant of HLA-A'*'2402. Also that two different non-expressed variants of 
A'*'2402 have been identified.
The loss of HLA class I expression through somatic m utation, has been 
associated as a possible means of tum our escape from im m une surveillance 
(Browning, et al 1996). The explanation for non-expression of HLA-A in a 
germ-line, and if this incurs any susceptibility to cancer, remains to be 
deduced.
Other HLA-A null alleles have also been described including an A '*'0201 
allele which failed to be expressed through a m utation in the untranslated  
regulatory region 5' region of the gene (Balas, et al 1994). A'^0215N is no t 
expressed through a m utation causing a stop codon and truncation of the 
class I heavy chain (Ishikawa, et al 1996). Another class I allele, A'*'0303N fails 
to be expressed through a six base pair deletion in exon 3. This deletion 
removes a structurally im portant cysteine from the m ature heavy chain 
which prevents the proper folding and so functioning of the class I m olecule 
(Lienert, et al 1996).
The reasons for the existence of HLA-A 'null' alleles may also suggest that 
under certain circumstances there may be some selective advantage of loss 
of expression of a particular specificity. The exact relevance may be
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understood better once its frequency, distribution and any disease 
associations with the null alleles are fully characterised.
6.5. D iscu ssio n .
The application of PCR-SSP to tissue typing has provided a novel 
perspective for the determination of HLA specificities, which has resulted in  
new alleles being identified. As a consequence of the work of this thesis, 
several new alleles have been characterised, their identification relying on  
the recognition of novel patterns of reaction in the PCR-SSP panel, or a 
discepancy in result in comparison with another method of typing. As the 
definition of polymorphism  at the DNA level becomes more and m ore 
established, so an increasing number of new alleles will be found.
The characterisation of HLA polymorphism  has also been addressed 
through the development of PCR 'gene-mapping'. PCR gene m apping offers 
a means of rapidly screening new variants to predict their sequence 
polymorphism. It is not an alternative to sequencing, which is still necessary 
for characterising new alleles. The data obtained from PCR gene m apping ' 
in this thesis has enabled the design of more than one specific SSP 
combination for identification of a new variant.
Characterisation of the composition of sequence polym orphism  by PCR 
'gene-mapping' has been possible because of the nature of polym orphism  in  
the HLA class I genes. The generation of polym orphism  in the HLA genes 
seems to have arisen through the mechanisms of gene conversion or double 
recombination rather than point m utation, in the examples identified in  
this thesis. The implication of this is seen in the shared nature of 
polymorphic sequence motifs between HLA specificities. The unique natu re  
of an allele is the result of the combination of these different polym orphic 
sequence motifs along the length of the gene. This suggests that there is an 
apparent finite number of polymorphic sequence motifs found amongst the 
HLA class I alleles. Defining the HLA specificity on the basis of these 
sequence motifs, provides a rapid and up to now, accurate approach to 
predicting the DNA sequence of alleles, as demonstrated in the use of PCR- 
SSP to tissue type, charactersise or confirm new specificities.
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This chapter also described the use of PCR-SSP to define serologically HLA 
'blank' specificities. In one study this was simply due to a novel HLA-A 
allele (A'*'8001), which was serologically ill-defined. W ith the sequenced 
published, it was possible to define the presence of A'*'8001 by PCR-SSP and 
also confirm its sequence composition by PCR 'gene-mapping'. A nother 
study involving identification of a serological blank in three independent 
families, produced an interesting observation. By PCR-SSP, the serological 
blank in all three families, typed as A'*'2402. Mutations have since been 
reported which account for the non-expression of the A'*'24 gene sequenced 
(A'*'2409N, A'*'2411N (Marsh, et al 1996)).
The ability to identify the non-expressed A'*'24 specificity by PCR-SSP does 
cause some concern. Typing these individuals by PCR-SSP alone would no t 
draw attention to the fact that it was not expressed. This raises an argum ent 
that tissue typing in the context of the expressed HLA molecule (i.e. serology 
or lEF), does hold relevance in the future of histocompatibility testing. The 
exact frequency of such cases, which appear rare may detract from this 
argument. However, as seen in this chapter, the comparison of observations 
made by different approaches to HLA typing does provide an objective view  
from which novel specificities can be identified.
The development and application of new typing approaches have therefore 
expanded the knowledge and perception we have of the HLA system. As 
more sequence based approaches are applied to identification of HLA 
polym orphism  in different populations, so it seems plausible that the 
identification of an increasing num ber of new alleles will follow. This will 
undoubtedly determine the true extent of HLA polymorphism , which will 
greatly benefit the fields of anthropology, disease association and 
transplantation.
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Determining the significance of polymorphism 
amongst the A*30 allelic group.
7.1. In troduction .
The purpose of this thesis has been to establish a method for tissue typing at 
the HLA-A locus, which allows definition to an allelic level. This has been 
dem onstrated in the preceding chapters through the ability of SSP prim ers 
designed on the ARMS principle to distinguish between alleles of highly 
similar sequence in the PCR-SSP reaction. Having established the ability for 
such discrimination, it was also im portant to contemplate the relevance of 
typing to such a high level of resolution.
In comparing the DNA sequences of the class I alleles (Arnett and Parham  
1995), it is clear that the majority of polymorphism lies within exons 2 and 3. 
The significance of this becomes apparent when the location of these 
polymorphisms are considered within the expressed class I molecule. Exon 2 
and exon 3 code for the alpha-1 and alpha-2 domains of the class I m olecule. 
These two domains form a binding groove which presents peptide to the 
TCR. Changes w ithin this peptide binding groove have potential relevance 
as to the sequence of peptide bound together with its orientation. This in  
turn may elicit a different HLA restricted T cell response.
To explore the importance of sequence polym orphism  in terms of the 
presentation of peptide by the class I molecule, a group of alleles, 
serologically defined as HLA-A*30 were compared. HLA-A*30 alleles have 
been extensively considered in other parts of this thesis; their identification
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through nested PCR in chapter 4.4.3., their distribution in the Sardinian and 
Ugandan populations in chapter 5, and the identification and 
characterisation of a new allelic variant, A'*'3004, in chapter 6.3.1.
HLA-A'^30 was identified as a split of a serologically cross-reactive group of 
antigens known as HLA-A19. HLA-A'*'29, A**^ 31, A“^32, A'*'33 and A'^74 
constitute the other members of this group (Kato, et al 1989). HLA-A'*'30 has 
been included as part of the A19 group, mainly on the basis of its serological 
cross-reactivity with A'*'31. The serological definition of A'*'31 in the presence 
of A'*'30 has proved almost impossible, due to the specificity of available sera 
being limited to A'*'30 specific or A'*'30/A'*'31 specific, with no mono-specific 
sera for A'*'31 being easily available (Carpenter, et al 1989). The serological 
definition of A'^31 in the presence of A'^30 has therefore relied on family 
studies. The basis of this serological A'^30 cross-reactivity with A'*'31 lies w ith  
the sharing of an Argg^, which lies at the top and at the end of the alpha-1 a-
helix (figure 7.1a). This site would seem to be antigenic and accessible to 
binding of antibody.
Early molecular analysis of the A19 group through DNA sequencing (Kato, 
et al 1989), established that HLA-A30 (A'*'3001) was probably part of the 
A'*'01/A'*'03/A'*'ll family of specificities, rather than the A19 group. Inclusion 
of A'*'30 in the A19 serological group (as discussed above), was by virtue of its 
cross-reactivity with A'*'31. The isolation of A'^30 from the other members of 
the A19 group was further corroborated through early observations made in  
the development of the PCR-SSP system at HLA-A locus. In endeavoring to 
design a single PCR reaction to encompass the A19 group of specificities, it 
proved impossible to find an SSP combination that would also include 
A'*'30. The low resolution typing panel as described in chapter 3 (Table 3.4), 
therefore determined the A19 serological group through two reactions. One 
identifying A19 with the exception of A'^30, and the other amplifying only 
A'*'30. The A19 not A'*'30 amplification is achieved through the specificity of 
SSP AL#F. This primer identifies a silent polym orphism  at nucleotide 
position 105 in exon 3. This polymorphism is found uniquely in the A19 no t 
A'*'30 allele group, and further substantiates the exclusion of A'*'30 from this 
group of specificities.
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Met 45
9 Glu 63
4
Figure 7.1. (as shown on previous page), (a). A ribbon diagram showing positions of 
polymorphism within the four A*30 variant molecules. Positions are marked as per the 
mature protein. Positions marked in red denote polymorphic differences shared amongst the 
A*30 group as compared to a consensus sequence (Amett and Parham 1995). Positions marked in 
green denote sites of polymorphic differences between the A*30 variants. Note erratum; 
position 53 is marked incorrectly, this polymorphism should be at position 56, located at the 
top of the loop directly above position 53. Details of the polymorphism marked in green are 
given in Table 7.3. (b). A representation of peptide binding into the HLA-A*3002 molecule 
within the B pocket. The peptide sequence (AYSSWMYSY) was reported to bind and be 
presented by A*3002 (Alan Rickinson, personal communication). The detail shows the side- 
chain of the peptide P2 Tyr binding into the B pocket, forming a hydrogen bond with the Ser 
at position 9 of the A*3002 heavy chain. Both figures were generated in MOLSCRIPT 
(Kraulis, 1991, modification by R.Esnouf), and rendered with Raster3D (Merritt, et al 1994).
Early lEF analysis of HLA-A*30 revealed three variants (Yang, 1989a). Of the 
three IFF variants, A30.1 and A30.3 were found to be the most com m on, 
with A30.2 rarely seen. A fourth even rarer variant, A'*'3003, is also 
distinguishable by IFF (Choo, et al 1993). Figure 6.3 in chapter 6 provides 
examples of all four IFF definable A'*'30 variants. Analysis showed that of the 
two common variants, A30.1 is associated with B'*'18, while A30.3 is 
associated with B*13 in Caucasoids, and B*42 in Black populations. These 
two main IFF variants have now been DNA sequenced, as have the two 
rarer variants (Bodmer, J.G. et al 1995).
W hen considering cellular approaches to vaccine strategies, accurate tissue- 
typing is essential to establish the prevalent HLA restricted T cell m ediated 
im m une responses. With the view of a potential future HIV vaccination 
study, a cohort of 90 HIV positive individuals from a Ugandan sem i-urban 
population, were extensively HLA typed by PCR-SSP (chapter 5.4.). In this 
population, HLA-A'*'30 represented the most common allelic group am ongst 
the HLA-A locus specificities. Unlike HLA-A’*'02 (Rotzschke, et al 1992; 
Barouch, et al 1995; Sudo, et al 1995), very little is known with regard to 
peptide binding and presentation by the different allelic variants of HLA- 
A'*'30. Knowing the respective peptide motifs of the different allelic variants 
of HLA-A'*'30 is therefore an im portant part of any cellular based vaccine 
studies in which the target population contains a significant frequency of 
A'*'30 individuals.
This study therefore considered the relevance of the polym orphism  found 
amongst the four variants of HLA-A'*'30 in terms of peptide binding. To
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ascertain the functional differences between the four A'^ 'SO allelic variants, 
the peptide binding preference of each allele was determined. This required 
the construction of HLA transfectants, in which the different A*30 variants 
were expressed in a HLA class I negative cell background. Endogenously 
processed peptides were then eluted from the different expressed A'*^ 30 
alleles and the preferred peptide sequence determined. The similarities and 
differences observed in the peptide motifs eluted from the different A '*'30 
variants, provide additional insight into the relevance of HLA 
polymorphism  found within the peptide binding groove. As discussed, this 
also provides useful information for future cellular based vaccine studies.
7.2. C on stru ction  o f the HLA-A'^^SO transfectants.
7.2.1. Cloning and transfection.
The basic procedure for making transfectants for the four variants of HLA- 
A'*'30 is as described in chapter 2. The BCL as listed in Table 7.1, represent cell 
lines in which the four allelic subtypes of HLA-A'^30 have been identified 
through DNA sequencing. These BCL provided the A'*'30 genes which were 
transfected and expressed in the class I reduced (CIR) cell line. In brief, this 
involved first preparing mRNA from growing cells, and then m aking first 
strand cDNA through RT-PCR. The full length HLA-A cDNA was am plified 
using specific primers as detailed in figure 2.2 in chapter 2. This HLA-A PCR 
was then ligated into a pMOSblue T vector to facilitate cloning of the A '*'30 
alleles. The ligated vector was then used to transform competent cells and 
clones were picked, grown and plasmid DNA prepared. This DNA was then  
screened by PCR-SSP using an A'*'30 specific prim er com bination 
(AL#12/AL#G). DNA amplifying with this SSP pair were identified as A '*'30. 
These clones were then DNA sequenced. Only one clone contained a 
num ber of errors from the published sequence. Further sequencing of 
additional clones confirmed the published sequence and suggested 
incorporation of Taq errors in the problematic clone.
Having confirmed the published sequence for all four subtypes, the HLA 
insert was cut out of the cloning vector and ligated into the pKG4 expression 
vector. This required the use of an intermediary 'shuttle vector'
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(pBluescript), due to a lack of compatible enzyme restriction sites between 
the cloning and expression vectors. At each of these steps, clones were 
picked and plasmid DNA subtyped for A*30 by PCR-SSP (see chapter 4.4.3). 
HLA typing the plasmid DNA at each stage confirmed both the presence and 
subtype of the A'*’30 insert (figure 7.2).
BCL HLA-A HLA-B HLA-C
A30 lEF 
subtype
Accession
N um ber
LBF A*3001 B*1302 Cw6 A30.3 M30576
CR-B A*3002 A*6602 B17 B18 A30.1 X61702
JS A*3003 A3 B7 B18 - M93657
W7(CC) A*3004 A ll B49 B37 A30.2 Z34921
Table 7.1. HLA types of the B cell lines from which the A*30 allelic variants were cloned. 
Corresponding A30 lEF subtypes are also given. EMBL accession numbers for each of the A*30 
sequences are also given.
a b e d  a b c d M
Figure 7.2. PCR-SSP typing screen to verify A*30 clones. Reaction a=A*30 (AL#12/AL#G), 
b=A*3001 (AL#6/AL#K) c=A*3002 (AL#10/AL#T) d=A*3003 (AL#10/AL#U), with SSP 
combinations in brackets. Lane M denotes the size marker. All bands are in the region of 350bp, 
consistent with the expected size for amplification of cDNA. Hence, clone 1 types as A*3001 
(positive with a-hb), clone 2 types as A*3004 (positive with a only), clones 3 and 4 type as 
A*3002 (positive with a+c) and clones 5 and 6 type as A*3003 (positive with a-i-d).
177
Having established the presence of all four A*30 variants in the pKG4 
transfection vector, a maxiprep preparation of the plasmid DNA was m ade 
and purified through a CsCl gradient. This purified plasmid DNA was 
subsequently linearised (using restriction enzyme Seal) and electroporated 
into growing CIR cells. CIR cells have reduced surface expression of HLA-A 
and B molecules (Edwards, et al 1982; Storkus, et al 1987; Zem m our and 
Parham 1992). The plasmid DNA was also digested with the H indlll, Bam H l 
restriction enzymes used to ligate into the vector and viewed on an agarose 
gel (figure 7.3). This was used as a simple screen to ensure the integrity of the 
insert and vector prior to transfection. Cells were then cultured in selection 
and transfectants observed growing out after a period of two to three weeks 
following electroporation.
1 2 3 4  M 5 6 7 8
6.9kb
S.Bkb
1.1 kb
Figure 7.3. Restriction digests to 
verify integrity of the A*30/pKG4 
expression vector constructs prior to 
transfection. Digestion is shown for 
the A*3001 construct (lanes 1 and 5), 
A*3002 (lanes 2 and 6), A*3003 (lanes 
3 and 7), A*3004 (lanes 4 and 8). Lane 
M is the size marker. Verification of 
linearisation of constructs w ith  
restriction enzyme Seal (lanes 1-4) is 
seen as a single 6.9kb band. Digestion 
with H indlll/Bam H l restriction 
enzymes (lanes 5-8) excises the A*30 
inserts (1.1 kb) from the pKG4 vector 
(5.8kb). Hindlll and BamHI 
restriction sites facilitated ligation of 
the A*30 cloned cDNA into the pKG4 
expression vector.
7.2.2. V erification  o f expression .
Expression of the transfected A*30 was verified through FACS analysis. 
Unfortunately, no A'^30 specific antibody was available for this screening 
and the HLA class I specific monoclonal W 6/32 (Brodsky, et al 1979), was 
used for used to detect HLA class I expression (figure 7.4). More specific 
screening of expression was possible in conjunction with Mike Bunce at the 
Oxford Transplant Centre. The four transfectants were analysed for 
expression by serology using the complement mediated lymphocytotoxicity
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assay (Terasaki and McClelland 1964; Bodmer and Bodmer 1979), as described 
in chapter 1.2.1.
The serological results (Table 7.2) of this characterisation provided a 
perception of the relationship between the detection of HLA-A30 by antibody 
and sequence polymorphism. Screening with the reaction panel produced 
two predom inant patterns of reactivity. Firstly, using antibodies FE82 and 
MP6, lysis was observed with the A'*'3002, A'*'3003 and A'*'3004 but not the 
A'*'3001 transfectants. The specificity of this sera and m onoclonal antibodies 
had been described as A'*'30 positive but negative for the lEF variant A30.3 
(Mazzoleni, et al 1991). As discussed above, the A30.3 lEF varian t 
corresponds to A'^3001. The results observed with the four A '*'30 
transfectants and the A'*'3002 (lEF A30.1) B cell line confirmed the described 
specificity of FE82 and MP6. In comparing the amino acid sequence of all 
four A'*'30 subtypes, a num ber of possible polymorphic differences exist 
which may explain these observations. A'^3001 differs from the other A '*'30 
variants by three amino acid substitutions in the alpha-1 domain. These 
substitutions are Hisyo-^Glnyo, Gluy^^Valy^ and Asnyy^Aspyy in A'*'3001, as 
listed in Table 7.3. These substitutions are found within the a-helix of the 
alpha-1 domain, and are at positions potentially accessible to antibody (figure 
7.1a).
The other serological pattern of reactivity observed was positive w ith 
A'*'3001, A'*'3002 and A'*'3004, but negative with A'*'3003. This pattern of 
reactivity was present with some of the sera used in Table 7.2. As discussed 
in the introduction to this chapter, sera detecting A'*'30 often cross-reacted 
with A'*'31. In viewing the amino acid sequences of A'*'30 and A'*'31, this can 
be explained in part by the sharing of a common polym orphism  (Argg^) 
found in the alpha-1 domain. Interestingly, at this position A'^3003 differs 
from the other A'*'30 subtypes and A'*'31 by having a Gly. The negative result 
obtained with A'*'3003 with several of the sera therefore maps the specificity 
of the A'*'30/A'*'31 sera to this polymorphism  in the alpha-1 domain. This 
site is on the a-helix at the end of the peptide binding groove, and should be 
accessible to antibody (figure 7.1a).
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Figure 7.4. FACS analysis of four A*30 
transfectants by staining of cells with Class I 
monoclonal antibody W6/32. Class I 
expression of each transfectant is compared to 
the CIR background cell and a negative 
control in which no specific antibody was 
added. Panel A contains a positive control B 
cell line (LBF). Panel B = transfectant L3A1 
(A*3001) , C ^transfectant C4B1 (A*3002), D 
= transfectant J2B1 (A*3003), E = transfectant 
W3B1 (A*3004). All four transfectants show a 
marked increase of expression compared to 
the CIR background cell line.
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A third pattern of reactivity had been reported whereby A*3002 (lEF A30.1) 
was negative while the other A*30 alleles were positive (Carpenter, et al 
1989). This pattern of reactivity was not observed w ith the panel of sera used 
in this characterisation. The above results do however indicate that the 
transfectants are expressed, and conformationally correct w ithin the context 
of the A*30 sera specificity. One anomaly was observed with antisera 14948,
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being positive with the A'*'3002 BCL (CR-B), but negative with the 
corresponding transfectant. This observation may be due to the lower 
expression of A'^30 on the transfectant, or a different than reported specificity 
for the sera or an error in typing.
Sera Spec i f ic i t y L
T ransfectants  
C J w
Controls  
0 1 R CR-B
FE82 A30 ,C w 5 ( lEF A 30 .3  neg) 0 4 3 3 0 4
M P 6 * A30, ( lEF A 30 .3  neg) 0 4 4 4 0 4
M y M  02 A 3 0 4 4 0 3 1 4
S 1 5 4 8 8 A30, A 31, A33, A 29 4 4 2 4 0 4
Kinloch A30, A 31, A33, A 29 3 4 2 2 0 4
8 7 8 8 A30, A 31, A33, A 29 3 4 0 3 0 4
1 4 9 4 8 A30, A31, A33, A 29 0 0 1 0 1 4
Tom e A30 A31 4 4 3 4 2 4
1 :1 4 4 1 4 0 4
1 :3 4 4 0 3 0 4
1 : 7 II II 3 3 0 3 0 3
Table 7.2. Serological characterisation of the four A*30 transfectants (L=A*3001, C=A*3002, 
J=A*3003, W=A*3004). The transfectants, together with a negative (CIR) and A*30 positive 
cell line (CR-B=A*3002) were tested against a panel of A*30 antisera and monoclonal 
antibody (*) in a complement mediated lymphocytotoxicity assay. The sera Tome was tested 
in the given dilutions to avoid crossreactivity as seen when used neat. Reactivity with the 
sera was registered using a scoring system (0-4). A score of 0 = no significant lysis above 
background, 1 = around 10-25% lysis above background, 2 = around 25-50% lysis above 
background, 3 = around 50-75% lysis above background and 4 = 75-100% lysis above 
background.
56
alpha-1
70
domain
76 77
alpha-2 dom ain 
151 152 156
A'^3001 R Q V D R W L
A'^3002 R H E N R R L
A*3003 G H E N R R L
A'^3004 R H E N H V W
Table 7.3. A comparison of the amino acid differences between four A30 variants in the alpha- 
1 and alpha-2 domains of the HLA Class I molecule.
181
7.2.3. Peptide elution and sequencing.
The process of peptide elution was performed in collaboration w ith 
Professor Ramensee's laboratory at the Institut Für Zellbiologie, Eberhard- 
Karls-Universitat, Tübingen, Germany. The trifluoroacetic acid (TEA) 
elution method was performed essentially as described previously (Falk, et 
al 1991) and briefly outlined in chapter 2.3.6.
A comparison of the peptides eluted from each of the four HLA-A'*'30 alleles, 
provided an opportunity to consider the influence of the defining 
polymorphic differences separating the four variants. It also allowed the 
comparison of HLA-A'^30 as a group, in comparison to other HLA-A 
specificities.
HPLC analysis of the eluate from the HLA class I column identified several 
peaks which were absent in the non-specific glycine control. These peaks 
were observed between 15 and 50 minutes following loading of the sam ple 
onto the FIPLC. Edman sequencing of the material contained w ithin these 
peaks identified several individual peptides endogenously processed by the 
CIR transfectants (Table 7.4). Additionally, the fractions (not including the 
largest peaks and potentially non-specific fractions) were pooled for 
sequencing.
7.3 R esu lts o f p ep tid e e lu tion .
The results of Edman degradation sequencing of the peptides eluted from  
the four A*30 variants are shown in Table 7.4. Sequencing of the pooled 
peptide fractions showed that peptide motifs existed (Falk, et al 1991) for each 
of the four A*30 molecules. It was also possible to identify ind iv idual 
ligands for each of the four A*30 variants (Table 7.4). Two ligands were 
identified for A'*'3001, four identified for A'*'3002, four for A*3003 and five for 
A'*'3004. The probable proteins from which these peptides may have 
originated are also listed. One ligand identified in A'*'3003 (HBBF) was 
derived from a bovine protein. This peptide represents the endogenous
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A*3001 PI P2 P3 P4 P5 P6 P7 P8 P9
anchors F F
preferred LY P D V N
ligand Y F D P A N G K F EF2 (265-73)
K T K D I V N G L CAPB (235-243)
A*3002 PI P2 P3 P4 P5 P6 P7 P8 P9
anchors VL
Y
Y
preferred MF H
K
PE
D
I K
ligands A Y K K Q F S Q Y RL5 (217-25)
R I S G V D R Y Y unknown
R L A H E V G W K Y RI 3A (139-48)
R V L P P N W K Y RS30 (132-40)
A*3003 PI P2 P3 P4 P5 P6 P7 P8 P9
anchors F Y
preferred GI ILQ N 
VW
P DE
RH
Y
ligands R I S G V D R Y Y unknown
S L F V S N H A Y ALFA (355-363)
S G H A I I A Y Y unknown
V V T G V A N A L A H R Y HBBF Bovine (132- 
44)
A*3004 PI P2 P3 P4 P5 P6 P7 P8 P9
anchors QT
VY
M
Y
preferred FI
L
A
N
KF
PD
G
E IL
M
HY MR
VF
Y
ligands A Y K K Q F S Q Y RL5 (217-25)
K M K E I A E A Y HS71 (126-34)
K Y F D E H Y E Y CKS2 (11-19)
H T S D V P G K L I Y ITB2 (520-30)
K Q F A E M Y V A K F EF2 (226-36)
Table 7.4. Legend on following page.
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Table 7.4. (shown en previous page) Results of Edman sequencing of peptides eluted from the 
four A*30 transfectants. PI to P9 represent residue positions within the peptide. Both 
individual sequences of ligands and anchor and preferred residues determined from pool 
sequencing are shown. Amino acid residues depicted in bold represent proposed anchor residues 
within the peptide sequence.
processing of protein found in foetal calf serum introduced through the 
tissue culture media. This phenom ena still represents norm al endogenous 
peptide processing and has been observed on other occasions (Christian 
Miinz, personal communication).
The data detailed in Table 7.4 identifies anchor preferences for all four A*30 
variants at positions P2 and P9 (amino to carboxyl) w ithin the peptide 
sequence. Individual peptides longer than 9 amino acids (between 10 and 13 
residues) were sequenced, with the terminal amino acid corresponding to 
the deduced anchor residue. Anchor residues were assigned on the basis of a 
greater than 50% increase and decrease of signal in the previous and 
following cycles respectively (raw data not shown). The peptide anchor 
residues for A'*'3001 identify a strong preference for amino acids F at both P2 
and P9. Preferred residues of L and Y are also noted at the P2 position. 
A*3002, A*3003 and A’*'3004 differ from A'*'3001 by having a preference for Y 
at P9. At P2, A’*^ 3002 favours large or moderate sized hydrophobic residues 
(V,L,Y,M,F) which is similar to that observed with A'^3003. A'*'3004 also 
prefers larger hydrophobic residues at P2 (V,Y,M) but can also accommodate 
Q and T as anchors.
The similarities in the determined motifs, particularly between A'*'3002, 
A'*'3003 and A'*'3004 are strengthened when considering the ind iv idual 
ligands identified for each of the variants. The same ligand was eluted and 
sequenced from both A'*'3002 and A'*'3003 (RISGVDRYY). In addition, an 
identical ligand was determined for both A'*'3002 and A'*'3004 (AYKKQFSQY). 
Both these ligands contain hydrophobic residues at P2 and the A '*'3002, 
A'^3003, A'*'3004 shared Y anchor preference at P9.
There were preferred residues at other positions w ithin the determ ined 
motifs for all four A'*'30 variants. At P3, there was an apparent preference for 
charged residues (H,K,R,D,N), at P4 there was some preference for sm aller
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residues (P,G,D) and at P5, there was a suggested preference for charged 
residues (D,E,). A*3004 also shows some preference for larger hydrophobic 
residues at P6 (I,L,M) and polar hydrophobic residues at P7 (H,Y). The 
preference of the A*30 molecules for these minor positions within the 
peptide sequence may further determine the nature of peptide bound.
7.4 D iscu ssion .
The MHC restricted im m une response consists of three main com ponents, 
namely the MHC molecule, its peptide ligand and the specificity of the T cell 
receptor. MHC molecules exhibit specificity for the peptides they bind, with a 
preference for certain anchor residues within the peptide sequence (Falk et 
al. 1990; Falk et al. 1991). This preference for a particular motif w ithin the 
peptide is related to the polymorphism in the binding site of the HLA 
molecule. In addition to a selectivity for peptide motifs, polym orphism  
within the peptide binding groove may influence the orientation of the 
peptide and so the antigenic surface presented to the TCR. The specificity of 
the TCR will relate to the orientation of a particular sequence w ithin the 
context of a given MHC molecule.
HLA polymorphism. This study examined the HFA molecule peptide 
interaction in a group of closely related alleles. These variants of HFA-A"^30 
differ from each other in and around the peptide binding groove as 
illustrated in figure 7.1a. As summ arised in Table 7.5 below, the four A*30 
variants differ from each other by one to six amino acid residues. The 
functional relevance of these polymorphisms depends upon their position 
within the HFA molecule and how this influences the binding of ligand and 
interaction with the TCR.
A 3001 A/3002 A*3003 A*3004
A*3001 0 4 5 6
A*3002 0 1 3
j^*3003 0 4
A*3004 0
Table 7.5. A comparison of the number of amino acid differences between each of the four A*30 
variants.
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The polymorphic differences as depicted in figure 7.1a and listed in Table 7.3, 
all lie around the peptide binding groove. Several of the polym orphism  
found amongst the A*30 variants as a group are in positions sensitive to 
binding of anchor residues within the peptide sequence. Polym orphism  at 
position 9 w ithin the m ature class 1 heavy chain has been shown to be 
im portant amongst the A"^ 02 allelic group, with relation to the character of 
the B pocket and its interaction with binding of the P2 side chain of the 
peptide (Bjorkman et al. 1987; Madden et al. 1993). In the A"^ 30 molecules, 
Ser occupies this position. The small size of the Ser side chain has a steric 
effect, creating additional space within the B pocket, enabling it to 
accommodate and bind bulkier side chains. Other polym orphism s at am ino 
acid positions Glu^24 and His^^ play a potential role in the D and F pockets 
respectively. G lu^^ may confer a preference for a P3 charged side chain 
residue binding into the D pocket, which is supported by the sequencing data 
from the eluted peptides (Table 7.4). The polymorphism  and amino acid 
composition around the F pocket (amongst which Glu or Valyg, Asp or 
Asnyy, Glyyg, ThrgQ, His^^g contribute), suggest a pocket that is both large and 
fairly neutral.
Polymorphism between the A*30 variants, as shown in figure 7.1a and 
detailed in Table 7.3, may also be relevant with respect to the peptide binding 
characteristics. Differences between A’*'3001 and the other A“^30 variants are 
present at a number of amino acid positions, including 76 and 77 (Table 7.3). 
This polymorphism  may contribute to the P9 anchor residue differences 
observed between A’^ dOOl and the other A*30 variants (Table 7.4). On the 
other a-helix , polymorphic differences between the A*30 variants at 
position 151, 152 and 156 may contribute to conformation changes in the 
m iddle of the peptide. There are three patterns of polym orphism  in this 
region of the molecule, (as seen in (a). A"^3001, (b). A*3002/3 and (c). A ’^ 3004), 
which may cause the peptide to bind in three different orientations w ith in  
the binding groove. A*3002 and A"^3003 have practically identical sequence 
except for a Arg->Gly change at position 56. This position may not effect the 
peptide binding motif, but it is solvent accessible and may have som e 
interaction with the TCR. This position is discussed below in relation to the 
TCR.
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The peptide motif. The Edman sequencing of the peptides eluted from the 
A"^ 30 transfectants reveal a preference by all four variants for anchor 
residues at P2 and P9 (or terminal residue if greater than 9 amino acids in  
length) within the peptide. At both of these anchor residues, and in all four 
variants, there is a preference for binding large to moderate sized 
hydrophobic residues. This peptide motif fits into the observations m ade 
above as to the large B and F pockets and their accommodation of bulkier 
peptide side chains. The similarities of the peptide motifs can be considered 
in the context of the shared polymorphism  which characterises the A ’^BO 
variants a group.
The P2 anchors (Phe, Val, Feu, Tyr, Gin, Thr, Met) show a preference by all 
four A*30 variants, for binding large hydrophobic residues into the B pocket. 
As mentioned, the Ser? in the A*30 heavy chain is common to all four A*30 
variants and may facilitate this interaction by contributing to a large B 
pocket. HFA-A’^ 23 and A^ 2^4 specificities also have a Ser^. The sim ilarity 
between A*30 and A"^ 24 in the context of Serg is reflected in the Tyr P2 
anchor motif determined for A24 (Rammensee et al. 1995). A representation 
of the possible interaction between a slightly polar P2 Tyr peptide side chain 
and Serg of the A"^ 30 molecule, is depicted in figure 7.1b. Figure 7.1b also 
shows the importance of Glugg in interacting with the N-term inal peptide 
residues.
The characterisation of the variant A*30 P9 peptide anchors revealed 
variation amongst the group of specificities. A’*'3001 shows a preference for 
Phe at P9 while the three other A’^BO specificities all show a preference for a 
Tyr P9 peptide anchor. Both of these anchor residues are large, aromatic and 
hydrophobic, but there is a clear difference in the preferences seen am ongst 
the A'^ BO group. As discussed, the dichotomy of preferences observed at the 
P9 anchor residue, coincides with the polymorphic differences between 
A'^BOOl and the other A*30 variants, particularly at positions 70, 76 and 77 in  
the alpha-1 domain (Table 7.3 and figure 7.1a).
The similarities in the sequences determined for ligands of the A*30 group, 
suggests that on the basis of peptide, there is scope for a TCR to crossreact 
between the four variants. The extent of this crossreaction will be dependent
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on a particular TCR's sensitivity to HLA polym orphism  and any 
conformational changes in peptide orientation.
The TCR. The combination of peptide bound to the class I HLA m olecule 
provides a picture within a frame that an appropriate TCR can recognise. 
W ithin this study, it has not been possible to examine the specificity of the 
TCR to the different peptide-A^30 complexes. But the results obtained in  
terms of the peptide binding motifs together with the polym orphism  that 
exists between the A*30 variants, suggests a possible spectrum of 
interactions. It is therefore interesting to speculate as to the different possible 
responses that may be observed between combinations of peptide, HLA-A"^30 
variants and HLA restricted CTL clones.
Recently, a picture of the interaction between the TCR, peptide and HLA-A2 
has been determined through the crystal structure of this complex (Carboczi 
et al. 1996; Carcia et al. 1996). This has provided a both clear and inform ative 
insight into the relationship between all three components of the MHC 
restricted im m une response. The following few paragraphs describe, the 
structure of the TCR and its interaction of peptide bound to HLA, as reported 
in Carboczi's paper (Carboczi et al. 1996). The results from this chapter are 
then considered in the light of these TCR observations.
The membrane bound TCR comprises of an alpha and beta chain each 
consisting of constant and variable domains (Davis and Bjorkman 1988). 
The variable domains are generated through a rearrangem ent of gene 
segments which allow the wide diversity observed in the T cell repertoire. 
Each of the variable domains consists of a num ber of loops or 
complimentarity determining regions (CDRl, 2, 3). The CDR loops of the 
alpha and beta chain combine to form a flat surface which interacts with the 
MHC molecule and bound peptide.
In determ ining the crystal structure of TCR-Peptide-HLA complex, the 
positioning of the TCR was found to be in a diagonal orientation over the 
HLA-A2 and peptide, with the CDR loops in line with the beta pleated sheets 
of the class I molecule. This configuration fits within the two "high points" of 
the HLA class I molecule, located at N-terminal of the Alpha-1 dom ain a- 
helix and the N-term inal of the alpha-2 domain a-helix (Carboczi et al.
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1996). The positioning of the CDR loops has also been determ ined in  
relation to the peptide and the HLA molecule. Both alpha and beta variable 
domains of the TCR contact both peptide and HLA class 1 molecule.
In general, it was found that the TCR covers a substantial area of the 
peptide/M HC complex and appears to push the peptide down into the 
binding groove. This pressing down on the peptide by the TCR causes a 
small but noticeable shift in the MHC conformation. The TCR covers the 
length of the peptide, with the TCR pocket (formed mainly by the CDR3a 
and CDR3p loops), aligned over the middle peptide residues.
CDR3P, the potentially most diverse of the variable loops, spans across the 
binding groove, associating with both helices of the class I molecule (at 
amino acid residues 72 in the alpha 1 domain a-helix and 149, 150, 151, 155 
in the alpha 2 domain a-helix) and residues P5-P8 of the HTLV-1 Tax 
peptide bound in this study (Carboczi et al. 1996). The TCR central pocket 
covers the middle of the peptide, contacting residues P4 and P5. In addition 
the CDR3a loop contacts amino acid residues 65, 66, 68 and 69 of the alpha-1 
dom ain a-helix . CD Rla contacts the amino end of the peptide and is 
positioned over both a-helices (at around amino acid residue 58 in the 
alpha-1 domain a-helix and 163, 167, 170 in the alpha-2 dom ain a-helix). 
CDRlp associates with the P8 residue of the peptide. CDR2a sits over the 
alpha-2 domain a-helix making contact with residues 155, 158 and 166.
The CDR2p loop is positioned over the alpha-1 domain, but makes no  
apparent contact with peptide or the HLA molecule. The lack of contact 
between CDR2(3 and the HLA-peptide complex may be due to the absence of 
a carbohydrate moiety attached to the HLA molecule in the crystallised 
structure. This is probably a consequence of generating the complex in  
bacteria. This carbohydrate is usually attached to a conserved Asn residue at 
position 86 in the alpha-1 domain a-helix (Barber, et al 1996), and may be 
im portant in interacting with the TCR CDR2P directly or assisting in the 
interaction with the alpha-1 domain of the HLA molecule (Parham, 1996). It 
has also been speculated that the failure of the CDR2p loop to contact a 
region of the HLA molecule (residues 73-84), associated with binding to 
receptors found on natural killer cells, may be linked to a function of these 
cells (Parham 1996).
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Applying the observations made in the HLA-A2-Tax peptide-TCR complex 
to the A*30 group, provides possible insights concerning the likely 
interactions between the different components of the complex. HLA 
polym orphism s that are common across the A*30 group and are likely to 
contact the TCR, are found at amino-acid residues 62 and 65 in the alpha-1 
dom ain a-helix, which as discussed above, are in a region which may 
contact the CD Rla and CDR3a loops of the TCR. As stated, the com m on 
A*30 polymorphism s identified at amino acid residues 79 and 80 in the 
alpha-1 domain a-helix do not appear to bind to the CDR2p loop, a lthough 
they are proximal to each other. As discussed, this may be a consequence of 
the lack of N linked glycosolation to residue 86 of the class I heavy chain, or 
some function of NK activity (Parham 1996).
In considering the crystal structure of the TCR-Peptide-HLA interaction 
(Carboczi et al. 1996), certain polymorphic differences between the HLA- 
A*30 variants may be definitive with regard to interacting with the TCR. In 
viewing figure 7.1a and Table 7.3, the polymorphism  that exist at am ino 
acid residues 151 and 152, and a possible interaction with the CDR3p loop 
may be a key point of discernment in which the TCR exhibits its specificity. 
This is an im portant area amongst the A*30 sequences, since three patterns 
of polym orphism  exist (Table 7.3), distinguishing A’^ dOOl from both 
A*3002/3 and A“^3004. The polymorphic differences at these positions within 
the HLA sequences may be significant in respect of defining restriction for 
the TCR.
As discussed, the only difference between A’^ 3002 and A’^ 3003 lies at am ino 
acid position 56 in the HLA sequence. This is located in the N -term inal 
region of the alpha-1 domain a-helix and under Carboczi's observations 
(Carboczi et al. 1996), would have no direct interaction with the TCR. It is 
likely therefore that a TCR specific for one of these two variants w ould 
crossreact with the other. However, this is only speculation and w hether a 
polym orphism  at amino acid position 56 holds any relevance as to peptide 
binding or contact with the CD R la loop of the TCR, remains to be 
established.
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How a particular TCR and peptide interact in different A*30 varian t 
backgrounds, will be dependent on the relevance of changes in peptide 
orientation w ithin the binding groove and how sensitive the TCR is to 
those changes. The orientation of the peptide will in part determine w hich 
residues are accessible to the TCR. In the case of the A*30 ligands, residues 
which are im portant in contacting the TCR are found w ithin the m iddle of 
the peptide, with P2 and P9 (or terminal residue) being employed as anchor 
sites for binding to the A*30 molecules. The PI side chain may also be 
accessible to the TCR, since this peptide residue is non-specifically anchored 
into the A pocket of the HLA class I molecule through the amino group on  
its main chain. As discussed, the TCR covers the majority of the peptide and 
potentially can be sensitive to subtle changes in peptide conformation. In 
this respect, it seems plausible that a TCR specific for a particular peptide 
bound to say A*3002 or A*3003, could be sensitive to changes in the peptide's 
orientation if bound to A*3001 (through the influences of polym orphism  at 
amino acid residues 70, 77, 152) or A*3004 (through the influence of 
polymorphism at residues 152 and 156 in the class I heavy chain).
It is also feasible that a TCR specific for peptide bound within one HLA-A*30 
variant, will recognise the same peptide bound to one or more of the A*30 
variants. This is possible because of the similarities in peptide m otifs 
determined for all four A*30 variants. In addition, a TCR may be tolerant of 
polymorphic differences between each of the A*30 alleles, which w ould 
manifest itself as crossreactivity by the TCR in recognising more than one of 
the A*30 variants.
In summary, this study has compared the preferences for peptide binding of 
four variants of HLA-A*30. The sequencing of peptide from each of the four 
A*30 variants has characterised both similarities and differences in the 
preferred ligands. All four variants of A*30 have preferred anchor residues 
at P2 and P9 (or term inal carboxyl residue if longer). All four A*30 variants 
preferred binding peptides with large to moderate sized anchor residues. 
However, a clear difference was noted at the P9 (or terminal residue if 
longer), with A*3001 preferring a Phe anchor while the other A*30 variants 
preferring a Tyr. Although the A*3002, A*3003, A*3004 have similar peptide 
motif preferences, the role of the polymorphic differences that define them  
may have significant influence on peptide orientation and MHC restriction.
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It was not possible to address these functional issues with regard to TCR 
specificity within this thesis, but this will hopefully be achieved as part of an 
ongoing study.
This study both demonstrates and contemplates the relevance of 
polym orphism  with regard to the functioning of the HLA molecule in the 
MHC restricted T cell response. The study also shows that very similar HLA 
molecules have different peptide motif preferences, and speculates that as 
with variants of A*02 (Rotzschke, et al 1992; Barouch, et al 1995; Sudo, et al 
1995), T cell responses will be both specific and cross reactive, depending on  
the requirements of the TCR. The differences observed in peptide binding 
and the suggested effects of HLA polymorphic differences on peptide 
orientation and presentation to the TCR amongst this group of A*30 
molecules, supports the requirement to type at a resolution that identifies 
the functionally distinct HLA molecule.
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HLA-A’^ 02 polymorphism and function.
This chapter is based on a review article written by the thesis author for the European Journal 
Immunogenetics, 1996: 23: 261-274.
8.1. Introduction.
HLA class I molecules bind and present peptides derived from endogenously 
processed proteins. These peptides are presented to CD8^ T cells, with the 
interaction restricted through HLA type. The extent of polymorphism and so 
the variety of HLA specificities, is a striking characteristic of the HLA system. 
Serological discrim ination of HLA types has demonstrated this variety 
through the specificity of antisera. But serology by no means revealed the 
true level of polymorphism, which became increasingly apparent th rough  
the fine discrim ination of the T cell in HLA restricted im m une responses 
(Gotch, et al 1985; Latron, et al 1991; Rotzschke, et al 1992; Utz, et al 1992, v an  
der Poel, et al 1986; Tussey, et al 1994; Barouch, et al 1995a; Sudo, et al 1995). 
DNA sequencing and developments in DNA-based HLA typing have show n 
polym orphism  well beyond that defined through serology, as witnessed 
through recent nomenclature reports (Bodmer, J.G. et al 1995). The m ajority 
of polym orphism  detected at the DNA level is im portant in the context of 
causing amino acids changes in regions of the HLA molecule, sensitive to 
the discriminatory binding and presentation of peptide.
A good dem onstration of the effect of serologically silent polym orphism  in  
relation to the function of the HLA molecule can be found amongst the
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allelic variants of HLA-A*02. HLA-A*02 has been well defined serologically 
and is the most common HLA type in many population groups. But this one 
serological specificity has been shown to consist of a num ber of allelic 
variants. At the time of writing, some sixteen expressed variants of HLA- 
A*02 have been described (Bodmer, 1995), (a seventeenth, A*0215N is no t 
expressed). In addition, the distribution of HLA-A*02 variants differs, 
according to the population group studied (Carcassi, et al 1995; Krausa, et al 
1995). Many of the polymorphisms which distinguish the HLA-A*02 
variants have been shown to have functional relevance in terms of binding 
and presentation of peptide to the T cell receptor (Gotch, et al 1985; 
McMichael, et al 1988; Barouch, et al 1995a; Sudo, et al 1995).
This chapter will describe the nature and possible evolution of 
polym orphism  found amongst the HLA-A*02 alleles. It will further discuss 
how the distribution of HLA-A*02 subtypes varies in different population  
groups. The significance of HLA-A*02 polymorphism s with regard to 
peptide binding and the T cell mediated imm une response, will also be 
considered. The sequence polymorphism observed between the A*02 alleles 
can be considered as a possible response to pathogenic pressure which gives 
further insight into the diversity of the HLA system.
8.2. The nature of HLA-A" 0^2 polymorphism.
Seventeen (A*0201-A*0217) allelic variants of HLA-A*02 have been 
described (Bodmer, 1995) at the time of writing. Most have been DNA 
sequenced, (A*0208 A*0209 have been amino acid sequenced). In com paring 
the sequences, it is clear that the majority of polymorphism is found around 
the peptide binding groove of the HLA molecule (figure 8.1, figure 8.2), and 
so has potential relevance in determining the sequence characteristics and 
conform ation of the bound peptide. However, A*0209 and A*0215N differ 
from other A*02 alleles through polymorphic differences in exon 4, both 
probably as a result of point mutation. A*0215N is not expressed due to this 
polymorphism leading to a stop codon and so truncation of the heavy chain 
m idway through the alpha-3 domain.
HLA-A*02 alleles contain polymorphisms which clearly define them as a 
group of related alleles and explain their serological specificity. In the alpha-
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1 domain, there are a num ber of polymorphisms restricted to the A*02 
allelic group, and in the alpha-2 domain, there are several sites of 
polym orphism  shared between A*02 and A28 alleles (figure 8.1). The 
presence of such polymorphic sites explains serological observations in the 
clear identification of the HLA-A*02 specificity and its crossreactivity w ith  
A28 alleles. In addition to this, there exists an array of polym orphism s 
which define the differences between HLA-A*02 allelic variants, few of 
which are discriminated serologically. As illustrated in figure 8.1, the 
majority of polymorphic differences between A*02 allelic gene products 
cluster around the peptide binding groove. Consequently, many of the 
polymorphic differences between A*02 alleles have potential functional 
significance in peptide presentation.
C
Figure 8.1. A ribbon diagram representing the a-1 and oc-2 domains of the class I molecule, 
which together form the peptide binding groove. Location of pockets within the groove is 
shown (A-F). Polymorphic amino acid positions which differentiate between the different 
A*02 alleles are represented as solid boxes. Striped positions identify sites of polymorphism 
which define the HLA-A2/28 broad specificity. The polymorphism at amino acid position 62 
is specific to HLA-A*02 at the A locus, positions 142, 145 are specific for A2/A28 and positions 
114,116 and 127 are specific for A2/A28/A9.
The nature of polym orphism  which distinguishes the majority of HLA- 
A*02 alleles, seems to have arisen through the process of gene conversion, 
or recombination events (Parham, et al 1988; Erlich, et al 1991b; Geraghty, et
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al 1992; Kuhner, et al 1992). Hence polymorphism  observed in a particular 
hypervariable region is often shared with other alleles, usually but no t 
necessarily from the same locus. As examples, the polym orphism  observed 
in A*0216 at amino acid position Glu^^g is also found in A*6602, A*8001, 
B*0702-5, B*1301-2, B*2702-9, B*4001-4,6-8, B*7301, B*8101, Cw*0201-2, 
Cw*1701. It therefore appears that A*0216 has arisen as a gene conversion 
event with one of these alleles (Barouch, et al 1995b). Also, the 
polym orphism  observed in A*0217 at amino acid position Leugg, Metgy, 
Phegg is also found amongst A*24 alleles. A*0217 was found in a South 
American Warao population, in which A*24 is present at high frequency. 
This suggests A*0217 might have resulted as a gene conversion event 
between an A*24 allele and an A*02 allele (Selvakumar, et al 1995). In 
viewing alignments of class I sequences (Arnett and Parham, 1995), it is 
apparent that gene conversion is a probable major generator of HLA 
diversity not only between A*02 alleles but for class I as a whole (Wells and 
Parham, 1996).
A comparison of the nucleotide sequences of A*02 alleles suggests they were 
all derived from a common ancestral allele which may or may not be one of 
the variants already identified. Alleles which have certain polym orphic 
elements related to HLA-A*02 have been described in the gorilla Major 
Histocompatibility Complex (Lawlor, et al 1991). Thus, the polym orphism  
found within the HLA-A*02 alleles may have been generated over a long 
period. In examining the possible relationship between HLA-A*02 alleles as 
a function of probable gene conversion events or point m utations (figure 
8.3), it is clear that two groups of alleles exist. One group clusters around 
A*0201, the other around A*0205. The distinction between the two groups is 
apparent, with the A*0205 group (A*0202, A*0205, A*0208, A*0214) differing 
from A*0201 at amino acid positions Gln^g^Arg^g and Valgg^Leugg (figure 
8.2). In particular, the polymorphism at Arg^g is unique to the A*0205 group. 
The relation between the A*0205 group is further strengthened, through the 
presence of a silent polymorphism, probably the result of a point m utation , 
at nucleotide position 59'G' in exon 3 (consensus 'C'). The silent 
polym orphism  implies that the A*0205 allelic group arose from a com m on 
ancestral allele which subsequently diversified through processes of gene 
conversion or recombination.
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Figure 8.2. A comparison of A*02 allelic amino acid sequences. The polymorphisms given for each A*02 
allele are differences observed from A’^ 201. The location of the polymorphism is given in the context of 
its amino acid position, the domain and whether it is found in the alpha helices or beta pleated sheet 
of the peptide binding groove.
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Figure 8.3. A representation of the possible relationship between alleles in terms of 
likely gene conversion events (G) or point mutations (P). It can be seen that the alleles 
split into two groups, one that can be derived from A*0201, the other which clusters 
around A*0205. The two groups are separated by a number of unknown intermediate 
alleles (A*02?), which may have been lost through selective pressures or remain 
unidentified.
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Figure 8.3 also suggests the existance of undiscovered interm ediate allelic 
variants which would explain those HLA-A“^02 alleles currently found. 
These intermediate forms may have been lost through lack of selective 
pressure, or simply not yet identified. It seems probable that, as increasing 
num bers of individuals and ethnic groups are investigated by high  
resolution typing and molecular approaches, new HLA-A’*'02 variants will 
be detected. This will possibly lead to clarification of the overall 
evolutionary relationship between the HLA-A"^02 alleles.
8.3. HLA-A"^02 a lle lic  variation  in  d ifferen t p op u la tion s.
In examining polymorphism  within the context of ethnic origin, it is clear 
that very different HLA-A"^02 allelic frequency structures exist between 
different populations. Chapter 5.3 describes these difference in reference to a 
num ber of key population groups, which are sum m arised in Table 5.2. The 
prom inence of A*0201 and relative lack of A*02 allelic diversity in the 
Oxford Caucasian population is in contrast with the diversity observed in  
the Singapore Chinese population. Not only is A*0201 replaced by A"^ 0207 as 
the most prom inent A*02 allele in the Singapore HLA-A’^ 02's tested, but 
several alleles (A’*'0203, A’^ 0206, A ’^ 0210) are not seen in the other population 
groups tested (Krausa, 1995). Similarly A’^ 0202 and A*0214 are only observed 
in the African populations typed, and A’^ 0204 and A*0217 appear specific to 
American Indian populations (Selvakumar, 1995).
Even between Caucasian populations, difference in frequencies of HLA-A’^ 02 
alleles exist. This is especially reflected in a comparison between the Oxford 
Caucasian and Sardinian populations (Carcassi, et al 1995; Krausa, et al 1995) 
as shown in Table 5.2. The high proportion of A*0205 in the Sardinian 
population as compared to the Oxford population underlines the potential 
HLA heterogeneity present between different population groups of sim ilar 
ethnicity. Also, w ithin the different African populations, different HLA- 
A*02 frequency structures are observed, with A*^0214 seemingly restricted to 
Uganda and Kenya, and not seen in the Gambia. These observations are 
limited however, in view of numbers tested.
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The general extent of this allelic variation is far from known, since it is only 
recently that the ability to discriminate definitively between such variants 
has been possible. However, the observed heterogeneity of HLA-A*02 allelic 
frequencies already suggests a difference in pathogenic pressures driv ing 
HLA polym orphism  within the different population groups. Such a 
mechanism has been proposed for acquiring protective im m unity in a HLA 
restricted cytotoxic T cell response against Malaria in an African population 
(Hill, et al 1992; Aidoo, et al 1995). The A’^ 02 allelic heterogeneity observed in 
the Sardinian population may in part be explained by the past history of 
endemic malaria on the island (Piazza, et al 1985). Therefore, the prevalence 
of HLA alleles w ithin different populations may provide an insight as to 
role of such alleles in terms of the T cell mediated immune response against 
a particular localised pathogenic pressure.
8.4. HLA-A"^02 structure.
The structural definition of the HLA-A2.1 molecule was elucidated by X-ray 
crystallography (Bjorkman, et al 1987). It revealed an HLA molecule which is 
capable of presenting a short peptide bound within a groove formed by two 
'parallel' alpha helices sitting on a base of beta pleated sheets. This HLA class 
I molecule is composed of an HLA-encoded heavy chain glycoprotein w ith  
transm em brane and cytoplasmic region, associated with beta-2 
microglobulin light chain, with the bound peptide completing the trim eric 
structure. The peptide binding domains of the molecule is formed by the 
alpha-1 and alpha-2 domains coded for by exons 2 and 3 of the HLA gene. 
The alpha-1 and alpha-2 domains sit on an alpha-3 dom ain further attached 
to a transm em brane region and cytoplasmic tail. The alpha-3 dom ain  
complexes non-covalently with beta-2 microglobulin, forming a platform  
which supports the alpha-1 and alpha-2 domain peptide binding groove.
Additional structural resolution of HLA-A’^ 02 revealed six pockets (A-F) 
within the groove (Saper, et al 1991); see figure 8.1. These six pockets have 
potential to bind amino acid side chains present in the peptide sequence. 
Table 8.1 shows some of the im portant amino acid residues with regard to 
these pockets. The properties of the amino acid residues which form the 
pockets within the binding groove will determine the nature of the anchor 
residue it may bind. Hence, a pocket may be deep or shallow, contain
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charged, polar, neutral or hydrophobic residues, all of which will be reflected 
in the compatibility of the anchor residue in relation to its side chain 
characteristics (Matsumura, et al 1992).
In comparing the expressed A*02 alleles in Table 8.1, it becomes apparent 
that, with the exception of A*0209, all the A*02 alleles listed contain 
polymorphism s in one or more pockets which render them distinct. These 
differences will have functional implications as to peptide bound and its 
conformation. In comparing A*02 as a group, polym orphism  also exists 
w ithin all the pockets as compared to the class I consensus sequence. This 
again will have a broad effect on the A"^ 02 specificity of peptide binding. Only 
the F pocket does not contain polymorphism between HLA-A*02 molecules, 
which probably explains the conservation of the dom inant C-term inal 
peptide anchor residue as Leu or Val for all A’*'02 molecules tested. 
Additionally, polymorphism at amino acid positions 107 and 149 have been 
implicated in binding with the T cell receptor (Saper, et al 1991). The 
comparison of peptide characteristics against HLA polym orphism  provides 
an insight into the mechanics of HLA-ligand interactions.
8.5. F unctional sign ifican ce  o f variation b e tw e en  HLA-A"^02 a lle les .
The discrim ination of the T cell provided evidence of the existence of 
functionally distinct subtypes of HLA-A’^ 02 (Gotch, et al 1985). A lloreactive 
CTL specific for A’^ 0201 failed to kill another A2 cell, later shown to be 
A*0205. The determ ination of the A2 crystal structure made apparent the 
importance of the polymorphic differences between these A2 subtypes in  
relation to the peptide binding groove (Bjorkman, et al 1987; Saper, et al 
1991).
8.5.1. The influence of the peptide.
Exploring the mechanisms for binding of peptide to HLA class I provided an 
increased understanding of HLA resticted CTL reaction. The specificity of 
peptide binding was shown to be a function of the six pockets (A-F) in the 
peptide binding groove (Saper, et al 1991; M atsumura, et al 1992; Colbert, et 
al 1993; Fruci, et al 1993; Madden, et al 1993; Kubo, et al 1994; Tanigaki, et al
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1994; Tussey, et al 1994). It was shown that peptide was bound in a particular 
conformation, with the A pocket binding the amino group and the F pocket 
binding the Carboxyl end of the peptide (Latron, et al 1991). The ends of the 
groove were also shown to be closed, which restricted the length of bound 
peptide, usually to a nonamer or decamer. This also has the effect of causing 
the peptide to bulge out of the groove, making residues more accessible to 
interaction with the T cell receptor (Saper, et al 1991; Matsumura, et al 1992).
Characterisation of peptides eluted from class I molecules showed that 
particular amino acids were preferred at certain positions within the peptide 
sequence (Falk, et al 1991; Rammensee, et al 1995). These preferred positions 
were termed anchor residues and shown to associate with one or more of 
the pockets (namely B,C,D,E and sometimes F) w ithin the peptide binding 
groove. Only a few residues within a particular peptide sequence constitute 
anchor residues, so only a few pockets within the groove tend to be 
involved in specific binding of peptide anchor residues. This implies that 
other pockets can accommodate a large number of different peptide residues, 
increasing the num ber of different peptides a particular HLA molecule can 
bind (M atsumura, et al 1992). The prevalence of specific anchor residues 
within the general protein pool will also determine the num ber of possible 
peptides a particular HLA molecule may bind. If a particular HLA 
molecule's preferred anchor residues are rarely found amongst protein 
sequences, then this will limit the num ber of peptides that HLA m olecule 
can bind and present (Kast, et al 1994). In the case of HLA-A*0201, its anchor 
residues are commonly found and so a large array of peptides can be 
presented (Falk, et al 1991). This may reflect the high frequency of HLA- 
A"^0201 present across a large number of different population groups.
The sequence of the bound peptide is an im portant component of the 
interaction between the HLA class I complex and the T cell. It was show n 
that altering the sequence of a A’^ 0201 specific flu matrix peptide at certain 
positions could have a number of different effects (Cotch, et al 1988). Certain 
changes had no influence on CTL recognition. Other changes in peptide 
sequence caused it not to be bound. However certain peptide analogues were 
shown to bind, yet abrogate recognition by the CTL clone. These 
observations therefore suggested that certain peptide residues were
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im portant in binding to the HLA molecule, whilst others had influence on 
the interaction with the T cell receptor.
The influence of peptide sequence on binding to HLA class I was fu rther 
explored by Madden (Madden, et al 1993). Five different viral peptides were 
co-precipitated with A’^ 0201 and the conformation within the groove 
studied by X-ray crystallography. Each of the different peptides showed 
dramatic conformational changes, particularly in the centre of the peptide 
sequence. Hence in comparing the five different peptides, peptide positions 
P5, P6, P7 were shown to either point down into the groove, across towards 
the alpha helices or up towards the T cell receptor. This variation in peptide 
conformation was shown to inflict m inor influence on the structure of 
A*0201. This suggests that the conformation of the peptide itself provides 
the dom inant antigenic identity of the HLA class I complex in respect of the 
T cell receptor. It also suggests that peptide residues which are not invo lved  
in binding to the HLA molecule may be available to interact with the T cell 
receptor.
8.5.2. The influence of HLA polymorphism.
Most of the sixteen expressed allelic variants can be distinguished from each 
other by polymorphic differences found w ithin the peptide binding groove 
(figure 8.2). Certain of these polymorphisms will have implications for the 
peptide anchor residues and so the binding specificity of the HLA-A*^02 
molecule. Others will exhibit influence on the conformation of peptide 
bound w ithin the groove, and whether peptide residues point towards or 
away from the T cell receptor.
The effect of polymorphism  on peptide binding and presentation has been 
investigated in a number of studies involving the use of m utagenesis 
(McMichael, et al 1988; Latron, et al 1991; Tussey, et al 1994). In one study, 
transplanting the B pocket of A"^0201 into B"^2705, caused the resulting class I 
molecule to present a different set of peptides compared to B*2705 with a 
resultant loss of B’^ 2705 allorecognition (Colbert, et al 1993). This again 
dem onstrated the importance of polymorphism  within the peptide binding 
groove with regard to CTL recognition.
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The positions of key amino acid residues within the class I molecule in the 
context of peptide binding and presentation has also been investigated 
(McMichael, et al 1988). CTL raised against the flu matrix peptide bound to 
A*0201 failed to lyse peptide pulsed A"^ 02 variant donor cells containing 
A’^ 0202, A*0203 and A’^ 0205. Further to this, point m utations at amino acid 
positions 62, 63, 66, 152, 156 and in some instances 9 and 70 of the A*0201 
molecule, caused loss of recognition by the A’^ 0201 specific CTL clone. 
M utations at positions 43, 74 and 107 had no effect on CTL recognition. In 
extending the study to examine another peptide in the context of A2 
polymorphism, it became apparent that changes at positions 152, 155 and 156 
did not abolish recognition in all cases. Hence these amino acid positions are 
more likely to determine the conformation of peptide w ithin the class I 
molecule as determined by the peptide sequence (Tussey, et al 1994).
The relevance of the six peptide binding pockets in terms of CTL recognition 
of the flu matrix peptide was further investigated using a panel of m utan ts 
of HLA-A’^ 0201 (Matsui, et al 1994). This study identified the importance of 
the B pocket in relation to presentation of this peptide. But it also showed 
the importance of other pockets in presentation of the peptide and CTL 
recognition. This study further underlines that even those pockets no t 
involved in binding peptide anchor residues still have a critical role in  
orientation and presentation of peptide for CTL recognition (Matsui, et al
1994).
The determ ination of anchor residues, and so peptide motifs for a num ber 
of A"^ 02 variants, has been established through several studies (Falk, et al 
1991; Rotzschke, et al 1992; Barouch, et al 1995a; Sudo, et al 1995). In 
comparing the peptide motifs derived from A"^ 0201 and A’^ 0205, it became 
apparent that, although a num ber of epitopes presented to T cells would be 
similar, a considerable num ber would be different (Rotzschke, et al 1992). 
This was confirmed when the study was extended to additionally consider 
A’^ 0202 and A’^ 0214, alleles commonly found in parts of Africa (Barouch, et 
al 1995a). A further study examined peptides eluted from A*0204, A ’^ 0206 
and A"^0207, all of which contain a single amino acid change from A"^0201 
(Sudo, et al 1995).
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Peptide motifs eluted in these particular studies further underlined the 
importance of amino acid position 9 in the HLA molecule. From Table 8.2, it 
can be seen that amongst the A’^ 02 alleles, Pheg (A’^ 0201, A*0202, A ’^ 0204, 
A"^0207) is associated with a Leu P2 anchor, whilst Tyrg (A*0205, A ’^ 0206, 
A’^ 0214) is associated with Val P2 anchor (Barouch, et al 1995a). This 
polymorphism at position 9 has relevance to the hydrophobic or hydrophilic 
nature of the B pocket, which effects the anchor residue bound at P2 
(Barouch, et al 1995a). In A*0207, an anchor residue of Asp was found at P3 
in addition to anchor residues of Leu at P2 and P9 (Sudo, et al 1995). The one 
amino acid substitution from A’^ 0201 (Tyrgg to Cysgg), could potentially 
change the A’^ 0207 D pocket in such a way that Asp at P3 could bind to a basic 
residue (His^^^) the bottom of the groove (Sudo, et al 1995).
The ability of different A"^ 02 alleles to bind particular peptides has also been 
investigated. Assays which quantify binding of peptide to the class I 
molecule (Townsend, et al 1990; Tussey, et al 1994) or serologically defined 
conformational recognition of folded class I as a function of peptide binding 
(Fruci, et al 1993), have been used to identify which peptide motifs bind to 
which A'*'02 subtypes. Various studies have shown that peptides bound by 
one A'*'02 variant would cross bind to a num ber of other A'*'02 variants 
(Fruci, et al 1993; Tanigaki, et al 1994; del Guercio, et al 1995). It was therefore 
suggested that the A2 alleles formed a supertype which presented sim ilar 
peptide motifs (del Guercio, et al 1995). This has been contradicted by others 
who have found that A'^02 subtypes demonstrate distinct specificity for 
peptide epitopes (Barouch, et al 1995a; Sudo, et al 1995). This is further 
supported by the early observation that A'^0202, A'*'0205 failed to present the 
A'*'0201 flu matrix peptide to influenza specific CTL (Gotch, et al 1985). 
Interestingly, in del Guercio's super type hypothesis, A'*'0207 was excluded on  
the basis of its failure to bind certain A'^02-type peptides (del Guercio, et al
1995). As discussed above, this may be explained by the peptide m otif 
determ ined for A'*'0207 (Sudo, et al 1995). It seems that although several 
peptides can be bound by number of different A'*'02 variants, no one peptide 
is ubiquitous to all (Barouch, et al 1995a; Sudo, et al 1995). It has also been 
observed that some peptides seem to be specifically bound by only certain 
A '*'02 subtypes (Tussey, et al 1994). The level of crossreactivity of specific 
peptide bound appears to be a function of both peptide sequence and A '*'02 
polym orphism .
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A series of mutagenesis experiments has also demonstrated that 
polymorphism within A2 can cause presentation of endogenously processed 
peptide and not the equivalent exogenously added peptide. The reverse 
situation was also noted. This suggests that the mechanisms for class I 
assembly is different for presenting endogenously or exogenously derived 
peptides, and that these mechanisms are influenced by the A*02 m u tan t 
polymorphism (Matsui, et al 1995).
8.5.3. T he role o f CTL recognition .
The significance of A’^ 02 polymorphism  in terms of peptide presentation is 
further revealed in the specificity of HLA restricted CTL response. Certain 
CTL clones will recognise the same peptide bound to more than one A^^02 
variant. Other CTL clones differentiate between different A“^02 variants 
binding the same peptide. Thus, both peptide and A’^ 02 allele specificity 
contribute to T cell recognition, and different peptides in the context of A'^02 
polymorphism will exhibit different profiles of CTL clonal crossreactivity. 
These different observations are supported by comparing binding of peptide 
with CTL recognition. This has been done in a comparison of A ’^ 0201, 
A’^ 0202, A^0205 and A’^ 0214 (Barouch, et al 1995a). The binding of H IV -lpol 
and flu matrix peptides were compared in the above four A*02 alleles. Both 
peptides bound well to A*0201 and A’^ 0202, but less well to A"^0205 and 
A*0214. When performing CTL recognition using a clone specific for each of 
the two peptides, the pol specific CTL recognised A"^0201 and A*0202 but no t 
A*0205 peptide pulsed cells, whilst the flu matrix specific CTL would only 
recognise this peptide bound to A’^ 0201. The fact that a CTL can differentiate 
between two A"^ 02 subtypes binding the same peptide suggests a change in  
peptide conformation as a result of A*02 polym orphism  within the binding 
groove.
Hence, A*02 variants will exhibit certain differences in peptide binding 
through their preferred anchor residues (Table 8.2). Other sites of 
polym orphism  within the peptide binding groove will determine the 
conformation of the peptide. This conformation will then determine w hich 
amino acid side chains within a particular peptide are accessible to the T cell 
receptor and so affect CTL recognition. Presentation of peptide to a T cell
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receptor can therefore be seen as a function of peptide sequence and 
orientation as dictated by polymorphism within the HLA molecule to w hich 
it is bound.
8 .6. C on clu sion .
The dissection of HLA-A*02 as a group of closely related specificities has 
enabled a extended understanding of HLA polym orphism  in a num ber of 
areas. The existance of HLA polymorphism can be conjectured as a response 
to selective pressures (Lawlor, et al 1990; Hill, et al 1991), and this seems 
borne out through the low level of silent nucleotide substitutions, the high 
level of polymorphism in the functionally sensitive peptide binding groove, 
and the conservation of polymorphic motifs in hypervariable regions 
through gene conversion events.
In analysis of HLA-A*02 polymorphism, the importance of even sm all 
changes in the peptide binding groove can be shown to have a marked effect 
on how the HLA molecule functions in presenting peptide to the T cell. As 
discussed, it seems likely that the generation of such polym orphism  is in  
response to selective pathogenic pressure, as illustrated in the HLA-B53 
restricted response to malaria in West Africa (Hill, et al 1991). It also seems 
probable that HLA diversity present in a particular population in part 
reflects the local history of pathogenic pressure.
Anthropological diversity can be illustrated amongst the variants of HLA- 
A’^ 02, which are found at different frequencies in different populations 
(chapter 5, Table 5.2). Certain allelic variants seem prevalent in certain 
populations, which as mentioned may be in response to selective pressures. 
However the exact nature and diversity of A*02 alleles in different 
populations is still unclear due to the limited number of studies at this level 
of resolution. This lack of typing discrimination is certainly true for m any 
class I alleles, but as typing resolution improves, so an increased 
understanding of HLA association with regard to anthropology, disease, 
transplantation and cellular function will follow.
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The ability to type at allelic resolution has strengthened observations of 
linkage disequilibrium in different populations, as demonstrated w ith the 
A*0205 and B58 haplotype in Sardinia (Carcassi, et al 1995) and A’^ 0207 and 
B46 in Singapore (Krausa, et al 1995). Disease association with HLA-A*02 has 
also become more apparent when considered at an allelic level of definition. 
Hence, an association has been made between A“^0206 and Grave's disease, 
and between A"^ 0207 and Hashimoto's thyroiditis in the Japanese population 
(Sudo, et al 1995).
HLA-A'^02 provides an ideal allelic group to gauge the importance of 
polym orphism  with respect to the functioning of the T cell m ediated 
im m une response. As additional studies address the role of HLA 
polym orphism , so a greater understanding of the mechanisms of im m u n e  
interactions may provide positive solutions for the fields of transplantation, 
disease association and cellular immunology.
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Concluding Discussion
9.1 Aims & objectives for development of a PCR-SSP typing system 
at the HLA-A locus.
This thesis considers the definition of HLA-A locus alleles from DNA. The 
project was initiated at a time when HLA typing for class I specificities was 
securely within the domain of serology, with no practical DNA approach 
available. Serology had been firmly established as the method of choice for 
something approaching 30 years (Terasaki and McClelland, 1964). Over those 
years, serological definition of class I specificities had become increasingly 
refined as more was understood about HLA polymorphism through the 
improving interpretation of the specificity of antisera. Serology was 
nevertheless limited. It was not able to discriminate adequately between 
many class I specificities due to serological cross-reactivity which made the 
definition of certain specificities difficult, particularly when expressed in  
association with other class I specificities.
The application of molecular biological techniques to tissue-typing (Mullis, 
et all986; Saiki, et al 1986; Saiki, et al 1989) initially provided no alternative 
to class I serology, since it was applied to the serologically impractical class II 
loci. HLA class II serology proved difficult through the requirement to 
isolate sufficient class II expressing B cells from the PBMC's. Also class II 
antisera had to be treated to remove the interference of class I specific 
antibodies. For these reasons amongst others, other methods of detecting
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polymorphism were considered, including RFLP (Bell, et al 1987) and 
subsequently PCR-SSOP (Saiki, et al 1986), as discussed in chapter 1.
The analysis of class II polymorphism at the nucleotide level required the 
characterisation of all known specificities by DNA sequencing. This 
sequencing effort established expertise in defining polymorphism w ithin  
DNA and led to an increased awareness of the complexity of polymorphism  
of HLA genes. It was inevitable that as more characterisation was directed at 
class n, so an increasing number of class I specificities would also become 
sequenced. However, serological tissue-typing for class I was considered 
adequate for most purposes, which diminished the incentive for 
development of DNA based approaches.
It has been apparent for some time, that serology was not sufficiently 
sensitive to identify all class I polymorphism, as observed in the HLA 
restricted discrimination of the T cell (Biddison, et al 1980; Gotch, et al 1985) 
or lEF analysis (Yang, 1989b) amongst other methods. However, these 
methods were not definitive in their own right and they provided no  
comprehensive alternative to serology. The relevance of serologically silent 
polymorphisms located around the peptide binding groove (Bjorkman, et al 
1987) had implications as to the function of the class I molecule in binding 
and presenting antigen for immune surveillance. By not identifying these 
polymorphisms, serological typing was failing to discriminate between 
functionally distinct alleles.
In this thesis, the development of a DNA based HLA-A typing system 
provided an opportunity to identify these serologically silent yet 
functionally important polymorphisms within the HLA class I genes. The 
development of a DNA based method was permissible through the 
increased number of sequenced class I specificities. The specificity achievable 
through ARMS designed sequence specific primers (Newton, et al 1989) 
made feasible a simple PCR based approach, whereby the determination of 
polymorphism defining HLA specificity was resolved by the presence or 
absence of an amplification product. At the beginning of this thesis, this 
approach had been applied to definition of HLA class II specificities (Olerup 
and Zetterquist, 1991; Olerup and Zetterquist, 1992). The application of this 
approach with regard to HLA class I began simply, by identifying broad HLA-
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A locus specificities. Through subsequent development, the system became 
increasingly refined through the use of more discriminatory primer 
combinations and the application of nested PCR, finally to provide a method 
which was capable of allele specific discrimination at the HLA-A locus 
(Krausa, et al 1996).
9.2. Comparison with other typing methods.
As discussed above, serology currently persists as the main approach to 
definition of class I specificities. At a practical level, DNA based methods 
hold many advantages over the serological approach to HLA typing. A 
significant limitation of serology lies in its reliance on viable PBMCs. 
Typings have to be done from fresh blood, or cells have to be suitably frozen 
to retain viability, if processing is required at a further date. The scarcity of 
good antisera, which are an increasingly limited and non-renewable 
resource, represents an additional restriction on the performance of 
serological typing. For this reason, different laboratories use different panels 
of antisera, which can contribute to typing inconsistencies through a lack of 
standardisation.
DNA based methods do not suffer from such restrictions. Good quality DNA  
can be extracted from a number of sources, including saliva, buccal scrapes 
and hair (Higuchi, et al 1988; Allen, et al 1994; Aron, et al 1994). DNA is 
easily stored and remains stable for long periods. This reduces the 
restrictions on sample transportation, increasing the scope of DNA  
approaches to type different population groups or archival material. DNA  
approaches can be standardised, particularly since oligonucleotides used as 
primers or probes, are synthetic and represent a renewable resource. 
Standardisation is also assisted by the use of conventional laboratory 
equipment in performing many of the DNA based techniques. A major 
advantage in applying DNA based approaches to HLA typing is that these 
methods offer a much higher resolution than that possible with serology.
The PCR-SSP method developed in this thesis requires a suitable PCR 
machine and gel electrophoresis equipment, items found routinely in many 
research and clinical laboratory settings. The widespread ability to perform
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PCR facilitates the adoption of DNA based HLA typing methods into many 
laboratories.
A number of different DNA approaches have been developed in recent years 
and applied to detection of HLA polymorphism. There are four m ain  
generic methods of DNA typing currently used, although a range of variants 
for each have been described. These four general approaches (as reviewed in  
chapter 1), are (a) PCR-SSOP, (b) heteroduplex and SSCP analysis, (c) 
sequence based typing (SET) and (d) PCR-SSP. Each method offers particular 
advantages which dictate their use for the appropriate applications. The 
attributes of the different approaches are discussed below.
(a) PCR-SSOP. PCR-SSOP has the advantage that large numbers of samples 
can be screened at each hybridisation event. However each sample requires 
hybridisation against a substantial number of probes which is time 
consuming. Situations may also occur using PCR-SSOP, when heterozygous 
combinations are difficult to interpret through the broadness of the initial 
PCR amplification. This can to some extent be rectified by performing a 
number of more specific PCR reactions (Fernandez-Vina, et al 1995; 
Middleton, et al 1995) so simplifying the interpretation of the hybridisation 
patterns.
PCR-SSOP can also detect and characterise the identification of new alleles. 
Novel hybridisation patterns may indicate new specificities. Because 
informative typing by PCR-SSOP requires screening with an extensive panel 
of oligonucleotide probes, the resulting characterisation of a new allele can 
provide a concise profile of its polymorphic content.
The use of PCR-SSOP through several past histocompatibility workshops 
has maintained and further developed this approach (Allen, et al 1994; 
Fernandez-Vina, et al 1995; Middleton, et al 1995; Gallardo, et al 1996). Such 
development has accumulated a wealth of experience in performing PCR- 
SSOP HLA typing, particularly in terms of the conditions crucial to obtaining 
consistent and accurate results. The communication of these experiences 
through workshops and publications, has allowed other laboratories to 
incorporate PCR-SSOP as one of their methods of histocompatibility testing. 
However, laboratories new to the field of molecular biology may find that
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this inexperience represents a problem in performance of DNA based HLA 
typing techniques. For this reason, simplification and standardisation of the 
methods, making them accessible to a greater number of laboratories, has 
been an issue. The production of kits, particularly for the reverse dot-blot 
approach (Bugawan, et al 1994) (chapter 1), provides one approach for 
making a PCR-SSOP technique available for use in laboratories limited in  
molecular experience.
(h) Heteroduplex and SSCP analysis. Heteroduplex analysis and single 
stranded conformational polymorphism (PCR-SSCP) analyse the 
electrophoretic mobility of amplified DNA as determined by the nucleotide 
sequence. Heteroduplex analysis, as described in chapter 1, involves the 
denaturing and reanealing of PCR products, to create double stranded DNA  
combmalions, not necessarily matched in terms of their sequence 
conformity. These novel combinations of DNA strands migrate differently 
in an electrophoresis gel as compared to a homoduplex, which can be 
applied to determining HLA sequence differences between a donor and 
recipient. However, this method does not determine the exact nature of a 
polymorphism in terms of its sequence. Hence it is a method of screening 
for polymorphism rather than for its specific definition in terms of HLA 
type.
Similarly, PCR-SSCP examines the migration of single stranded PCR product 
through a gel. The conformation of the single strand will be dependent 
upon its nucleotide sequence, which in turn determines its mobility 
through a gel under the appropriate conditions. This method again screens 
for polymorphism without identification of its exact nature in terms of its 
nucleotide sequence. Heteroduplex and SSCP analysis do not produce 
discriminatory results, and so fail to provide a comprehensive typing 
approach. They do however provide a useful method of screening for the 
presence of additional polymorphisms between seemingly matched 
individuals.
(c) Sequence based typing. In contrast to heteroduplex and PCR-SSCP 
analysis, the application of sequenced based typing (SBT) has the potential of 
providing the most definitive means of analysis of HLA polymorphism at 
the DNA level. SBT involves the direct sequencing of PCR products
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amplified from regions of definitive polymorphism. By identifying all the 
given polymorphism within a region, this approach offers by far the most 
concise method of HLA typing. New alleles containing novel 
polymorphism within the regions sequenced will be definitively 
characterised by this method. The other molecular approaches may not 
always detect the presence of such polymorphism or may fail to provide a 
definitive characterisation as to their nature.
However, the SBT approach, although made easier through automated 
sequencing, is currently limited in terms of sample throughput and 
performance time. These limitations are being addressed through the 
application of new technology in terms of fluorescent labeled sequencing 
primers and sequencing equipment. Initial problems through the 
incorporation of Taq errors within the PCR prior to sequencing have also 
been dealt with by the use of improved proof reading enzymes. At present, 
SBT is not a replacement for PCR-SSOP and PCR-SSP, since these approaches 
have high capacity or speed respectively on their side. However, in  
situations were the most accurate method of typing is required, then SBT 
becomes highly attractive.
(d) PCR-SSP. PCR-SSP, which has been developed for typing at the HLA-A 
locus in this thesis, represents a simple and easy to interpret DNA based 
approach to tissue-typing. A considerable advantage of the PCR-SSP 
approach is the capability to perform a complete typing of a sample, at both 
class I and class II loci, under a standard set of conditions, in a relatively 
short period of time (Bunce, et al 1995b). This has obvious appeal in  
situations where a sample has to be characterised quickly. However, the 
number of samples that can be typed in any one period is limited in terms of 
the number of PCR amplifications that can be performed. The PCR-SSP 
approach is therefore in contrast to the sample batching and large 
throughput approach which characterises PCR-SSOP. PCR-SSP does hold  
similarities with the reverse dot-blot approach since both involve typing of a 
sample in a single event, be it against a panel of specific PCR reactions or 
hybridisation with a panel of oligonucleotide probes.
An advantage that PCR-SSP holds over PCR-SSOP is with regard to 
interpretation. With PCR-SSP, amplification of DNA requires the
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determination of two points of polymorphisms along the length of its 
sequence as discriminated by the specificity of each primer. This in effect 
links two points of polymorphism present along a single stretch of sequence. 
Additionally, the use of nested PCR-SSP can characterise a given sequence 
on the basis of four points of linked polymorphism as determined by the 
specificity of each primer used in the initial and subsequent PCR. This is in  
contrast to PCR-SSOP, where each probing event is independent. The shared 
nature of polymorphism amongst HLA specificities, makes the 
interpretation of certain heterozygous combinations difficult by PCR-SSOP, 
since it becomes uncertain as to which polymorphisms are present together 
on which allelic sequence. Heterozygote combinations have not presented a 
problem for the PCR-SSP approaches developed in this thesis. As 
demonstrated in chapter 4.4.4, the ambiguity of defining certain A*02 
heterozygote combinations was simply resolved through the addition of 
discriminatory PCR-SSP amplifications.
The requirement for the simultaneous performance of a large number of 
PCR amplifications has compelled PCR-SSP methods to embrace microtitre 
plate technology. This has facilitated easier performance of the typing 
technique, so allowing an increased throughput of samples. Microtitre plate 
formats are now available in 192 well and 384 wells per plate, which greatly 
increase the volume of typings and bring forward the possibility of 
automation (Merel, et al 1996). In addition, the basic philosophy of PCR-SSP 
can also be applied to testing for other polymorphic loci and these can be 
appended to the HLA typing panel. Hence, a single sample can be tested 
simultaneously for a whole array of polymorphism, in addition to the HLA 
loci.
New HLA sequences may be detected by PCR-SSP through a novel pattern of 
reactivity with the reaction panel. Conversely, PCR-SSP is limited in as 
much as it may fail to detect n o v e l sequence p o lym orp h ism s which cannot 
be determined within the discrimination of the existing panel of primer 
combinations. Hence, a novel HLA sequence, which is functionally discreet, 
may be misassigned. PCR-SSP can only be completely reliable within the 
context of the known sequences. This is also true for PCR-SSOP. Typing by 
more than one typing method allows a sample to be gauged from a number 
of different perspectives. Any inconsistency between different typing
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methods may herald the discovery of a new HLA specificity. SBT has a 
distinct advantage in the detection of new HLA specificities, since all the 
polymorphism is sequenced and determined within a given region of 
interest.
As described in chapter 6, several new HLA-A specificities have been 
determined through the course of this thesis. Three of the four alleles 
described presented as anomalies in the expected typing result as a 
consequence of their novel sequence recombination. The fourth allele was 
characterised because of a discrepancy between methods, and would not 
have been determined with the existing PCR-SSP panel, another 
endorsement of a SBT approach. The use of PCR 'gene-mapping' was applied 
to the three anomalous typing results. This method provided rapid 
verification of the observed reaction patterns seen in the new alleles, and 
correctly predicted their polymorphic content (as confirmed by conventional 
DNA sequencing) within the context of SSPs defining known sequence 
motifs. In this thesis, PCR-SSP is shown to detect and characterise new  
alleles, but situations may occur when a novel specificity is either 
misassigned or not detected.
The ability to tissue-type from DNA is now well established, and is being 
swept along with the innovations increasingly offered in the field of 
molecular biology. The PCR-SSP approach developed in this work clearly 
demonstrated the feasibility of tissue-typing at the HLA-A locus at a time 
when molecular approaches were not widely regarded for class I specificities. 
Additionally, it showed the ability for high resolution allelic definition, so 
demonstrating the advantages of DNA based approaches over serological 
testing. On occasion, typing based on surface expression of HLA molecules 
does have an advantage, particularly if DNA based approaches fail to 
discriminate aUeles which are not expressed, detected as blanks by serology. 
Several such instances, as described in chapter 6 do exist but appear to be 
rare. However once the sequence polymorphism which identifies them is 
determined, then DNA based methods again can be used for their 
identification.
The developments from this thesis provided an alternative approach to 
serology at the HLA-A locus. Work at other loci determined that a complete
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PCR-SSP approach was feasible for both class I and class II detection (Olerup 
and Zetterquist, 1992; Olerup, et al 1993; Bunce, et al 1994; Sadler, et al 1994; 
Bunce, et al 1995a). The developments made at the HLA-A locus in this 
thesis together with work at other loci, has contributed to a PCR-SSP method 
for typing HLA class I in the 12th International Histocompatibility 
Workshop and for class I and class II in work by Bunce et al (Bunce, et al 
1995b).
The application of different techniques to the field of HLA testing has 
generated a battery of methods, each with their perceived advantages and 
disadvantages, each with their supporters and critics. The reasons why a 
sample is HLA typed will determine to some extent the method by which  
this is achieved. Factors such as speed, volume, technical expertise, cost, 
required resolution amongst others, further identify the most appropriate 
approach. Serology has been the method of choice for class I typing for many 
years. It is unlikely in view of the strides made in development of DNA  
approaches whether the dominance of serology will persevere (Dupont, 
1995). Given the relative merits of different methods in different 
applications, no single approach may emerge as the method of choice, 
although the high level of discrimination offered by SBT suggests it may 
become the "gold standard" for high definition typing. As new DNA based 
methods emerge, and knowledge increases as to the significance of HLA 
polymorphism in the immune function, it is unclear as to which 
approaches will be adopted for the different applications of histocompatibilty 
testing.
9.3. The applications of the PCR-SSP approach.
HLA typing represents an important aspect for a number of fields, including 
transplantation, population studies, cellular immunology and disease 
association. Following the development of the PCR-SSP system for HLA-A 
locus typing, a number of studies presented themselves in which a high  
resolution typing approach would be both informative and useful. Some of 
these studies have been described in the preceding chapters. In detail, these 
include population studies (chapter 5), characterisation of new HLA 
specificities (chapter 6), significance in cellular immunology (chapters 7 and
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8). In addition, the method has been used to investigate disease association 
and this will be commented on below.
(a). Characterising new alleles. The application of PCR-SSP to the typing of 
HLA-A locus specificities created a novel perspective from which a number 
of new alleles were identified. The issues involved in the identification of 
new HLA-A alleles are discussed in full in chapter 6. The development of a 
PCR-SSP approach for HLA-A locus provided a realisation as to the 
sensitivity of the technique in defining HLA polymorphism. Through the 
specificity of ARMS (Newton, et al 1989) designed SSP, it was possible to 
differentiate between two sequences on the basis of a single nucleotide 
difference. This power of this discrimination provided the basis of the 
developed PCR-SSP system.
The possible discrimination also offered a means of rapidly analysing 
sequences w;ithin the context of known SSP sites. This was facilitated 
through the shared nature of polymorphism and relative lack of unique 
sequence substitutions, found amongst class I alleles. This was the basis of 
the development of the PCR gene-mapping technique (chapter 6.2), whereby 
a panel of SSP could define the sequence motifs present within a particular 
allele, in the context of known polymorphism. This method successfully 
predicted the sequence of a number of new aUeles, as described in chapter 6 
and elsewhere (Browning, et al 1995). The method fails to predict a sequence 
where the polymorphism is not defined by the SSP panel. Characterisation 
of new alleles by this method proved rapid, and allowed the quick design of 
new SSP combinations for the determination of the new specificity. It also 
allowed the evaluation of the typing panel specificity with regard to the new  
allelic sequence. Samples which potentially contained the new specificity 
could be quickly screened with the appropriate SSP combinations. N ew  
alleles defined by PCR-SSP still required full length sequencing, to verify the 
polymorphism present, and confirm the sequence in regions not 
characterised by the gene-mapping approach.
The application of PCR gene mapping, proved reliable for the sequence 
characterisation of alleles tested in chapter 6. But in performing gene- 
mapping, it is important to be aware of the limitations of the method, 
particularly with regard to the analysis of aUeles containing novel
220
polymorphisms (e.g. A*8001) which may fall outside of the hypervariable 
regions of the class I sequence (e.g. A*0209, A*0215N). SBT offers a more 
substantive approach to detection and characterisation of a new allele. But 
even this technique may be inadequate in characterising a new allele, if the 
distinguishing polymorphism falls outside of the sequencing template.
As discussed in chapter 1, the number of HLA alleles has increased 
dramatically with the expansive application of molecular biological 
techniques. In examining the polymorphism amongst this increasing 
database of HLA sequences, it is clear that a mechanism such as gene 
conversion (Parham, et al 1988) has contributed to a large proportion of the 
diversity seen within the HLA system. To this end, the extent of HLA 
diversity has probably not been fully determined, and there is considerable 
scope for identification of new alleles generated from new gene conversion  
events. PCR-SSP may identify such alleles through observations made in  
typing, and the approach of PCR gene-mapping provides a rapid means for 
their preliminary characterisation. The application of DNA based typing 
techniques to different population groups may also uncover new alleles, as 
demonstrated in this thesis with respect to A*3004 (Sardinia) and A*0214 
(Kenya) (chapter 6.3).
(b). Population studies. Examples of serological characterisation of HLA class 
I specificities in different populations have been reported in a number of 
studies (duToit, et al 1990; Allsopp, et al 1992; Contu, et al 1992; Halle, et al 
1994), and as part of Histocompatibility Workshops (Imanishi, et al 1992a; 
Imanishi, et al 1992b). Serology does reveal differences between population 
groups, but fails to show this to its full extent, through a lack of resolution. 
The application of a high resolution typing approach as detailed in this 
thesis provided the opportunity for a more precise analysis of HLA within a 
population.
In determining HLA polymorphism within a population, particularly 
through family studies it is evident that certain HLA specificities are 
inherited together as part of a haplotype. This was demonstrated in a 
Sardinian study (Contu, et al 1992), were A*30 was found to be within one of 
the major haplotypes within the population. Nested PCR-SSP subtyping was 
performed on A*30 individuals from this population (chapter 5.2) to
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determine if any particular A*30 allele constituted a member of this 
haplotype. The results indicated that A*3002 was the allele in the haplotype, 
greatly strengthening this association. In other studies (chapter 5), A*0205 
was found to be the allele in an A2-B17 haplotype observed in the Sardinian 
population. Similarly A*0207 was found to be in linkage disequilibrium  
with B*46, strengthening an A2-B46 association noted in the Singapore 
Chinese population. These associations had initially been made through 
serological observations and were weakened through lack of resolution. The 
application of a high resolution DNA approach was shown to focus the 
association between HLA specificities, so strengthening the relationship.
The application of high resolution PCR-SSP provided a means for 
comparison of HLA-A*02 subtypes in a number of different population 
groups (chapter 5.3). A*02 is commonly found in many different 
populations, and this study showed that the A*02 allelic composition varied 
greatly between the groups investigated. Hence, the resolution offered by 
PCR-SSP determined heterogeneity between populations, which was not 
apparent through serological analysis.
PCR-SSP was also applied to typing a Ugandan population (chapter 5.4), 
using both the PCR-SSP Phototyping method (Bunce, et al 1995b), with  
additional high resolution typing performed by nested PCR. The serological 
determination of many of the specificities identified, would have proven  
difficult, through a lack of antisera determining specificities both peculiar to 
and common in African populations. Such specificities were readily 
identified by PCR-SSP. On a practical note, serological analysis of this 
population would have proven restrictive through the requirement for 
viable cells, a constraint not made on the DNA approach. The application of 
high resolution HLA typing revealed a more defined HLA profile than that 
possible with serology. The population differences demonstrated by high  
resolution typing have major implications for the fields of transplantation 
and cellular immunology with regard to matching between groups. In 
addition, the high resolution analysis of HLA in different populations may 
provide an improved anthropological insight into the relationship between 
different ethnic groups.
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(c). Disease association. This application of the PCR-SSP HLA-A typing 
approach to disease association was not addressed as a study in this thesis. 
However, through the development of the method, various studies have  
benefited from the typing system through a number of collaborations. One 
such collaboration involved the typing part of a cohort of commercial sex 
workers, attending a clinic in Nairobi (Plourde, et al 1992). It was noted that 
some of the women attending the clinic failed to become HIV infected, 
despite a history of multiple contact with HTV positive partners. An initial 
serological definition of this population proved inaccurate. The application 
of PCR-SSP typing at A locus provided more definitive results. 
Unfortunately no clear correlation was observed at the HLA-A locus with  
non-infection with HIV.
Anollier collaborative study examiiied the relationship between HLA and 
scarring trachoma in The Gambia in West Africa. Infected individuals were 
serologically HLA typed and an association was noted between HLA-A28 and 
contracting scarring trachoma as compared to the control group. The 
application of PCR-SSP both removed mistypings (A28 is difficult to 
determine by serology, particularly in the presence of A2), and showed that 
amongst the A28 samples, the association was clearly with the A*6802 
subtype (Conway, 1996).
Both the above studies exemplified the inadequacies of serology in  
providing accurate data for determination of a disease association. The 
application of high resolution DNA based approaches as illustrated, provide 
more informative data from which the presence of any associations could be 
determined.
(d). HLA and functional significance. In the latter part of this thesis, the 
importance of allelic polymorphism was both explored and discussed 
(chapters 7 and 8). The purpose of this thesis was to determine HLA-A locus 
specificities to an allelic level. These two chapters contemplate the 
importance of that polymorphism with regard to the functioning of the 
HLA molecule in the MHC restricted immune response.
Chapter 7 examines the relevance of HLA polymorphism in respect to the 
binding of peptide for presentation to the TCR. Unfortunately, it was not
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possible to determine the contribution made by the TCR in this study, 
although this will be addressed in future work. However, the data obtained 
from eluting peptides from variants of A*30, showed a difference in anchor 
residues preference in A*3001 as opposed to the other variants. The 
significance of other A*30 variant polymorphic differences not involved in  
binding peptide anchor residues was also discussed in chapter 7, although 
the conclusions drawn can only be validated through the discrimination of 
the TCR.
Chapter 8 reviewed polymorphism in HLA-A*02 and its relationship to 
function. As described, a number of studies have examined and showed the 
relevance of polymorphism amongst various A*02 alleles with regard to the 
T cell response. The observations made in chapter 7 and 8 and their 
implications provide validation of HLA typing to a high resolution, as a 
means of accurately determining functionally distinct molecules at the 
cellular level. The importance of HLA typing to the allelic level is therefore 
a prerequisite for the confident interpretation of MHC based cellular 
interactions.
9.4. The future.
The demands for tissue typing remain through the requirements of 
transplantation, forensics, studies in disease association, anthropology and 
T-cell mediated immunity. Each of these areas has different requirements as 
to the degree of resolution and methodology, which explains the variety of 
techniques available for HLA tissue typing. The advent and rapid progress of 
DNA methodology has provided a workable alternative to serology, 
although serology will probably remain the routine method for HLA class I 
typing in many HLA laboratories for the near future.
The practice of serology will inevitably decline as the opportunity for DNA  
typing reaches an increasing number of laboratories, through the vehicles of 
workshops, and commercial kits. The availability of DNA based kits, which  
require only standard laboratory equipment, will potentially take tissue 
typing out of the realm of the professional histocompatibility testing 
laboratory, into the hands of anyone who has a reason for doing it. Increased 
automation may further reduce specialised knowledge. However, the
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complexity of the HLA system and diversity of available methods should 
ensure that the requirement for professional histocompatibility testing 
laboratories persists for the near future.
The information generated by DNA based methods has contributed to a 
more precise understanding of the HLA system from a number of different 
perspectives. For instance, HLA typing at a high resolution has uncovered 
previously unseen heterogeneity between population groups in terms of 
their comparative structure of HLA gene frequencies (see chapter 5). DNA  
based HLA typing will hopefully improve the area of transplantation by 
identifying more precisely which specificities or combinations of sequence 
polymorphisms are crucial for matching to ensure graft survival. W ith  
many of the HLA polymorphisms having functional significance at the 
level of the T cell mediated immune response, high resolution typing also 
has implications for interpretation of HLA restriction in both research and 
clinical settings. For these reasons, the requirement for precise and 
dependable typing methods will continue to ensure further progress and 
development in the field of HLA typing.
The current advances and improvement of typing resolution, has generated 
an extensive effort in further characterising polymorphism within the HLA 
system. As demonstrated in this thesis, new alleles are constantly being 
found and their functional and anthropological significance can 
subsequently be investigated. The information gained from such efforts w ill 
enhance current understanding of the structure, function and evolution of 
the HLA system. The diversity of methods currently available for HLA 
typing, provides the investigator a degree of choice, flexibility and accuracy 
not previously known in HLA typing.
9.5 In summary.
This thesis demonstrates the feasibility and subsequent development of a 
molecular typing of HLA class I polymorphism. The PCR-SSP method  
developed is a straightforward and easy to interpret approach to the 
definition of HLA polymorphism. The method was developed to allow a 
considerable number of sequence specific reactions to be performed
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simultaneously under a set of standard conditions. The presence of a 
sequence is defined simply by its amplification by one or more of a panel of 
PCR reactions. By visualising the panel of PCR amplifications, a tissue type 
can be determined simply by the presence or absence of product in each of 
the panel of specific reactions. This thesis describes the development of a 
PCR-SSP approach as applied to defining specificities at the HLA-A locus.
Establishing that molecular approaches could be applied at the class I HLA-A 
locus demonstrated that an alternative existed to serological definition. In 
addition the advantages of typing from DNA were realised since viable cells 
were no longer necessary. Distant population groups, as described in chapter 
5, could be typed without the inherent restrictions accompanying serological 
definition. Combinations of specificities which serological typing finds 
difficult were easily and distinctly defined by PCR-SSP.
The major advantage of typing from DNA lies in the high resolution  
possible. Serology is limited in that it appHes only to the definition of those 
polymorphisms which are either accessible or effect sites that are accessible 
to detection by antibody. Analysis of the nucleotide sequence provides the 
opportunity to analyse all the sites of polymorphism present within a HLA 
specificity, plus intronic sequences and promoter polymorphism. The ability 
to differentiate between specificities upon the basis of their sequence proffers 
the possibility of discriminating to a level of resolution at which the allele 
can be unambiguously identified. This thesis has demonstrated the 
application of PCR-SSP techniques, in defining HLA-A locus specificities 
well beyond the resolution of serology, so as to be able to type definitively to 
the level of the allele.
In a clinical or cellular setting, it may not be necessary to discriminate 
between all alleles, as some may contain polymorphisms that have no  
functional impact. However, for tfiis to be established requires initial 
analysis based on allelic definition. In situations in which HLA is used as a 
marker, for instance in anthropology or disease association studies, then  
definition at the allelic level is more appropriate. As molecular HLA typing 
techniques become increasingly robust, easier to perform and standardised, 
then it will be convenient to type at the highest level of resolution for all
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applications since this will provide a universal and standard form of 
information.
The necessity of typing to the point of defining the allele is addressed in  
chapters 7 and 8 of this thesis. The definition of HLA polymorphism and its 
study in comparison to function, provides a valuable insight into the 
mechanisms shaping the MHC restricted immune response. As investigated 
in this thesis, the appropriate HLA polymorphism determines the 
preference for residues bound within a peptide sequence. In addition, 
polymorphism will also effect how peptide lies within the binding groove 
and which residues provide a surface in the context of the class I m olecule 
for interaction with the T cell receptor. The functional significance of 
polymorphism which distinguish the majority of class I alleles provide 
strong reasons for their accurate identification and so the use of a definitive 
typing method.
This thesis has therefore addressed the issue of providing an accurate and 
powerful DNA based system for definition and discrimination of alleles of 
the HLA-A locus. It describes strategies which simply and clearly facilitate 
allelic resolution. The approaches developed in this work have been 
adopted and validated in other laboratories (Bozôn, et al 1996), and found to 
be an accurate and practical approach to class I DNA based typing. This thesis 
therefore marks an important point in the field of histocompatibility testings 
demonstrating the feasibility and importance of PCR-SSP, as a means of 
providing high resolution typing for alleles of the HLA-A locus.
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